<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC2386848/results/search/drugs/results.xml">
   <result pre="review the medical literature concerning the efficacy and tolerability of" exact="topiramate" post="in the prophylactic treatment of migraine in children and"/>
   <result pre="review the medical literature concerning the efficacy and tolerability of" exact="topiramate" post="in the prophylactic treatment of migraine in children and"/>
   <result pre="years) who had been enrolled in three pivotal RCTs of" exact="topiramate" post="for migraine prophylaxis in adults and two open studies."/>
   <result pre="randomized (in a 1:1 ratio) to receive either placebo or" exact="topiramate" post="(titrated to 100 mg a day) for 12 weeks."/>
   <result pre="is clearly evident in the topiramate-treated group. Patients treated with" exact="topiramate" post="suffered at least five episodes a month before entering"/>
   <result pre="who were randomized in a 2:1 ratio to receive either" exact="topiramate" post="(which was titrated over 8 weeks to 2–3 mg/kg"/>
   <result pre="of 2.6 ± 2.6 migraine days per month in the" exact="topiramate" post="group compared with a mean reduction of 2.0 ±"/>
   <result pre="The dropout rate for adverse events was 6.3% for the" exact="topiramate" post="group and 4% for the placebo group. In the"/>
   <result pre="frequency at baseline was lower (range 2–9 in the ITT" exact="topiramate" post="population) and children with chronic migraine were excluded. An"/>
   <result pre="that it may take a few weeks before treatment with" exact="topiramate" post="reaches its maximum efficacy. Winner et al. [ 13]"/>
   <result pre="years) who had been enrolled in three pivotal trials of" exact="topiramate" post="for migraine prophylaxis in adults. Patients were to have"/>
   <result pre="of adverse events was higher in the group treated with" exact="topiramate" post="at the dosage of 200 mg, which did not"/>
   <result pre="One class IV study [ 14], assessing the efficacy of" exact="topiramate" post="for pediatric migraine, included 97 children, 75 of which"/>
   <result pre="50.7% of patients were on additional prophylactic medication (most often" exact="amitriptyline" post="or divalproex). In an open, prospective case series (class"/>
   <result pre="an open, prospective case series (class IV) study [ 15]," exact="topiramate" post="was administered to 24 children with migraine, who had"/>
   <result pre="and trazodone, while data from uncontrolled studies suggest cyproheptadine, amitriptyline," exact="naproxen" post="and antiepileptic drugs (topiramate, valproic acid and gabapentin) to"/>
   <result pre="uncontrolled studies suggest cyproheptadine, amitriptyline, naproxen and antiepileptic drugs (topiramate," exact="valproic acid" post="and gabapentin) to be effective. Since this review was"/>
   <result pre="Since this review was published, two randomized, placebo-controlled trials evaluating" exact="topiramate" post="in the preventive treatment of pediatric migraine have been"/>
   <result pre="Taken together, data from the papers we reviewed suggest that" exact="topiramate" post="is effective in the preventive treatment of pediatric migraine."/>
   <result pre="is effective in the preventive treatment of pediatric migraine. Furthermore," exact="topiramate" post="dosages, which seem to be effective in the treatment"/>
   <result pre="the childrens’ quality of life [ 10, 14]. In conclusion," exact="topiramate" post="seems to be a promising therapeutic option, though, clearly,"/>
   <result pre="Powers SW Vockell AL LeCates S Kabbouche M Effectiveness of" exact="topiramate" post="in the prevention of childhood headaches Headache 2002 42"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC2778404/results/search/drugs/results.xml">
   <result pre="of life. For management of acute attacks of migraine both" exact="acetaminophen" post="and ibuprofen are recommended for use in children. Many"/>
   <result pre="For management of acute attacks of migraine both acetaminophen and" exact="ibuprofen" post="are recommended for use in children. Many drugs like"/>
   <result pre="children. Comparison of efficacy and safety at doses of 15 mg/kg" exact="acetaminophen" post="and 10 mg/kg ibuprofen, respectively, found no significant differences ["/>
   <result pre="there is no difference in efficacy, safety and tolerability between" exact="acetaminophen" post="15 mg/kg and Nimuselide 2.5 mg/kg [ 14]. Aspirin-containing compounds are"/>
   <result pre="of Reye's syndrome. Although a combination of aspirin, caffeine, and" exact="acetaminophen" post="is effective in adult acute migraine, it has not"/>
   <result pre="adults. Oral treatment has been assessed with sumatriptan, rizatriptan, and" exact="zolmitriptan" post="and found to be without benefit [ 15– 18]."/>
   <result pre="benefit [ 15– 18]. In one trial of 32 patients" exact="zolmitriptan" post="was superior to placebo [ 19]. There is inadequate"/>
   <result pre="[ 19]. There is inadequate data for effectiveness of subcutaneous" exact="sumatriptan" post="in children. In adolescents, only intranasal administration has demonstrated"/>
   <result pre="In adolescents, only intranasal administration has demonstrated efficacy, for both" exact="sumatriptan" post="and zolmitriptan [ 20– 22]. 12. Other Medications for"/>
   <result pre="only intranasal administration has demonstrated efficacy, for both sumatriptan and" exact="zolmitriptan" post="[ 20– 22]. 12. Other Medications for Acute Migraine"/>
   <result pre="but current evidence finds no difference in effect between oral" exact="dihydroergotamine" post="and placebo [ 23]. Prochlorperazine is more effective than"/>
   <result pre="dihydroergotamine and placebo [ 23]. Prochlorperazine is more effective than" exact="ketorolac" post="in the reduction of symptoms 1 hour after intake"/>
   <result pre="results with mixed success. Recent Cochrane data base review found" exact="propranolol" post="to be effective for prophylaxis of pediatric migraine ["/>
   <result pre="prophylaxis of pediatric migraine [ 27]. The side effects of" exact="propranolol" post="including insomnia, weight gain, tiredness, and depressive symptoms often"/>
   <result pre="prophylactic agents in children. Among the calcium channel blockers only" exact="flunarizine" post="has shown consistent efficacy and safety as prophylactic agent"/>
   <result pre="[ 29]. Winner et al. [ 30] reported effectiveness of" exact="topiramate" post="in children and adolescents in dose of 2-3 mg/kg/day (maximum"/>
   <result pre="month. One retrospective study assessed the efficacy and safety of" exact="levetiracetam" post="for pediatric migraine at doses of 125–250 mg twice"/>
   <result pre="true efficacy. Other anticonvulsant drugs like acetazolamide, clonazepam, lamotrigine, and" exact="vigabatrin" post="do not produce results superior to placebo [ 31]."/>
   <result pre="Hämäläinen ML Hoppu K Valkeila E Santavuori P Ibuprofen or" exact="acetaminophen" post="for the acute treatment of migraine in children: a"/>
   <result pre="Naccarella C Tozzi E Fiumana E Fanaro S Nimesulide and" exact="acetaminophen" post="for the treatment of juvenile migraine: a study for"/>
   <result pre="randomized placebo-controlled study. Do children with migraine respond to oral" exact="sumatriptan" post="differently from adults? Neurology 1997 48 4 1100 1103"/>
   <result pre="C et al. Treatment of childhood migraine attacks with oral" exact="zolmitriptan" post="and ibuprofen Neurology 2006 67 3 497 499 16775229"/>
   <result pre="al. Treatment of childhood migraine attacks with oral zolmitriptan and" exact="ibuprofen" post="Neurology 2006 67 3 497 499 16775229 20 Lewis"/>
   <result pre="Lewis DW Winner P Hershey AD Wasiewski WW Efficacy of" exact="zolmitriptan" post="nasal spray in adolescent migraine Pediatrics 2007 120 2"/>
   <result pre="396 17671066 23 Hämäläinen ML Hoppu K Santavuori PR Oral" exact="dihydroergotamine" post="for therapy-resistant migraine attacks in children Pediatric Neurology 1997"/>
   <result pre="29 Serdaroglu G Erhan E Tekgul H et al. Sodium" exact="valproate" post="prophylaxis in childhood migraine Headache 2002 42 8 819"/>
   <result pre="children Acetaminofen, PO 15 mg/kg Comparable efficacy and safety profile with" exact="ibuprofen" post="Nimuselide, PO 2.5 mg/kg Triptans Sumatriptan Nasal spray, 5 mg,"/>
   <result pre="years Other medication Ketorolac IV 0.5 mg/kg; maximum 30 mg IV" exact="prochlorperazine" post="is superior to IV ketorolac in the acute treatment"/>
   <result pre="0.5 mg/kg; maximum 30 mg IV prochlorperazine is superior to IV" exact="ketorolac" post="in the acute treatment of migraine headaches in emergency"/>
   <result pre="in the acute treatment of migraine headaches in emergency department" exact="prochlorperazine" post="IV (0.15 mg/kg; maximum 10 mg) Table 6 Drugs used"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC3451993/results/search/drugs/results.xml">
   <result pre="in general. Although 45% of GPs argued they were prescribing" exact="ibuprofen" post="as first-line abortive drug, only 3% were aware of"/>
   <result pre="Other triptan 7. Aspirin Question 3 b When you prescribe" exact="ibuprofen" post="for a migraine attack, which dose of ibuprofen do"/>
   <result pre="you prescribe ibuprofen for a migraine attack, which dose of" exact="ibuprofen" post="do you prescribe? 1. 7.5–10 mg/kg/dose 2. Dose recommended"/>
   <result pre="body weight 3. Other Question 4 b When you prescribe" exact="ibuprofen" post="for a migraine attack, which number of ibuprofen doses"/>
   <result pre="you prescribe ibuprofen for a migraine attack, which number of" exact="ibuprofen" post="doses do you prescribe for a single migraine attack?"/>
   <result pre="2 doses Question 5 a If you do not prescribe" exact="ibuprofen" post="as first intention acute medication for a migraine attack,"/>
   <result pre="Aspirin 12 14 10 1.5 [0.6–3.9] Question 3. Dose of" exact="ibuprofen" post="1. 7.5–10 mg/kg/dose 3 2 4 0.5 [0.08–2.7] 2."/>
   <result pre="Other 1 2 0 5.2 [0.2–111] Question 4. Number of" exact="ibuprofen" post="doses 1. 1–2 doses 44 50 38 1.6 [0.7–3.6]"/>
   <result pre="doses 56 50 62 0.6 [0.3–1.4] Question 5. Reasons of" exact="ibuprofen" post="non prescription 1. Not the reference medication 17 20"/>
   <result pre="(Questions 1–5) Acute medications Forty-five GPs argued they were prescribing" exact="ibuprofen" post="as first-line abortive drug, whereas 44 GPs argued they"/>
   <result pre="first-line abortive drug, whereas 44 GPs argued they were prescribing" exact="ibuprofen" post="as second-line intention migraine abortive drug. The second most"/>
   <result pre="as second-line drug by 12 GPs. Eleven GPs asserted prescribing" exact="sumatriptan" post="nasal spray as second-line drug. Target dose Among the"/>
   <result pre="as second-line drug. Target dose Among the 99 GPs prescribing" exact="ibuprofen" post="(as first or second-line acute treatment), 96 targeted no"/>
   <result pre="a dose of 10 mg/kg and 1 GP was prescribing" exact="ibuprofen" post="at a dose of 5 mg/kg. Administration schedule The"/>
   <result pre="migraine attack by 44 GPs. Reasons for refusing to prescribe" exact="ibuprofen" post="as first-line acute treatment Among the 55 GPs who"/>
   <result pre="acute treatment Among the 55 GPs who did not prescribe" exact="ibuprofen" post="as first-line acute treatment, 26 (47%) did so by"/>
   <result pre="the potential adverse events, 15 (27%) had in mind that" exact="ibuprofen" post="was not the reference medication of pediatric migraine attack,"/>
   <result pre="of pediatric migraine attack, 8 (15%) were unaccustomed to prescribe" exact="ibuprofen" post="in pediatric migraine, 5 (9%) were finding ibuprofen ineffective"/>
   <result pre="to prescribe ibuprofen in pediatric migraine, 5 (9%) were finding" exact="ibuprofen" post="ineffective in pediatric migraine, and 1 (2%) were finding"/>
   <result pre="ineffective in pediatric migraine, and 1 (2%) were finding that" exact="ibuprofen" post="onset of action was too long. Preventive treatment (Questions"/>
   <result pre="management of pediatric migraine. Figure also shows GPs prescription of" exact="ibuprofen" post="according to their knowledge of the treatment of reference."/>
   <result pre="being aware of the reference treatment, 33 (61%) were prescribing" exact="ibuprofen" post="as first-line acute drug for pediatric migraine (Fig. 1)."/>
   <result pre="1). Among these 46 GPs, 12 (26%) were nevertheless prescribing" exact="ibuprofen" post="as first-line acute (Fig. 1). Seventy-seven GPs stated that"/>
   <result pre="significant ( P = 0.008). Fig. 1 HAS guidelines and" exact="ibuprofen" post="prescription according to knowledge of reference treatment. HAS Haute"/>
   <result pre="trial dedicated to abortive treatment of pediatric migraine. It compared" exact="acetaminophen" post="(15 mg/kg) and ibuprofen (10 mg/kg) in a single"/>
   <result pre="treatment of pediatric migraine. It compared acetaminophen (15 mg/kg) and" exact="ibuprofen" post="(10 mg/kg) in a single dose three-way crossover study"/>
   <result pre="in relieving migraine attacks. Another study showed that a lower" exact="ibuprofen" post="dosage (7.5 mg/kg) was more effective than placebo in"/>
   <result pre="et al. [ 13] compared the efficacy of oral zolmitriptan," exact="ibuprofen" post="and placebo. They found that ibuprofen 200–400 mg was"/>
   <result pre="efficacy of oral zolmitriptan, ibuprofen and placebo. They found that" exact="ibuprofen" post="200–400 mg was more effective than placebo in meeting"/>
   <result pre="sent to each GP working in France. The HAS recommended" exact="ibuprofen" post="as the mainstay drug for acute migraine attacks in"/>
   <result pre="ergot derivatives from the age of 10 onward and to" exact="sumatriptan" post="nasal spray in children and adolescents 12 or older"/>
   <result pre="ibuprofen. Although the HAS did not advocate the use of" exact="paracetamol" post="in its guidelines for the treatment of migraine in"/>
   <result pre="guidelines for the treatment of migraine in adults and children," exact="paracetamol" post="was the drug of choice favoured by GPs. Moreover,"/>
   <result pre="a little less than half of the GPs would prescribe" exact="ibuprofen" post="as first intention drug for migraine attack, only 3%"/>
   <result pre="to our out-patient neuropaediatric department [ 8]. In this study," exact="ibuprofen" post="was prescribed to only 30.3% of the children and"/>
   <result pre="of the children were both prescribed an appropriate dose of" exact="ibuprofen" post="and told to take it early in the course"/>
   <result pre="of inefficacy, they often advised children and adolescents to take" exact="paracetamol" post="more frequently, and in last resort, every day ["/>
   <result pre="MO rate amounted to respectively, 82.5 and 65%. Reasons for" exact="ibuprofen" post="under prescription One of the reasons that may impede"/>
   <result pre="ibuprofen under prescription One of the reasons that may impede" exact="ibuprofen" post="as first intention choice abortive drug is the fear"/>
   <result pre="studies and one multicenter double-blind randomized control trial) had reported" exact="ibuprofen" post="adverse effects at therapeutics doses. They documented an increased"/>
   <result pre="adverse clinical events requiring hospitalization among febrile children treated with" exact="acetaminophen" post="or ibuprofen were low and did not vary significantly"/>
   <result pre="events requiring hospitalization among febrile children treated with acetaminophen or" exact="ibuprofen" post="were low and did not vary significantly with choice"/>
   <result pre="from each other or from placebo. Nevertheless, as a precaution," exact="ibuprofen" post="was not recommended for the treatment of fever or"/>
   <result pre="studies more accurately quantified the risk of adverse events of" exact="ibuprofen" post="in children. As a consequence, fearing of GPs appears"/>
   <result pre="Hämäläinen ML Hoppu K Valkeila E Santavuori P Ibuprofen or" exact="acetaminophen" post="for the acute treatment of migraine in children: a"/>
   <result pre="Neurology 1997 48 103 107 9008503 12. Lewis DW Children’s" exact="ibuprofen" post="suspension for the acute treatment of pediatric migraine Headache"/>
   <result pre="IW Frese A Treatment of childhood migraine attacks with oral" exact="zolmitriptan" post="and ibuprofen Neurology 2006 67 497 499 10.1212/01.wnl.0000231138.18629.d5 16775229"/>
   <result pre="A Treatment of childhood migraine attacks with oral zolmitriptan and" exact="ibuprofen" post="Neurology 2006 67 497 499 10.1212/01.wnl.0000231138.18629.d5 16775229 14. Moore"/>
   <result pre="Piira T Goodenough B Champion GD Efficacy and safety of" exact="acetaminophen" post="vs. ibuprofen for treating children’s pain or fever: a"/>
   <result pre="Goodenough B Champion GD Efficacy and safety of acetaminophen vs." exact="ibuprofen" post="for treating children’s pain or fever: a meta-analysis Arch"/>
   <result pre="10.1001/archpedi.158.6.521 15184213 29. Lesko SM Mitchell AA The safety of" exact="acetaminophen" post="and ibuprofen among children younger than two years old"/>
   <result pre="29. Lesko SM Mitchell AA The safety of acetaminophen and" exact="ibuprofen" post="among children younger than two years old Pediatrics 1999"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC3611901/results/search/drugs/results.xml">
   <result pre="3611901 JPN-7-171 doi: 10.4103/1817-1745.106470 : Original Article Effective dose of" exact="topiramate" post="in pediatric migraine prophylaxis Abbaskhanian Ali Sadeghi Hamid Reza"/>
   <result pre="was planned and performed to evaluate the efficacy of low-dose" exact="topiramate" post="in pediatric migraine prophylaxis. Materials and Methods: A prospective"/>
   <result pre="were randomly divided into two treatment groups – treated by" exact="topiramate" post="&amp;lt; 2 mg/kg/day and &amp;gt; 2 mg/kg/day. All the"/>
   <result pre="the study for the clinical response. Results: The patients receiving" exact="topiramate" post="&amp;lt; 2 mg/kg/day (mean dose of 1.2 ± 0.7"/>
   <result pre="(±2.1) to 2.2 (±1.3) h. In the patients treated with" exact="topiramate" post="&amp;gt; 2 mg/kg/day (mean dose of 2.4 ± 0.5"/>
   <result pre="( P &amp;gt; 0.05). The most common side effects of" exact="topiramate" post="were paresthesias (five patients), anorexia (four patients), drowsiness (four"/>
   <result pre="Conclusion: The results of this study demonstrated that low-dose of" exact="topiramate" post="(&amp;lt;2 mg/kg/day) is effective, well-tolerated, safe, and suggested as"/>
   <result pre="an alternative prophylactic treatment for pediatric migraine. Pediatric migraine prophylaxis" exact="topiramate" post="Introduction Migraine is a common neurological disorder in childhood"/>
   <result pre="Limited data is available for the efficacy and safety of" exact="topiramate" post="in the pediatric population.[ 5] The exact mechanism of"/>
   <result pre="topiramate in the pediatric population.[ 5] The exact mechanism of" exact="topiramate" post="is unknown.[ 6] It is proposed that epilepsy and"/>
   <result pre="8] Few uncontrolled studies done to evaluate the efficacy of" exact="topiramate" post="in migraine prophylaxis especially in refractory causes confirmed that"/>
   <result pre="to support the effectiveness, tolerability, and adequate dosage of pediatric" exact="topiramate" post="are not well-reported. The present study was planned and"/>
   <result pre="was planned and performed to evaluate the efficacy of low-dose" exact="topiramate" post="in pediatric migraine prophylaxis. Materials and Methods The study"/>
   <result pre="children (between 5 and 15 years of age) treated with" exact="topiramate" post="for prevention of migraine headaches, at a pediatric neurology"/>
   <result pre="Neuroimaging studies indicative of a focal neurological lesion Contraindications for" exact="topiramate" post="(e.g., glaucoma, renal stone) Patients with known case of"/>
   <result pre="epilepsy. After simple randomized dividing the patients into two groups," exact="topiramate" post="was started at a dose of greater or lower"/>
   <result pre="based on the Visual Analog Scale (VAS). The response to" exact="topiramate" post="treatment was recorded according to the patients and parents′"/>
   <result pre="monthly headache frequency at the beginning of the study with" exact="topiramate" post="in two groups receiving &amp;gt; 2 mg/kg/day and &amp;lt;"/>
   <result pre="8 weeks of treatment The most common side effects of" exact="topiramate" post="were paresthesias (five patients), anorexia (four patients), and drowsiness"/>
   <result pre="study was designed and performed to compare different dosage of" exact="topiramate" post="in pediatric migraine prophylaxis. In our study, the mean"/>
   <result pre="prophylaxis. In our study, the mean dose in patients receiving" exact="topiramate" post="(&amp;lt;2 mg/kg/day) was 1.2 ± 0.7 mg/kg/day. (Range: 0.5-2"/>
   <result pre="group receiving more than 2 mg/kg/day. The mean dose of" exact="topiramate" post="used in several studies varied from 1.7 ± 1"/>
   <result pre="9 20] However, Winner et al.[ 20] suggested that possibly" exact="topiramate" post="at dose of 50 mg/day, administered prophylactically, may reduce"/>
   <result pre="Lewis et al.[ 21] evaluated the efficacy and safety of" exact="topiramate" post="for migraine prevention in pediatric subjects aged 12-17 years."/>
   <result pre="prevention in pediatric subjects aged 12-17 years. They found that" exact="topiramate" post="at 100 mg/day, but not 50 mg/day, resulted in"/>
   <result pre="Campistol et al.[ 22] presented that effective mean dose of" exact="topiramate" post="in pediatric migraine prophylaxis is 3.5 ± 1.7 mg/kg/day."/>
   <result pre="topiramate. In this report 62% of families reported that low-dose" exact="topiramate" post="(average dose of 30 mg/day) was successful in reducing"/>
   <result pre="episodes. Campistol et al.[ 22] presented 24 children treated with" exact="topiramate" post="for 4 months. And recorded a reduction in migraine"/>
   <result pre="side effects. Another study, evaluating the safety, and tolerability of" exact="topiramate" post="show that the most common side effects were paresthesia,"/>
   <result pre="tolerability, optimal dose, length of treatment, and long-term effects of" exact="topiramate" post="in this population. In conclusion, the results of this"/>
   <result pre="conclusion, the results of this study demonstrated that low-dose of" exact="topiramate" post="(&amp;lt;2 mg/kg/day) is effective, well-tolerated, safe, and suggested as"/>
   <result pre="2005 11 373 86 16061523 8 Faught E Efficacy of" exact="topiramate" post="as adjunctive therapy in refractory partial seizures: United States"/>
   <result pre="Khurana DS Yum S et al. Efficacy and tolerability of" exact="topiramate" post="in pediatric migraine Pediatr Neurol 2009 41 167 70"/>
   <result pre="Yum S Hardison HH et al. Efficacy and tolerability of" exact="topiramate" post="in children younger than 2 years old J Child"/>
   <result pre="19 Von Seggern RL Mannix LK Adelman JU Efficacy of" exact="topiramate" post="in migraine prophylaxis: A retrospective chart analysis Headache 2002"/>
   <result pre="double-blind, placebo-controlled study to evaluate the efficacy and safety of" exact="topiramate" post="for migraine prevention in pediatric subjects 12-17 years of"/>
   <result pre="15832623 23 Borzy JC Koch TK Schimschock JR Effectiveness of" exact="topiramate" post="in the treatment of pediatric chronic daily headache Pediatr"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC3996073/results/search/drugs/results.xml">
   <result pre="most frequently with migraine headache (94%) and treated with prescribed" exact="ibuprofen" post="(57%) and/or nortriptyline (17%). Table 3 shows the breakdown"/>
   <result pre="migraine headache (94%) and treated with prescribed ibuprofen (57%) and/or" exact="nortriptyline" post="(17%). Table 3 shows the breakdown of these values"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC4239406/results/search/drugs/results.xml">
   <result pre="could be beneficial in childhood episodic syndromes. Nonspecific analgesics like" exact="ibuprofen" post="and acetaminophen are widely used in pediatrics to control"/>
   <result pre="beneficial in childhood episodic syndromes. Nonspecific analgesics like ibuprofen and" exact="acetaminophen" post="are widely used in pediatrics to control pain and"/>
   <result pre="to completely eliminate pain and related symptoms. Nonspecific analgesics like" exact="ibuprofen" post="and acetaminophen are widely used in pediatrics in order"/>
   <result pre="eliminate pain and related symptoms. Nonspecific analgesics like ibuprofen and" exact="acetaminophen" post="are widely used in pediatrics in order to control"/>
   <result pre="for acute migraine treatment [ 47, 48]. Although nasal spray" exact="sumatriptan" post="[ 49- 51] and zolmitriptan [ 52] have positive"/>
   <result pre="47, 48]. Although nasal spray sumatriptan [ 49- 51] and" exact="zolmitriptan" post="[ 52] have positive randomized trials in children, only"/>
   <result pre="zolmitriptan [ 52] have positive randomized trials in children, only" exact="almotriptan" post="[ 53] (in adolescents aged 12-17 years) and rizatriptan"/>
   <result pre="only almotriptan [ 53] (in adolescents aged 12-17 years) and" exact="rizatriptan" post="[ 54] (for 6-17 years olds) are now FDA-approved"/>
   <result pre="olds) are now FDA-approved for pediatric use. Generally ergot alkaloid" exact="dihydroergotamine" post="[ 55], dopamine receptor antagonists [ 56] and opioids"/>
   <result pre="FDA-approved for pediatric use. Generally ergot alkaloid dihydroergotamine [ 55]," exact="dopamine" post="receptor antagonists [ 56] and opioids are not considered"/>
   <result pre="are particularly long and debilitating [ 60]. Among migraine preventives," exact="topiramate" post="[ 61- 63], flunarizine [ 64], amitriptyline [ 65,"/>
   <result pre="debilitating [ 60]. Among migraine preventives, topiramate [ 61- 63]," exact="flunarizine" post="[ 64], amitriptyline [ 65, 66] and divalproex sodium"/>
   <result pre="Among migraine preventives, topiramate [ 61- 63], flunarizine [ 64]," exact="amitriptyline" post="[ 65, 66] and divalproex sodium [ 67, 68]"/>
   <result pre="[ 18]. A favourable response to subcutaneous and nasal spray" exact="sumatriptan" post="has been reported [ 68] and represents another argument"/>
   <result pre="migraine generally responds to triptans [ 106]. Preventive treatment with" exact="flunarizine" post="can be considered if attacks are frequent or long-lasting"/>
   <result pre="Exercise as migraine prophylaxis: a randomized study using relaxation and" exact="topiramate" post="as controls Cephalalgia 2011 31 1428 1438 10.1177/0333102411419681 21890526"/>
   <result pre="LM Toor S Northam RS White LW Lawson L Children’s" exact="ibuprofen" post="suspension for the acute treatment of pediatric migraine Headache"/>
   <result pre="Hamalainen ML Hoppu K Valkeila E Santavuori P Ibuprofen or" exact="acetaminophen" post="for the acute treatment of migraine in children: a"/>
   <result pre="47. Ahonen K Hamalainen ML Rantala H Hoppu K Nasal" exact="sumatriptan" post="is effective in treatment of migraine attacks in children:"/>
   <result pre="Austin R Peykamian M A randomized, double-blind, placebo-controlled study of" exact="sumatriptan" post="nasal spray in the treatment of acute migraine in"/>
   <result pre="Lewis DW Winner P Hershey AD Wasiewski WW Efficacy of" exact="zolmitriptan" post="nasal spray in adolescent migraine Pediatrics 2007 120 390"/>
   <result pre="Finlayson G Ishkanian G Lewis DW Efficacy and tolerability of" exact="almotriptan" post="in adolescents: a randomized, double-blind, placebo-controlled trial Headache 2008"/>
   <result pre="Hamalainen ML Eerola M Hoppu K A randomized trial of" exact="rizatriptan" post="in migraine attacks in children Neurology 2006 67 1135"/>
   <result pre="1140 10.1212/01.wnl.0000238179.79888.44 16943370 52. Saper JR Silberstein S Pharmacology of" exact="dihydroergotamine" post="and evidence for efficacy and safety in migraine Headache"/>
   <result pre="double-blind, placebo-controlled study to evaluate the efficacy and safety of" exact="topiramate" post="for migraine prevention in pediatric subjects 12 to 17"/>
   <result pre="Lewis D Paradiso E A double-blind, dose comparison study of" exact="topiramate" post="for prophylaxis of basilar-type migraine in children: a pilot"/>
   <result pre="Hershey AD Powers SW Bentti AL Degrauw TJ Effectiveness of" exact="amitriptyline" post="in the prophylactic management of childhood headaches Headache 2000"/>
   <result pre="Uematsu M Yokoyama H Sato T Tsuchiya S Efficacy of" exact="sumatriptan" post="in two pediatric cases with abdominal pain-related functional gastrointestinal"/>
   <result pre="25 234 237 10.1177/0883073809336875 19509407 107. Kothare SV Efficacy of" exact="flunarizine" post="in the prophylaxis of cyclical vomiting syndrome and abdominal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5515721/results/search/drugs/results.xml">
   <result pre="5515721 pmid: 28721545 776 doi: 10.1186/s10194-017-0776-4 : Research Article Is" exact="topiramate" post="effective for migraine prevention in patients less than 18"/>
   <result pre="assess the currently published data pertaining to the efficacy of" exact="topiramate" post="for migraine prevention in patients less than 18 years"/>
   <result pre="465 patients. Of these patients, 329 were included in the" exact="topiramate" post="group, and 136 were included in the placebo group."/>
   <result pre="the placebo group. This meta-analysis revealed that compared with placebo," exact="topiramate" post="failed to decrease the number of patients experiencing a"/>
   <result pre="Higher rates of side effects and adverse events in the" exact="topiramate" post="group than in the placebo group were observed in"/>
   <result pre="migraines in patients less than 18 years of age, and" exact="topiramate" post="may lead to more side effects or adverse events"/>
   <result pre="United States since 2004 [ 7]. The exact mechanism of" exact="topiramate" post="in the treatment of migraine is unknown, although it"/>
   <result pre="unknown, although it may be associated with the influence of" exact="topiramate" post="on pain transmission in the trigeminocervical complex and the"/>
   <result pre="series and open-label trials [ 9– 13] have shown that" exact="topiramate" post="served as a preventive treatment for pediatric migraines, while"/>
   <result pre="[ 14] indicated that there were no significant differences between" exact="topiramate" post="and placebo in the prevention of pediatric migraine. Hence,"/>
   <result pre="of randomized controlled trials (RCTs) to evaluate the efficacy of" exact="topiramate" post="for the prevention of migraine in patients less than"/>
   <result pre="Library (inception to April 2017) to retrieve the RCTs of" exact="topiramate" post="in migraine prevention for patients less than 18 years"/>
   <result pre="the following criteria: (1) the study was a trial comparing" exact="topiramate" post="with placebo in migraine patients, (2) the study had"/>
   <result pre="a clinical RCT, (5) the intent-to-treat population numbers in the" exact="topiramate" post="and placebo groups were provided, and (6) the number"/>
   <result pre="did not contain placebo (for example, the trial only used" exact="propranolol" post="or sodium valproate as a control), and (5) the"/>
   <result pre="placebo (for example, the trial only used propranolol or sodium" exact="valproate" post="as a control), and (5) the trial involved adults"/>
   <result pre="The main information, including the numbers of participants in the" exact="topiramate" post="and placebo groups, the diagnostic tool, the dose and"/>
   <result pre="total of 465 randomized patients, including 329 patients in the" exact="topiramate" post="group and 136 in the placebo group, and the"/>
   <result pre="[ 21]. One trial [ 18] used 2 doses of" exact="topiramate" post="versus placebo. Another trial [ 14] used amitriptyline and"/>
   <result pre="doses of topiramate versus placebo. Another trial [ 14] used" exact="amitriptyline" post="and topiramate as the two treatment arms, and we"/>
   <result pre="topiramate versus placebo. Another trial [ 14] used amitriptyline and" exact="topiramate" post="as the two treatment arms, and we extracted the"/>
   <result pre="the two treatment arms, and we extracted the results of" exact="topiramate" post="versus placebo. The duration of the included trials consisted"/>
   <result pre="included patients who ended trial early †35 subjects treated with" exact="topiramate" post="at 50 mg/day, 35 subjects treated with topiramate at"/>
   <result pre="treated with topiramate at 50 mg/day, 35 subjects treated with" exact="topiramate" post="at 100 mg/day Risk of bias of the included"/>
   <result pre="Table 2, all 4 included trials investigated the effects of" exact="topiramate" post="on migraine prevention via the numbers of patients experiencing"/>
   <result pre="meta-analysis show that, there were no significant differences between the" exact="topiramate" post="and placebo groups in terms of the numbers of"/>
   <result pre="Forest plot of comparison:≥50% Relative reduction in headache frequency of" exact="topiramate" post="versus placebo Secondary outcomes All 4 trials included in"/>
   <result pre="found no significant difference in mean headache days between the" exact="topiramate" post="and placebo groups ( n = 465, MD = −0.77, 95% CI = [−2.31, 0.76],"/>
   <result pre="Forest plot of comparison: headache days per 28-day period of" exact="topiramate" post="versus placebo Fig. 5 Forest plot of comparison: PedMIDAS"/>
   <result pre="placebo Fig. 5 Forest plot of comparison: PedMIDAS score of" exact="topiramate" post="versus placebo Side effects and adverse events All included"/>
   <result pre="overall incidence of most adverse events was higher in the" exact="topiramate" post="group than in the placebo group, with ten of"/>
   <result pre="suicide attempts and other disabling events) occurring only in the" exact="topiramate" post="group. Detailed side effects and adverse events and their"/>
   <result pre="6b, n = 380, RR = 4.38, 95% CI = [1.92, 10.01], Z = 3.51, P = 0.0005) in the" exact="topiramate" post="group. The evidence collected in our meta-analysis shows no"/>
   <result pre="event aValues expressed as N (%) #Reported only in the" exact="topiramate" post="treatment group Fig. 6 Forest plot of comparison: Side"/>
   <result pre="tract infection, dizziness, fever, nausea, pharyngitis, sinusitis and somnolence) of" exact="topiramate" post="versus placebo(*There was a significant difference between topiramate and"/>
   <result pre="somnolence) of topiramate versus placebo(*There was a significant difference between" exact="topiramate" post="and placebo groups) Publication bias Since our meta-analysis included"/>
   <result pre="not be performed. Discussion This meta-analysis examined the efficacy of" exact="topiramate" post="in comparison with placebo for the prevention of migraines"/>
   <result pre="March 2014, the U.S. Food and Drug Administration (FDA) approved" exact="topiramate" post="for migraine prevention in the population aged 12 to"/>
   <result pre="of reduced mean headache days in a 28-day period showed" exact="topiramate" post="as more efficacious than placebo in our meta-analysis of"/>
   <result pre="meta-analysis of four RCTs. According to the definition [ 22]," exact="topiramate" post="showed no statistically significant benefit over placebo in reducing"/>
   <result pre="treatment period. In fact, the 50% response rate of the" exact="topiramate" post="group in 2 trials [ 14, 20] was not"/>
   <result pre="18] a similar result was presented for the 50 mg/day" exact="topiramate" post="treatment group. The finding conflicts with the outcomes of"/>
   <result pre="is higher than the rates reported in previous studies of" exact="topiramate" post="preventing adult migraine (0–34.2%) [ 28– 31]. Rothner et"/>
   <result pre="adults deserves further discussion. (2) The minimum age at which" exact="topiramate" post="was approved for treatment of migraine was 12 years"/>
   <result pre="meta- analysis. The second finding of our meta-analysis is that" exact="topiramate" post="decreased PedMIDAS scores in migraine patients. PedMIDAS is often"/>
   <result pre="alleviated by topiramate. However, mean PedMIDAS scores in both the" exact="topiramate" post="group and the placebo group decreased between baseline and"/>
   <result pre="the cause of the heterogeneity. As with all antiepileptic drugs," exact="topiramate" post="has many potential side effects or adverse events, some"/>
   <result pre="37]. The rate of adverse events in patients treated with" exact="topiramate" post="was higher than that with placebo in our included"/>
   <result pre="disorder or aphasia, occurred in adults and pediatric patients taking" exact="topiramate" post="in previous trials. Other adverse events, such as changes"/>
   <result pre="secondary closed angle glaucoma, have also been reported. In addition," exact="topiramate" post="(100 mg/day) was related to modest increases in psychomotor"/>
   <result pre="that has been observed in people taking antiepileptic drugs, including" exact="topiramate" post="[ 39]. Thus, while the pathomechanism of migraine is"/>
   <result pre="also be limitations. Conclusions This is the first meta-analysis of" exact="topiramate" post="for migraine prevention in patients less than 18 years"/>
   <result pre="patients less than 18 years of age. We found that" exact="topiramate" post="did not achieve a more effective clinical trial endpoint"/>
   <result pre="migraine in patients less than 18 years of age, and" exact="topiramate" post="was associated with more adverse events in the included"/>
   <result pre="329 330 10.1007/s13312-012-0040-6 22565082 11. Abbaskhanian ASHREAMS Effective dose of" exact="topiramate" post="in pediatric migraine prophylaxis In J Pediatr Neurosci 2012"/>
   <result pre="Divanizadeh MS Karimi M Mirouliaei M Shamszadeh A Topiramate and" exact="propranolol" post="for prophylaxis of migraine Indian J Pediatr 2013 80"/>
   <result pre="Powers SW Vockell ALB LeCates S Kabbouche M Effectiveness of" exact="topiramate" post="in the prevention of childhood headaches Headache 2002 42"/>
   <result pre="double-blind, placebo-controlled study to evaluate the efficacy and safety of" exact="topiramate" post="for migraine prevention in pediatric subjects 12 to 17"/>
   <result pre="Jordan D Karvois D Kamin M Efficacy and tolerability of" exact="topiramate" post="200 mg/d in the prevention of migraine with/without aura"/>
   <result pre="data from two pivotal controlled trials on the efficacy of" exact="topiramate" post="in the prevention of migraine J Am Osteopath Assoc"/>
   <result pre="P Singh S Goyal V Shukla G Behari M Low-dose" exact="topiramate" post="versus lamotrigine in migraine prophylaxis (the Lotolamp study) Headache"/>
   <result pre="S Goyal V Shukla G Behari M Low-dose topiramate versus" exact="lamotrigine" post="in migraine prophylaxis (the Lotolamp study) Headache 2007 47"/>
   <result pre="E Eerdekens M Bilder RM Ford L Cognitive effects of" exact="topiramate" post="in migraine patients aged 12 through 17 years Pediatr"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5532325/results/search/drugs/results.xml">
   <result pre="to identify factors that can predict the treatment response to" exact="topiramate" post="prophylaxis in pediatric patients with migraine. Methods One hundred"/>
   <result pre="thirteen patients who were older than 7 years and received" exact="topiramate" post="for at least 3 months were recruited from the"/>
   <result pre="more than 50% in the number of migraine episodes after" exact="topiramate" post="treatment. Proposed predictive factors such as migraine characteristics including"/>
   <result pre="associated symptoms were not significantly related to a response to" exact="topiramate" post="treatment. Conclusions Migraine characteristics and associated symptoms were not"/>
   <result pre="associated symptoms were not significantly related to a response to" exact="topiramate" post="treatment. However, patients with significant impairment in daily activities"/>
   <result pre="activities showed significant benefit from the treatment, and so prophylactic" exact="topiramate" post="treatment should be strongly encouraged in this patient group."/>
   <result pre="strongly encouraged in this patient group. migraine predictive factor prophylaxis" exact="topiramate" post="INTRODUCTION Headache is one of the most common complaints"/>
   <result pre="require prophylactic medication. 7 Prophylactic treatment usually involves flunarizine, topiramate," exact="valproic acid," post="propranolol, or amitriptyline, and has been shown to be"/>
   <result pre="the predictive factors for a response to prophylactic therapy using" exact="topiramate" post="in pediatric patients. METHODS This study was approved by"/>
   <result pre="to understand and describe their symptoms adequately. Patients who received" exact="topiramate" post="prophylaxis for more than 3 months were included. The"/>
   <result pre="additional medication for migraine prophylaxis within 3 months after starting" exact="topiramate" post="prophylaxis, and 4) a period of discontinuation of topiramate"/>
   <result pre="starting topiramate prophylaxis, and 4) a period of discontinuation of" exact="topiramate" post="prophylaxis within the first 3 months after therapy initiation"/>
   <result pre="to receive prophylaxis were also included. Treatment was started with" exact="topiramate" post="at 1 mg/kg daily as a single dose before"/>
   <result pre="headache frequency of more than 50% compared to baseline. The" exact="topiramate" post="dosage was increased in increments of 50% of the"/>
   <result pre="if the frequency reduction did not reach 50% after receiving" exact="topiramate" post="for 3 months. We considered the following factors as"/>
   <result pre="and 10.3±2.8 years at disease onset, and their duration of" exact="topiramate" post="treatment was 8.3±5.1 months. The duration of disease was"/>
   <result pre="of determining if any of these factors were associated with" exact="topiramate" post="prophylaxis response in pediatric migraine patients. The presence of"/>
   <result pre="family history were not significantly related to a response to" exact="topiramate" post="treatment. The findings of previous studies have been inconsistent."/>
   <result pre="amitriptyline) 22 or were no associated with the response (for" exact="topiramate" post="and flunarizine). 23 24 Most studies have found no"/>
   <result pre="not related to the treatment response in two studies (for" exact="amitriptyline" post="and cinnarizine), 20 22 but one study suggested an"/>
   <result pre="was significantly more common in patients who responded well to" exact="topiramate" post="prophylaxis. However, a previous study of topiramate prophylaxis in"/>
   <result pre="responded well to topiramate prophylaxis. However, a previous study of" exact="topiramate" post="prophylaxis in adults utilizing the Migraine Disability Scale (MIDAS)"/>
   <result pre="results. Based on the findings to date, we suggest that" exact="topiramate" post="prophylaxis should be actively considered in patients even with"/>
   <result pre="attempt to discover predictive factors for a treatment response to" exact="topiramate" post="prophylaxis in pediatric patients. We also included dizziness as"/>
   <result pre="conducted in a single tertiary center targeting patients treated with" exact="topiramate" post="for at least 3 months, which means that the"/>
   <result pre="and associated symptoms were not related to the response to" exact="topiramate" post="treatment. However, impairment of daily activities was more common"/>
   <result pre="common in patients exhibiting good responses. Thus, prophylactic treatment with" exact="topiramate" post="should be actively considered in patients who experience impairment"/>
   <result pre="11292228 8 Bidabadi E Mashouf M A randomized trial of" exact="propranolol" post="versus sodium valproate for the prophylaxis of migraine in"/>
   <result pre="E Mashouf M A randomized trial of propranolol versus sodium" exact="valproate" post="for the prophylaxis of migraine in pediatric patients Paediatr"/>
   <result pre="Hershey AD Powers SW Bentti AL Degrauw TJ Effectiveness of" exact="amitriptyline" post="in the prophylactic management of childhood headaches Headache 2000"/>
   <result pre="Lim BC Chae JH Choi J et al. Comparison of" exact="flunarizine" post="and topiramate for the prophylaxis of pediatric migraines Eur"/>
   <result pre="Chae JH Choi J et al. Comparison of flunarizine and" exact="topiramate" post="for the prophylaxis of pediatric migraines Eur J Paediatr"/>
   <result pre="H Oksel F Erermis S Uyar M et al. Sodium" exact="valproate" post="prophylaxis in childhood migraine Headache 2002 42 819 822"/>
   <result pre="double-blind, placebo-controlled study to evaluate the efficacy and safety of" exact="topiramate" post="for migraine prevention in pediatric subjects 12 to 17"/>
   <result pre="Koch G Wessely P Long-term results of migraine prophylaxis with" exact="flunarizine" post="and beta-blockers Cephalalgia 1991 11 251 256 1790569 22"/>
   <result pre="Franz G Marecek S et al. Two different doses of" exact="amitriptyline" post="ER in the prophylaxis of migraine: long-term results and"/>
   <result pre="prognostic factors in a randomized controlled trial of acupuncture versus" exact="topiramate" post="treatment in patients with chronic migraine Clin J Pain"/>
   <result pre="as predictive factors of the response to migraine prophylaxis using" exact="topiramate" post="Total ( n=113) Responders ( n=70) Nonresponders ( n=43)"/>
   <result pre="Results of ordered logistic regression analysis of predictive factors for" exact="topiramate" post="prophylaxis Factors OR (95% CI) p Headache duration 0.87"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5548702/results/search/drugs/results.xml">
   <result pre="attacks) or to differential effects of gonadal hormones (testosterone versus" exact="estradiol" post="or progesterone) on hippocampal function and brain circuitry ["/>
   <result pre="these play a role in the synthesis and release of" exact="nitric oxide" post="and of neuropeptides; and in the function of receptors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5573746/results/search/drugs/results.xml">
   <result pre="pmcid: 5573746 doi: 10.3345/kjp.2017.60.7.227 : Original Article Effects of low-dose" exact="topiramate" post="on language function in children with migraine Han Seung-A"/>
   <result pre="Purpose This study aimed to verify the safety of low-dose" exact="topiramate" post="on language development in pediatric patients with migraine. Methods"/>
   <result pre="Methods Thirty newly diagnosed pediatric patients with migraine who needed" exact="topiramate" post="were enrolled and assessed twice with standard language tests,"/>
   <result pre="computerized speech laboratory analysis. Data were collected before treatment, and" exact="topiramate" post="as monotherapy was sustained for at least 3 months."/>
   <result pre="months. The mean follow-up period was 4.3±2.7 months. The mean" exact="topiramate" post="dosage was 0.9 mg/kg/day. Results The patient's mean age"/>
   <result pre="parameters of the TOPs were not changed significantly after the" exact="topiramate" post="treatment as follows: Determine cause, from 15.0±4.4 to 15.4±4.8"/>
   <result pre="the patients; however, the number of vocabularies used decreased. Therefore," exact="topiramate" post="should be used cautiously for children with migraine. Child"/>
   <result pre="prescribed for migraine prophylaxis. Among these drugs, antiepileptic drugs, especially" exact="topiramate" post="(TPM), are most frequently prescribed for children and adolescents."/>
   <result pre="Schmidt D Reid S et al. Double-blind, placebo-controlled trial of" exact="topiramate" post="as add-on therapy in patients with refractory partial seizures"/>
   <result pre="Reife R Pledger G et al. Double-blind, placebo-controlled study of" exact="topiramate" post="in patients with refractory partial epilepsy Epilepsy Res 1996"/>
   <result pre="Shorvon S Henriksen O et al. Double-blind, placebo-controlled trial of" exact="topiramate" post="(600 mg daily) for the treatment of refractory partial"/>
   <result pre="Elger CE Helmstaedter C Efficacy and cognitive side effects of" exact="tiagabine" post="and topiramate in patients with epilepsy Epilepsy Behav 2005"/>
   <result pre="Helmstaedter C Efficacy and cognitive side effects of tiagabine and" exact="topiramate" post="in patients with epilepsy Epilepsy Behav 2005 6 373"/>
   <result pre="X Lui S et al. Altered cerebral activity associated with" exact="topiramate" post="and its withdrawal in patients with epilepsy with language"/>
   <result pre="Kim SJ Kim MY Choi YM Song MK Effects of" exact="topiramate" post="on language functions in newly diagnosed pediatric epileptic patients"/>
   <result pre="41 968 975 11903524 18 Brandes JL Practical use of" exact="topiramate" post="for migraine prevention Headache 2005 45 Suppl 1 S66"/>
   <result pre="S Shajari A Fromandi M The efficacy and safety of" exact="topiramate" post="for prophylaxis of migraine in children Iran J Child"/>
   <result pre="F Zakizade N Nasr V Comparison of the effect of" exact="topiramate" post="and sodium valporate in migraine prevention: a randomized blinded"/>
   <result pre="KL Ding M Eberly LE et al. The effect of" exact="topiramate" post="plasma concentration on linguistic behavior, verbal recall and working"/>
   <result pre="T Carmo I et al. Cognitive effects of therapy with" exact="topiramate" post="in patients with refractory partial epilepsy Rev Neurol 2002"/>
   <result pre="Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with" exact="valproate" post="or topiramate Epilepsy Behav 2006 8 606 609 16504593"/>
   <result pre="of patients with juvenile myoclonic epilepsy treated with valproate or" exact="topiramate" post="Epilepsy Behav 2006 8 606 609 16504593 Table 1"/>
   <result pre="45.3±13.6 Values are presented as mean±standard deviation. Pre TPM, before" exact="topiramate" post="treatment; Post TPM, during topiramate treatment. Table 2 The"/>
   <result pre="mean±standard deviation. Pre TPM, before topiramate treatment; Post TPM, during" exact="topiramate" post="treatment. Table 2 The total mean length of utterance"/>
   <result pre="* Values are presented as mean±standard deviation. Pre TPM, before" exact="topiramate" post="treatment; Post TPM, during topiramate treatment. * P&amp;lt;0.05. Table"/>
   <result pre="mean±standard deviation. Pre TPM, before topiramate treatment; Post TPM, during" exact="topiramate" post="treatment. * P&amp;lt;0.05. Table 3 The results of the"/>
   <result pre="1,161.80±484.9 Values are presented as mean±standard deviation. Pre TPM, before" exact="topiramate" post="treatment; Post TPM, during topiramate treatment; F1, formants 1;"/>
   <result pre="mean±standard deviation. Pre TPM, before topiramate treatment; Post TPM, during" exact="topiramate" post="treatment; F1, formants 1; F2, formants 2."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5720689/results/search/drugs/results.xml">
   <result pre="of NSAIDs (aHR: 6.50, 95% CI: 1.81, 23.4, p&amp;lt;0.01) and" exact="acetaminophen" post="(aHR: 4.87, 95% CI: 1.46, 16.3, p&amp;lt;0.01). Although regression"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5745369/results/search/drugs/results.xml">
   <result pre="Laboratory findings in adults include an increase in levels of" exact="nitric oxide," post="CCRP, and urea, low bicarbonate level, electrolyte imbalance, and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5745373/results/search/drugs/results.xml">
   <result pre="have been reported as midline in location and response to" exact="indomethacin" post="is not always universal (as in adults). Finally, some"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5760673/results/search/drugs/results.xml">
   <result pre="present research was to compare the effectiveness and tolerability of" exact="melatonin" post="and amitriptyline in pediatric migraine prevention. Materials &amp;amp; Methods:"/>
   <result pre="was to compare the effectiveness and tolerability of melatonin and" exact="amitriptyline" post="in pediatric migraine prevention. Materials &amp;amp; Methods: In a"/>
   <result pre="Yazd-Iran from 2013-2014, were randomly allocated to receive 1 mg/kg" exact="amitriptyline" post="or 0.3 mg/kg melatonin for three consecutive months. Results:"/>
   <result pre="randomly allocated to receive 1 mg/kg amitriptyline or 0.3 mg/kg" exact="melatonin" post="for three consecutive months. Results: Forty one girls (51.3%)"/>
   <result pre="yr were evaluated. Good response was seen in 82.5% of" exact="amitriptyline" post="and 62%.5 of melatonin groups and amitriptyline was statistically"/>
   <result pre="response was seen in 82.5% of amitriptyline and 62%.5 of" exact="melatonin" post="groups and amitriptyline was statistically significant more effective ("/>
   <result pre="in 82.5% of amitriptyline and 62%.5 of melatonin groups and" exact="amitriptyline" post="was statistically significant more effective ( P=0.04). Severity, duration"/>
   <result pre="Pediatric Migraine Disability Assessment score (PedMIDAS) of headache reduced with" exact="melatonin" post="from 6.05±1.63 to 4.03±1.54 scores, from 2.06±1.18 to 1.41±"/>
   <result pre="scores, respectively. Severity, duration and PedMIDAS of headache decreased with" exact="amitriptyline" post="from 6.41±1.67to 2.25±1.21, from 2.55 ±1.85to 0.56±0.51h, and from"/>
   <result pre="disability of headache. Daily sleepiness was seen in 7.5% of" exact="melatonin" post="group as a side effect and adverse events were"/>
   <result pre="side effect and adverse events were seen in 22.5% of" exact="amitriptyline" post="group including daily sleepiness in four, constipation in three"/>
   <result pre="four, constipation in three and fatigue in two children and" exact="melatonin" post="was safer than amitriptyline (value = 0.04). Conclusion: Amitriptyline"/>
   <result pre="and fatigue in two children and melatonin was safer than" exact="amitriptyline" post="(value = 0.04). Conclusion: Amitriptyline and melatonin are effective"/>
   <result pre="was safer than amitriptyline (value = 0.04). Conclusion: Amitriptyline and" exact="melatonin" post="are effective and safe in pediatric migraine prophylaxis but"/>
   <result pre="melatonin are effective and safe in pediatric migraine prophylaxis but" exact="amitriptyline" post="can be considered as a more effective drug. Key"/>
   <result pre="guideline for migraine prevention in children does not exist and" exact="flunarizine" post="and recently topiramate have been approved by Food and"/>
   <result pre="prevention in children does not exist and flunarizine and recently" exact="topiramate" post="have been approved by Food and Drug Administration in"/>
   <result pre="is the most common migraine preventive drug in children, but" exact="amitriptyline" post="should not be used in children with rapid or"/>
   <result pre="compound which is mainly produced in the pineal gland from" exact="tryptophan" post="amino acid and secreted into the blood and cerebrospinal"/>
   <result pre="modulation of the circadian rhythm of sleep .The level of" exact="melatonin" post="might be decreased in migraine headaches and it may"/>
   <result pre="effective drug in treatment of migraine headaches. Possible mechanisms of" exact="melatonin" post="in treatment of headache might be related to its"/>
   <result pre="toxic free radical scavenging effects, decrease of pro-inflammatory cytokine upregulation," exact="nitric oxide" post="synthase activity and inhibition of dopamine release, stabilizing of"/>
   <result pre="pro-inflammatory cytokine upregulation, nitric oxide synthase activity and inhibition of" exact="dopamine" post="release, stabilizing of membrane, glutamate neurotoxicity protection and neurovascular"/>
   <result pre="protection and neurovascular regulation&quot; ( 5). Effectiveness of three-milligram oral" exact="melatonin" post="at bedtime in 14 children with recurrent migraine headache,"/>
   <result pre="We aimed to test the hypothesis that whether or not" exact="melatonin" post="was superior to amitriptyline for migraine prophylaxis in 5-15"/>
   <result pre="the hypothesis that whether or not melatonin was superior to" exact="amitriptyline" post="for migraine prophylaxis in 5-15 yr-old children suffer frequent"/>
   <result pre="Clinic. We wanted to compare the effectiveness and tolerability of" exact="amitriptyline" post="and melatonin for pediatric migraine prevention. Materials and Methods"/>
   <result pre="wanted to compare the effectiveness and tolerability of amitriptyline and" exact="melatonin" post="for pediatric migraine prevention. Materials and Methods In a"/>
   <result pre="single-blind clinical, open-label, parallel group study, effectiveness and tolerability of" exact="amitriptyline" post="and melatonin for migraine prophylaxis in 5-15 yr old"/>
   <result pre="open-label, parallel group study, effectiveness and tolerability of amitriptyline and" exact="melatonin" post="for migraine prophylaxis in 5-15 yr old children who"/>
   <result pre="monthly headache frequency during the follow-up period) of 70% for" exact="melatonin" post="in pilot study ( 5) and an effect size"/>
   <result pre="were randomly allocated to two groups to receive 0.3 mg/kg" exact="melatonin" post="(maximum 6 mg) or 1mg/kg/day amitriptyline (maximum 50 mg)"/>
   <result pre="to receive 0.3 mg/kg melatonin (maximum 6 mg) or 1mg/kg/day" exact="amitriptyline" post="(maximum 50 mg) for 90 consecutive days. In both"/>
   <result pre="traditional medicine during the follow up period. Measurement equipment of" exact="amitriptyline" post="and melatonin blood level were not accessible in our"/>
   <result pre="during the follow up period. Measurement equipment of amitriptyline and" exact="melatonin" post="blood level were not accessible in our center. Safety"/>
   <result pre="The participants were allowed to use nonsteroidal anti-inflammatory analgesics (" exact="acetaminophen" post="or ibuprofen) for alleviation of moderate to severe headache"/>
   <result pre="P values of less than 0.05. Results Three children in" exact="melatonin" post="group and four patients in amitriptyline group loosed to"/>
   <result pre="Results Three children in melatonin group and four patients in" exact="amitriptyline" post="group loosed to follows: up and two patients in"/>
   <result pre="amitriptyline group loosed to follows: up and two patients in" exact="melatonin" post="group and two in amitriptyline discontinued drug usage during"/>
   <result pre="up and two patients in melatonin group and two in" exact="amitriptyline" post="discontinued drug usage during follow up period. Finally, 41girls"/>
   <result pre="monthly headache frequency) was seen in 25 patients (62.5%) of" exact="melatonin" post="(95% confidence interval: 0.45–0.71) and in 33 (82.5%) of"/>
   <result pre="melatonin (95% confidence interval: 0.45–0.71) and in 33 (82.5%) of" exact="amitriptyline" post="group (95% confidence interval: 0.75 –0.93) and amitriptyline was"/>
   <result pre="(82.5%) of amitriptyline group (95% confidence interval: 0.75 –0.93) and" exact="amitriptyline" post="was statistically significantly more effective ( P=0.04). Comparison of"/>
   <result pre="P=0.04). Comparison of headache characteristics before and after treatment in" exact="melatonin" post="and amitriptyline groups is presented in Table 2 and"/>
   <result pre="of headache characteristics before and after treatment in melatonin and" exact="amitriptyline" post="groups is presented in Table 2 and Table 3"/>
   <result pre="after treatment, which indicates that amitriptyline, was more effective than" exact="melatonin" post="in reduction of monthly frequency, severity, duration and disability"/>
   <result pre="number of analgesic usage was not statistically significant different in" exact="melatonin" post="and amitriptyline groups. Daily sleepiness, as a side effect,"/>
   <result pre="analgesic usage was not statistically significant different in melatonin and" exact="amitriptyline" post="groups. Daily sleepiness, as a side effect, was seen"/>
   <result pre="as a side effect, was seen in 7.5% (N=3) of" exact="melatonin" post="group. In 22.5% (N=9) of amitriptyline group, adverse events"/>
   <result pre="in 7.5% (N=3) of melatonin group. In 22.5% (N=9) of" exact="amitriptyline" post="group, adverse events were seen including daily sleepiness in"/>
   <result pre="in two children. The adverse events were more frequent in" exact="amitriptyline" post="group (value = 0.04). Excessive daytime sleepiness as a"/>
   <result pre="pediatric population. In the present research, effectiveness and tolerability of" exact="amitriptyline" post="and melatonin for pediatric migraine prophylaxis in 5-15 yr"/>
   <result pre="In the present research, effectiveness and tolerability of amitriptyline and" exact="melatonin" post="for pediatric migraine prophylaxis in 5-15 yr old children"/>
   <result pre="compared. The results showed that both drugs were effective, but" exact="amitriptyline" post="was more effective and melatonin was safer than amitriptyline."/>
   <result pre="both drugs were effective, but amitriptyline was more effective and" exact="melatonin" post="was safer than amitriptyline. Table 1 Comparison of some"/>
   <result pre="2 Comparison of headache characteristics before and after treatment in" exact="melatonin" post="group Group Before treatment (mean ±SD) After treatment (mean"/>
   <result pre="3 Comparison of headache characteristics before and after treatment in" exact="amitriptyline" post="group Group Before treatment (mean ±SD) After treatment (mean"/>
   <result pre="0.5 Independent t-test In 18-65 yr old migraineurs in Brazil," exact="melatonin" post="and amitriptyline in comparison with placebo-decreased frequency of migraine"/>
   <result pre="t-test In 18-65 yr old migraineurs in Brazil, melatonin and" exact="amitriptyline" post="in comparison with placebo-decreased frequency of migraine headache and"/>
   <result pre="comparison with placebo-decreased frequency of migraine headache and tolerability of" exact="melatonin" post="was more than amitriptyline ( 11). Effectiveness of melatonin"/>
   <result pre="of migraine headache and tolerability of melatonin was more than" exact="amitriptyline" post="( 11). Effectiveness of melatonin in reduction of monthly"/>
   <result pre="of melatonin was more than amitriptyline ( 11). Effectiveness of" exact="melatonin" post="in reduction of monthly frequency, severity, duration and disability"/>
   <result pre="monthly headache frequency was seen in 62.5% of children in" exact="melatonin" post="group. However, the rate of good response had been"/>
   <result pre="and excessive sleep can both cause migraine ( 12) and" exact="melatonin" post="irregular production has some links to sleep disorders, linked"/>
   <result pre="headache might cause sleeplessness and daytime drowsiness and effectiveness of" exact="melatonin" post="in control of migraine headache might be related to"/>
   <result pre="of sleep circadian rhythm ( 13). In the present study," exact="melatonin" post="was tolerated well and no life-threatening clinical side effects"/>
   <result pre="clinical side effects were seen in kids and safety of" exact="melatonin" post="similar to other researches ( 6, 14, 15). The"/>
   <result pre="16, 17). In the present research, 82.5% of patients in" exact="amitriptyline" post="group showed good response. Positive response rate for amitriptyline"/>
   <result pre="in amitriptyline group showed good response. Positive response rate for" exact="amitriptyline" post="was also 89% in Lewis et al. study ("/>
   <result pre="et al study in adults ( 20). In Dhaka, Bangladesh," exact="amitriptyline" post="was effective and with minimal side effects in prevention"/>
   <result pre="in prevention of migraine ( 21). However, in the USA," exact="amitriptyline" post="was more effective than placebo in prevention of migraine"/>
   <result pre="weeks ( 22). In this study, 22.5% of children in" exact="amitriptyline" post="group showed side effects such as daily sleepiness, constipation,"/>
   <result pre="as daily sleepiness, constipation, malaise, and majority of them tolerated" exact="amitriptyline" post="well and without life- threatening side effects. However, other"/>
   <result pre="techniques. In infants and younger kids who cannot swallow tablets," exact="cyproheptadine" post="might be superior. Amitriptyline as one of tricyclic antidepressants"/>
   <result pre="side effects. In comorbid situations such as migraine and depression," exact="amitriptyline" post="might be more beneficial and abundance of amitriptyline adverse"/>
   <result pre="and depression, amitriptyline might be more beneficial and abundance of" exact="amitriptyline" post="adverse events such as sleepiness can be decreased by"/>
   <result pre="research can be viewed as promising for it showed that" exact="amitriptyline" post="and melatonin are effective and without life-threatening adverse events"/>
   <result pre="be viewed as promising for it showed that amitriptyline and" exact="melatonin" post="are effective and without life-threatening adverse events in pediatric"/>
   <result pre="and without life-threatening adverse events in pediatric migraine prophylaxis but" exact="amitriptyline" post="was superior to melatonin and melatonin was tolerated better."/>
   <result pre="events in pediatric migraine prophylaxis but amitriptyline was superior to" exact="melatonin" post="and melatonin was tolerated better. Acknowledgment This study was"/>
   <result pre="pediatric migraine prophylaxis but amitriptyline was superior to melatonin and" exact="melatonin" post="was tolerated better. Acknowledgment This study was funded by"/>
   <result pre="Fallah R Shoroki FF Ferdosian F Safety and efficacy of" exact="melatonin" post="in pediatric migraine prophylaxis Curr Drug Saf 2015 10"/>
   <result pre="Divanizadeh MS Karimi M Mirouliaei M Shamszadeh A Topiramate and" exact="propranolol" post="for prophylaxis of migraine Indian J Pediatr 2013 80"/>
   <result pre="M Gonçalves A Double-blind, placebo controlled, randomized clinical trial comparing" exact="melatonin" post="3 mg, amitriptyline 25 mg and placebo for migraine"/>
   <result pre="Double-blind, placebo controlled, randomized clinical trial comparing melatonin 3 mg," exact="amitriptyline" post="25 mg and placebo for migraine prevention Neurology February"/>
   <result pre="15 Sánchez-Barceló EJ Mediavilla MD Reiter RJ Clinical uses of" exact="melatonin" post="in pediatrics Int J Pediatr 2011 2011 892624 21760817"/>
   <result pre="Hershey AD Powers SW Bentti AL Degrauw TJ Effectiveness of" exact="amitriptyline" post="in the prophylactic management of childhood headaches Headache 2000"/>
   <result pre="MA Alam MN Miah AH Uddin MS Efficacy of amitriptyline," exact="pizotifen" post="and propranolol in the prevention of migraine Mymensingh Med"/>
   <result pre="MN Miah AH Uddin MS Efficacy of amitriptyline, pizotifen and" exact="propranolol" post="in the prevention of migraine Mymensingh Med J 2013"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5770345/results/search/drugs/results.xml">
   <result pre="greater occipital nerve injections performed unilaterally with 30 mg 1%" exact="lidocaine" post="and 40 mg methylprednisolone, to treat disabling headache disorders"/>
   <result pre="were always performed unilaterally and consisted of 30 mg 1%" exact="lidocaine" post="and 40 mg methylprednisolone acetate. The clinician palpated over"/>
   <result pre="and consisted of 30 mg 1% lidocaine and 40 mg" exact="methylprednisolone" post="acetate. The clinician palpated over the greater occipital nerves"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5820821/results/search/drugs/results.xml">
   <result pre=": Letters Cinema-like sensory phenomena in a migraine patient on" exact="topiramate" post="Tandon R Verma SK [], rtlib161080@gmail.com ppub: 2018 64"/>
   <result pre="antiepileptic used for migraine prophylaxis. Several side effects may follow" exact="topiramate" post="use such as auditory and visual sensory phenomena.[ 1"/>
   <result pre="sleep. He took one or two analgesics/month and was on" exact="propranolol" post="and antianxiety medications with no relief. During the past"/>
   <result pre="no significant change in headache frequency and intensity, dose of" exact="amitriptyline" post="was increased to 25 mg; and subsequently 25 mg"/>
   <result pre="amitriptyline was increased to 25 mg; and subsequently 25 mg" exact="topiramate" post="daily was added. After 1 month, he experienced headache"/>
   <result pre="being run at fast mode. Due to these sensory phenomena," exact="topiramate" post="was stopped and 10 mg of flunarizine daily was"/>
   <result pre="these sensory phenomena, topiramate was stopped and 10 mg of" exact="flunarizine" post="daily was prescribed. Amitryptyline was, however, continued. His hematological"/>
   <result pre="missed school due to difficulty in concentrating. Two months following" exact="topiramate" post="withdrawal, these so called &quot;cinema-like sensory phenomena&quot; disappeared completely."/>
   <result pre="3] Change in serotonergic activity can cause palinopsia and combining" exact="amitriptyline" post="with topiramate may have lead to this phenomena or"/>
   <result pre="in serotonergic activity can cause palinopsia and combining amitriptyline with" exact="topiramate" post="may have lead to this phenomena or it is"/>
   <result pre="this phenomena or it is possible that cumulative doses of" exact="topiramate" post="after daily administration may have been the possible etiology.["/>
   <result pre="seems to be a need for greater vigilance while prescribing" exact="topiramate" post="for migraine prophylaxis and monitoring patients, especially pediatric and"/>
   <result pre="E Gilliam F Kuzniecky R Acute psychotic symptoms induced by" exact="topiramate" post="Seizure 1999 8 235 7 10452922 2 Jurgens TP"/>
   <result pre="Stork JH May A &quot;Alice in Wonderland syndrome&quot; associated with" exact="topiramate" post="for migraine prevention J Neurol Neurosurg Psychiatry 2011 82"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5836048/results/search/drugs/results.xml">
   <result pre="most case reports; however, some reports suggested efficacy of sodium" exact="valproate" post="and prochloroperazine as treatment modalities for acute confusional state"/>
   <result pre="confusional state [ 12, 19, 21, 22]. Prophylactic treatment with" exact="topiramate" post="seems to be effective in the treatment of recurrent"/>
   <result pre="effective in the treatment of recurrent ACM [ 24]. Recently," exact="propofol" post="was given to a patient who developed confusion and"/>
   <result pre="were often used. Migraine specific treatments such as triptans and" exact="ergotamine" post="or nonspecific treatments such as dopaminergic antagonist [ 21]"/>
   <result pre="Shibasaki K. Takahashi N. Takahashi M. The efficacy of sodium" exact="valproate" post="and a MRA finding in confusional migraine Brain Dev."/>
   <result pre="N. Acute confusional migraine in an adolescent: Response to intravenous" exact="valproate" post="Pediatrics 2010 125 e956 e959 10.1542/peds.2009-2717 20211950 23. Gantenbein"/>
   <result pre="D. &quot;Possessed&quot;: Acute confusional migraine in an adolescent, prevented by" exact="topiramate" post="Case Rep. Neurol. 2012 4 240 243 10.1159/000346208 23341814"/>
   <result pre="Sato K. Hida A. Arai N. Takeuchi S. Low-dose intravenous" exact="propofol" post="as a possible therapeutic option for acute confusional migraine"/>
   <result pre="16450381 60. Andreou A.P. Shields K.G. Goadsby P.J. GABA and" exact="valproate" post="modulate trigeminovascular nociceptive transmission in the thalamus Neurobiol. Dis."/>
   <result pre="memory disturbances (80%) Pre- (4), post-confusion (1) 0.5–24 h Ergotamine," exact="methysergide" post="Over brief period of time all patients had recurrent"/>
   <result pre="episodes Attacks were controlled after increasing the dose of sodium" exact="valproate" post="Sathe S. et al. [ 20] 7 5:2 42–58"/>
   <result pre="less agitation No further episodes of confusion and headache after" exact="topiramate" post="Pacheva I. and Ivanov I. [ 25, 26] 3"/>
   <result pre="and memory disturbances (67%) Pre-confusion (3) 8–10 h Diazepam and" exact="phenobarbital" post="None Two patients had 1–2 episodes of migraine without"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5844943/results/search/drugs/results.xml">
   <result pre="subcortical areas ( 5, 11). Moreover, some neurotransmitters, such as" exact="dopamine" post="and noradrenaline, mediate an important role in attention, working"/>
   <result pre="A Jagust W D’Esposito M . Working memory capacity predicts" exact="dopamine" post="synthesis capacity in the human striatum. J Neurosci ("/>
   <result pre="Laine M Någren K Rinne JO . Frontal and temporal" exact="dopamine" post="release during working memory and attention tasks in healthy"/>
   <result pre="healthy humans: a positron emission tomography study using the high-affinity" exact="dopamine" post="D2 receptor ligand [11C]FLB 457 . J Neurosci ("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5878019/results/search/drugs/results.xml">
   <result pre="5878019 doi: 10.19082/6279 epj-10-6279 : Original Article Prophylactic effect of" exact="riboflavin" post="on pediatric migraine: a randomized, double-blind, placebo-controlled trial Talebian"/>
   <result pre="study was carried out to determine the prophylactic effect of" exact="riboflavin" post="on migraine in children. Methods This randomized clinical trial"/>
   <result pre="to the placebo group (p=0.71 and p=0.74 respectively). Conclusion High-dose" exact="riboflavin" post="is a safe, well tolerated, cost-effective method of prophylaxis"/>
   <result pre="for them ( 1, 4, 5). Despite the use of" exact="topiramate" post="as a prophylactic agent for migraine, some studies have"/>
   <result pre="phosphorylation dysfunction in adults with migraine. So, supraphysiological doses of" exact="riboflavin" post="could be beneficial for this impairment ( 13).There are"/>
   <result pre="13).There are some studies that suggest the efficacy of high-dose" exact="riboflavin" post="(400 mg/day) for migraine prevention in adults ( 14–"/>
   <result pre="adults ( 14– 16), and doses of 100–400 mg/day of" exact="riboflavin" post="in children are concordant with adult studies ( 1,"/>
   <result pre="adult studies ( 1, 12). There is limited evidence for" exact="riboflavin" post="use among children ( 1). A randomized, placebo-controlled trial"/>
   <result pre="1). A randomized, placebo-controlled trial showed no effect of high-dose" exact="riboflavin" post="on migraine prophylaxis in children ( 13, 17). Another"/>
   <result pre="in Italy indicated decrease of migraine frequency and intensity by" exact="riboflavin" post="( 1). The side-effects of riboflavin have been shown"/>
   <result pre="frequency and intensity by riboflavin ( 1). The side-effects of" exact="riboflavin" post="have been shown as minimal, including diarrhea and polyuria"/>
   <result pre="of 43 adults). The most common harmless adverse effect of" exact="riboflavin" post="is yellow to orange color change of the urine"/>
   <result pre="( 13). Due to substantial controversy about the effectiveness of" exact="riboflavin" post="in children with migraine and a few side effects"/>
   <result pre="to determine the effect of low dose and high dose" exact="riboflavin" post="on intensity, duration and frequency of migraine 2. Material"/>
   <result pre="randomized to either receive a capsule of placebo, 100 mg" exact="riboflavin" post="(low-dose) or 200 mg riboflavin (high-dose) daily for 12"/>
   <result pre="capsule of placebo, 100 mg riboflavin (low-dose) or 200 mg" exact="riboflavin" post="(high-dose) daily for 12 weeks. No other prophylactic drugs"/>
   <result pre="drugs were similar according to their shape and taste. Both" exact="riboflavin" post="and carotene make yellow/orange urine discoloration. So, to assure"/>
   <result pre="data concerning childhood migraine ( 3) and the patients consumed" exact="acetaminophen" post="or ibuprofen orally during attacks. 2.3. Outcomes Severity (intensity)"/>
   <result pre="childhood migraine ( 3) and the patients consumed acetaminophen or" exact="ibuprofen" post="orally during attacks. 2.3. Outcomes Severity (intensity) of attacks"/>
   <result pre="two times, the first at the month before starting of" exact="riboflavin" post="(baseline or week 0) and the second at the"/>
   <result pre="week 0) and the second at the last month of" exact="riboflavin" post="prophylaxis (week 8 to 12 or in other word"/>
   <result pre="in two stages (baseline period and the last month of" exact="riboflavin" post="prophylaxis) of study including date, intensity and duration of"/>
   <result pre="in phase 2 compared to baseline (21.7±13.7 vs. 13.2±11.8) in" exact="riboflavin" post="group, α =0.05 and power equaled 0.8 ( 1)."/>
   <result pre="categorical data were shown by frequency and percentage. Comparison of" exact="riboflavin" post="effect between groups on attack frequency and intensity was"/>
   <result pre="on duration of headaches was conducted by independent-samples t-test. The" exact="riboflavin" post="effect on three headache items in each group was"/>
   <result pre="were randomly and equally allocated in each group (placebo, low-dose" exact="riboflavin" post="and high-dose riboflavin). Because the study had incorporated an"/>
   <result pre="intensity of migraine attacks at baseline and the end of" exact="riboflavin" post="prophylaxis and mean decrease of them (baseline - end)"/>
   <result pre="the last month of prophylaxis between the placebo and low-dose" exact="riboflavin" post="groups (0.30±1.12 vs. 0.17±1.49) (p=0.69). Meanwhile, there was a"/>
   <result pre="during the study. 4. Discussion The present study showed that" exact="riboflavin" post="prophylaxis significantly reduces migraine duration and frequency, but not"/>
   <result pre="probable cause of frequency reduction may be due to high-dose" exact="riboflavin" post="use in both studies. During an investigation on 48"/>
   <result pre="studies. During an investigation on 48 Australian children, 200 mg/day" exact="riboflavin" post="was not effective on frequency and severity of migraine"/>
   <result pre="1). This is incongruent with our research, because we used" exact="riboflavin" post="for three months. During a trial in the Netherlands"/>
   <result pre="in the Netherlands on 6 to 13-year-old children, 50 mg/day" exact="riboflavin" post="was prescribed for four months and no significant difference"/>
   <result pre="no significant difference in mean duration, frequency and intensity between" exact="riboflavin" post="and placebo groups was found ( 13). These findings"/>
   <result pre="frequency (15 or more attacks per month is indicative of" exact="riboflavin" post="resistance) was chosen as exclusion criterion and also, low-dose"/>
   <result pre="riboflavin resistance) was chosen as exclusion criterion and also, low-dose" exact="riboflavin" post="was used ( 13). The upper limit of eight"/>
   <result pre="headache frequency in our study. Condo et al. showed that" exact="riboflavin" post="prophylaxis reduced migraine intensity and frequency, and this is"/>
   <result pre="may have influence on riboflavin’s effect, probably due to various" exact="riboflavin" post="serum levels and pharmacokinetics ( 20). These findings are"/>
   <result pre="indicate no relationship between age and sex and effect of" exact="riboflavin" post="treatment on migraine intensity and frequency. Some adult studies"/>
   <result pre="migraine intensity and frequency. Some adult studies have suggested that" exact="riboflavin" post="prophylaxis diminishes migraine frequency but not migraine intensity, and"/>
   <result pre="Bruijn et al., cross-over design was performed for placebo and" exact="riboflavin" post="(50 mg daily) groups. Nevertheless, no effect was reported"/>
   <result pre="(mtDNA) respond better than those with haplogroup H mtDNA to" exact="riboflavin" post="therapy ( 21). In the present study, no riboflavin"/>
   <result pre="to riboflavin therapy ( 21). In the present study, no" exact="riboflavin" post="side-effects were reported which was consistent with other investigations"/>
   <result pre="was consistent with other investigations ( 1, 17). Half-life of" exact="riboflavin" post="is about 1 to 2 hours and its absorption"/>
   <result pre="to reach saturation rate at 30–50 mg ( 22). So," exact="riboflavin" post="dose between 100 to 400 mg daily in children"/>
   <result pre="during the study were negligible. 4- Two appropriate doses of" exact="riboflavin" post="were compared with the placebo group. To be noted,"/>
   <result pre="riboflavin were compared with the placebo group. To be noted," exact="riboflavin" post="is a low-cost drug without side-effects, so its use"/>
   <result pre="limitations of our investigation include the following: 1- Duration of" exact="riboflavin" post="prophylaxis was 3 months, whereas the minimum duration is"/>
   <result pre="for groups. 6. Conclusions The present study indicates that high-dose" exact="riboflavin" post="decreases the frequency and duration of migraine attacks in"/>
   <result pre="instead of other medications. It is recommended that high dose" exact="riboflavin" post="be used for migraine prophylaxis among children. Further studies"/>
   <result pre="Further studies with larger sample sizes and longer duration of" exact="riboflavin" post="treatment with cross-over design will be helpful in the"/>
   <result pre="Hosseini SA Samiei M et al. Efficacy and safety of" exact="cinnarizine" post="in the prophylaxis of migraine in children: a double-blind"/>
   <result pre="33 10.1055/s-0032-1333435 23315555 11 Sherwood M Goldman RD Effectiveness of" exact="riboflavin" post="in pediatric migraine prevention Can Fam Physician 2014 60"/>
   <result pre="H Passchier J Locher H Dijkstra N Arts WF Medium-dose" exact="riboflavin" post="as a prophylactic agent in children with migraine: a"/>
   <result pre="U Flach U Schuh-Hofer S Einhaupl KM Arnold G High-dose" exact="riboflavin" post="treatment is efficacious in migraine prophylaxis: an open study"/>
   <result pre="16 Schoenen J Jacquy J Lenaerts M Effectiveness of high-dose" exact="riboflavin" post="in migraine prophylaxis. A randomized controlled trial Neurology 1998"/>
   <result pre="FM Forrest KM Ratanayake PD Fagan E Antony J High-dose" exact="riboflavin" post="for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled"/>
   <result pre="et al. Mitochondrial DNA haplogroups influence the therapeutic response to" exact="riboflavin" post="in migraineurs Neurology 2009 72 18 1588 94 10.1212/WNL.0b013e3181a41269"/>
   <result pre="Galloway JR McCormick DB Pharmacokinetics of orally and intravenously administered" exact="riboflavin" post="in healthy humans Am J Clin Nutr 1996 63"/>
   <result pre="Baseline characteristics of the study groups Characteristics Placebo (n=30) Low-dose" exact="riboflavin" post="(n=30) High-dose riboflavin (n=30) p-value Age in years (mean"/>
   <result pre="the study groups Characteristics Placebo (n=30) Low-dose riboflavin (n=30) High-dose" exact="riboflavin" post="(n=30) p-value Age in years (mean ± SD) 7.90±2.19"/>
   <result pre="and intensity of migraine attacks at baseline and end of" exact="riboflavin" post="prophylaxis and mean decrease of them in each group"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5923275/results/search/drugs/results.xml">
   <result pre="inflammatory neuropeptides and neurotrasmitters including catecholamine gene-related peptide, substance-P, serotonin," exact="adenosine" post="diphosphate, platelet activating factor, nitric oxide resulting in migraine"/>
   <result pre="catecholamine gene-related peptide, substance-P, serotonin, adenosine diphosphate, platelet activating factor," exact="nitric oxide" post="resulting in migraine headache. A similar mechanism involving increased"/>
   <result pre="have been found to be effective for abortive therapy. Intranasal" exact="sumatriptan" post="therapy has been studied in patients with AM. 66"/>
   <result pre="conducted on patients with AM. The efficacy of NSAIDs and" exact="acetaminophen" post="needs to be studied with well-designed randomized control trials."/>
   <result pre="due to similarities in their pathogenesis. Scicchitano et al recommend" exact="propranolol" post="as the first-line choice of drug therapy when non-pharmaceutical"/>
   <result pre="interventions fail. Cyproheptadine is recommended as the second-line agent when" exact="propranolol" post="is ineffective or contraindicated. 61 Conclusion AM is a"/>
   <result pre="Peebles R Shaw RJ Abdominal migraine and treatment with intravenous" exact="valproic acid" post="Psychosomatics 2006 47 4 353 355 16844896 41 Jones"/>
   <result pre="MW Roberts RC Colvin W Reduced platelet phenolsulphotransferase activity towards" exact="dopamine" post="and 5-hydroxytryptamine in migraine Eur J Clin Pharmacol 1995"/>
   <result pre="Kakisaka Y Wakusawa K Haginoya K et al. Efficacy of" exact="sumatriptan" post="in two pediatric cases with abdominal pain-related functional gastrointestinal"/>
   <result pre="30 9 837 844 27503180 68 Kothare SV Efficacy of" exact="flunarizine" post="in the prophylaxis of cyclical vomiting syndrome and abdominal"/>
   <result pre="Symon DN Russell G Double blind placebo controlled trial of" exact="pizotifen" post="syrup in the treatment of abdominal migraine Arch Dis"/>
   <result pre=" Avoidance of triggers  Modified diet  Psychotherapy Pharmacotherapy  Abortive therapy   Intranasal" exact="sumatriptan" post="  IV valproate  Prophylactic therapies   Beta blocker: propranolol   5-HT antagonists:"/>
   <result pre="triggers  Modified diet  Psychotherapy Pharmacotherapy  Abortive therapy   Intranasal sumatriptan   IV" exact="valproate" post=" Prophylactic therapies   Beta blocker: propranolol   5-HT antagonists: cyproheptadine   Calcium"/>
   <result pre=" Abortive therapy   Intranasal sumatriptan   IV valproate  Prophylactic therapies   Beta blocker:" exact="propranolol" post="  5-HT antagonists: cyproheptadine   Calcium channel blockers: flunarizine   5-HT agonist"/>
   <result pre="sumatriptan   IV valproate  Prophylactic therapies   Beta blocker: propranolol   5-HT antagonists:" exact="cyproheptadine" post="  Calcium channel blockers: flunarizine   5-HT agonist with antihistamine properties:"/>
   <result pre="therapies   Beta blocker: propranolol   5-HT antagonists: cyproheptadine   Calcium channel blockers:" exact="flunarizine" post="  5-HT agonist with antihistamine properties: pizotifen Abbreviations: IV, intravenous;"/>
   <result pre="cyproheptadine   Calcium channel blockers: flunarizine   5-HT agonist with antihistamine properties:" exact="pizotifen" post="Abbreviations: IV, intravenous; HT, hydroxytryptamine. Table 6 Abortive and"/>
   <result pre="action Type of study Participants Interventions Results Abortive therapy with" exact="sumatriptan" post="(Kakisaka et al) 66 Serotonin/5-hydroxytryptophan agonist (5-HT ID) Case"/>
   <result pre="ID) Case report (2010) 1 child with abdominal migraine Intranasal" exact="sumatriptan" post="for acute attack of abdominal pain Complete resolution of"/>
   <result pre="abdominal pain Complete resolution of pain Abortive therapy with IV" exact="valproate" post="(Tan et al) 40 GABA agonist Case report (2006)"/>
   <result pre="agonist Case report (2006) 2 children with abdominal migraine IV" exact="valproate" post="Symptomatic relief Prophylactic therapy with cyproheptadine (Madani et al)"/>
   <result pre="with abdominal migraine IV valproate Symptomatic relief Prophylactic therapy with" exact="cyproheptadine" post="(Madani et al) 70 First-generation antihistamine with anti-serotoninergic and"/>
   <result pre="72% of patients with improvement in symptoms Prophylactic therapy with" exact="flunarizine" post="(Kothare) 68 Calcium channel blocker Clinical trial (2005) 8"/>
   <result pre="in frequency and 51% reduction in duration Prophylactic therapy with" exact="propranolol" post="vs cyproheptadine (Worawattanakul et al) 62 Propranolol – beta"/>
   <result pre="and 51% reduction in duration Prophylactic therapy with propranolol vs" exact="cyproheptadine" post="(Worawattanakul et al) 62 Propranolol – beta blocker Cyproheptadine"/>
   <result pre="with cyproheptadine; 24 treated with propranolol) Cyproheptadine 0.25–0.5 mg/kg/day of" exact="propranolol" post="10–20 mg BID–TID 33% complete resolution, 50% fair response,"/>
   <result pre="response, 8% fair response, 17% no response Prophylactic therapy with" exact="pizotifen" post="syrup (Symon and Russell) 69 Serotonin antagonist (5-HT 2A"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5954057/results/search/drugs/results.xml">
   <result pre="patients with IBS. Its proven efficacy is due to its" exact="menthol" post="component, which blocks Ca 2+ channels, possibly reducing colonic"/>
   <result pre="Episodes of abdominal pain were significantly reduced in children receiving" exact="drotaverine" post="compared with those receiving placebo; the authors reported no"/>
   <result pre="results for pain severity. Mebeverine is a beta-phenylethylamine derivative of" exact="reserpine" post="that has relatively specific action on smooth muscle cells"/>
   <result pre="[ 52] reported a significant benefit from the use of" exact="trimebutine" post="in children with IBS, but results were assessed by"/>
   <result pre="52]. The only other study to report the use of" exact="trimebutine" post="in children was that by Giannetti et al. ["/>
   <result pre="al. [ 53], but the number of patients treated with" exact="trimebutine" post="was too low, and the study itself did not"/>
   <result pre="efficacious in adults with IBS and FD. In low doses," exact="amitriptyline" post="is believed to work primarily by inducing pain tolerance"/>
   <result pre="and 3 weeks after treatment, significantly more children in the" exact="amitriptyline" post="group reported at least a 15% improvement in QOL"/>
   <result pre="of the trial, there was no significative difference between the" exact="amitriptyline" post="and placebo groups, both in results and in adverse"/>
   <result pre="results and in adverse effects. Thus, the therapeutic effects of" exact="amitriptyline" post="demonstrated in adults are not confirmed in children. The"/>
   <result pre="effectiveness (84% of the patients were classified as responders), so" exact="citalopram" post="was considered a promising treatment for pediatric FAPD ["/>
   <result pre="migraine. Sadeghian et al. [ 58] tested the effects of" exact="cyproheptadine" post="in a double-blind placebo-controlled trial in children with FAP."/>
   <result pre="of improvement was also measured. After 2 weeks of treatment," exact="cyproheptadine" post="proved superior to placebo in reducing/resolving pain, both in"/>
   <result pre="in reducing/resolving pain, both in frequency (86.7% of children receiving" exact="cyproheptadine" post="vs. 35.7% receiving placebo) and in intensity (86.7 vs."/>
   <result pre="of improvement reported by children was significantly better in the" exact="cyproheptadine" post="group than in the placebo group (86.7 vs. 35.7%)."/>
   <result pre="Madani et al. [ 60] retrospectively evaluated the effect of" exact="cyproheptadine" post="in patients with abdominal pain-related functional gastrointestinal disorders (AP-FGIDs)"/>
   <result pre="reviewed the studies conducted to date on the use of" exact="cyproheptadine" post="and confirmed its efficacy. They concluded that cyproheptadine could"/>
   <result pre="use of cyproheptadine and confirmed its efficacy. They concluded that" exact="cyproheptadine" post="could indeed be classified as an etiological treatment given"/>
   <result pre="randomly assigned to a 3-week-long treatment (treatment period 1) with" exact="famotidine" post="or placebo administered twice daily. If symptoms persisted at"/>
   <result pre="both groups, whereas global improvement was significantly higher in the" exact="famotidine" post="group (66.7 vs. 15.4% with placebo). Calcium-Channel Blockers Flunarizine"/>
   <result pre="Boccia et al. [ 64] confirmed these results: They tested" exact="flunarizine" post="in ten children with a diagnosis of AM compared"/>
   <result pre="of FAPDs. We found only one study [ 65] on" exact="pizotifen" post="in the literature. This drug is usually used to"/>
   <result pre="4-week-long treatment with PEG 3350 alone and in combination with" exact="tegaserod" post="in children with constipation-predominant IBS according to the Rome"/>
   <result pre="a key role in motility and moderate visceral sensitivity. However," exact="tegaserod" post="has been associated with serious cardiovascular ischemic events and"/>
   <result pre="by the US FDA. Antibiotics Two different trials have tested" exact="rifaximin" post="[ 67] and co-trimoxazole [ 68] versus placebo in"/>
   <result pre="a recent pilot study aiming to evaluate the efficacy of" exact="melatonin" post="in functional dyspepsia, performed a double-blind, randomized, placebo-controlled crossover"/>
   <result pre="observed no significant impact on pain in children treated with" exact="melatonin" post="compared with those treated with placebo [ 69]. Placebo"/>
   <result pre="Narang M Shah D Akhtar H Efficacy and safety of" exact="drotaverine" post="hydrochloride in children with recurrent abdominal pain: a randomized"/>
   <result pre="children using the Rome III criteria and the effect of" exact="trimebutine" post="treatment. J Neurogastr Motil. 2013;19:90–93. 53. Giannetti E Maglione"/>
   <result pre="BS Steinmetz B Ament ME Double-blind placebo controlled trial of" exact="amitriptyline" post="for the treatment of irritable bowel syndrome in adolescents"/>
   <result pre="P Cocjin J et al. Multicenter, randomized, placebo-controlled trial of" exact="amitriptyline" post="in children with functional gastrointestinal disorders Gastroenterology 2009 137"/>
   <result pre="Rodriguez L Diaz J Nurko S Safety and efficacy of" exact="cyproheptadine" post="for treating dyspeptic symptoms in children J Pediatr 2013"/>
   <result pre="Schechter CB Goldenberg MM Benkov KJ Double-blind, placebo-controlled trial of" exact="famotidine" post="in children with abdominal pain and dyspepsia: global and"/>
   <result pre="46 985 992 10.1023/A:1010793408132 11341669 63. Kothare SV Efficay of" exact="flunarizine" post="in the prophylaxis of cyclical vomiting syndrome and abdominal"/>
   <result pre="Staiano A Functional gastrointestinal disorders in migrainous children: efficacy of" exact="flunarizine" post="Cephalalgia 2006 26 1214 1219 10.1111/j.1468-2982.2006.01196.x 16961789 65. Symon"/>
   <result pre="Symon DN Russell G Double blind placebo controlled trial of" exact="pizotifen" post="syrup in the treatment of abdominal migraine Arch Dis"/>
   <result pre="C Landry L Effect of a laxative with and without" exact="tegaserod" post="in adolescents with constipation predominant irritable bowel syndrome Aliment"/>
   <result pre="69. Zybach K Friesen CA Schurman JV Therapeutic effect of" exact="melatonin" post="on pediatric functional dyspepsia: a pilot study World J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6025595/results/search/drugs/results.xml">
   <result pre="leukotriene synthesis and regulating calcium channels [ 20]. Magnesium and" exact="riboflavin" post="are considered by the AHS and AAN as Level"/>
   <result pre="tried more aggressive treatments, such as OnabotulinumtoxinA injections (16%) and" exact="valproic acid" post="(10%), suggesting that the patients receiving acupuncture had complex"/>
   <result pre="intractable headaches despite multiple interventions. CAMP is a five-day outpatient" exact="dihydroergotamine" post="(DHE) and magnesium infusion program. CAMP patients and their"/>
   <result pre="medication completely for several months but has since restarted daily" exact="amitriptyline" post="and occasionally requires rizatriptan or a combination abortive treatment"/>
   <result pre="months but has since restarted daily amitriptyline and occasionally requires" exact="rizatriptan" post="or a combination abortive treatment of ibuprofen, an antiemetic,"/>
   <result pre="oxide daily for headache prevention, and an abortive cocktail of" exact="ibuprofen" post="and diphenhydramine. Her abortive cocktail was limited to two"/>
   <result pre="increased anxiety. Her headache provider added a second preventive medication," exact="amitriptyline" post="daily, and encouraged her to initiate counseling. She was"/>
   <result pre="as she reported only one headache per week, alleviated by" exact="ibuprofen" post="and sleep. She was advised to continue lifestyle recommendations"/>
   <result pre="techniques to help manage and prevent headaches, along with daily" exact="amitriptyline" post="for prevention and an abortive cocktail as needed. 3.3."/>
   <result pre="management. Prior to her initial headache visit, Makayla was utilizing" exact="ibuprofen" post="or acetaminophen on an as needed basis without relief."/>
   <result pre="to her initial headache visit, Makayla was utilizing ibuprofen or" exact="acetaminophen" post="on an as needed basis without relief. Her nurse"/>
   <result pre="an as needed basis without relief. Her nurse practitioner initiated" exact="tizanidine" post="and magnesium gluconate daily for headache prevention. Additionally, meloxicam"/>
   <result pre="initiated tizanidine and magnesium gluconate daily for headache prevention. Additionally," exact="meloxicam" post="daily was initiated for 30 days, and rizatriptan was"/>
   <result pre="prevention. Additionally, meloxicam daily was initiated for 30 days, and" exact="rizatriptan" post="was prescribed as a headache abortive, limited to three"/>
   <result pre="similar results. When Makayla underwent an occipital nerve block with" exact="lidocaine" post="and bupivacaine, she developed a delayed hypersensitivity reaction to"/>
   <result pre="lidocaine and bupivacaine, she developed a delayed hypersensitivity reaction to" exact="lidocaine" post="with worsening headaches after the nerve block. She was"/>
   <result pre="The following day, she received intramuscular DHE, metoclopramide, ondansetron, and" exact="diphenhydramine" post="along with acupuncture. Her pain decreased from 4 out"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6029397/results/search/drugs/results.xml">
   <result pre="received fluid replacement ( n = 25), acid suppression ( n = 19) and" exact="ondansetron" post="( n = 1) in the local hospitals according to available"/>
   <result pre="care center. Eight patients were treated with sertraline, 10 received" exact="valproic acid," post="eight received sulpiride, and seven received cyproheptadine. Disease burden"/>
   <result pre="treatment of CVS. Retrospective studies showed favorable clinical responses with" exact="cyproheptadine" post="[ 29], propanolol and pizotifen [ 30]. Valproate is"/>
   <result pre="showed favorable clinical responses with cyproheptadine [ 29], propanolol and" exact="pizotifen" post="[ 30]. Valproate is also considered as an effective"/>
   <result pre="this tertiary care center generally received prophylactic medications, including cyproheptadine," exact="valproate" post="acid, or both. More than half of the patients"/>
   <result pre="Effective prophylactic therapy for cyclic vomiting syndrome in children using" exact="valproate" post="Brain and Development 2009 31 6 411 413 10.1016/j.braindev.2008.07.005"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6031985/results/search/drugs/results.xml">
   <result pre="was suspected on SPECT. All patients were started on prophylactic" exact="levetiracetam" post="postoperatively. Oxcarbazepine was started in a patient who had"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6078717/results/search/drugs/results.xml">
   <result pre="main feature of the stress response is the release of" exact="corticotropin" post="releasing hormone (CRH). Mast cells express CRH receptors which,"/>
   <result pre="children and adolescents with FD. [ 35] The use of" exact="montelukast" post="to treat migraine headaches or FD should be considered"/>
   <result pre="Friesen, Meenal Singh, Vivekanand Singh, Jennifer Schurman. Abbreviations: CRH =" exact="corticotropin" post="releasing hormone, FD = functional dyspepsia, FGID = functional"/>
   <result pre="GL Andre L et al. Clinical efficacy and pharmacokinetics of" exact="montelukast" post="in dyspeptic children with duodenal eosinophilia . J Pediatr"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6109211/results/search/drugs/results.xml">
   <result pre="within normal limits. Patient was empirically treated with polyetheleneglycol and" exact="cyproheptadine" post="with no observed benefit. Family history was positive for"/>
   <result pre="and were unremarkable. Patient was started on supportive care and" exact="oseltamivir" post="for acute viral illness dehydration with admission to pediatric"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6119173/results/search/drugs/results.xml">
   <result pre="available evidence including the conventional 21/7 combined hormonal contraception, the" exact="desogestrel" post="only oral pill, combined oral contraceptives with shortened pill-free"/>
   <result pre="oral contraceptives with shortened pill-free interval, combined oral contraceptives with" exact="estradiol" post="supplementation during the pill-free interval, extended regimen of combined"/>
   <result pre="with pill or patch, combined hormonal contraceptive vaginal ring, transdermal" exact="estradiol" post="supplementation with gel, transdermal estradiol supplementation with patch, subcutaneous"/>
   <result pre="hormonal contraceptive vaginal ring, transdermal estradiol supplementation with gel, transdermal" exact="estradiol" post="supplementation with patch, subcutaneous estrogen implant with cyclical oral"/>
   <result pre="to manage migraine in women of reproductive age include the" exact="desogestrel" post="progestogen-only pill (POP) [ 13, 14, 41, 42], extended"/>
   <result pre="supplementation during the pill-free interval [ 44], oral CHCs with" exact="estradiol" post="supplementation with patch during the pill-free interval [ 34],"/>
   <result pre="40], the combined hormonal contraceptive vaginal ring [ 45], transdermal" exact="estradiol" post="supplementation with gel [ 31, 32, 35], transdermal estradiol"/>
   <result pre="transdermal estradiol supplementation with gel [ 31, 32, 35], transdermal" exact="estradiol" post="supplementation with patch [ 29, 33, 37, 38], transdermal"/>
   <result pre="estradiol supplementation with patch [ 29, 33, 37, 38], transdermal" exact="estradiol" post="supplementation with patch in women induced in pharmacological menopause"/>
   <result pre="progestogen-only pill Four studies assessed the possible benefits of the" exact="desogestrel" post="POP in women with both MO and MA ["/>
   <result pre="studies had an observational design. The study drug was the" exact="desogestrel" post="75 μg/day oral pill in all studies. All the"/>
   <result pre="Desogestrel 75 μg/day vs continuous EE 20 μg plus oral" exact="desogestrel" post="150 μg 6 months of treatment (pre-treatment observation period"/>
   <result pre="contraception or medical reasons 144; 27 dropped-out (on treatment analysis)" exact="desogestrel" post="75 μg/day vs sequential (21/7) EE 20 μg plus"/>
   <result pre="desogestrel 75 μg/day vs sequential (21/7) EE 20 μg plus" exact="desogestrel" post="150 μg 6 months of treatment (pre-treatment observation period"/>
   <result pre="and on 28 women at cycle 6) Estradiol valerate +" exact="dienogest" post="pill using an estrogen step-down and progestogen step-up approach"/>
   <result pre="and in use of analgesics Combined oral contraceptives with oral" exact="estradiol" post="supplementation during the pill-free interval  Calhoun, 2004 [ 44]"/>
   <result pre="days and in weighted headache score Combined oral contraceptives with" exact="estradiol" post="supplementation with patch during the pill-free interval  MacGregor, 2002"/>
   <result pre="Aura frequency reduced; MRM eliminated in 91.3% of subjects Transdermal" exact="estradiol" post="supplementation with gel  de Lignieres, 1986 [ 31] Randomized,"/>
   <result pre="increase in migraine occurrence in the 5 days immediately after" exact="estradiol" post="use Transdermal estradiol supplementation with patch  Almen-Christensson, 2011 ["/>
   <result pre="occurrence in the 5 days immediately after estradiol use Transdermal" exact="estradiol" post="supplementation with patch  Almen-Christensson, 2011 [ 29] Randomized, placebo-controlled,"/>
   <result pre="headache 38 (10 treated with EE) Estradiol 25 μg vs" exact="frovatriptan" post="vs naproxen sodium 1 cycle of treatment (6 days"/>
   <result pre="(10 treated with EE) Estradiol 25 μg vs frovatriptan vs" exact="naproxen" post="sodium 1 cycle of treatment (6 days before expected"/>
   <result pre="in number of migraine attacks and severity of attacks with" exact="frovatriptan" post="than with estradiol or naproxen sodium  Pradalier, 1994 ["/>
   <result pre="migraine attacks and severity of attacks with frovatriptan than with" exact="estradiol" post="or naproxen sodium  Pradalier, 1994 [ 37] Randomized, open-label"/>
   <result pre="and severity of attacks with frovatriptan than with estradiol or" exact="naproxen" post="sodium  Pradalier, 1994 [ 37] Randomized, open-label study MM"/>
   <result pre="women specifically treated for headache 24 Estradiol 25 μg vs" exact="estradiol" post="100 μg 1 cycle of observation, 2 cycles of"/>
   <result pre="analgesic use No differences between active treatment and placebo Transdermal" exact="estradiol" post="supplementation with patch in women induced in pharmacological menopause"/>
   <result pre="specifically treated for headache 23; 2 dropped-out (on treatment analysis)" exact="goserelin" post="3.6 mg implant with estradiol 100 μg patches every"/>
   <result pre="2 dropped-out (on treatment analysis) goserelin 3.6 mg implant with" exact="estradiol" post="100 μg patches every 6 days vs goserelin 3.6"/>
   <result pre="implant with estradiol 100 μg patches every 6 days vs" exact="goserelin" post="3.6 mg implant with placebo patches 1 lead-in month,"/>
   <result pre="1 lead-in month, 2.5 months of placebo, 1 month of" exact="goserelin" post="injection, 2 months of randomization Headache index, disability index,"/>
   <result pre="according to the use of CHCs before inclusion. Treatment with" exact="desogestrel" post="was associated with a significant reduction in migraine days"/>
   <result pre="extend oral CHC regimen. The authors found that treatment with" exact="desogestrel" post="was associated with a reduction in migraine days per"/>
   <result pre="extend oral CHC regimen. The authors found that treatment with" exact="desogestrel" post="was associated with a reduction in severity on a"/>
   <result pre="vs 15.9 ± 4.4; P &amp;lt; 0.001) of migraine attacks. Side effects associated with" exact="desogestrel" post="use included higher headache frequency, prolonged bleeding, spotting, and"/>
   <result pre="agent (desogestrel pill). Available data indicate that treatment with oral" exact="desogestrel" post="may be associated with improvement in migraine in women"/>
   <result pre="contraception or medical reasons. The available data refer to the" exact="desogestrel" post="pill only and no information is available for the"/>
   <result pre="desogestrel pill only and no information is available for the" exact="norethisterone" post="or levonorgestrel pills or for progestogen-only non-oral methods such"/>
   <result pre="only and no information is available for the norethisterone or" exact="levonorgestrel" post="pills or for progestogen-only non-oral methods such as subdermal"/>
   <result pre="such as subdermal implant, depot-injection, and levonorgestrel-releasing intrauterine system. As" exact="desogestrel" post="is safe in terms of cardiovascular risk it is"/>
   <result pre="and additional vascular risk factors [ 22]. Recommendations for the" exact="desogestrel" post="POP are reported in Table 5. Table 5 Recommendations"/>
   <result pre="Low Weak No evidence available for progestogen only-pills other than" exact="desogestrel" post="75 μg/day Women with estrogen withdrawal headache or worsening"/>
   <result pre="headache Not suggested None Weak Combined oral contraceptives with oral" exact="estradiol" post="supplementation during the pill-free interval* Women with migraine, related"/>
   <result pre="withdrawal headache Not suggested None Weak Combined oral contraceptives with" exact="estradiol" post="supplementation with patch during the pill-free interval* Women with"/>
   <result pre="treatment for contraception or medical reasons Suggested Low Weak Transdermal" exact="estradiol" post="supplementation with estradiol gel Women with pure menstrual migraine"/>
   <result pre="or medical reasons Suggested Low Weak Transdermal estradiol supplementation with" exact="estradiol" post="gel Women with pure menstrual migraine Suggested Low Weak"/>
   <result pre="Low Weak Women with estrogen-withdrawal headache Suggested None Weak Transdermal" exact="estradiol" post="supplementation with patch Women with pure menstrual migraine Not"/>
   <result pre="Weak Women with estrogen-withdrawal headache Not suggested Low Weak Transdermal" exact="estradiol" post="supplementation with patch in women induced in pharmacological menopause"/>
   <result pre="design. The study drugs were ethinylestradiol (EE) 30 μg/day +" exact="levonorgestrel" post="150 μg/day [ 30], EE 20 μg/day + desogestrel"/>
   <result pre="+ levonorgestrel 150 μg/day [ 30], EE 20 μg/day +" exact="desogestrel" post="150 μg/day [ 13, 14], and EE 20 μg/day"/>
   <result pre="150 μg/day [ 13, 14], and EE 20 μg/day +" exact="drospirenone" post="3 mg/day [ 15]. One study was performed in"/>
   <result pre="HC. During the extended HC regimen women were randomized to" exact="frovatriptan" post="or placebo for the treatment of acute attacks. The"/>
   <result pre="30 μg + levonorgestrel 150 μg [ 30], oral EE 20 μg + oral" exact="desogestrel" post="150 μg for 6 months [ 13, 14], and"/>
   <result pre="the two treatments [ 13, 14]. The study drugs were" exact="desogestrel" post="75 μg/day oral pill versus EE 20 μg/day +"/>
   <result pre="desogestrel 75 μg/day oral pill versus EE 20 μg/day +" exact="desogestrel" post="150 μg/day. Details of the studies are reported in"/>
   <result pre="data of 31 women with MO who were treated with" exact="desogestrel" post="75 μg/day and 22 women with MO who were"/>
   <result pre="who were treated with continuous ethinylestradiol (EE) 20 μg/day +" exact="desogestrel" post="150 μg/day [ 14]. The authors found that desogestrel"/>
   <result pre="+ desogestrel 150 μg/day [ 14]. The authors found that" exact="desogestrel" post="75 μg/day as compared to the continuous EE 20"/>
   <result pre="μg/day as compared to the continuous EE 20 μg/day +" exact="desogestrel" post="150 μg/day was associated with a reduction in the"/>
   <result pre="data of 62 women with MO who were treated with" exact="desogestrel" post="75 μg/day and 82 women with MO who were"/>
   <result pre="MO who were treated with continuous EE 20 μg/day +" exact="desogestrel" post="150 μg/day for 6 months [ 13]. The authors"/>
   <result pre="μg/day for 6 months [ 13]. The authors found that" exact="desogestrel" post="75 μg/day as compared to the continuous EE 20"/>
   <result pre="μg/day as compared to the continuous EE 20 μg/day +" exact="desogestrel" post="150 μg was associated with a reduction in pain"/>
   <result pre="studies performed in the gynecological setting and refer only to" exact="desogestrel" post="versus EE + desogestrel. Available data suggest more benefit from desogestrel"/>
   <result pre="to desogestrel versus EE + desogestrel. Available data suggest more benefit from" exact="desogestrel" post="over the oral CHC but evidence is too preliminary"/>
   <result pre="mg for 21 days + 7 placebo days [ 39], and" exact="estradiol" post="valerate + dienogest using an estrogen step-down and progestogen"/>
   <result pre="days + 7 placebo days [ 39], and estradiol valerate +" exact="dienogest" post="using an estrogen step-down and progestogen step-up approach for"/>
   <result pre="interval are reported in Table 5. Combined oral contraceptives with" exact="estradiol" post="supplementation with patch during the pill-free interval One interventional"/>
   <result pre="interval One interventional study assessed the possible benefits of transdermal" exact="estradiol" post="supplementation with patch in women with migraine during the"/>
   <result pre="oral contraceptives [ 34]. The study drug was 50 μg" exact="estradiol" post="patch specifically prescribed for headache management. Details of the"/>
   <result pre="14 women [ 34]. The authors addressed as active treatment" exact="estradiol" post="50 μg/24 h transdermal patch. The active treatment was"/>
   <result pre="included in the study were taking a CHC pill. The" exact="estradiol" post="patch was used for 2 cycles during the pill-free"/>
   <result pre="with migraine with associated symptoms. Adverse events related to transdermal" exact="estradiol" post="supplementation were changes in withdrawal bleeding patterns reported by"/>
   <result pre="these data from a single study show no benefit of" exact="estradiol" post="supplementation with patches on migraine occurrence during the pill-free"/>
   <result pre="weeks, followed by 1 week of 0.075 mg transdermal 17β" exact="estradiol" post="patches, 5 stopped the ring. Ten of the women"/>
   <result pre="hormonal contraceptive vaginal ring are reported in Table 5. Transdermal" exact="estradiol" post="supplementation with gel Three studies assessed the role of"/>
   <result pre="supplementation with gel Three studies assessed the role of transdermal" exact="estradiol" post="supplementation with gel in women with MM [ 31,"/>
   <result pre="studies were randomized [ 32, 35]. The study drug was" exact="estradiol" post="gel 1.5 mg for 6 [ 35] or 7"/>
   <result pre="7 days [ 31, 32]. In all the studies, transdermal" exact="estradiol" post="gel was evaluated against placebo [ 31, 32, 35]."/>
   <result pre="use of aspirin. Menstrual attacks occurred in 30.8% of the" exact="estradiol" post="cycles and in 96.3% of the placebo cycles ("/>
   <result pre="of the placebo cycles ( P &amp;lt; 0.01). Attacks that occurred during" exact="estradiol" post="treatment were considerably milder and shorter than those occurring"/>
   <result pre="out of 20 patients had migraine three days after stopping" exact="estradiol" post="treatment. Dennerstein et al. performed a randomized, placebo-controlled, double-blind,"/>
   <result pre="severe intensity migraine during the months of treatment with percutaneous" exact="estradiol" post="compared with placebo gel ( t = 2.67; P &amp;lt; 0.05). As the"/>
   <result pre="omitted. They found that the alleviation of headaches by percutaneous" exact="estradiol" post="compared with placebo was then significant ( t = 3.96; P &amp;lt; 0.001)."/>
   <result pre="t = 3.96; P &amp;lt; 0.001). Additionally, significantly less medication was utilized during percutaneous" exact="estradiol" post="use, compared with placebo. MacGregor et al. performed a"/>
   <result pre="increase in migraine occurrence in the 5 days immediately following" exact="estradiol" post="use compared to placebo (RR 1.40; 95% CI 1.03"/>
   <result pre="P = 0.03). Of the 22 women who benefited from using the" exact="estradiol" post="gel (they had fewer migraines compared to using placebo),"/>
   <result pre="had more migraine days during the 5 days after the" exact="estradiol" post="gel compared to the 5 days after placebo). In"/>
   <result pre="serious adverse events were reported associated with the use of" exact="estradiol" post="gel. Some of the patients experienced cutaneous rash, anxiety,"/>
   <result pre="35]. In conclusion, current evidence on the use of transdermal" exact="estradiol" post="supplementation with gel in women with migraine is limited."/>
   <result pre="supplementation with gel in women with migraine is limited. Transdermal" exact="estradiol" post="supplementation with gel is easy and well tolerated, thus"/>
   <result pre="of post-gel estrogen withdrawal migraine are that the dose of" exact="estradiol" post="was inadequate; the duration of treatment was too short;"/>
   <result pre="rise of endogenous estrogen. Extending the duration of use of" exact="estradiol" post="supplements until endogenous estrogen had risen might prevent post-supplement"/>
   <result pre="those circumstances treatment should be withheld. Recommendations for the transdermal" exact="estradiol" post="supplementation with gel are reported in Table 5. Transdermal"/>
   <result pre="estradiol supplementation with gel are reported in Table 5. Transdermal" exact="estradiol" post="supplementation with patch Four studies assessed the possible benefits"/>
   <result pre="with patch Four studies assessed the possible benefits of transdermal" exact="estradiol" post="supplementation with patch in women with PMM [ 29,"/>
   <result pre="and one was observational [ 33]. The study drug was" exact="estradiol" post="patch releasing from 25 to 100 μg/24 h. In"/>
   <result pre="according to ICHD-2 criteria. The authors addressed as active treatment" exact="estradiol" post="100 μg/24 h transdermal patch. The treatment was compared"/>
   <result pre="according to ICHD-2 criteria. The authors addressed as active treatments" exact="estradiol" post="25 μg transdermal patch or frovatriptan or naproxen sodium."/>
   <result pre="addressed as active treatments estradiol 25 μg transdermal patch or" exact="frovatriptan" post="or naproxen sodium. Each treatment was started 2 days"/>
   <result pre="active treatments estradiol 25 μg transdermal patch or frovatriptan or" exact="naproxen" post="sodium. Each treatment was started 2 days before expected"/>
   <result pre="for 6 days for a single cycle. Authors reported that" exact="frovatriptan" post="was associated with reduced migraine incidence and severity while"/>
   <result pre="ICHD-1 criteria. The authors studied two different doses of the" exact="estradiol" post="patch (25 vs 100 μg/24 h). There was 1"/>
   <result pre="according to ICHD-1 criteria. The authors addressed as active treatment" exact="estradiol" post="25 μg/24 h transdermal patch. The treatment was compared"/>
   <result pre="between active treatment and placebo. Adverse events related to transdermal" exact="estradiol" post="supplementation occurred in a variable proportion across studies and"/>
   <result pre="38]. In conclusion, current evidence on the use of transdermal" exact="estradiol" post="supplementation with patch in women with MM or PMM"/>
   <result pre="MM or PMM is limited. As the aim of transdermal" exact="estradiol" post="supplementation is to maintain estradiol concentrations stable at the"/>
   <result pre="As the aim of transdermal estradiol supplementation is to maintain" exact="estradiol" post="concentrations stable at the time of the anticipated start"/>
   <result pre="available studies pointed out that 25 and 50 μg of" exact="estradiol" post="supplementation may be too low to achieve clinical benefits"/>
   <result pre="increase risk of ischemic stroke [ 33]. Also, duration of" exact="estradiol" post="supplementation may impact on efficacy. Limitations of transdermal estradiol"/>
   <result pre="of estradiol supplementation may impact on efficacy. Limitations of transdermal" exact="estradiol" post="supplementation may also include difficulties in establishing the time"/>
   <result pre="ovulation. As there are currently no data showing benefits of" exact="estradiol" post="supplementation with patches on migraine occurrence, this cannot be"/>
   <result pre="considered as a possible therapeutic option. Recommendations for the transdermal" exact="estradiol" post="supplementation with patch are reported in Table 5. Transdermal"/>
   <result pre="according to ICHD-1 criteria. All patients received a 3.6 mg" exact="goserelin" post="implant to induce medical oophorectomy. Thereafter women were randomized"/>
   <result pre="implant to induce medical oophorectomy. Thereafter women were randomized to" exact="estradiol" post="100 μg/24 h every 6 days vs placebo patches."/>
   <result pre="headaches. In conclusion, evidence referring to the use of transdermal" exact="estradiol" post="supplementation in women induced in pharmacological menopause is very"/>
   <result pre="be minimized by estrogen add-back therapy. Medical menopause associated with" exact="estradiol" post="treatment is not appropriate for most women of reproductive"/>
   <result pre="of their headache during the perimenopause. Recommendations for the transdermal" exact="estradiol" post="supplementation with patch in women induced in pharmacological menopause"/>
   <result pre="according to ICHD criteria. Authors addressed as active treatment an" exact="estradiol" post="implant (100 mg then decreased to 50 mg) plus"/>
   <result pre="estradiol implant (100 mg then decreased to 50 mg) plus" exact="norethisterone" post="5 mg/day for 7 days per month to induce"/>
   <result pre="gynecological reasons. Available data, albeit very weak, indicate that the" exact="desogestrel" post="75 μg /day pill is the option which may"/>
   <result pre="it is also the safest form [ 22, 46]. The" exact="desogestrel" post="pill may improve migraine frequency and severity in women"/>
   <result pre="It is important to note that in some patient the" exact="desogestrel" post="pill may worsen migraine or may be associated with"/>
   <result pre="during natural cycles, a therapeutic option may the administration of" exact="estradiol" post="gel. However, this option may be associated with delayed"/>
   <result pre="TJ Clark JW Extended cycle combined oral contraceptives and prophylactic" exact="frovatriptan" post="during the hormone-free interval in women with menstrual-related migraines"/>
   <result pre="Touboul PJ Bousser MG Prevention of menstrual migraine by percutaneous" exact="estradiol" post="Br Med J 1986 293 1540 10.1136/bmj.293.6561.1540 3099950 32."/>
   <result pre="Smith M Menstrual migraine: a double blind trial of percutaneous" exact="estradiol" post="Gynecol Endocrinol 1988 2 113 120 10.3109/09513598809023619 3055819 33."/>
   <result pre="C Guidotti F Belloni C Frovatriptan vs. transdermal oestrogens or" exact="naproxen" post="sodium for the prophylaxis of menstrual migraine J Heachache"/>
   <result pre="Beaulieu P Baudersson G Launey J-M Rose F Correlation between" exact="estradiol" post="plasma level and therapeutic effect on menstrual migraine New"/>
   <result pre="Vaccaro V Polatti F Facchinetti F Effects of an estrogen-free," exact="desogestrel" post="containing oral contraceptive in women with migraine with aura:"/>
   <result pre="Tassorelli C Spinillo A Effect of a contraceptive pill containing" exact="estradiol" post="valerate and dienogest (E2V/DNG) in women with menstrually-related migraine"/>
   <result pre="A Effect of a contraceptive pill containing estradiol valerate and" exact="dienogest" post="(E2V/DNG) in women with menstrually-related migraine (MRM) Contraception 2013"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6119283/results/search/drugs/results.xml">
   <result pre="frequency and severity of migraine attacks by dietary supplementation with" exact="folic acid" post="in patients with high homocysteine blood levels, based on"/>
   <result pre="study confirms the absence of correlation Therefore, dietary supplementation with" exact="folic acid" post="or a diet rich in folate to change homocysteine"/>
   <result pre="Ingegneri G Sgrò D Pustorino G et al. Efficacy of" exact="folic acid" post="in children with migraine hyperhomocysteinemia and MTHFR polymorphisms Headache"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6167431/results/search/drugs/results.xml">
   <result pre="comply with these terms. Abstract Background: Valproic acid (VPA) and" exact="topiramate" post="(TPM), initially developed as antiepileptics, are approved for migraine"/>
   <result pre="migraine condition, which were assessed peripherally by the depletion of" exact="calcitonin" post="gene-related peptide (CGRP) in sensory nerve fibers of the"/>
   <result pre="the development of new pediatric anti-migraine drugs in the future." exact="valproic acid" post="topiramate age difference migraine CGRP Funding National Taiwan University"/>
   <result pre="of new pediatric anti-migraine drugs in the future. valproic acid" exact="topiramate" post="age difference migraine CGRP Funding National Taiwan University Hospital"/>
   <result pre="mater ( Fan et al., 2012). Valproic acid (VPA) and" exact="topiramate" post="(TPM), both clinically effective in migraine prophylaxis were used"/>
   <result pre="trigeminal neuronal culture, TPM decreased CGRP release induced by KCl," exact="nitric oxide" post="and proton in a time- and concentration-dependent manner without"/>
   <result pre="(TG) and dura of adult and pediatric rats treated with" exact="valproic acid" post="(VPA). (A) The immunochemical stain of c-Fos shows c-Fos-ir"/>
   <result pre="(TG) and dura of adult and pediatric rats treated with" exact="topiramate" post="(TPM). (A) The immunochemical stain of c-Fos shows c-Fos-ir"/>
   <result pre="of various anti-migraine agents, including clinically effective VPA and a" exact="sumatriptan" post="analog ( Cutrer and Moskowitz, 1996; Cutrer et al.,"/>
   <result pre="Shabanian R. Zamani G. R. Mahfelati F. ( 2005). Sodium" exact="valproate" post="versus propranolol in paediatric migraine prophylaxis. Eur. J. Paediatr."/>
   <result pre="Zamani G. R. Mahfelati F. ( 2005). Sodium valproate versus" exact="propranolol" post="in paediatric migraine prophylaxis. Eur. J. Paediatr. Neurol. 9"/>
   <result pre="V. Ayata G. Moskowitz M. A. ( 1995a). Attenuation by" exact="valproate" post="of c-fos immunoreactivity in trigeminal nucleus caudalis induced by"/>
   <result pre="Panahian N. Moskowitz M. A. ( 1995b). Suppression by the" exact="sumatriptan" post="analogue, CP-122,288 of c-fos immunoreactivity in trigeminal nucleus caudalis"/>
   <result pre="Limmroth V. Moskowitz M. A. ( 1997). Possible mechanisms of" exact="valproate" post="in migraine prophylaxis. Cephalalgia 17 93– 100. 10.1046/j.1468-2982.1997.1702093.x 9137844"/>
   <result pre="Ayata G. Sanchez del Rio M. ( 1999). Attenuation by" exact="butalbital" post="of capsaicin-induced c-fos-like immunoreactivity in trigeminal nucleus caudalis. Headache"/>
   <result pre="M. A. ( 1996). Wolff award 1996. The actions of" exact="valproate" post="and neurosteroids in a model of trigeminal pain. Headache"/>
   <result pre="L. Niemann C. Cady R. ( 2006). Repression of stimulated" exact="calcitonin" post="gene-related peptide secretion by topiramate. Headache 46 1291– 1295."/>
   <result pre="Durham P. L. Russo A. F. ( 1999). Regulation of" exact="calcitonin" post="gene-related peptide secretion by a serotonergic antimigraine drug. J."/>
   <result pre="A. Sufka K. J. ( 2017). The effects of repeated" exact="nitroglycerin" post="administrations in rats; modeling migraine-related endpoints and chronification. J."/>
   <result pre="Wang J. Ali A. I. Guo Y. ( 2017). Is" exact="topiramate" post="effective for migraine prevention in patients less than 18"/>
   <result pre="McCrory D. C. ( 2013). Valproate (valproic acid or sodium" exact="valproate" post="or a combination of the two) for the prophylaxis"/>
   <result pre="( 1990). Origins and distribution of cerebrovascular nerve fibers showing" exact="calcitonin" post="gene-related peptide-like immunoreactivity in the major cerebral artery of"/>
   <result pre="T. ( 1988). Cerebral arterial innervation by nerve fibers containing" exact="calcitonin" post="gene-related peptide (CGRP): I. Distribution and origin of CGRP"/>
   <result pre="Innervation of the feline cerebral vasculature by nerve fibers containing" exact="calcitonin" post="gene-related peptide: trigeminal origin and co-existence with substance P."/>
   <result pre="N. Ozturk A. ( 2008). Comparison of the effectiveness of" exact="topiramate" post="and sodium valproate in pediatric migraine. J. Child Neurol."/>
   <result pre="( 2008). Comparison of the effectiveness of topiramate and sodium" exact="valproate" post="in pediatric migraine. J. Child Neurol. 23 1377– 1381."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6190553/results/search/drugs/results.xml">
   <result pre="the migraine symptoms, including prodromal symptoms, can be provoked with" exact="dopamine" post="receptor stimulation, and some can even be quantified in"/>
   <result pre="pathology, and the effective ADHD drug, methylphenidate, acts by inhibiting" exact="dopamine" post="reuptake. However, the comorbidity could also be more complex"/>
   <result pre="CR Cortese S Caye A et al. Long-term efficacy of" exact="methylphenidate" post="immediate-release for the treatment of childhood ADHD J Atten"/>
   <result pre="T et al. A large, double-blind, randomized clinical trial of" exact="methylphenidate" post="in the treatment of adults with attention-deficit/hyperactivity disorder Biol"/>
   <result pre="S Halleland H Halmoy A et al. Genetic analyses of" exact="dopamine" post="related genes in adult ADHD patients suggest an association"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6213149/results/search/drugs/results.xml">
   <result pre="43]. A therapeutic regimen of vitamin A supplements, GFD, and" exact="acetazolamide" post="proved very effective. Rani et al. reported a single"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6258963/results/search/drugs/results.xml">
   <result pre="congenital malformations in 3. Medications were used in 29 patients:" exact="acetaminophen" post="in 17, ibuprofen in 8, naproxen sodium in 1,"/>
   <result pre="3. Medications were used in 29 patients: acetaminophen in 17," exact="ibuprofen" post="in 8, naproxen sodium in 1, and topiramate or"/>
   <result pre="used in 29 patients: acetaminophen in 17, ibuprofen in 8," exact="naproxen" post="sodium in 1, and topiramate or amitriptyline in 3."/>
   <result pre="in 17, ibuprofen in 8, naproxen sodium in 1, and" exact="topiramate" post="or amitriptyline in 3. Conclusion In children aged &amp;lt;7"/>
   <result pre="ibuprofen in 8, naproxen sodium in 1, and topiramate or" exact="amitriptyline" post="in 3. Conclusion In children aged &amp;lt;7 years, headache"/>
   <result pre="used acetaminophen, 8 (5.5%) used ibuprofen, and 1 (0.7%) used" exact="naproxen" post="sodium to control the acute pain. In addition, 2"/>
   <result pre="to control the acute pain. In addition, 2 (1.4%) took" exact="topiramate" post="and 1 (0.7%) used amitriptyline. In terms of prognosis,"/>
   <result pre="version has less diagnostic power for children. Acetaminophen, ibuprofen, and" exact="naproxen" post="sodium were used in a total of 26 patients"/>
   <result pre="for children patients with acute headache [ 24]. Topiramate and" exact="amitriptyline" post="were chosen as preventive medicines for 3 patients. According"/>
   <result pre="half of patients were treated with acute medication such as" exact="ketoprofen" post="or paracetamol and 13.6% took a prophylactic pharmacological treatment."/>
   <result pre="patients were treated with acute medication such as ketoprofen or" exact="paracetamol" post="and 13.6% took a prophylactic pharmacological treatment. They suggested"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6277635/results/search/drugs/results.xml">
   <result pre="( 13, 16), headache education ( 14, 15), education plus" exact="amitriptyline" post="( 12), amitriptyline or gabapentin ( 22). The majority"/>
   <result pre="headache education ( 14, 15), education plus amitriptyline ( 12)," exact="amitriptyline" post="or gabapentin ( 22). The majority of the studies"/>
   <result pre="( 14, 15), education plus amitriptyline ( 12), amitriptyline or" exact="gabapentin" post="( 22). The majority of the studies evaluated the"/>
   <result pre="to education ( 13, 14), TAU ( 15, 16) or" exact="amitriptyline" post="plus education ( 12). Two of these studies focused"/>
   <result pre="a group of patients who received a preventative medication, either" exact="amitriptyline" post="or gabapentin. The multimodal treatment group was instructed to"/>
   <result pre="AD Powers SW Bentti AL Degrauw TJ . Effectiveness of" exact="amitriptyline" post="in the prophylactic management of childhood headaches. Headache ("/>
   <result pre="Slater SK Zafar M. et al. Cognitive behavioral therapy plus" exact="amitriptyline" post="for chronic migraine in children and adolescents: a randomized"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6293067/results/search/drugs/results.xml">
   <result pre="2 conditions, it is not surprising that several AEDs, including" exact="valproic acid" post="and topiramate, have shown to be effective and are"/>
   <result pre="pain regulation. 34, 35 A potential common pathogenic role of" exact="dopamine" post="in depression and migraine has been suggested by the"/>
   <result pre="and migraine has been suggested by the involvement of the" exact="dopamine" post="D2 receptor gene in migraine with aura and MDD."/>
   <result pre="include carbamazepine, phenobarbital, primidone, and phenytoin, and the second‐generation AEDS," exact="topiramate" post="and oxcarbazepine, which have lower enzyme‐inducing properties and which"/>
   <result pre="in homocysteine and C‐reactive protein (CRP). 45 Of note, although" exact="valproic acid" post="is a CYP enzyme inhibitor, it has been associated"/>
   <result pre="treated with these AEDs. Conversely, discontinuation and/or switch from either" exact="phenytoin" post="or carbamazepine to AEDs with no enzyme‐inducing properties (e.g.,"/>
   <result pre="these AEDs. Conversely, discontinuation and/or switch from either phenytoin or" exact="carbamazepine" post="to AEDs with no enzyme‐inducing properties (e.g., lamotrigine or"/>
   <result pre="phenytoin or carbamazepine to AEDs with no enzyme‐inducing properties (e.g.," exact="lamotrigine" post="or levetiracetam) resulted in a significant reduction of several"/>
   <result pre="cholesterol, triglycerides, and CRP. 46 In addition, PWE in whom" exact="carbamazepine" post="was discontinued were found to have a drop in"/>
   <result pre="have a drop in lipoprotein levels, whereas those taken off" exact="phenytoin" post="had a decrease in homocysteine blood levels. In addition,"/>
   <result pre="phenytoin had a decrease in homocysteine blood levels. In addition," exact="oxcarbazepine" post="and topiramate, at doses &amp;gt;200 mg and 900 mg/day,"/>
   <result pre="seizures was found among patients randomized to 2 antidepressant drugs," exact="bupropion" post="and clomipramine, than in those randomized to placebo. In"/>
   <result pre="those randomized to placebo. In a separate study, the antidepressant" exact="maprotiline" post="was reported to increase the risk of seizures in"/>
   <result pre="71 demonstrated by the elevated plasma corticosterone level and/or positive" exact="dexamethasone" post="(DEX) or DEX/Corticotropin‐releasing hormone tests. 72 Furthermore, mice that"/>
   <result pre="78, 79 status epilepticus (SE) induced by pilocarpine 80 and" exact="kainic acid," post="81 produced persistent interictal behavioral (e.g., anhedonia and despair/hopelessness"/>
   <result pre="79, 88, 89, 90, 91 native serotonin molecule, 92 and" exact="norepinephrine" post="reuptake inhibitors (NERIs) 88, 93 exert antiepileptic effects in"/>
   <result pre="effects in animal models of TLE, including kindling, pilocarpine, and" exact="kainic acid" post="models. 2.12 Can a bidirectional relation between migraine and"/>
   <result pre="of the elevated plus maze). Furthermore, significantly lower serotonin and" exact="dopamine" post="levels were detected in the prefrontal cortex of the"/>
   <result pre="have a persistent decrease in serotonin levels. Furthermore, the low" exact="dopamine" post="cortical concentrations demonstrated in this animal model of migraine"/>
   <result pre="model of migraine is supported by previous reports of low" exact="dopamine" post="levels in patients with migraine, in whom a D2"/>
   <result pre="Comorbid migraine with aura, anxiety, and depression is associated with" exact="dopamine" post="D2 receptor (DRD2) NcoI alleles . Mol Med 1998;"/>
   <result pre=", Gurbel PA , O'Connor CM . Platelet inhibition by" exact="sertraline" post="and N‐demethylsertraline: A possible missing link between depression, coronary"/>
   <result pre=", Meurs A , et al. Anticonvulsant action of hippocampal" exact="dopamine" post="and serotonin is independently mediated by D2 and 5‐HT1A"/>
   <result pre="after status epilepticus: behavioural and biochemical deficits and effects of" exact="fluoxetine" post=". Brain 2008; 131: 2071– 2083. 18559371 81 Becker"/>
   <result pre="Redwine HM , et al. Effects of selective serotonin and" exact="norepinephrine" post="reuptake inhibitors on depressive‐ and impulsive‐like behaviors and on"/>
   <result pre=", Staley KJ . Chapter 40. Post‐sstatus epilepticus models: systemic" exact="kainic acid" post="In Pitkanen A , Buckmaster PS , Galanopoulou AS"/>
   <result pre="EJ , Williams PA , Dudek FE . Effects of" exact="fluoxetine" post="and TFMPP on spontaneous seizures in rats with pilocarpine‐induced"/>
   <result pre=", Aonurm‐Helm A , Kalda A , et al. Repeated" exact="citalopram" post="administration counteracts kainic acid‐induced spreading of PSA‐NCAM‐immunoreactive cells and"/>
   <result pre=", Nakamura M , et al. Prolonged but not acute" exact="fluoxetine" post="administration produces its inhibitory effect on hippocampal seizures in"/>
   <result pre="Massie A , Smolders I , et al. The antidepressants" exact="citalopram" post="and reboxetine reduce seizure frequency in rats with chronic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6294621/results/search/drugs/results.xml">
   <result pre=", Kurt S. and Ates O. ( 2016) Analysis of" exact="dopamine" post="beta hydroxylase gene polymorphisms in migraine. Clin. Neurol. Neurosurg."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6306866/results/search/drugs/results.xml">
   <result pre="patients at the Mayo Clinic, over 40% used CAM, and" exact="melatonin" post="for sleep disorders was the most commonly used therapy"/>
   <result pre="and intensity has been shown to improve with magnesium and" exact="riboflavin" post="(vitamin B2) [ 87, 88]. Furthermore, screening and treating"/>
   <result pre="particularly helpful in treating her abdominal migraine episodes. Supplements included" exact="melatonin" post="nightly and peppermint oil by mouth as needed for"/>
   <result pre="for daily meditation to augment anxiety treatment. She weaned off" exact="amitriptyline" post="and topiramate without incident and reserved only ondansetron and"/>
   <result pre="meditation to augment anxiety treatment. She weaned off amitriptyline and" exact="topiramate" post="without incident and reserved only ondansetron and clonazepam on"/>
   <result pre="weaned off amitriptyline and topiramate without incident and reserved only" exact="ondansetron" post="and clonazepam on an as needed basis for acute"/>
   <result pre="amitriptyline and topiramate without incident and reserved only ondansetron and" exact="clonazepam" post="on an as needed basis for acute discomfort. In"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6320380/results/search/drugs/results.xml">
   <result pre="(prostacyclin receptor) and activates this receptor. Following this event, cyclic" exact="adenosine" post="monophosphate is produced and activates protein kinase A. Finally,"/>
   <result pre="2004 2 257 265 15320791 9 Armstead W Role of" exact="nitric oxide" post="and cAMP in prostaglandin-induced pial arterial vasodilation Am J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6327687/results/search/drugs/results.xml">
   <result pre="several other cardiovascular as well as noncardiovascular therapeutic uses of" exact="propranolol" post="were discovered. Propranolol soon became a powerful tool for"/>
   <result pre="and pheochromocytoma. Owing to its action at multiple receptor sites," exact="propranolol" post="exerts several central and peripheral effects and is therefore"/>
   <result pre="reduction in postmyocardial mortality to control of anxiety in performers," exact="propranolol" post="plays an important role in a plethora of medical"/>
   <result pre="newer indications of this age-old drug are being discovered. Moreover," exact="propranolol" post="treatment has been found to be cost-effective when compared"/>
   <result pre="In this article, we attempt to recount the journey of" exact="propranolol" post="right from its inception to the present day. Keywords:"/>
   <result pre="the present day. Keywords: Anxiety beta-blocker myocardial infarction portal hypertension" exact="propranolol" post="I NTRODUCTION The invention of the beta-adrenergic receptor antagonist,"/>
   <result pre="led to the development of propranolol.[ 3 4 5] Until" exact="propranolol" post="was invented, the only drugs available to treat angina"/>
   <result pre="which were effective only partially. Soon, it was discovered that" exact="propranolol" post="is not only effective in the treatment of angina,"/>
   <result pre="2 6 7 8] Over the years, other applications of" exact="propranolol" post="in several noncardiovascular conditions including migraine, essential tremors, anxiety,"/>
   <result pre="conditions. In this article, we will review the journey of" exact="propranolol" post="from its inception to the present day. M ECHANISM"/>
   <result pre="beta-1 and beta-2 adrenergic receptors. By blocking the beta-adrenergic sites," exact="propranolol" post="inhibits sympathetic effects that act through these receptors.[ 11"/>
   <result pre="Two-dimensional (a) and three-dimensional (b) representation of molecular structure of" exact="propranolol" post="(C16H21NO2) Propranolol is highly lipophilic. Following oral administration, complete"/>
   <result pre="of its metabolites are excreted in urine. Plasma half-life of" exact="propranolol" post="is 3–6 h.[ 11 12] A long-acting preparation of"/>
   <result pre="propranolol is 3–6 h.[ 11 12] A long-acting preparation of" exact="propranolol" post="has also been developed with a half-life of 8–11"/>
   <result pre="HERAPEUTIC U SES OF P ROPRANOLOL The widespread use of" exact="propranolol" post="in cardiovascular diseases including ischemic heart disease, arrhythmias, and"/>
   <result pre="50 years. Here, we will also discuss the role of" exact="propranolol" post="in various noncardiovascular conditions with special emphasis on its"/>
   <result pre="commonly used class of drugs for managing cardiovascular diseases. Although" exact="propranolol" post="was first developed to manage angina pectoris, soon its"/>
   <result pre="= 3837), which was designed to evaluate whether administration of" exact="propranolol" post="postmyocardial infarction led to reduction in mortality. Results were"/>
   <result pre="was found to be acceptable. The results also showed that" exact="propranolol" post="has an antiarrhythmic effect which may, at least in"/>
   <result pre="positive results of this study led to widespread use of" exact="propranolol" post="for reduction in morbidity and mortality associated with myocardial"/>
   <result pre="15] Many new generation cardioselective beta-blockers are now available. Nevertheless," exact="propranolol" post="continues to be used in specific conditions. Propranolol has"/>
   <result pre="acute myocardial infarction. Propranolol, being cost-effective, can be preferred over" exact="carvedilol" post="for this indication.[ 16] Barton et al. assessed the"/>
   <result pre="Barton et al. assessed the efficacy and safety of high-dose" exact="propranolol" post="for the management of supraventricular tachyarrhythmias (SVTs) in infants"/>
   <result pre="through entire inpatient stay, and 87.7% of those discharged on" exact="propranolol" post="were recurrence-free at follow-up.[ 17] Several other studies also"/>
   <result pre="follow-up.[ 17] Several other studies also support the efficacy of" exact="propranolol" post="in treating SVT in infants.[ 18 19] Apart from"/>
   <result pre="in treating SVT in infants.[ 18 19] Apart from propranolol," exact="digoxin" post="has also been used to treat SVT in this"/>
   <result pre="this patient population. The evidence related to comparative efficacy/safety of" exact="propranolol" post="and digoxin has been conflicting. Bolin et al. conducted"/>
   <result pre="population. The evidence related to comparative efficacy/safety of propranolol and" exact="digoxin" post="has been conflicting. Bolin et al. conducted a large"/>
   <result pre="retrospective database study including 2657 neonates and found that while" exact="digoxin" post="and propranolol were the most commonly prescribed drugs for"/>
   <result pre="study including 2657 neonates and found that while digoxin and" exact="propranolol" post="were the most commonly prescribed drugs for SVT in"/>
   <result pre="commonly prescribed drugs for SVT in infants, the use of" exact="digoxin" post="decreased to 23% and propranolol increased to 77% of"/>
   <result pre="in infants, the use of digoxin decreased to 23% and" exact="propranolol" post="increased to 77% of all the antiarrhythmic medications prescribed"/>
   <result pre="2015. They also found that odds for mortality in the" exact="propranolol" post="arm were 0.32 times than that for the digoxin"/>
   <result pre="the propranolol arm were 0.32 times than that for the" exact="digoxin" post="arm (confidence interval [CI]: 0.17–0.59; P &amp;lt; 0.001). Moreover,"/>
   <result pre="[CI]: 0.17–0.59; P &amp;lt; 0.001). Moreover, hospital costs in the" exact="propranolol" post="group were significantly lesser than that in the digoxin"/>
   <result pre="the propranolol group were significantly lesser than that in the" exact="digoxin" post="group ( P = 0.003). Thus, it can be"/>
   <result pre="P = 0.003). Thus, it can be safely said that" exact="propranolol" post="is superior to digoxin in the management of SVT"/>
   <result pre="it can be safely said that propranolol is superior to" exact="digoxin" post="in the management of SVT in infants.[ 20] Furthermore,"/>
   <result pre="digoxin in the management of SVT in infants.[ 20] Furthermore," exact="propranolol" post="has also shown promising results in heart failure caused"/>
   <result pre="the exact mechanism of its antihypertensive effect is not known," exact="propranolol" post="is known to work through several mechanisms including peripheral"/>
   <result pre="and renin–angiotensin–aldosterone–sympathetic axis inhibition.[ 11] Further, the anxiolytic effect of" exact="propranolol" post="is also well known.[ 23] Based on all these"/>
   <result pre="also well known.[ 23] Based on all these factors, presently," exact="propranolol" post="is being considered for the treatment of resistant arterial"/>
   <result pre="27] Rabkin et al. accidentally found the therapeutic effect of" exact="propranolol" post="for migraine while they were studying its use in"/>
   <result pre="pectoris.[ 2] Since then, several studies have been conducted wherein" exact="propranolol" post="was found to be safe and effective in managing"/>
   <result pre="such studies (N = 2403) that assessed the effect of" exact="propranolol" post="on migraine headaches. Reduction in migraine activity was 44%"/>
   <result pre="and global patient reports were used to assess efficacy) for" exact="propranolol" post="and only 14% for placebo.[ 32] A Cochrane review"/>
   <result pre="Rossnagel evaluated 58 clinical trials assessing efficacy and safety of" exact="propranolol" post="compared to placebo and other drugs (including other beta-blockers,"/>
   <result pre="several other drugs) in adults with migraine. The results showed" exact="propranolol" post="to be more effective than placebo and as effective"/>
   <result pre="CI: −1.86–−0.07; divalproex: −1.28, 95% CI: −2.44–−0.27). Moreover, patients with" exact="topiramate" post="or propranolol also exhibited significantly reduced headache frequency compared"/>
   <result pre="divalproex: −1.28, 95% CI: −2.44–−0.27). Moreover, patients with topiramate or" exact="propranolol" post="also exhibited significantly reduced headache frequency compared to placebo"/>
   <result pre="−1.17, 95% CI: −1.98–−0.35; propranolol: −1.37, 95% CI: −2.49–−0.29). Further," exact="propranolol" post="was found to be safer and more tolerable when"/>
   <result pre="found to be safer and more tolerable when compared to" exact="topiramate" post="(propranolol vs. topiramate, all adverse events: odds ratio (OR):"/>
   <result pre="2.09, 95% CI: 1.11–4.52). Thus, considering all the parameters together," exact="propranolol" post="was the most beneficial treatment for migraine.[ 34] Propranolol"/>
   <result pre="for migraine treatment in children, of the several drugs studied," exact="propranolol" post="(propranolol vs. placebo: OR: 27.6, 95% CI: 6.58–115.77, P"/>
   <result pre="be effective.[ 35] In a randomized double-blind trial which compared" exact="propranolol" post="with sodium valproate for migraine prophylaxis in pediatric patients,"/>
   <result pre="In a randomized double-blind trial which compared propranolol with sodium" exact="valproate" post="for migraine prophylaxis in pediatric patients, while both drugs"/>
   <result pre="parameters, the reduction in baseline headache frequency was better with" exact="propranolol" post="( P = 0.044).[ 36] Hence, the beneficial effect"/>
   <result pre="( P = 0.044).[ 36] Hence, the beneficial effect of" exact="propranolol" post="in reducing headache frequency as seen in the network"/>
   <result pre="tremors start to affect activities of daily living. Propranolol and" exact="primidone" post="(anticonvulsant medication) are the first-line medications used, and propranolol"/>
   <result pre="and primidone (anticonvulsant medication) are the first-line medications used, and" exact="propranolol" post="is the only drug approved by the United States"/>
   <result pre="(FDA) for the treatment of essential tremors.[ 38] Efficacy of" exact="propranolol" post="in the treatment of essential tremors was first reported"/>
   <result pre="first reported in the early 1970s. The exact mechanism of" exact="propranolol" post="in essential tremors is not yet clear. However, it"/>
   <result pre="by the American Academy of Neurology published in 2011 recommend" exact="propranolol" post="and primidone as the first line of treatment (Level"/>
   <result pre="American Academy of Neurology published in 2011 recommend propranolol and" exact="primidone" post="as the first line of treatment (Level A, established"/>
   <result pre="been observed that about 50%–70% of the patients respond to" exact="propranolol" post="and 50% respond to primidone, when compared to placebo."/>
   <result pre="when compared to placebo. In addition, the dropout rate with" exact="propranolol" post="is &amp;lt;20% while that for primidone is 20%–30%.[ 38]"/>
   <result pre="the dropout rate with propranolol is &amp;lt;20% while that for" exact="primidone" post="is 20%–30%.[ 38] Thus, propranolol appears to have an"/>
   <result pre="is &amp;lt;20% while that for primidone is 20%–30%.[ 38] Thus," exact="propranolol" post="appears to have an advantage over primidone. Moreover, because"/>
   <result pre="an advantage over primidone. Moreover, because of limited availability of" exact="primidone" post="in India, propranolol turns out to be the first"/>
   <result pre="primidone. Moreover, because of limited availability of primidone in India," exact="propranolol" post="turns out to be the first choice.[ 40] Anxiety"/>
   <result pre="study, anxiety and depression scores were significantly lower in the" exact="propranolol" post="group ( P &amp;lt; 0.0001) when compared to the"/>
   <result pre="group.[ 42] Another study compared the efficacy and safety of" exact="propranolol" post="in patients receiving two different doses of propranolol (20"/>
   <result pre="safety of propranolol in patients receiving two different doses of" exact="propranolol" post="(20 mg and 40 mg) with those not receiving"/>
   <result pre="not receiving any anxiolytic medication. Anxiolysis scores improved significantly in" exact="propranolol" post="groups compared with control group ( P &amp;lt; 0.05).["/>
   <result pre="be changing in the recent years. Studies have shown that" exact="propranolol" post="can alter the way memories are stored in the"/>
   <result pre="This finding has led to a number of studies evaluating" exact="propranolol" post="in PTSD. A study by Vaiva et al. reported"/>
   <result pre="PTSD symptoms were reduced in patients with trauma exposure receiving" exact="propranolol" post="as compared to those not receiving the drug ("/>
   <result pre="( P = 0.037).[ 46] As per Mahabir et al.," exact="propranolol" post="not only alleviates the unpleasant memories related to a"/>
   <result pre="to prevent hemorrhage. Treatment options include nonselective beta-blockers such as" exact="propranolol" post="and endoscopic variceal ligation (EVL). The mechanism of action"/>
   <result pre="and endoscopic variceal ligation (EVL). The mechanism of action of" exact="propranolol" post="in portal hypertension is through both beta-1 and beta-2"/>
   <result pre="splanchnic vasoconstriction via unopposed alpha-adrenergic activity.[ 49 50] Studies comparing" exact="propranolol" post="and EVL have found both these measures to be"/>
   <result pre="is, therefore, considered as the first line of treatment. Moreover," exact="propranolol" post="is also believed to have a role in preventing"/>
   <result pre="for variceal bleeding in cirrhotic patients. This beneficial effect of" exact="propranolol" post="is due to reduction in bacterial translocation by increasing"/>
   <result pre="In patients with small varices but high risk of bleeding," exact="propranolol" post="is recommended as EVL may be technically difficult in"/>
   <result pre="with medium to large varices can be treated with either" exact="propranolol" post="or EVL.[ 50 51] The combination of propranolol and"/>
   <result pre="with either propranolol or EVL.[ 50 51] The combination of" exact="propranolol" post="and EVL is used in the prevention of recurrent"/>
   <result pre="a high native HVPG and a reduction in HVPG following" exact="propranolol" post="treatment, thus demonstrating that treatment with propranolol is also"/>
   <result pre="in HVPG following propranolol treatment, thus demonstrating that treatment with" exact="propranolol" post="is also effective in patients with advanced portal hypertension.["/>
   <result pre="recent study by Kim et al. compared the effectiveness of" exact="candesartan" post="and propranolol combination therapy with propranolol monotherapy in reducing"/>
   <result pre="by Kim et al. compared the effectiveness of candesartan and" exact="propranolol" post="combination therapy with propranolol monotherapy in reducing portal hypertension"/>
   <result pre="compared the effectiveness of candesartan and propranolol combination therapy with" exact="propranolol" post="monotherapy in reducing portal hypertension in patients with cirrhosis."/>
   <result pre="therapy and monotherapy ( P = 0.674). Therefore, addition of" exact="candesartan" post="to propranolol in treating patients with portal hypertension is"/>
   <result pre="monotherapy ( P = 0.674). Therefore, addition of candesartan to" exact="propranolol" post="in treating patients with portal hypertension is not recommended.["/>
   <result pre="hyperthyroidism. In addition to relieving the troublesome symptoms of hyperthyroidism," exact="propranolol" post="is known to have an additional advantage of decreasing"/>
   <result pre="Pretreatment with a combination of an alpha-adrenergic blocker such as" exact="phenoxybenzamine" post="and beta-blocker propranolol helps in preventing such complications.[ 61"/>
   <result pre="combination of an alpha-adrenergic blocker such as phenoxybenzamine and beta-blocker" exact="propranolol" post="helps in preventing such complications.[ 61 62] Recent advances"/>
   <result pre="62] Recent advances The first report of the use of" exact="propranolol" post="in infantile hemangioma was published in 2008.[ 63] Further"/>
   <result pre="hemangioma was published in 2008.[ 63] Further studies have reported" exact="propranolol" post="to be safe and effective for this indication.[ 64"/>
   <result pre="safe and effective for this indication.[ 64 65 66] Recently," exact="propranolol" post="has also shown promise in certain other conditions. A"/>
   <result pre="17) showed that in substance-dependent subjects, drug-related memory reactivation under" exact="propranolol" post="reduced craving.[ 67] In another study, propranolol was associated"/>
   <result pre="memory reactivation under propranolol reduced craving.[ 67] In another study," exact="propranolol" post="was associated with less cancer-related psychological distress in patients"/>
   <result pre="newly diagnosed with cancer.[ 68] Furthermore, potential benefits of perioperative" exact="propranolol" post="in decreasing perioperative tumor growth have been suggested.[ 69]"/>
   <result pre="can be managed conservatively without requiring discontinuation of medication. Further," exact="propranolol" post="has demonstrated safety for use in pediatric patients.[ 11"/>
   <result pre="70] S UMMARY AND F UTURE D IRECTIONS In summary," exact="propranolol" post="was first developed to treat cardiovascular diseases but soon"/>
   <result pre="patients for surgery in hyperthyroidism and pheochromocytoma. Beta-adrenergic blockade by" exact="propranolol" post="also helps in reversing the hemodynamic abnormalities in portal"/>
   <result pre="the FDA for the treatment of essential tremors. In addition," exact="propranolol" post="is cost-effective compared to other available treatment options. Although"/>
   <result pre="propranolol is cost-effective compared to other available treatment options. Although" exact="propranolol" post="has now been around for more than 50 years"/>
   <result pre="Stables DP Levin NW Suzman MM The prophylactic value of" exact="propranolol" post="in angina pectoris Am J Cardiol 1966 18 370"/>
   <result pre="300 1 6 Besterman EM Friedlander DH Clinical experiences with" exact="propranolol" post="Postgrad Med J 1965 41 526 35 5827672 7"/>
   <result pre="5827672 7 Prichard BN Gillam PM Treatment of hypertension with" exact="propranolol" post="Br Med J 1969 1 7 16 5761914 8"/>
   <result pre="from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf 12 Routledge PA Shand DG Clinical pharmacokinetics of" exact="propranolol" post="Clin Pharmacokinet 1979 4 73 90 378502 13 Nace"/>
   <result pre="Lichstein E Byington R Beta-blocker heart attack trial: Impact of" exact="propranolol" post="therapy on ventricular arrhythmias Prev Med 1985 14 346"/>
   <result pre="SO Miyake C Kim JJ Efficacy and safety of high-dose" exact="propranolol" post="for the management of infant supraventricular tachyarrhythmias J Pediatr"/>
   <result pre="Valdes SO Miyake CY Decker JA et al. Efficacy of" exact="digoxin" post="in comparison with propranolol for treatment of infant supraventricular"/>
   <result pre="Decker JA et al. Efficacy of digoxin in comparison with" exact="propranolol" post="for treatment of infant supraventricular tachycardia: Analysis of a"/>
   <result pre="multicenter, randomized controlled trial comparing the efficacy and safety of" exact="digoxin" post="versus propranolol for prophylaxis of supraventricular tachycardia in infants"/>
   <result pre="controlled trial comparing the efficacy and safety of digoxin versus" exact="propranolol" post="for prophylaxis of supraventricular tachycardia in infants Circ Arrhythm"/>
   <result pre="Bolin EH Lang SM Tang X Collins RT Propranolol versus" exact="digoxin" post="in the neonate for supraventricular tachycardia (from the pediatric"/>
   <result pre="Weeraratne C Galappatthy P Rajapakse S et al. Addition of" exact="propranolol" post="in resistant arterial hypertension treatment (APROPRIATE study): Study protocol"/>
   <result pre="S Kudrow L Stevens J Shapiro DB Long-term study of" exact="propranolol" post="in the treatment of migraine Headache 1982 22 268"/>
   <result pre="71 7174304 30 Rosen JA Observations on the efficacy of" exact="propranolol" post="for the prophylaxis of migraine Ann Neurol 1983 13"/>
   <result pre="CD002761 36 Bidabadi E Mashouf M A randomized trial of" exact="propranolol" post="versus sodium valproate for the prophylaxis of migraine in"/>
   <result pre="E Mashouf M A randomized trial of propranolol versus sodium" exact="valproate" post="for the prophylaxis of migraine in pediatric patients Paediatr"/>
   <result pre="4 8679756 43 Khadke VV Khadke SV Khare A Oral" exact="propranolol" post="– Efficacy and comparison of two doses for peri-operative"/>
   <result pre="B Lestavel P Brunet A et al. Immediate treatment with" exact="propranolol" post="decreases posttraumatic stress disorder two months after trauma Biol"/>
   <result pre="BC et al. Equal efficacy of endoscopic variceal ligation and" exact="propranolol" post="in preventing variceal bleeding in patients with noncirrhotic portal"/>
   <result pre="Na JH Kim HS Kim HA et al. Effects of" exact="candesartan" post="and propranolol combination therapy versus propranolol monotherapy in reducing"/>
   <result pre="Kim HS Kim HA et al. Effects of candesartan and" exact="propranolol" post="combination therapy versus propranolol monotherapy in reducing portal hypertension"/>
   <result pre="et al. Effects of candesartan and propranolol combination therapy versus" exact="propranolol" post="monotherapy in reducing portal hypertension Clin Mol Hepatol 2014"/>
   <result pre="62 Mihai R Sadler GP Bridge H Adrenergic blockade with" exact="phenoxybenzamine" post="and propranolol in a cohort of 60 patients undergoing"/>
   <result pre="R Sadler GP Bridge H Adrenergic blockade with phenoxybenzamine and" exact="propranolol" post="in a cohort of 60 patients undergoing surgery for"/>
   <result pre="Posiunas G et al. A randomized, controlled trial of oral" exact="propranolol" post="in infantile hemangioma N Engl J Med 2015 372"/>
   <result pre="J Prey S Lebbé G et al. Safety of oral" exact="propranolol" post="for the treatment of infantile hemangioma: A Systematic review"/>
   <result pre="Brown TG Brunet A et al. Reactivating addiction-related memories under" exact="propranolol" post="to reduce craving: A pilot randomized controlled trial J"/>
   <result pre="TJ Choi CH Lee JW et al. Perioperative administration of" exact="propranolol" post="to women undergoing ovarian cancer surgery: A pilot study"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6331488/results/search/drugs/results.xml">
   <result pre="The relationship between repetitive behaviors and growth hormone response to" exact="sumatriptan" post="challenge in adult autistic disorder Neuropsychopharmacology 2000 22 2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6332564/results/search/drugs/results.xml">
   <result pre="with oral empirical antibiotics (amoxicillin/clavulanate syrup for 9 days and then" exact="cefpodoxime" post="syrup for 4 days), leukotriene receptor antagonist, and steroid nasal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6353836/results/search/drugs/results.xml">
   <result pre="which does not comply with these terms. Abstract Background: Plasma" exact="calcitonin" post="gene-related peptide (CGRP) plays a key role in the"/>
   <result pre="higher in patients requiring migraine prevention and responsive to short-term" exact="topiramate" post="treatment. These results are clinically significant, especially for the"/>
   <result pre="for the diagnosis and treatment of pediatric migraine. pediatric migraine" exact="calcitonin" post="gene-related peptide plasma biomarker anti-migraine drugs topiramate fig-count: table-count:"/>
   <result pre="migraine. pediatric migraine calcitonin gene-related peptide plasma biomarker anti-migraine drugs" exact="topiramate" post="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Migraine, characterized"/>
   <result pre="headache severity score &amp;gt;5 were given an acute treatment with" exact="acetaminophen" post="(10–15 mg/kg), naproxen (250 mg), or sumatriptan (50 mg)"/>
   <result pre="&amp;gt;5 were given an acute treatment with acetaminophen (10–15 mg/kg)," exact="naproxen" post="(250 mg), or sumatriptan (50 mg) as the first-,"/>
   <result pre="acute treatment with acetaminophen (10–15 mg/kg), naproxen (250 mg), or" exact="sumatriptan" post="(50 mg) as the first-, second-, and third-line therapies,"/>
   <result pre="severity score &amp;gt;5 every month received a preventive treatment with" exact="flunarizine" post="(5 mg) or topiramate (50 mg) prescribed randomly as"/>
   <result pre="month received a preventive treatment with flunarizine (5 mg) or" exact="topiramate" post="(50 mg) prescribed randomly as the first-line therapy for"/>
   <result pre="&amp;gt;50% headache reduction. For non-responders, a second-line drug, such as" exact="propranolol" post="(20 mg), gabapentin (300 mg), or valproic acid (500–750"/>
   <result pre="For non-responders, a second-line drug, such as propranolol (20 mg)," exact="gabapentin" post="(300 mg), or valproic acid (500–750 mg), was randomly"/>
   <result pre="drug, such as propranolol (20 mg), gabapentin (300 mg), or" exact="valproic acid" post="(500–750 mg), was randomly prescribed to replace or to"/>
   <result pre="requiring acute therapy, 20 of 48 patients (42%) responded to" exact="acetaminophen" post="with headache reduction &amp;gt;50%, while 15 of 27 (56%)"/>
   <result pre="27 (56%) and 6 of 13 (46%) patients responded to" exact="naproxen" post="and sumatriptan, respectively (Figure 2). There was no adverse"/>
   <result pre="respectively (Figure 2). There was no adverse effect reported with" exact="acetaminophen" post="intake, two (7%) complained of abdominal pain after taking"/>
   <result pre="acetaminophen intake, two (7%) complained of abdominal pain after taking" exact="naproxen" post="and four (29%) reported nausea, flushing, numbness, or general"/>
   <result pre="who needed acute therapy were treated with acetaminophen, naproxen, or" exact="sumatriptan" post="as the first-, second-, and third-line choices, respectively. The"/>
   <result pre="8 (50%) to propranolol, and 3 of 4 (75%) to" exact="valproic acid" post="(Figure 2). Three patients (10%) treated with flunarizine suffered"/>
   <result pre="to valproic acid (Figure 2). Three patients (10%) treated with" exact="flunarizine" post="suffered from dizziness, depression, and skin rash, respectively. Two"/>
   <result pre="depression, and skin rash, respectively. Two patients (10%) who took" exact="topiramate" post="had paresthesia or vomiting. One (8%) who was on"/>
   <result pre="topiramate had paresthesia or vomiting. One (8%) who was on" exact="gabapentin" post="had prolonged headache and two (50%) on valproic acid"/>
   <result pre="was on gabapentin had prolonged headache and two (50%) on" exact="valproic acid" post="had hair loss or visual hallucination. There was no"/>
   <result pre="visual hallucination. There was no obvious adverse effect reported with" exact="cyproheptadine" post="or propranolol (Figure 3). Figure 3 Responsiveness to preventive"/>
   <result pre="There was no obvious adverse effect reported with cyproheptadine or" exact="propranolol" post="(Figure 3). Figure 3 Responsiveness to preventive anti-migraine therapy"/>
   <result pre="preventive anti-migraine therapy using cyproheptadine, flunarizine, topiramate, gabapentin, propranolol, or" exact="valproic acid." post="The ordinate is the numbers of patients with 0"/>
   <result pre="responders and non-responders in each drug-treatment group. The responders to" exact="topiramate" post="had higher CGRP levels (437 ± 131 pg/ml, n"/>
   <result pre="different and those with higher CGRP levels responded better to" exact="topiramate" post="(Figure 5). Using a threshold of 62.57 or 125.97"/>
   <result pre="pg/ml, the sensitivity of the plasma CGRP level in predicting" exact="topiramate" post="responders was 0.86 and specificity 0.67, or 0.71 and"/>
   <result pre="than acetaminophen. For preventive therapy, the short-term response rate to" exact="topiramate" post="(70%) was higher than that of flunarizine (55%) among"/>
   <result pre="response rate to topiramate (70%) was higher than that of" exact="flunarizine" post="(55%) among the first-line monotherapy. One-third of cyproheptadine-treated children"/>
   <result pre="study of childhood migraine ( 28). The response rate of" exact="acetaminophen" post="(42%) in the present study is relatively lower than"/>
   <result pre="of choice for acute migraine treatment, NSAIDs are better than" exact="acetaminophen" post="(response rate: 56 vs. 42%) in Taiwanese children, similar"/>
   <result pre="in a parallel pediatric study in USA ( 29). Oral" exact="sumatriptan" post="has been reported to be not significantly superior to"/>
   <result pre="in 46% of Taiwanese patients here who were refractory to" exact="acetaminophen" post="or NSAIDs, although the placebo effect was not examined"/>
   <result pre="headache ( 31). Only one-third of patients here responded to" exact="cyproheptadine" post="at 2 weeks of therapy although there was no"/>
   <result pre="the other first-line preventive therapies, the short-term response rate to" exact="topiramate" post="(70%) was higher than that of flunarizine (55%). This"/>
   <result pre="response rate to topiramate (70%) was higher than that of" exact="flunarizine" post="(55%). This is different from the comparable response rates"/>
   <result pre="treatment in a Korean study ( 32). It suggests that" exact="topiramate" post="is more efficient to achieve short-term responsiveness than flunarizine"/>
   <result pre="that topiramate is more efficient to achieve short-term responsiveness than" exact="flunarizine" post="although the long-term effectiveness is comparable to flunarizine ("/>
   <result pre="responsiveness than flunarizine although the long-term effectiveness is comparable to" exact="flunarizine" post="( 32). The incidences of adverse effects are similar"/>
   <result pre="the present study whereas more adverse effects were noted in" exact="topiramate" post="than flunarizine (10 vs. 5%) in the Korean study"/>
   <result pre="study whereas more adverse effects were noted in topiramate than" exact="flunarizine" post="(10 vs. 5%) in the Korean study ( 32)."/>
   <result pre="of the collected population. Among the second-line preventive therapies, including" exact="valproic acid," post="propranolol, and gabapentin, the response rate of valproic acid,"/>
   <result pre="including valproic acid, propranolol, and gabapentin, the response rate of" exact="valproic acid," post="which has been approved by the United States Food"/>
   <result pre="migraine remains controversial ( 35– 37). This study shows that" exact="propranolol" post="has 50% responsiveness and no side effects, which together"/>
   <result pre="and no side effects, which together with the results of" exact="valproic acid," post="is in agreement with the findings of Bidabadi and"/>
   <result pre="Mashouf ( 38) in pediatric migraine prophylaxis. The effectiveness of" exact="gabapentin" post="in pediatric migraine has rarely been studied ( 33,"/>
   <result pre="39). The present study shows a similar responsiveness (50%) to" exact="gabapentin" post="as to propranolol although the adverse effects in gabapentin"/>
   <result pre="study shows a similar responsiveness (50%) to gabapentin as to" exact="propranolol" post="although the adverse effects in gabapentin are relatively higher."/>
   <result pre="to gabapentin as to propranolol although the adverse effects in" exact="gabapentin" post="are relatively higher. Interestingly, the use of gabapentin was"/>
   <result pre="effects in gabapentin are relatively higher. Interestingly, the use of" exact="gabapentin" post="was found to be ineffective in adult migraine treatment"/>
   <result pre="for preventive therapy. Among the treatment drugs in our study," exact="topiramate" post="was the only medication to which the responders had"/>
   <result pre="sensitivity and specificity of the plasma CGRP level in predicting" exact="topiramate" post="responders was 0.86 and 0.67, or 0.71 and 0.83,"/>
   <result pre="45). Multi-center, randomized, double-blind, placebo-controlled trials established the efficacy of" exact="topiramate" post="in significantly reducing the frequency and severity of migraine"/>
   <result pre="50). Pre-clinical studies in migraine animal models have shown that" exact="topiramate" post="inhibited neurogenic dural vasodilation by inhibiting CGRP release from"/>
   <result pre="by noxious inoculation ( 17, 51). We also found that" exact="topiramate" post="inhibited CGRP immunoreactivity in the trigeminal ganglia and dura"/>
   <result pre="remains to be elucidated whether the α6GABA AR-modulating effect of" exact="topiramate" post="contributes to its antimigraine activity. The finding that plasma"/>
   <result pre="antimigraine activity. The finding that plasma CGRP levels in the" exact="topiramate" post="responders are significantly higher than the non-responders provides clinical"/>
   <result pre="clinical evidence supporting the notion that the prophylactic effect of" exact="topiramate" post="is mediated by a suppression of CGRP release, which"/>
   <result pre="mass index (BMI), which might be a confounding factor because" exact="topiramate" post="may cause body weight loss in some patients ("/>
   <result pre="topiramate-responsive. Our results also suggest that NSAIDs are better than" exact="acetaminophen" post="for acute therapy whereas topiramate is superior to flunarizine"/>
   <result pre="that NSAIDs are better than acetaminophen for acute therapy whereas" exact="topiramate" post="is superior to flunarizine in short-term responsiveness for preventive"/>
   <result pre="than acetaminophen for acute therapy whereas topiramate is superior to" exact="flunarizine" post="in short-term responsiveness for preventive therapy of pediatric migraine."/>
   <result pre="et al. . NO-induced migraine attack: strong increase in plasma" exact="calcitonin" post="gene-related peptide (CGRP) concentration and negative correlation with platelet"/>
   <result pre="Chang SH Lee WT Wu RM Chiou LC . Plasma" exact="calcitonin" post="gene-related peptide in diagnosing and predicting paediatric migraine. Cephalalgia"/>
   <result pre="Caproni S Pisani A et al. . Critical role of" exact="calcitonin" post="gene-related peptide receptors in cortical spreading depression. Proc Natl"/>
   <result pre="MT Chiou LC Fan PC . Age-dependent anti-migraine effects of" exact="valproic acid" post="and topiramate in rats. Front Pharmacol. ( 2018) 9:"/>
   <result pre="Fan PC . Age-dependent anti-migraine effects of valproic acid and" exact="topiramate" post="in rats. Front Pharmacol. ( 2018) 9: 1095. 10.3389/fphar.2018.01095"/>
   <result pre="ML Hoppu K Valkeila E Santavuori P . Ibuprofen or" exact="acetaminophen" post="for the acute treatment of migraine in children: a"/>
   <result pre="Burke B Frank LM Toor S et al. . Children's" exact="ibuprofen" post="suspension for the acute treatment of pediatric migraine. Headache"/>
   <result pre="randomized placebo-controlled study. Do children with migraine respond to oral" exact="sumatriptan" post="differently from adults? Neurology ( 1997) 48: 1100– 3."/>
   <result pre="BC Chae JH Choi J et al. . Comparison of" exact="flunarizine" post="and topiramate for the prophylaxis of pediatric migraines. Eur"/>
   <result pre="JH Choi J et al. . Comparison of flunarizine and" exact="topiramate" post="for the prophylaxis of pediatric migraines. Eur J Paediatr"/>
   <result pre="K Macdonald JT Uden DL . Comparison of self-hypnosis and" exact="propranolol" post="in the treatment of juvenile classic migraine. Pediatrics ("/>
   <result pre="Ashrafi MR Shabanian R Zamani GR Mahfelati F . Sodium" exact="valproate" post="versus propranolol in paediatric migraine prophylaxis. Eur J Paediatr"/>
   <result pre="Shabanian R Zamani GR Mahfelati F . Sodium valproate versus" exact="propranolol" post="in paediatric migraine prophylaxis. Eur J Paediatr Neurol. ("/>
   <result pre="38. Bidabadi E Mashouf M . A randomized trial of" exact="propranolol" post="versus sodium valproate for the prophylaxis of migraine in"/>
   <result pre="Mashouf M . A randomized trial of propranolol versus sodium" exact="valproate" post="for the prophylaxis of migraine in pediatric patients ."/>
   <result pre="Linde M Mulleners WM Chronicle EP Mccrory DC Gabapentin or" exact="pregabalin" post="for the prophylaxis of episodic migraine in adults. Cochr"/>
   <result pre="Schifter S Jansen-Olesen I Olesen J . Plasma levels of" exact="calcitonin" post="gene-related peptide in chronic tension-type headache. Neurology ( 2000)"/>
   <result pre="SW Vockell AL Lecates S Kabbouche M . Effectiveness of" exact="topiramate" post="in the prevention of childhood headaches. Headache ( 2002)"/>
   <result pre="Simeone TA Wilcox KS White HS . Subunit selectivity of" exact="topiramate" post="modulation of heteromeric GABA(A) receptors. Neuropharmacology ( 2006) 50:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6360466/results/search/drugs/results.xml">
   <result pre="days, her symptoms resolved and she was discharged home on" exact="doxycycline" post="due to suspicion for Bartonella encephalitis. The patient admitted"/>
   <result pre="in encephalitis, although more rarely. 3 She was started on" exact="levetiracetam" post="for seizure prophylaxis due to concern that her initial"/>
   <result pre="friend’s kitten two months prior to admission. Empiric treatment with" exact="doxycycline" post="was initiated due to suspected Bartonella encephalitis. The patient"/>
   <result pre="due to suspected Bartonella encephalitis. The patient was discharged on" exact="doxycycline" post="100 mg twice daily and completed a total 14-day"/>
   <result pre="the patient had made a complete recovery. She stayed on" exact="levetiracetam" post="for six months and then was weaned off the"/>
   <result pre="the diagnosis of Bartonella encephalitis. The infectious disease team chose" exact="doxycycline" post="monotherapy rather than adding rifampin due to concerns about"/>
   <result pre="about the family’s compliance with taking antibiotics as well as" exact="levetiracetam" post="when discharged from the hospital. Doxycycline with rifampin is"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6369373/results/search/drugs/results.xml">
   <result pre="as a teenager. The paternal great uncle was treated with" exact="phenobarbital" post="but self-discontinued the medication, since it did not improve"/>
   <result pre="The mother reported occasional migraine headaches. For our case patient," exact="oxcarbazepine" post="was initiated at a moderate dosage of 300 mg"/>
   <result pre="Ding Y Xu S Jiang Y et al. Oxcarbazepine versus" exact="carbamazepine" post="in the treatment of paroxysmal kinesigenic dyskinesia Int J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6375438/results/search/drugs/results.xml">
   <result pre="new article, Mitchell and colleagues show that exposure to both" exact="acetaminophen" post="and ibuprofen adversely affected germ cell development in rodent"/>
   <result pre="Mitchell and colleagues show that exposure to both acetaminophen and" exact="ibuprofen" post="adversely affected germ cell development in rodent and human"/>
   <result pre="fetal gonadal tissue. The U.S. Food and Drug Administration considers" exact="acetaminophen" post="the safest analgesic to take throughout pregnancy when used"/>
   <result pre="grew the tissue pieces in culture, exposing them to either" exact="ibuprofen" post="or acetaminophen at levels consistent with human therapeutic doses."/>
   <result pre="tissue pieces in culture, exposing them to either ibuprofen or" exact="acetaminophen" post="at levels consistent with human therapeutic doses. The cultured"/>
   <result pre="a 43% reduction in gonocyte number in acetaminophen-treated tissue, and" exact="ibuprofen" post="exposure reduced gonocytes by 49%. During pregnancy, women typically"/>
   <result pre="into mice, they found that grafts from mice dosed with" exact="acetaminophen" post="had 17% fewer gonocytes after 24 hours than grafts"/>
   <result pre="than grafts from untreated mice. Previous studies have suggested that" exact="acetaminophen" post="may have antiandrogenic effects in the fetal environment. 4"/>
   <result pre="reduction in gonocyte number that they observed. Mild analgesics, including" exact="acetaminophen" post="and ibuprofen, are known to target the prostaglandin pathway."/>
   <result pre="article, Mitchell and colleagues reported that exposing pregnant rats to" exact="indomethacin" post="or acetaminophen blocked prostaglandin signaling in fetal ovarian tissue."/>
   <result pre="and colleagues reported that exposing pregnant rats to indomethacin or" exact="acetaminophen" post="blocked prostaglandin signaling in fetal ovarian tissue. 10 In"/>
   <result pre="2 signaling in human germ cells mimicked the effects of" exact="acetaminophen" post="and ibuprofen in the same cell line. The findings"/>
   <result pre="in human germ cells mimicked the effects of acetaminophen and" exact="ibuprofen" post="in the same cell line. The findings support previous"/>
   <result pre="same cell line. The findings support previous studies showing that" exact="acetaminophen" post="exposure can affect both male and female gonadal development,"/>
   <result pre="Jørgensen A , et al. 2018. Effects of exposure to" exact="acetaminophen" post="and ibuprofen on fetal germ cell development in both"/>
   <result pre=", et al. 2018. Effects of exposure to acetaminophen and" exact="ibuprofen" post="on fetal germ cell development in both sexes in"/>
   <result pre=", Smith LB , et al. 2015. Prolonged exposure to" exact="acetaminophen" post="reduces testosterone production by the human fetal testis in"/>
   <result pre="LB , et al. 2015. Prolonged exposure to acetaminophen reduces" exact="testosterone" post="production by the human fetal testis in a xenograft"/>
   <result pre="of fetal exposure of the rat to the cyclooxygenase inhibitor" exact="indomethacin" post=". PLoS One 8( 5): e62556, PMID: 23671609, 10.1371/journal.pone.0062556"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6380461/results/search/drugs/results.xml">
   <result pre="conjugates. Of these, 7 (tremelimumab, spartalizumab, BCD-100, omburtamab, mirvetuximab soravtansine," exact="trastuzumab" post="duocarmazine, and depatuxizumab mafodotin) are being evaluated in clinical"/>
   <result pre="more than 10 have been granted marketing approvals. In 2002," exact="adalimumab" post="became the first mAb therapeutic derived from phage display"/>
   <result pre="mogamulizumab-kpkc, moxetumomab pasudotox-tdfk, tildrakizumab-asmn. Abbreviations: CD, cluster of differentiation; CGRP," exact="calcitonin" post="gene-related peptide; dsFv, disulfide-stabilized variable fragment; EU European Union;"/>
   <result pre="in adults. Erenumab is a human IgG2 mAb that targets" exact="calcitonin" post="gene-related peptide (CGRP) receptor, thereby blocking the activity of"/>
   <result pre="patients administered mogamulizumab compared to 3.1 months for patients taking" exact="vorinostat" post="in this clinical trial. 31 Poteligeo was designated as"/>
   <result pre="or to tildrakizumab 200 mg, tildrakizumab 100 mg, placebo, or" exact="etanercept" post="50 mg (2:2:1:2; reSURFACE 2). In these trials, the"/>
   <result pre="tolerated and found to be efficacious compared with placebo and" exact="etanercept" post="in the treatment of patients with moderate-to-severe chronic plaque"/>
   <result pre="NCT03250962) of camrelizumab with or without decitabine, the addition of" exact="decitabine" post="increased the complete response rate of patients with relapsed/refractory"/>
   <result pre="factor; BCMA, B-cell maturation antigen; BLyS, B lymphocyte stimulator; CGRP," exact="calcitonin" post="gene-related peptide; MASP-2, mannose-binding protein-associated serine protease 2; TACI,"/>
   <result pre="or 3 mg brolucizumab (HAWK study only) versus 2 mg" exact="aflibercept" post="in patients with nAMD. The primary efficacy endpoint of"/>
   <result pre="nAMD. The primary efficacy endpoint of the studies, non-inferiority to" exact="aflibercept" post="(EYLEA®) in mean change in best-corrected visual acuity (BCVA)"/>
   <result pre="5.9 letters for brolucizumab 6 mg versus 5.3 letters for" exact="aflibercept" post="in the HAWK study, and 6.1 letters versus 6.6"/>
   <result pre="fluid was 24% for brolucizumab 6 mg vs. 37% for" exact="aflibercept" post="in HAWK (p = 0.0001) and 24% vs. 39%,"/>
   <result pre="-175 µm for brolucizumab 6 mg versus -149 µm for" exact="aflibercept" post="in HAWK (p = 0.0057) and -198 µm versus"/>
   <result pre="infusion in combination with standard doses of bendamustine (B) and" exact="rituximab" post="(R) or obinutuzumab in patients with relapsed or refractory"/>
   <result pre="with standard doses of bendamustine (B) and rituximab (R) or" exact="obinutuzumab" post="in patients with relapsed or refractory follicular lymphoma (FL)"/>
   <result pre="The combination of polatuzumab vedotin with R-CHP protocol (rituximab, cyclophosphamide," exact="doxorubicin" post="and prednisone) versus R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone)"/>
   <result pre="protocol (rituximab, cyclophosphamide, doxorubicin and prednisone) versus R-CHOP (rituximab-cyclophosphamide, doxorubicin," exact="vincristine" post="and prednisone) in DLBCL patients is currently being investigated"/>
   <result pre="ICARIA study (NCT02990338), the effects of isatuximab in combination with" exact="pomalidomide" post="and low-dose dexamethasone are being compared to those of"/>
   <result pre="the effects of isatuximab in combination with pomalidomide and low-dose" exact="dexamethasone" post="are being compared to those of only the chemotherapy"/>
   <result pre="(NCT02967692) evaluating the safety and efficacy of spartalizumab combined with" exact="dabrafenib" post="(a BRAF inhibitor) and trametinib (a MEK inhibitor) versus"/>
   <result pre="efficacy of spartalizumab combined with dabrafenib (a BRAF inhibitor) and" exact="trametinib" post="(a MEK inhibitor) versus matching placebo in combination with"/>
   <result pre="trametinib (a MEK inhibitor) versus matching placebo in combination with" exact="dabrafenib" post="and trametinib in previously untreated patients with BRAF V600–mutant"/>
   <result pre="MEK inhibitor) versus matching placebo in combination with dabrafenib and" exact="trametinib" post="in previously untreated patients with BRAF V600–mutant unresectable or"/>
   <result pre="plans to submit marketing applications for PDR001 in combination with" exact="trametinib" post="+ dabrafenib for the treatment of metastatic BRAF V600+"/>
   <result pre="submit marketing applications for PDR001 in combination with trametinib +" exact="dabrafenib" post="for the treatment of metastatic BRAF V600+ melanoma in"/>
   <result pre="Phase 2 L-MIND study (NCT02399085), which evaluated MOR208 combined with" exact="lenalidomide" post="in patients with relapsed or refractory DLBCL. 83 A"/>
   <result pre="primarily on the L-MIND study. 84 MOR208 with bendamustine versus" exact="rituximab" post="with bendamustine is being evaluated in the Phase 2/3"/>
   <result pre="of ublituximab and TGR-1202, a PI3K delta inhibitor, versus anti-CD20" exact="obinutuzumab" post="plus chlorambucil in untreated and previously treated CLL patients."/>
   <result pre="and TGR-1202, a PI3K delta inhibitor, versus anti-CD20 obinutuzumab plus" exact="chlorambucil" post="in untreated and previously treated CLL patients. The primary"/>
   <result pre="are evaluating the efficacy and safety of ublituximab compared to" exact="teriflunomide" post="in 440 patients with relapsing multiple sclerosis. For both"/>
   <result pre="2/3 study (NCT03470922) of anti-LAG3 relatlimab (Bristol-Myers Squibb) combined with" exact="nivolumab" post="versus nivolumab in patients with previously untreated metastatic or"/>
   <result pre="(NCT03470922) of anti-LAG3 relatlimab (Bristol-Myers Squibb) combined with nivolumab versus" exact="nivolumab" post="in patients with previously untreated metastatic or unresectable melanoma"/>
   <result pre="July 2020. ADC ‘antibodies to watch’ include mirvetuximab soravtansine (ImmunoGen)," exact="trastuzumab" post="duocarmazine (Synthon BioPharmaceuticals), and depatuxizumab mafodotin (Abbvie). Mirvetuximab soravtansine,"/>
   <result pre="first half of 2019. The safety and efficacy of anti-HER2" exact="trastuzumab" post="duocarmazine (Synthon BioPharmaceuticals) is being evaluated in the Phase"/>
   <result pre="C5 complement component 5 CCR4 CC chemokine receptor 4 CGRP" exact="calcitonin" post="gene-related peptide CHMP Committee for Medicinal Products for Human"/>
   <result pre=", Li Q , et al Tildrakizumab versus placebo or" exact="etanercept" post="for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2):"/>
   <result pre=", et al Camrelizumab (SHR-1210) alone or in combination with" exact="gemcitabine" post="plus cisplatin for nasopharyngeal carcinoma: results from two single-arm,"/>
   <result pre="al Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus" exact="cisplatin" post="for nasopharyngeal carcinoma: results from two single-arm, phase 1"/>
   <result pre="collab: Novartis Two-year data for Novartis brolucizumab reaffirm superiority versus" exact="aflibercept" post="in reducing retinal fluid in patients with nAMD ."/>
   <result pre=", et al Adding polatuzumab vedotin (POLA) to bendamustine and" exact="rituximab" post="(BR) treatment improves survival in patients with relapsed/refractory DLBCL:"/>
   <result pre="MorphoSys reports updated data from L-MIND study of MOR208 plus" exact="lenalidomide" post="in aggressive lymphoma (r/r DLBCL) . 3 13, 2018"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6413701/results/search/drugs/results.xml">
   <result pre="patients younger than 6 years; p &amp;lt; 0.005). Amitriptyline and" exact="topiramate" post="were the most effective drugs ( p &amp;lt; 0.05),"/>
   <result pre="increases with age. Although our &quot;real word&quot; study shows that" exact="amitriptyline" post="and topiramate are the most effective drugs regardless of"/>
   <result pre="age. Although our &quot;real word&quot; study shows that amitriptyline and" exact="topiramate" post="are the most effective drugs regardless of the CPH"/>
   <result pre="patients (72.1%). The drugs used for prophylaxis included 5-hydroxytryptophan, flunarizine," exact="amitriptyline" post="and topiramate. The most frequently used drug was amitriptyline"/>
   <result pre="flunarizine, amitriptyline and topiramate. The most frequently used drug was" exact="amitriptyline" post="(81.6%), followed by topiramate (21.7%), flunarizine (12%), and 5-hydroxytryptophan"/>
   <result pre="The most frequently used drug was amitriptyline (81.6%), followed by" exact="topiramate" post="(21.7%), flunarizine (12%), and 5-hydroxytryptophan (6.9%), while 13.9% of"/>
   <result pre="frequently used drug was amitriptyline (81.6%), followed by topiramate (21.7%)," exact="flunarizine" post="(12%), and 5-hydroxytryptophan (6.9%), while 13.9% of patients needed"/>
   <result pre="not have follow-up data for 29.5% of patients. Amitriptyline and" exact="topiramate" post="were the drugs with higher percentage of efficacy ("/>
   <result pre="much lower than the in adult patients. - Amitriptyline and" exact="topiramate" post="were the most effective drugs in our CPH patients."/>
   <result pre="in children and adolescents are available for flunarizine, topiramate, and" exact="trazodone" post="(unavailable in the USA), topiramate and trazodone ( 22)."/>
   <result pre="available for flunarizine, topiramate, and trazodone (unavailable in the USA)," exact="topiramate" post="and trazodone ( 22). The use of amitriptyline, combined"/>
   <result pre="flunarizine, topiramate, and trazodone (unavailable in the USA), topiramate and" exact="trazodone" post="( 22). The use of amitriptyline, combined with psychological"/>
   <result pre="currently unavailable. In our population, the most effective drugs were" exact="amitriptyline" post="and topiramate without significant differences between them. Mack et"/>
   <result pre="In our population, the most effective drugs were amitriptyline and" exact="topiramate" post="without significant differences between them. Mack et al., ("/>
   <result pre="them. Mack et al., ( 24) investigated the efficacy of" exact="amitriptyline" post="in patients with high-frequency headache and found that both"/>
   <result pre="chronic daily headaches or continuous headaches appeared to respond to" exact="amitriptyline" post="( 24). As for topiramate, its efficacy in the"/>
   <result pre="high frequency TTH or chronic headaches. The good efficacy of" exact="topiramate" post="in our population suggests that this drug should be"/>
   <result pre="particularly high in patients older than 15 years. Amitriptyline and" exact="topiramate" post="proved the most effective drugs, regardless of the headache"/>
   <result pre="JR Slater SK et al. . Cognitive behavioral therapy plus" exact="amitriptyline" post="for children and adolescents with chronic migraine reduces headache"/>
   <result pre="adolescent chronic migraine patients: results from the cognitive-behavioral therapy and" exact="amitriptyline" post="trial . Clin J Pain ( 2017) 33: 892–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6419324/results/search/drugs/results.xml">
   <result pre="Studio Cefalee (SISC) support the use of feverfew, Mg 2+," exact="riboflavin" post="and CQ10 a Level III recommendation [ 16]. Tanacetum"/>
   <result pre="from platelets and white blood cells, reduction of iNOS (inducible" exact="nitric oxide" post="synthase) activation, inhibition of nuclear factor-kappaB (a transcriptional factor"/>
   <result pre="[ 21]. Several studies revealed decreased levels of the micronutrients" exact="riboflavin" post="(Vit B2), magnesium (Mg) and CQ10 in plasma and"/>
   <result pre="the adult model of headache treatment, in which, for example," exact="amitriptyline" post="and topiramate, have been effective, may not apply to"/>
   <result pre="food and drugs administration IKK inhibiting kinase complex iNOS inducible" exact="nitric oxide" post="synthase MA Migraine Without Aura MO Migraine With Aura"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6423905/results/search/drugs/results.xml">
   <result pre="former prodromal symptoms reflect dopaminergic hypersensitivity and are mediated by" exact="nitric oxide" post="pathways ( 42). Del Zompo et al. have shown"/>
   <result pre="susceptibility to migraine, at least in some migraine patients, and" exact="dopamine" post="can play a key role in activating the biochemical"/>
   <result pre="( 51) or brainstem may persist after headache relief by" exact="sumatriptan" post="( 52), lending support to the hypothesis that some"/>
   <result pre="in children and adults ( 66), including increased levels of" exact="calcitonin" post="gene-related peptide ( 67), decreased levels of coenzyme Q"/>
   <result pre="statement are scarce but the efficacy in migraine prevention of" exact="naratriptan" post="and dopamine antagonists is suggested by nonrandomized trials ("/>
   <result pre="scarce but the efficacy in migraine prevention of naratriptan and" exact="dopamine" post="antagonists is suggested by nonrandomized trials ( 75, 76)."/>
   <result pre="placebo-controlled, randomized trials to ascertain this hypothesis. Similarly, domperidone, a" exact="dopamine" post="antagonist, may block a migraine attack, provided it is"/>
   <result pre="adolescents. It has been shown, in adult migraine sufferers, that" exact="nitroglycerin" post="and pituitary adenylate-cyclase activating protein could induce postdromal symptoms,"/>
   <result pre="M Bocchetta A Gessa GL et al. . Association between" exact="dopamine" post="receptor genes and migraine without aura in a Sardinian"/>
   <result pre="Chang SH Lee WT Wu RM Chiou LC . Plasma" exact="calcitonin" post="gene-related peptide in diagnosing and predicting paediatric migraine. Cephalalgia."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6426199/results/search/drugs/results.xml">
   <result pre="50 placebo-controlled and 58 comparative effectiveness trials. Compared to placebo," exact="propranolol" post="reduced episodic migraine headaches by 1.5 headaches/month at 8"/>
   <result pre="comparable to other medications known to be effective including flunarizine," exact="topiramate" post="and valproate. For chronic migraine, propranolol was more likely"/>
   <result pre="be effective including flunarizine, topiramate and valproate. For chronic migraine," exact="propranolol" post="was more likely to reduce headaches by at least"/>
   <result pre="for tension-type headache. Conclusions There is high quality evidence that" exact="propranolol" post="is better than placebo for episodic migraine headache. Other"/>
   <result pre="27], botulinum toxin-A [ 28], calcium channel blockers [ 29]," exact="flunarizine" post="[ 17], pizotifen [ 17], serotonin agonists [ 30],"/>
   <result pre="[ 28], calcium channel blockers [ 29], flunarizine [ 17]," exact="pizotifen" post="[ 17], serotonin agonists [ 30], serotonin reuptake inhibitors"/>
   <result pre="The 2012 American Academy of Neurology guideline recommends beta-blockers, specifically" exact="propranolol" post="and metoprolol, as first line therapy for preventing migraines"/>
   <result pre="In Europe, commonly prescribed prophylactic agents include antiepileptics, beta-blockers, flunarizine," exact="pizotifen" post="and TCAs [ 35]. Other studies found that specialists"/>
   <result pre="studies. Trial sequential analysis was performed for the comparisons of" exact="propranolol" post="to placebo for headache frequency (at 8 weeks), using"/>
   <result pre="Ten different beta-blockers were studied. Propranolol (n = 74) and" exact="metoprolol" post="(n = 21) were the most commonly evaluated beta-blockers."/>
   <result pre="= 21) were the most commonly evaluated beta-blockers. Atenolol, nadolol," exact="pindolol" post="and timolol had two studies each. Several beta-blockers were"/>
   <result pre="were the most commonly evaluated beta-blockers. Atenolol, nadolol, pindolol and" exact="timolol" post="had two studies each. Several beta-blockers were evaluated in"/>
   <result pre="beta-blockers were evaluated in only a single trial (acebutolol, alprenolol," exact="bisoprolol" post="and oxprenolol). Study characteristics for included trials are provided"/>
   <result pre="weeks were both graded as high-quality evidence. TSA analysis of" exact="propranolol" post="vs. placebo for headache frequency demonstrated that it is"/>
   <result pre="effective than placebo at 8 weeks ( Fig 4) included" exact="bisoprolol" post="(-0.70 ha/month, 95% CI: -1.4 to -0.05, low quality),"/>
   <result pre="bisoprolol (-0.70 ha/month, 95% CI: -1.4 to -0.05, low quality)," exact="metoprolol" post="(-0.86 ha/month, 95% CI: -1.4 to -0.34, moderate quality)"/>
   <result pre="(-0.86 ha/month, 95% CI: -1.4 to -0.34, moderate quality) and" exact="timolol" post="(-0.77 ha/month, 95% CI: -1.4 to -0.12, moderate quality)."/>
   <result pre="1.1–1.8, NNT: 4.5, 95% CI: 2.8–12.9). Other effective beta-blockers included" exact="atenolol" post="(RR: 1.8, 95% CI: 1.0–3.2, NNT: 6.3, 95% CI:"/>
   <result pre="(RR: 1.8, 95% CI: 1.0–3.2, NNT: 6.3, 95% CI: 3.2–332.4)," exact="metoprolol" post="(RR: 1.9, 95% CI: 1.3–2.8, NNT: 4.7, 95% CI:3.0–10.4)"/>
   <result pre="(RR: 1.9, 95% CI: 1.3–2.8, NNT: 4.7, 95% CI:3.0–10.4) and" exact="timolol" post="(RR: 1.8, 95% CI: 1.4–2.3, NNT: 4.2, 95% CI:"/>
   <result pre="CI: 1.4–2.3, NNT: 4.2, 95% CI: 2.7–8.8,). At 8 weeks," exact="metoprolol" post="reduced analgesic medication use (-4.0 doses/month, 95% CI: -7.5"/>
   <result pre="use (-4.0 doses/month, 95% CI: -7.5 to -0.48) as did" exact="propranolol" post="at 12 weeks (-2.1 doses/month, 95% CI: -3.2 to"/>
   <result pre="was modestly reduced by a number of different beta-blockers including" exact="atenolol" post="(SMD: -0.62, 95% CI: -1.2 to -0.004), metoprolol (SMD:"/>
   <result pre="beta-blockers including atenolol (SMD: -0.62, 95% CI: -1.2 to -0.004)," exact="metoprolol" post="(SMD: -0.42, 95% CI: -0.77 to -0.07), propranolol (SMD:"/>
   <result pre="to -0.004), metoprolol (SMD: -0.42, 95% CI: -0.77 to -0.07)," exact="propranolol" post="(SMD: -0.48, 95% CI: -0.75 to -0.22) and timolol"/>
   <result pre="-0.07), propranolol (SMD: -0.48, 95% CI: -0.75 to -0.22) and" exact="timolol" post="(SMD: -0.53, 95% CI: -0.84 to -0.21). At 8"/>
   <result pre="At 8 weeks, headache severity was modestly reduced by both" exact="metoprolol" post="(SMD: -0.53, 95% CI: -0.71 to -0.14) and propranolol"/>
   <result pre="both metoprolol (SMD: -0.53, 95% CI: -0.71 to -0.14) and" exact="propranolol" post="(SMD: -0.51, 95% CI: -0.76 to -0.26). Headache duration"/>
   <result pre="95% CI: -0.76 to -0.26). Headache duration was reduced by" exact="metoprolol" post="(-2.0 hours, 95% CI: -3.7 to -0.26) and propranolol"/>
   <result pre="by metoprolol (-2.0 hours, 95% CI: -3.7 to -0.26) and" exact="propranolol" post="(-6.1 hours, 95% CI: -16.2 to -0.39). Network meta-analysis"/>
   <result pre="8 weeks (p = 0.27) in effectiveness in comparisons between" exact="propranolol" post="(n = 9) compared to bisoprolol (n = 2),"/>
   <result pre="effectiveness in comparisons between propranolol (n = 9) compared to" exact="bisoprolol" post="(n = 2), metoprolol (n = 3) and nadolol"/>
   <result pre="propranolol (n = 9) compared to bisoprolol (n = 2)," exact="metoprolol" post="(n = 3) and nadolol (n = 3). Similarly,"/>
   <result pre="to bisoprolol (n = 2), metoprolol (n = 3) and" exact="nadolol" post="(n = 3). Similarly, at 12 weeks, there was"/>
   <result pre="no difference (p = 0.84) n effectiveness in comparisons between" exact="propranolol" post="(n = 9) compared to bisoprolol (n = 2),"/>
   <result pre="effectiveness in comparisons between propranolol (n = 9) compared to" exact="bisoprolol" post="(n = 2), nadolol (n = 3) and timolol"/>
   <result pre="propranolol (n = 9) compared to bisoprolol (n = 2)," exact="nadolol" post="(n = 3) and timolol (n = 2). The"/>
   <result pre="to bisoprolol (n = 2), nadolol (n = 3) and" exact="timolol" post="(n = 2). The 8- and 12-week analysis confirmed"/>
   <result pre="were from single trials (5-hydroxytryptophan, aspirin, atenolol, candesartan, clonidine, cyclandelate," exact="mefenamic acid," post="naproxen, nifedipine, nimodipine, nortriptyline, pindolol, riboflavin). Comparisons with more"/>
   <result pre="nortriptyline, pindolol, riboflavin). Comparisons with more than one study included:" exact="amitriptyline" post="(n = 2), femoxetine (n = 2), flunarizine (n"/>
   <result pre="study included: amitriptyline (n = 2), femoxetine (n = 2)," exact="flunarizine" post="(n = 11), metoprolol (n = 4), nadolol (n"/>
   <result pre="= 2), femoxetine (n = 2), flunarizine (n = 11)," exact="metoprolol" post="(n = 4), nadolol (n = 3), nimodipine (n"/>
   <result pre="= 2), flunarizine (n = 11), metoprolol (n = 4)," exact="nadolol" post="(n = 3), nimodipine (n = 2), timolol (n"/>
   <result pre="= 11), metoprolol (n = 4), nadolol (n = 3)," exact="nimodipine" post="(n = 2), timolol (n = 2) tofenamic acid"/>
   <result pre="= 4), nadolol (n = 3), nimodipine (n = 2)," exact="timolol" post="(n = 2) tofenamic acid (n = 2), topiramate"/>
   <result pre="2), timolol (n = 2) tofenamic acid (n = 2)," exact="topiramate" post="(n = 3) and valproate (n = 3). Several"/>
   <result pre="tofenamic acid (n = 2), topiramate (n = 3) and" exact="valproate" post="(n = 3). Several combinations were tested including propranolol"/>
   <result pre="and valproate (n = 3). Several combinations were tested including" exact="propranolol" post="+ amitriptyline vs. amitriptyline (n = 1), and propranolol"/>
   <result pre="(n = 3). Several combinations were tested including propranolol +" exact="amitriptyline" post="vs. amitriptyline (n = 1), and propranolol + flunarizine"/>
   <result pre="3). Several combinations were tested including propranolol + amitriptyline vs." exact="amitriptyline" post="(n = 1), and propranolol + flunarizine was compared"/>
   <result pre="including propranolol + amitriptyline vs. amitriptyline (n = 1), and" exact="propranolol" post="+ flunarizine was compared to flunarizine. Propranolol combined with"/>
   <result pre="+ amitriptyline vs. amitriptyline (n = 1), and propranolol +" exact="flunarizine" post="was compared to flunarizine. Propranolol combined with topiramate was"/>
   <result pre="propranolol + flunarizine was compared to flunarizine. Propranolol combined with" exact="topiramate" post="was compared with topiramate alone. Nonpharmacologic interventions were compared"/>
   <result pre="compared to flunarizine. Propranolol combined with topiramate was compared with" exact="topiramate" post="alone. Nonpharmacologic interventions were compared to propranolol in three"/>
   <result pre="was compared with topiramate alone. Nonpharmacologic interventions were compared to" exact="propranolol" post="in three trials (acupuncture, behavioral management, biofeedback). Metoprolol was"/>
   <result pre="with nonpharmacologic (acupuncture). Metoprolol was compared to a combination of" exact="metoprolol" post="and fluoxetine in 2 trials and the combination of"/>
   <result pre="(acupuncture). Metoprolol was compared to a combination of metoprolol and" exact="fluoxetine" post="in 2 trials and the combination of metoprolol and"/>
   <result pre="metoprolol and fluoxetine in 2 trials and the combination of" exact="metoprolol" post="and flunarizine was compared to flunarizine alone in 2"/>
   <result pre="fluoxetine in 2 trials and the combination of metoprolol and" exact="flunarizine" post="was compared to flunarizine alone in 2 trials. The"/>
   <result pre="and the combination of metoprolol and flunarizine was compared to" exact="flunarizine" post="alone in 2 trials. The primary outcome comparison (headache"/>
   <result pre="effective than clomipramine, though comparable to acupuncture, bisoprolol, clonidine, flunarizine," exact="nebivolol" post="and pizotifen. Adding fluoxetine to metoprolol or flunarizine to"/>
   <result pre="comparable to acupuncture, bisoprolol, clonidine, flunarizine, nebivolol and pizotifen. Adding" exact="fluoxetine" post="to metoprolol or flunarizine to either propranolol or metoprolol"/>
   <result pre="acupuncture, bisoprolol, clonidine, flunarizine, nebivolol and pizotifen. Adding fluoxetine to" exact="metoprolol" post="or flunarizine to either propranolol or metoprolol did not"/>
   <result pre="clonidine, flunarizine, nebivolol and pizotifen. Adding fluoxetine to metoprolol or" exact="flunarizine" post="to either propranolol or metoprolol did not improve headache"/>
   <result pre="and pizotifen. Adding fluoxetine to metoprolol or flunarizine to either" exact="propranolol" post="or metoprolol did not improve headache frequency. All comparisons"/>
   <result pre="Adding fluoxetine to metoprolol or flunarizine to either propranolol or" exact="metoprolol" post="did not improve headache frequency. All comparisons were graded"/>
   <result pre="were graded as low-quality. Propranolol was more effective than femoxetine," exact="mefenamic acid," post="naproxen, nifedipine and very low-dose (40mg) nortriptyline, but comparable"/>
   <result pre="low-quality. Propranolol was more effective than femoxetine, mefenamic acid, naproxen," exact="nifedipine" post="and very low-dose (40mg) nortriptyline, but comparable to 5-hydroxytryptophan,"/>
   <result pre="candesartan, clonidine, cyclandelate, flunarizine, metoprolol, nadolol, naproxen, nimodipine, riboflavin, timolol," exact="tolfenamic acid," post="topiramate and valproic acid. All comparisons were single trials"/>
   <result pre="cyclandelate, flunarizine, metoprolol, nadolol, naproxen, nimodipine, riboflavin, timolol, tolfenamic acid," exact="topiramate" post="and valproic acid. All comparisons were single trials and"/>
   <result pre="metoprolol, nadolol, naproxen, nimodipine, riboflavin, timolol, tolfenamic acid, topiramate and" exact="valproic acid." post="All comparisons were single trials and were rated as"/>
   <result pre="as low-quality evidence with the exception of the comparisons to" exact="flunarizine" post="and metoprolol at 8 weeks that were graded as"/>
   <result pre="evidence with the exception of the comparisons to flunarizine and" exact="metoprolol" post="at 8 weeks that were graded as moderate or"/>
   <result pre="high-quality. The network meta-analysis confirmed these findings, but suggested that" exact="metoprolol" post="was also superior to naproxen (SMD: -1.2, 95% CI:"/>
   <result pre="these findings, but suggested that metoprolol was also superior to" exact="naproxen" post="(SMD: -1.2, 95% CI: -1.6 to -0.78). 10.1371/journal.pone.0212785.t004 Table"/>
   <result pre="were placebo controlled. ( Table 6). Propranolol was compared to" exact="flunarizine" post="[ 151], nortriptyline [ 76], valproic acid [ 105]"/>
   <result pre="( Table 6). Propranolol was compared to flunarizine [ 151]," exact="nortriptyline" post="[ 76], valproic acid [ 105] and to the"/>
   <result pre="Propranolol was compared to flunarizine [ 151], nortriptyline [ 76]," exact="valproic acid" post="[ 105] and to the combination of propranolol and"/>
   <result pre="76], valproic acid [ 105] and to the combination of" exact="propranolol" post="and flunarizine [ 151]. In addition, a combination of"/>
   <result pre="acid [ 105] and to the combination of propranolol and" exact="flunarizine" post="[ 151]. In addition, a combination of propranolol and"/>
   <result pre="propranolol and flunarizine [ 151]. In addition, a combination of" exact="propranolol" post="and topiramate was compared to topiramate alone [ 129]."/>
   <result pre="flunarizine [ 151]. In addition, a combination of propranolol and" exact="topiramate" post="was compared to topiramate alone [ 129]. Propranolol was"/>
   <result pre="addition, a combination of propranolol and topiramate was compared to" exact="topiramate" post="alone [ 129]. Propranolol was no better than valproic"/>
   <result pre="to topiramate alone [ 129]. Propranolol was no better than" exact="valproic acid" post="or flunarizine and the combinations (propranolol + topiramate and"/>
   <result pre="[ 129]. Propranolol was no better than valproic acid or" exact="flunarizine" post="and the combinations (propranolol + topiramate and propranolol +"/>
   <result pre="than valproic acid or flunarizine and the combinations (propranolol +" exact="topiramate" post="and propranolol + flunarizine) was no better than topiramate"/>
   <result pre="acid or flunarizine and the combinations (propranolol + topiramate and" exact="propranolol" post="+ flunarizine) was no better than topiramate and flunarizine"/>
   <result pre="+ topiramate and propranolol + flunarizine) was no better than" exact="topiramate" post="and flunarizine alone ( Table 6). 10.1371/journal.pone.0212785.t006 Table 6"/>
   <result pre="and propranolol + flunarizine) was no better than topiramate and" exact="flunarizine" post="alone ( Table 6). 10.1371/journal.pone.0212785.t006 Table 6 Non-episodic trials."/>
   <result pre="only one trial evaluating tension-type headache, comparing the combination of" exact="pindolol" post="and amitriptyline to placebo and to amitriptyline alone ["/>
   <result pre="trial evaluating tension-type headache, comparing the combination of pindolol and" exact="amitriptyline" post="to placebo and to amitriptyline alone [ 57]. The"/>
   <result pre="the combination of pindolol and amitriptyline to placebo and to" exact="amitriptyline" post="alone [ 57]. The combination of pindolol and amitriptyline"/>
   <result pre="placebo and to amitriptyline alone [ 57]. The combination of" exact="pindolol" post="and amitriptyline was more effective than placebo at reducing"/>
   <result pre="to amitriptyline alone [ 57]. The combination of pindolol and" exact="amitriptyline" post="was more effective than placebo at reducing headache frequency"/>
   <result pre="efficacy of beta-blockers for episodic migraine headaches. Compared to placebo," exact="propranolol" post="was effective in reducing episodic migraine frequency. The effect"/>
   <result pre="reduction from 4.8 to 3.5 headaches a month. Subjects given" exact="propranolol" post="were more likely to report at least 50% reduction"/>
   <result pre="in duration compared to those receiving placebo. Outcomes from the" exact="propranolol" post="comparisons to placebo were rated as high-quality evidence. In"/>
   <result pre="to placebo were rated as high-quality evidence. In three trials," exact="metoprolol" post="also reduced headache frequency, though the reduction was less"/>
   <result pre="as most were studied in just one trial each. Atenolol," exact="bisoprolol" post="and timolol had weak evidence of benefit. Acebutolol, alprenolol"/>
   <result pre="were studied in just one trial each. Atenolol, bisoprolol and" exact="timolol" post="had weak evidence of benefit. Acebutolol, alprenolol and nadolol"/>
   <result pre="Atenolol, bisoprolol and timolol had weak evidence of benefit. Acebutolol," exact="alprenolol" post="and nadolol appeared to be ineffective in migraine prophylaxis."/>
   <result pre="and timolol had weak evidence of benefit. Acebutolol, alprenolol and" exact="nadolol" post="appeared to be ineffective in migraine prophylaxis. This is"/>
   <result pre="to properties of the beta-blockers. Propranolol is nonselective as is" exact="alprenolol" post="and nadolol. Metoprolol, also effective is a ß-1 selective"/>
   <result pre="also effective is a ß-1 selective drug as is atenolol," exact="bisoprolol" post="and acebutolol. Given that acebutolol, alprenolol and nadolol were"/>
   <result pre="drug as is atenolol, bisoprolol and acebutolol. Given that acebutolol," exact="alprenolol" post="and nadolol were only studied in one trial each,"/>
   <result pre="is atenolol, bisoprolol and acebutolol. Given that acebutolol, alprenolol and" exact="nadolol" post="were only studied in one trial each, it is"/>
   <result pre="mostly of single-trials with the exception of the comparison of" exact="propranolol" post="to metoprolol (moderate quality, no difference) and to flunarizine"/>
   <result pre="single-trials with the exception of the comparison of propranolol to" exact="metoprolol" post="(moderate quality, no difference) and to flunarizine (high quality,"/>
   <result pre="of propranolol to metoprolol (moderate quality, no difference) and to" exact="flunarizine" post="(high quality, no difference). Flunarizine, not available in the"/>
   <result pre="beta-blockers are compared to other commonly used prophylactic regimens. Propranolol," exact="metoprolol" post="and flunarizine appear to have similar efficacy. The other"/>
   <result pre="compared to other commonly used prophylactic regimens. Propranolol, metoprolol and" exact="flunarizine" post="appear to have similar efficacy. The other comparisons were"/>
   <result pre="meta-analysis of chronic migraines, tricyclic antidepressants were more effective than" exact="propranolol" post="[ 17] but propranolol was similar in efficacy to"/>
   <result pre="tricyclic antidepressants were more effective than propranolol [ 17] but" exact="propranolol" post="was similar in efficacy to antiepileptics and flunarizine, similar"/>
   <result pre="First, while the quality of evidence for the comparison between" exact="propranolol" post="and placebo was high, in general, the remaining comparisons"/>
   <result pre="3 headaches a month. This means that migraine sufferers given" exact="propranolol" post="will have substantial residual headache burden. Propranolol reduces headaches"/>
   <result pre="the severity or duration of the headaches experienced. Propranolol and" exact="metoprolol" post="exert similar effects and propranolol is as effective as"/>
   <result pre="the headaches experienced. Propranolol and metoprolol exert similar effects and" exact="propranolol" post="is as effective as flunarizine. The data for other"/>
   <result pre="A Randomized Controlled Trial comparing the efficacy of low-dose amitriptyline," exact="amitriptyline" post="with pindolol and surrogate placebo in the treatment of"/>
   <result pre="Controlled Trial comparing the efficacy of low-dose amitriptyline, amitriptyline with" exact="pindolol" post="and surrogate placebo in the treatment of chronic tension-type"/>
   <result pre="3908306 59 al-Qassab HK , Findley LJ . Comparison of" exact="propranolol" post="LA 80 mg and propranolol LA 160 mg in"/>
   <result pre="Findley LJ . Comparison of propranolol LA 80 mg and" exact="propranolol" post="LA 160 mg in migraine prophylaxis: a placebo controlled"/>
   <result pre="LT , Hamik A , Peroutka SJ . Nifedipine versus" exact="propranolol" post="for the initial prophylaxis of migraine. Headache 1989; 29("/>
   <result pre=", Akbari M . A double-blind, randomized trial of low-dose" exact="topiramate" post="vs propranolol in migraine prophylaxis . 2008; 118( 5):"/>
   <result pre="M . A double-blind, randomized trial of low-dose topiramate vs" exact="propranolol" post="in migraine prophylaxis . 2008; 118( 5): 301– 305."/>
   <result pre=", D'Alessandro R , Baruzzi A et al. Propranolol and" exact="acetylsalicylic acid" post="in migraine prophylaxis. Double-blind crossover study . Acta Neurol"/>
   <result pre="Long-term outcome of migraine therapy: predictive value of the frontotemporal" exact="nitroglycerin" post="test . Neurology 1998; 51( 5): 1475– 1478. 9818888"/>
   <result pre="MA , Ciciarelli MC , Speciali JG . Propranolol vs" exact="flunarizine" post="vs flunarizine plus propranolol in migraine without aura prophylaxis."/>
   <result pre="Ciciarelli MC , Speciali JG . Propranolol vs flunarizine vs" exact="flunarizine" post="plus propranolol in migraine without aura prophylaxis. A double-blind"/>
   <result pre=", Speciali JG . Propranolol vs flunarizine vs flunarizine plus" exact="propranolol" post="in migraine without aura prophylaxis. A double-blind trial ."/>
   <result pre="Savundra PA , Cleave N , McAinsh J . Long-acting" exact="propranolol" post="in the prophylaxis of migraine: a comparative study of"/>
   <result pre="clearcut longterm prophylactic effect of one month of treatment with" exact="propranolol" post="in migraineurs . Cephalalgia 1987; 7: 459– 460. 72"/>
   <result pre="a randomized, parallel, double-blind study in comparison with placebo and" exact="propranolol" post=". collab: The Study group. Cephalalgia 1996; 16( 6):"/>
   <result pre="et al. A comparative study of oral acetylsalicyclic acid and" exact="metoprolol" post="for the prophylactic treatment of migraine. A randomized, controlled,"/>
   <result pre="G et al. Efficacy and tolerability in migraine prophylaxis of" exact="flunarizine" post="in reduced doses: a comparison with propranolol 160 mg"/>
   <result pre="migraine prophylaxis of flunarizine in reduced doses: a comparison with" exact="propranolol" post="160 mg daily . Cephalalgia 2002; 22( 3): 209–"/>
   <result pre="al. Topiramate in migraine prophylaxis—results from a placebo-controlled trial with" exact="propranolol" post="as an active control . J Neurol 2004; 251("/>
   <result pre="of low doses of propranolol, nortriptyline, and the combination of" exact="propranolol" post="and nortriptyline for the preventive treatment of migraine ."/>
   <result pre="doses of propranolol, nortriptyline, and the combination of propranolol and" exact="nortriptyline" post="for the preventive treatment of migraine . 2009; 67("/>
   <result pre="Arnott WS . Comparison of the efficacy and safety of" exact="flunarizine" post="to propranolol in the prophylaxis of migraine . Can"/>
   <result pre=". Comparison of the efficacy and safety of flunarizine to" exact="propranolol" post="in the prophylaxis of migraine . Can J Neurol"/>
   <result pre="E , Niederberger U . Responders and non-responders to metoprolol," exact="propranolol" post="and nifedipine treatment in migraine prophylaxis: a dose-range study"/>
   <result pre="Niederberger U . Responders and non-responders to metoprolol, propranolol and" exact="nifedipine" post="treatment in migraine prophylaxis: a dose-range study based on"/>
   <result pre=", Bolsche F , Wedekind W et al. Cyclandelate versus" exact="propranolol" post="in the prophylaxis of migraine—a double-blind placebo-controlled study ."/>
   <result pre="HP , Husstedt IW . [ Prevention of migraine with" exact="metoprolol" post="and flunarizine. A double-blind crossover study]. Nervenarzt 1988; 59("/>
   <result pre=", Schlake HP , Husstedt IW . Acetylsalicylic acid vs." exact="metoprolol" post="in migraine prophylaxis—a double-blind cross-over study . Headache 1990;"/>
   <result pre="H , Hokkanen E , Myllyla VV . Long acting" exact="propranolol" post="in the prophylaxis of migraine. Comparison of the daily"/>
   <result pre="J , Mogelvang B , Simonsen H . Acupuncture versus" exact="metoprolol" post="in migraine prophylaxis: a randomized trial of trigger point"/>
   <result pre="RH , Hornabrook RW , Lambie DG . Comparison of" exact="mefenamic acid" post="and propranolol with placebo in migraine prophylaxis. Acta Neurol"/>
   <result pre="RW , Lambie DG . Comparison of mefenamic acid and" exact="propranolol" post="with placebo in migraine prophylaxis. Acta Neurol Scand 1986;"/>
   <result pre="3524092 98 Kangasniemi P , Hedman C . Metoprolol and" exact="propranolol" post="in the prophylactic treatment of classical and common migraine."/>
   <result pre="AH , Petersen E . Femoxetine—a new 5-HT uptake inhibitor—and" exact="propranolol" post="in the prophylactic treatment of migraine . Acta neurologica"/>
   <result pre="6606930 101 Kaniecki RG . A comparison of divalproex with" exact="propranolol" post="and placebo for the prophylaxis of migraine without aura"/>
   <result pre="102 Kass B , Nestvold K . Propranolol (Inderal) and" exact="clonidine" post="(Catapressan) in the prophylactic treatment of migraine. A comparative"/>
   <result pre="V . Biofeedback assisted diaphragmatic breathing and systematic relaxation versus" exact="propranolol" post="in long term prophylaxis of migraine . Complement Ther"/>
   <result pre=", Soelberg SP , Hansen PE . Tolfenamic acid versus" exact="propranolol" post="in the prophylactic treatment of migraine. Acta Neurol Scand"/>
   <result pre=". An open label cross-over comparison of divalproex sodium and" exact="propranolol" post="HCl in the prevention of migraine headaches . HEADACHE"/>
   <result pre="53. 106 Kozubski W , Prusinski A . [ Sodium" exact="valproate" post="versus propranolol in the prophylactic treatment of migraine]. Neurol"/>
   <result pre="Kozubski W , Prusinski A . [ Sodium valproate versus" exact="propranolol" post="in the prophylactic treatment of migraine]. Neurol Neurochir Pol"/>
   <result pre="E , Mayer K , Schroth G . Clomipramine and" exact="metoprolol" post="in migraine prophylaxis—a double-blind crossover study. Headache 1985; 25("/>
   <result pre="P , Schoenen J , Hedman C . Metoprolol v." exact="clonidine" post="in the prophylactic treatment of migraine. Cephalalgia 1985; 5("/>
   <result pre="W , Schmidt R , Soyka D . Flunarizine vs." exact="propranolol" post="in the prophylaxis of migraine: two double-blind comparative studies"/>
   <result pre="8: 21– 26. 3180198 111 Ludin HP . Flunarizine and" exact="propranolol" post="in the treatment of migraine. Headache 1989; 29( 4):"/>
   <result pre="HP . [ Comparison of the effect of 5-hydroxytryptophan and" exact="propranolol" post="in the interval treatment of migraine ]. Schweiz Med"/>
   <result pre="KK , Christiansen LV . Prophylactic treatment of migraine with" exact="tolfenamic acid," post="propranolol and placebo. Acta Neurol Scand 1986; 73( 4):"/>
   <result pre="Christiansen LV . Prophylactic treatment of migraine with tolfenamic acid," exact="propranolol" post="and placebo. Acta Neurol Scand 1986; 73( 4): 423–"/>
   <result pre="Nambiar NJ , Aiyappa C , Srinivasa R . Oral" exact="riboflavin" post="versus oral propranolol in migraine prophylaxis: An open label"/>
   <result pre="Aiyappa C , Srinivasa R . Oral riboflavin versus oral" exact="propranolol" post="in migraine prophylaxis: An open label randomized controlled trial"/>
   <result pre="HJ , Melville ID . A double blind trial of" exact="acebutolol" post="for migraine prophylaxis. Headache 1978; 18( 1): 20– 22."/>
   <result pre="B , Gustavsson CL , Furberg B . Nadolol and" exact="propranolol" post="in migraine management. Headache 1986; 26( 10): 490– 493."/>
   <result pre=", Hedman G , Johansson F et al. Metoprolol and" exact="propranolol" post="in migraine prophylaxis: a double-blind multicentre study. Acta Neurol"/>
   <result pre="Palferman TG , Gibberd FB , Simmonds JP . Prophylactic" exact="propranolol" post="in the treatment of headache. Br J Clin Pract"/>
   <result pre="E , Feve J , Masson M et al. Long-acting" exact="propranolol" post="in migraine prophylaxis: results of a double-blind, placebo-controlled study"/>
   <result pre="89– 94. 6128710 125 Ryan RE Sr. Comparative study of" exact="nadolol" post="and propranolol in prophylactic treatment of migraine. Am Heart"/>
   <result pre="6128710 125 Ryan RE Sr. Comparative study of nadolol and" exact="propranolol" post="in prophylactic treatment of migraine. Am Heart J 1984;"/>
   <result pre="Corbett J , Eisner L et al. A comparison of" exact="naproxen" post="sodium to propranolol hydrochloride and a placebo control for"/>
   <result pre="Eisner L et al. A comparison of naproxen sodium to" exact="propranolol" post="hydrochloride and a placebo control for the prophylaxis of"/>
   <result pre="H , Graf C , Brixius K . Nebivolol and" exact="metoprolol" post="for treating migraine: an advance on beta-blocker treatment? Headache"/>
   <result pre="Fritz VU , Levien SL . A comparative trial of" exact="flunarizine" post="and propranolol in the prevention of migraine. S Afr"/>
   <result pre=", Levien SL . A comparative trial of flunarizine and" exact="propranolol" post="in the prevention of migraine. S Afr Med J"/>
   <result pre="M , Mathew NT et al. Randomized, placebo-controlled trial of" exact="propranolol" post="added to topiramate in chronic migraine . Neurology 2012;"/>
   <result pre="NT et al. Randomized, placebo-controlled trial of propranolol added to" exact="topiramate" post="in chronic migraine . Neurology 2012; 78( 13): 976–"/>
   <result pre="H , Averkina N et al. Central mechanisms of controlled-release" exact="metoprolol" post="in migraine: a double-blind, placebo-controlled study . Cephalalgia 2007;"/>
   <result pre=", Iversen H , Alslev T et al. Flunarizine versus" exact="metoprolol" post="in migraine prophylaxis: a double-blind, randomized parallel group study"/>
   <result pre="1769820 132 Soyka D , Oestreich W . Flunarizine versus" exact="propranolol" post="in interval treatment of migraine. Nervenheilkunde 1990; 9: 45–"/>
   <result pre="45– 51. 133 Standnes B . The prophylactic effect of" exact="timolol" post="versus propranolol and placebo in common migraine: beta-blockers in"/>
   <result pre="133 Standnes B . The prophylactic effect of timolol versus" exact="propranolol" post="and placebo in common migraine: beta-blockers in migraine ."/>
   <result pre="AH , Sand T et al. A comparative study of" exact="candesartan" post="versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled,"/>
   <result pre="Sand T et al. A comparative study of candesartan versus" exact="propranolol" post="for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over"/>
   <result pre="S et al. Effectiveness and tolerability of acupuncture compared with" exact="metoprolol" post="in migraine prophylaxis . Headache 2006; 46( 10): 1492–"/>
   <result pre=", Stern MA , Meyer JH . Comparative efficacy of" exact="nadolol" post="and propranolol in the management of migraine. Headache 1987;"/>
   <result pre="MA , Meyer JH . Comparative efficacy of nadolol and" exact="propranolol" post="in the management of migraine. Headache 1987; 27( 8):"/>
   <result pre="P , Hakkarainen H , Olesen J . Timolol vs" exact="propranolol" post="vs placebo in common migraine prophylaxis: a double-blind multicenter"/>
   <result pre="S , Standnes B , Hedman C . Metoprolol and" exact="pizotifen" post="in the prophylactic treatment of classical and common migraine."/>
   <result pre="Nair KG . A pilot study of the value of" exact="propranolol" post="in migraine. J Postgrad Med 1975; 21( 3): 111–"/>
   <result pre="111– 113. 1107526 148 Chen J . Clinical study of" exact="topiramate" post="in preventing migraine attacks. Sichuan Medical Journal 2009; 30("/>
   <result pre="S , Hassanein R , Seim J . Propranolol and" exact="amitriptyline" post="in prophylaxis of migraine. Pharmacokinetic and therapeutic effects ."/>
   <result pre="150 Gong X , Zhang J . Therapeutic effect of" exact="metoprolol" post="tartrate combined with flunarizine on migraine in the treatment"/>
   <result pre="Zhang J . Therapeutic effect of metoprolol tartrate combined with" exact="flunarizine" post="on migraine in the treatment of migraine . Journ"/>
   <result pre="14): 24– 2957. 151 Ke D . Sibiling combined with" exact="propranolol" post="to treat migraine. Modern Practical Medicine 2003; 15( 12):"/>
   <result pre="120– 121. 153 Li S . Therapeutic effect of sodium" exact="valproate" post="on prevention of migraine recurrence. Sichuan Medical Journal 2004;"/>
   <result pre="25( 4): 416. 154 Ma W . Therapeutic effect of" exact="metoprolol" post="tartrate combined with flunarizine on migraine in the treatment"/>
   <result pre="Ma W . Therapeutic effect of metoprolol tartrate combined with" exact="flunarizine" post="on migraine in the treatment of migraine . Modern"/>
   <result pre="Y , Wang G . Observation on the efficacy of" exact="propranolol" post="in preventing menopausal migraine. Chinese Journal of Misdiagnosis 2006;"/>
   <result pre="24): 4760– 4761. 157 Yang Y . The effect of" exact="metoprolol" post="combined with fluoxetine on preventing migraine and its effect"/>
   <result pre="157 Yang Y . The effect of metoprolol combined with" exact="fluoxetine" post="on preventing migraine and its effect on serotonin ."/>
   <result pre="Q , Lu X . Preliminary randomized controlled trial of" exact="topiramate" post="and propranolol to prevent migraine attacks . Huaxi Pharmaceutical"/>
   <result pre="Lu X . Preliminary randomized controlled trial of topiramate and" exact="propranolol" post="to prevent migraine attacks . Huaxi Pharmaceutical Journal 2005;"/>
   <result pre=", Lin L , Tian X . The efficacy of" exact="metoprolol" post="combined with fluoxetine in preventing migraine. Journal of Clinical"/>
   <result pre=", Tian X . The efficacy of metoprolol combined with" exact="fluoxetine" post="in preventing migraine. Journal of Clinical and Experimental Medicine"/>
   <result pre="124– 128. 4401692 163 Dongxiang H . Clinical trial of" exact="propranolol" post="and amitriptyline in the treatment of migraine. Yunnan Medicine"/>
   <result pre="4401692 163 Dongxiang H . Clinical trial of propranolol and" exact="amitriptyline" post="in the treatment of migraine. Yunnan Medicine 2010; 31("/>
   <result pre=", Xiong X . A clinical study of sibelium combining" exact="topiramate" post="in prophylactic treatment of migraine. Chinese JMAP 2002; 19("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6451865/results/search/drugs/results.xml">
   <result pre="Sadeghi M Sedighi M Karimzadeh P Ghofrani M Comparison of" exact="propranolol" post="and pregabalin for prophylaxis of childhood migraine: a randomised"/>
   <result pre="Sedighi M Karimzadeh P Ghofrani M Comparison of propranolol and" exact="pregabalin" post="for prophylaxis of childhood migraine: a randomised controlled trial"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6469474/results/search/drugs/results.xml">
   <result pre="15 years relevant efforts have been made to demonstrate that" exact="calcitonin" post="gene-related peptide (CGRP) antagonism is a valuable and druggable"/>
   <result pre="future also for patients affected by other primary headaches. Keywords" exact="calcitonin" post="gene-related peptide headache LY2951742 monoclonal antibody prophylaxis CGRP Introduction"/>
   <result pre="(eg, amitriptyline, nortriptyline), serotonin receptor antagonists (eg, pizotifene), and selective" exact="norepinephrine" post="reuptake inhibitors (SNRIs). 6 Preventive therapies may be prescribed"/>
   <result pre="to both EM and CM patients. With the exceptions of" exact="topiramate" post="and onabotulinum toxin A (the latter authorized only for"/>
   <result pre="perivascular fibers that release neuropeptides, such as substance P, and" exact="calcitonin" post="gene-related peptide (CGRP), 30 that are directly responsible for"/>
   <result pre="CGRP is a neuropeptide produced from alternative splicing of the" exact="calcitonin" post="gene. CGRP is a highly potent vasodilator and has"/>
   <result pre="a G protein-coupled receptor of the B-type constituted by the" exact="calcitonin" post="receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1),"/>
   <result pre="meningeal arteries and the middle cerebral arteries that reverses after" exact="sumatriptan" post="administration; 46 and, finally, 3) animal data suggest that"/>
   <result pre="the launch of triptans and for the first time after" exact="methysergide" post="has been withdrawn from the market, migraine patients may"/>
   <result pre="D Ghadikolaei HS Siavashi M Levetiracetam in compare to sodium" exact="valproate" post="for prophylaxis in chronic migraine headache: a randomized double-blind"/>
   <result pre="9 Assarzadegan F Tabesh H Hosseini-Zijoud SM et al. Comparing" exact="zonisamide" post="with sodium valproate in the management of migraine headaches:"/>
   <result pre="Tabesh H Hosseini-Zijoud SM et al. Comparing zonisamide with sodium" exact="valproate" post="in the management of migraine headaches: double-blind randomized clinical"/>
   <result pre="Linde M Gravdahl GB et al. A comparative study of" exact="candesartan" post="versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled,"/>
   <result pre="Gravdahl GB et al. A comparative study of candesartan versus" exact="propranolol" post="for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over"/>
   <result pre="Johari MS Beladi-Moghadam N Mazhabdar-Ghashghai H Comparing the effects of" exact="atorvastatin" post="with sodium valproate (divalproex) on frequency and intensity of"/>
   <result pre="N Mazhabdar-Ghashghai H Comparing the effects of atorvastatin with sodium" exact="valproate" post="(divalproex) on frequency and intensity of frequent migraine headaches:"/>
   <result pre="Sharafkhah M Abdolrazaghnejad A Moham-madbeigi A Faraji F Use of" exact="melatonin" post="versus valproic acid in prophylaxis of migraine patients: a"/>
   <result pre="Abdolrazaghnejad A Moham-madbeigi A Faraji F Use of melatonin versus" exact="valproic acid" post="in prophylaxis of migraine patients: a double-blind randomized clinical"/>
   <result pre="A Kane SA Tajti J Edvinsson L Differential distribution of" exact="calcitonin" post="gene-related peptide and its receptor components in the human"/>
   <result pre="Szolcsanyi J Bagdy G Sumatriptan causes parallel decrease in plasma" exact="calcitonin" post="gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin"/>
   <result pre="plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during" exact="nitroglycerin" post="induced migraine attack Cephalalgia 2005 25 3 179 183"/>
   <result pre="Lassen LH Jacobsen VB Haderslev PA et al. Involvement of" exact="calcitonin" post="gene-related peptide in migraine: regional cerebral blood flow and"/>
   <result pre="Zhang Z Wemmie JA Anderson MG Russo AF Role of" exact="calcitonin" post="gene-related peptide in light-aversive behavior: implications for migraine J"/>
   <result pre="and tolerability of MK-0974 (telcagepant), a new oral antagonist of" exact="calcitonin" post="gene-related peptide receptor, compared with zolmitriptan for acute migraine:"/>
   <result pre="new oral antagonist of calcitonin gene-related peptide receptor, compared with" exact="zolmitriptan" post="for acute migraine: a randomised, placebo-controlled, parallel-treatment trial Lancet"/>
   <result pre="study investigators Safety and efficacy of ALD403, an antibody to" exact="calcitonin" post="gene-related peptide, for the prevention of frequent episodic migraine:"/>
   <result pre="DS Safety and efficacy of LY2951742, a monoclonal antibody to" exact="calcitonin" post="gene-related peptide, for the prevention of migraine: a phase"/>
   <result pre="Darling RJ et al. Development of a novel antibody to" exact="calcitonin" post="gene-related peptide for the treatment of osteoarthritis-related pain Osteoarthritis"/>
   <result pre="effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins," exact="calcitonin" post="gene-related peptide and other neuropeptides Neuroscience 1988 24 3"/>
   <result pre="Benschop RJ Van Hecken A et al. Translational pharmacodynamics of" exact="calcitonin" post="gene-related peptide monoclonal antibody LY2951742 in a capsaicin-induced dermal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6473667/results/search/drugs/results.xml">
   <result pre="Several clinical and laboratory studies also demonstrate that estrogen and" exact="progesterone" post="levels may play a neuroprotective role following mTBI ["/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6480981/results/search/drugs/results.xml">
   <result pre="double vision. She was initially diagnosed with migraines and prescribed" exact="amitriptyline" post="without improvement in symptoms. Thereafter, she went to an"/>
   <result pre="and read as &quot;normal.&quot; She was then prescribed a 7-day" exact="prednisone" post="taper and fioricet for migraine. While on the prednisone,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6514150/results/search/drugs/results.xml">
   <result pre="BJ Lee KH . Development of extensive brain lesions following" exact="fingolimod" post="(FTY720) treatment in a patient with neuromyelitis optica spectrum"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6520671/results/search/drugs/results.xml">
   <result pre="to energy metabolism and/or mitochondrial functioning, such as: high dose" exact="riboflavin" post="(200–400 mg) [ 96, 97, 98, 99, 100], coenzyme"/>
   <result pre="[ 176]. Further reduction in excitability might be achieved via" exact="adenosine" post="signalling through A1 purinergic receptors [ 177] and regulation"/>
   <result pre="inflammation&quot; in migraine pain (review [ 187, 188]). Most importantly," exact="calcitonin" post="gene related peptide (CGRP) [ 189, 190, 191, 192,"/>
   <result pre="P, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP)," exact="nitric oxide" post="(NO) [ 135, 195, 196, 197, 198] and to"/>
   <result pre="U. Flach U. Schuh-Hofer S. Einhäupl K.M. Arnold G. High-dose" exact="riboflavin" post="treatment is efficacious in migraine prophylaxis: An open study"/>
   <result pre="99. Schoenen J. Jacquy J. Lenaerts M. Effectiveness of high-dose" exact="riboflavin" post="in migraine prophylaxis. A randomized controlled trial Neurology 1998"/>
   <result pre="treatment of migraines and tension-type headaches with intravenous and oral" exact="niacin" post="(nicotinic acid): Systematic review of the literature Nutr. J."/>
   <result pre="S. Elger C.E. Kunz W.S. The mechanism of neuroprotection by" exact="topiramate" post="in an animal model of epilepsy Epilepsia 2004 45"/>
   <result pre="Motevalian M. Shabab B. Neuroprotective effects of various doses of" exact="topiramate" post="against methylphenidate induced oxidative stress and inflammation in rat"/>
   <result pre="Shabab B. Neuroprotective effects of various doses of topiramate against" exact="methylphenidate" post="induced oxidative stress and inflammation in rat isolated hippocampus"/>
   <result pre="P. A meta-analysis of biomarkers related to oxidative stress and" exact="nitric oxide" post="pathway in migraine Cephalalgia 2015 35 931 937 10.1177/0333102414564888"/>
   <result pre="Boison D. A ketogenic diet suppresses seizures in mice through" exact="adenosine" post="A₁ receptors J. Clin. Investig. 2011 121 2679 2683"/>
   <result pre="T. Inoue T. Epilepsy treatment. Targeting LDH enzymes with a" exact="stiripentol" post="analog to treat epilepsy Science 2015 347 1362 1367"/>
   <result pre="173 178 10.1046/j.1468-1331.2001.00191.x 11284996 197. OLESEN J. The role of" exact="nitric oxide" post="(NO) in migraine, tension-type headache and cluster headache Pharmacol."/>
   <result pre="157 171 10.1016/j.pharmthera.2008.08.003 18789357 198. Olesen J. Ashina M. Can" exact="nitric oxide" post="induce migraine in normal individuals? Cephalalgia 2015 35 1125"/>
   <result pre="inflammation, improving the microbiome and increasing digestive health. ATP =" exact="adenosine" post="triphosphate; CSD = cortical spreading depressions; D-BHB = D-β-hydroxybutyrate;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6533686/results/search/drugs/results.xml">
   <result pre="medication as well. Substances indicated as used &quot;attack medication&quot; were" exact="ibuprofen" post="by 18 (56.3%), paracetamol by 8 (25.0%), mefenamic acid"/>
   <result pre="indicated as used &quot;attack medication&quot; were ibuprofen by 18 (56.3%)," exact="paracetamol" post="by 8 (25.0%), mefenamic acid by 7 (21.9%), acetylic-salicylic"/>
   <result pre="medication&quot; were ibuprofen by 18 (56.3%), paracetamol by 8 (25.0%)," exact="mefenamic acid" post="by 7 (21.9%), acetylic-salicylic acid by 5 (15.6%), caffeine"/>
   <result pre="acetylic-salicylic acid by 5 (15.6%), caffeine by 2 (6.3%), and" exact="metamizole" post="and naproxen each by one (3.1%). Substances used for"/>
   <result pre="by 5 (15.6%), caffeine by 2 (6.3%), and metamizole and" exact="naproxen" post="each by one (3.1%). Substances used for &quot;preventative medication&quot;"/>
   <result pre="each by one (3.1%). Substances used for &quot;preventative medication&quot; were" exact="propranolol" post="( n = 1) and zonisamid ( n = 1). None of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6541167/results/search/drugs/results.xml">
   <result pre="trauma in seven cases. All had failed standard pharmacotherapy, including" exact="amitriptyline" post="and topiramate. An average of 2.47 ± 1.6 BoNTA"/>
   <result pre="trauma in seven cases. All had failed standard pharmacotherapy, including" exact="amitriptyline" post="and topiramate. Results are reported in a mean ±"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6558181/results/search/drugs/results.xml">
   <result pre="both periods when compared to healthy controls; CCL5, IL-10 and" exact="nitric oxide" post="were only elevated during attack periods and TNFα, IL-1,"/>
   <result pre="C Aksakal FN . The importance of cytokines, chemokines and" exact="nitric oxide" post="in pathophysiology of migraine. J Neuroimmunol. ( 2006) 171:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6572967/results/search/drugs/results.xml">
   <result pre="gave hopeful results of treating children having eye strain with" exact="chlordiazepoxide" post="in 1963. 12 Thus headache due to eye strain"/>
   <result pre="migraine associated with eyestrain. Preliminary report of a trial of" exact="chlordiazepoxide" post="Br J Ophthalmol 1963 47 246 247 14188329 13"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6582055/results/search/drugs/results.xml">
   <result pre="pain was attributed to this diagnosis. The patient was prescribed" exact="azithromycin" post="as well as an oral antihistamine. A steroid injection"/>
   <result pre="afebrile upon presentation to the ED. He was administered empiric" exact="ceftriaxone" post="and clindamycin for 2 days. On physical exam, the"/>
   <result pre="nearly closed. His home medications included bismuth subsalicylate, acetaminophen, and" exact="pseudoephedrine" post="which did not appear to alleviate his symptoms. According"/>
   <result pre="the left oculomotor nerve ( Fig. 2B). He was administered" exact="topiramate" post="with significant improvement in the severity of his headaches"/>
   <result pre="Fig 2C). The patient's symptoms improved during the admission on" exact="topiramate" post="therapy, and the headache had resolved on discharge. Discussion"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6593911/results/search/drugs/results.xml">
   <result pre="was diagnosed with mirror movement disorder and migraine and began" exact="flunarizine" post="treatment. During the patient’s reevaluation at the end of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6620449/results/search/drugs/results.xml">
   <result pre="patients received Pocral (chloral hydrate), six received ketamine, five received" exact="midazolam" post="alone, and the remaining four patients received two or"/>
   <result pre="as a single agent in 10 patients, 4 patients received" exact="lorazepam" post="and midazolam, and 2 received lorazepam and valproic acid."/>
   <result pre="patients, 4 patients received lorazepam and midazolam, and 2 received" exact="lorazepam" post="and valproic acid. Follow-up MRI was performed after 24"/>
   <result pre="patients received lorazepam and midazolam, and 2 received lorazepam and" exact="valproic acid." post="Follow-up MRI was performed after 24 hours in one"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6629194/results/search/drugs/results.xml">
   <result pre="recommended as acute and short-term prophylactic treatment. Recombinant C1-INH and" exact="icatibant" post="are licensed for the acute treatment of pediatric patients."/>
   <result pre="14 ). If pdC1-INH is not available, attenuated oral androgen" exact="danazol" post="5 mg/kg/day or 10 mL/kg solvent detergent plasma (SDP)"/>
   <result pre="plasma (SDP) can be administered ( 14 ). Prophylaxis with" exact="danazol" post="should start 5 days before and be continued for"/>
   <result pre="Plasma-derived C1-INH, recombinant C1-INH (for children above 12 years) and" exact="icatibant" post="(for children above 2 years) are licensed for the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6631099/results/search/drugs/results.xml">
   <result pre="overview of migraine, including current therapeutics and the link to" exact="calcitonin" post="gene-related peptide (CGRP), a neuropeptide strongly implicated in migraine"/>
   <result pre="some drugs used only with migraine prevention objectives, such as" exact="flunarizine" post="and pizotifene [ 1]. Importantly, recent clinical evidence has"/>
   <result pre="used only with migraine prevention objectives, such as flunarizine and" exact="pizotifene" post="[ 1]. Importantly, recent clinical evidence has supported the"/>
   <result pre="involvement of neurogenic inflammation and, in particular, of the neuropeptide" exact="calcitonin" post="gene related peptide (CGRP) [ 12]. Neurogenic inflammation is"/>
   <result pre="Migraine CGRP, a neuropeptide produced from alternative splicing of the" exact="calcitonin" post="gene, acts as a relevant signaling peptide in mammalian"/>
   <result pre="CGRP acts via a G protein-coupled receptor constituted by the" exact="calcitonin" post="receptor-like receptor (CLR), the receptor activity-modifying protein 1 (RAMP1)"/>
   <result pre="vessels on the headache side during migraine attacks triggered by" exact="cilostazol" post="has recently been found, a finding that the authors"/>
   <result pre="are unclear, but preclinical studies using repeated 30-day administration of" exact="eletriptan" post="or indomethacin found increased TRPV1 (and TRPA1) in the"/>
   <result pre="but preclinical studies using repeated 30-day administration of eletriptan or" exact="indomethacin" post="found increased TRPV1 (and TRPA1) in the trigeminal ganglia,"/>
   <result pre="as an analgesic mechanism as is the case for topical" exact="menthol" post="[ 53]. Consistent with this idea is a recent"/>
   <result pre="such as hydrogen sulfide (H 2S) as well as to" exact="nitric oxide" post="(NO), both of which are well known to cause"/>
   <result pre="ganglion. Consistent with this study was another report showing that" exact="nitroglycerin" post="can increase hyperalgesia in the orofacial formalin test in"/>
   <result pre="this circuitry has also been emerging for other drugs. Both" exact="valproic acid" post="and topiramate have been shown to inhibit the capsaicin-induced"/>
   <result pre="also been emerging for other drugs. Both valproic acid and" exact="topiramate" post="have been shown to inhibit the capsaicin-induced elevation of"/>
   <result pre="adult and pediatric rats [ 136]. Finally, the pretreatment with" exact="valproic acid" post="has been shown to attenuate the enhanced blood flow"/>
   <result pre="A. Kane S.A. Tajti J. Edvinsson L. Differential distribution of" exact="calcitonin" post="gene-related peptide and its receptor components in the human"/>
   <result pre="Szolcsanyi J. Bagdy G. Sumatriptan causes parallel decrease in plasma" exact="calcitonin" post="gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin"/>
   <result pre="plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during" exact="nitroglycerin" post="induced migraine attack Cephalalgia 2005 25 179 183 10.1111/j.1468-2982.2005.00836.x"/>
   <result pre="Sperling B. Iversen H.K. Olesen J. Tfelt-Hansen P. Involvement of" exact="calcitonin" post="gene-related peptide in migraine: Regional cerebral blood flow and"/>
   <result pre="Zhang Z. Wemmie J.A. Anderson M.G. Russo A.F. Role of" exact="calcitonin" post="gene-related peptide in light-aversive behavior: Implications for migraine J."/>
   <result pre="and tolerability of MK-0974 (telcagepant), a new oral antagonist of" exact="calcitonin" post="gene-related peptide receptor, compared with zolmitriptan for acute migraine:"/>
   <result pre="new oral antagonist of calcitonin gene-related peptide receptor, compared with" exact="zolmitriptan" post="for acute migraine: A randomised, placebo-controlled, parallel-treatment trial Lancet"/>
   <result pre="et al. Safety and efficacy of ALD403, an antibody to" exact="calcitonin" post="gene-related peptide, for the prevention of frequent episodic migraine:"/>
   <result pre="D.S. Safety and efficacy of LY2951742, a monoclonal antibody to" exact="calcitonin" post="gene-related peptide, for the prevention of migraine: A phase"/>
   <result pre="843 854 10.1002/ejp.986 27977070 118. Olesen J. The role of" exact="nitric oxide" post="(NO) in migraine, tension-type headache and cluster headache Pharmacol."/>
   <result pre="Z. Zhu X. Li D. He H. The role of" exact="nitric oxide" post="in orofacial pain Nitric Oxide 2012 26 32 37"/>
   <result pre="V.P. Ferreira S.H. Pain and analgesia: The dual effect of" exact="nitric oxide" post="in the nociceptive system Nitric Oxide 2011 25 243"/>
   <result pre="I. Geisslinger G. No NO, no pain? The role of" exact="nitric oxide" post="and cGMP in spinal pain processing Trends Neurosci. 2009"/>
   <result pre="E. Cuzzocrea S. Salvemini D. Modulation of prostaglandin biosynthesis by" exact="nitric oxide" post="and nitric oxide donors Pharmacol. Rev. 2005 57 217"/>
   <result pre="Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and" exact="nitric oxide" post="donors Pharmacol. Rev. 2005 57 217 252 10.1124/pr.57.2.1 15914468"/>
   <result pre="M.E. Cady R. Durham P. An exploratory study of salivary" exact="calcitonin" post="gene-related peptide levels relative to acute interventions and preventative"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6636407/results/search/drugs/results.xml">
   <result pre="This study aimed to assess the effect of pretreatment with" exact="naproxen" post="and liposomal curcumin compared with naproxen and curcumin solution"/>
   <result pre="effect of pretreatment with naproxen and liposomal curcumin compared with" exact="naproxen" post="and curcumin solution on oxidative stress parameters and pain"/>
   <result pre="rat model of migraine (n=54) induced by intraperitoneal injection of" exact="nitroglycerin" post="(1 mg/0.1 kg). The rat model group was divided"/>
   <result pre="into an untreated control group (n=9), a group pretreated with" exact="naproxen" post="alone (2.8 mg/kg) (n=9), a group pretreated with naproxen"/>
   <result pre="with naproxen alone (2.8 mg/kg) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) combined with curcumin solution (1 mg/0.1 kg)"/>
   <result pre="curcumin solution (1 mg/0.1 kg) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) combined with curcumin solution (2 mg/0.1 kg)"/>
   <result pre="curcumin solution (2 mg/0.1 kg) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) combined with liposomal curcumin solution (1 mg/0.1"/>
   <result pre="curcumin solution (1 mg/0.1 kg) (n=9) a group pretreated with" exact="naproxen" post="(2.8 mg/kg) combined with liposomal curcumin solution (2 mg/0.1"/>
   <result pre="and enhanced nociception were significantly increased following pretreatment with combined" exact="naproxen" post="and liposomal curcumin compared with curcumin solution or naproxen"/>
   <result pre="combined naproxen and liposomal curcumin compared with curcumin solution or" exact="naproxen" post="alone (P&amp;lt;0.001). Combined curcumin solution and naproxen were more"/>
   <result pre="curcumin solution or naproxen alone (P&amp;lt;0.001). Combined curcumin solution and" exact="naproxen" post="were more effective at a concentration of 2 mg/0.1"/>
   <result pre="rat model of migraine, combined therapy with liposomal curcumin and" exact="naproxen" post="showed an improved antioxidant effect and anti-nociceptive effect. MeSH"/>
   <result pre="species, including hydroxyl (OH) radicals, superoxide anions, hydrogen peroxide, and" exact="nitric oxide" post="(NO), which disrupt antioxidant defense systems. Increased NO production"/>
   <result pre="that contributes to migraine pathophysiology. In experimental migraine, treatment with" exact="nitroglycerin" post="induces an increase of nitric oxide concentration in the"/>
   <result pre="In experimental migraine, treatment with nitroglycerin induces an increase of" exact="nitric oxide" post="concentration in the blood due to its proprieties to"/>
   <result pre="[ 6]. The underlying mechanism of the nociception evoked by" exact="nitroglycerin" post="is unknown. The pro-algesic receptors (TRPA1) expressed by trigeminal"/>
   <result pre="studies have supported a more favorable cardiovascular risk profile for" exact="naproxen" post="treatment compared with other NSAIDs [ 17]. However, the"/>
   <result pre="have been previously described [ 31]. The enhanced efficiency of" exact="sumatriptan" post="has previously been reported by adding liposomal curcumin ["/>
   <result pre="This study aimed to assess the effect of pretreatment with" exact="naproxen" post="and liposomal curcumin compared with naproxen and curcumin solution"/>
   <result pre="effect of pretreatment with naproxen and liposomal curcumin compared with" exact="naproxen" post="and curcumin solution on oxidative stress parameters and pain"/>
   <result pre="rat model of migraine (n=54) induced by intraperitoneal injection of" exact="nitroglycerin" post="(1 mg/0.1 kg). The rat model group (n=54) was"/>
   <result pre="into an untreated control group (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) (n=9), a group pretreated with naproxen (2.8"/>
   <result pre="pretreated with naproxen (2.8 mg/kg) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and curcumin solution (1 mg/0.1 kg) (n=9),"/>
   <result pre="curcumin solution (1 mg/0.1 kg) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and curcumin solution (2 mg/0.1 kg) (n=9),"/>
   <result pre="curcumin solution (2 mg/0.1 kg) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and liposomal curcumin solution (1 mg/0.1 kg)"/>
   <result pre="curcumin solution (1 mg/0.1 kg) (n=9) a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and liposomal curcumin solution (2 mg/0.1 kg)"/>
   <result pre="experimental rat model, migraine was induced by intraperitoneal administration of" exact="nitroglycerin" post="at a dose of 1 mg/0.1 kg. In the"/>
   <result pre="of 1 mg/0.1 kg. In the migraine model treated with" exact="naproxen" post="(M+NP), naproxen (2.8 mg/kg) was administrated by intraperitoneal injection,"/>
   <result pre="mg/0.1 kg. In the migraine model treated with naproxen (M+NP)," exact="naproxen" post="(2.8 mg/kg) was administrated by intraperitoneal injection, 60 minutes"/>
   <result pre="nociception test Orbital sinus blood samples were collected under intraperitoneal" exact="ketamine" post="anesthesia (5 mg/kg) from each animal at the end"/>
   <result pre="and malondialdehyde (MDA) [ 36], and an indirect indicator of" exact="nitric oxide" post="(NO) synthesis [ 37]. Spectroscopy measured the parameters for"/>
   <result pre="was used to evaluate nociception four hours after administration of" exact="nitroglycerin" post="[ 31, 32]. Rat behavior was evaluated by counting"/>
   <result pre="Figure 1). Compared with curcumin solution, liposomal curcumin combined with" exact="naproxen" post="pretreatment resulted in a significant decrease in all measured"/>
   <result pre="values significantly increased with treatment using the curcumin solution and" exact="naproxen" post="combination compared with naproxen pretreatment alone ( Table 3,"/>
   <result pre="treatment using the curcumin solution and naproxen combination compared with" exact="naproxen" post="pretreatment alone ( Table 3, Figure 2). A similar"/>
   <result pre="phases of the formalin test (Mann-Whitney test, P&amp;lt;0.001). Pretreatment with" exact="naproxen" post="significantly decreased the response to nociceptive stimulus in the"/>
   <result pre="rat model of migraine, combined treatment with liposomal curcumin and" exact="naproxen" post="had a beneficial therapeutic effect on the nociception phase"/>
   <result pre="of the combination of curcumin, as a liposomal formula, and" exact="naproxen" post="on oxidative stress and nociception. Pretreatment with liposomal curcumin"/>
   <result pre="both oxidative stress, by reducing the levels of malondialdehyde (MDA)," exact="nitric oxide" post="(NO), and total oxidative status, and nociception. Schwartz et"/>
   <result pre="The findings of the present study showed that treatment with" exact="nitroglycerin" post="resulted in a significant increase in oxidative stress and"/>
   <result pre="study, the significant increase in NO production after treatment with" exact="nitroglycerin" post="influenced the production of ROS, resulting in central and"/>
   <result pre="effect when curcumin is combined with steroidal anti-inflammatory agents, including" exact="methylprednisolone" post="sodium succinate, in reducing the inflammatory process more than"/>
   <result pre="the immunosuppressant tacrolimus, and selective estrogen receptor modulators, raloxifene, and" exact="tamoxifen" post="[ 63]. The findings of the present study showed"/>
   <result pre="for combined treatment with curcumin and naproxen, when compared with" exact="naproxen" post="alone. There was one exception, as the thiol level"/>
   <result pre="mg/0.1 kg), but was not significantly reduced when compared with" exact="naproxen" post="treatment alone). The liposomal curcumin formula had a higher"/>
   <result pre="effect on the rat experimental migraine model, when associated with" exact="naproxen" post="treatment ( Table 4, Figure 3). These findings showed"/>
   <result pre="Figure 3). These findings showed that combining liposomal curcumin with" exact="naproxen" post="had an effect on vasodilatation induced by nociception processes"/>
   <result pre="reduces its therapeutic efficiency [ 26]. Liposomal curcumin combined with" exact="naproxen" post="therapy improved its efficacy in this study, proving an"/>
   <result pre="in migraine, such as erenumab, a human monoclonal antibody against" exact="calcitonin" post="gene-related peptide (CGRP) [ 85, 86]. Conclusions In a"/>
   <result pre="rat model of migraine, combined therapy with liposomal curcumin and" exact="naproxen" post="showed an improved antioxidant effect and anti-nociceptive effect. The"/>
   <result pre="enhances the propagation of cortical spreading depression: Comparative studies with" exact="sumatriptan" post="and novel kynurenic acid analogues Drug Des Devel Ther"/>
   <result pre="Angiolillo DJ Weisman SM Clinical pharmacology and cardiovascular safety of" exact="naproxen" post="Am J Cardiovasc Drugs 2017 17 97 107 27826802"/>
   <result pre="et al. Sensitization of central trigeminovascular neurons: Blockade by intravenous" exact="naproxen" post="infusion Neuroscience 2007 148 573 83 17651900 22 Maasumi"/>
   <result pre="effect of intravenous administration of liposomal curcumin in addition to" exact="sumatriptan" post="treatment in an experimental migraine model in rats Int"/>
   <result pre="C Greco R Wang D et al. Prostaglandins, glutamate and" exact="nitric oxide" post="synthase mediate nitroglycerin-induced hyperalgesia in the formalin test Eur"/>
   <result pre="I et al. Development of antiproliferative long circulating liposomes co-encapsulating" exact="doxorubicin" post="and curcumin, through the use of a QbD approach"/>
   <result pre="Mohammad A Ali N Reza B Ali K Effect of" exact="ascorbic acid" post="supplementation on nitric oxide metabolites and systolic blood pressure"/>
   <result pre="Reza B Ali K Effect of ascorbic acid supplementation on" exact="nitric oxide" post="metabolites and systolic blood pressure in rats exposed to"/>
   <result pre="AP et al. Clinically relevant behavioral endpoints in a recurrent" exact="nitroglycerin" post="migraine model in rats J Headache Pain 2016 17"/>
   <result pre="RX Fluoxetine inhibits dendrite atrophy of hippocampal neurons by decreasing" exact="nitric oxide" post="synthase expression in rat depression model Acta Pharmacol Sin"/>
   <result pre="EA et al. NO-induced migraine attack: Strong increase in plasma" exact="calcitonin" post="gene-related peptide (CGRP) concentration and negative correlation with platelet"/>
   <result pre="Sorkin LS Formalin-evoked activity in identified primary afferent fibers: Systemic" exact="lidocaine" post="suppresses phase-2 activity Pain 1996 64 345 55 8740613"/>
   <result pre="Y Zhao J et al. The efficacy and safety of" exact="calcitonin" post="gene-related peptide monoclonal antibody for episodic migraine: A meta-analysis"/>
   <result pre="patterns of expression of the oxidative stress biomarkers malondialdehyde (MDA)," exact="nitric oxide" post="(NO), and total oxidative status (TOS) in the pretreated"/>
   <result pre="of migraine (M) (n=54), was induced by intraperitoneal injection of" exact="nitroglycerin" post="(1 mg/0.1 kg). The groups include the untreated control"/>
   <result pre="the untreated control group (M-C) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) (M+NP) (n=9), a group pretreated with naproxen"/>
   <result pre="with naproxen (2.8 mg/kg) (M+NP) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and curcumin solution (1 mg/0.1 kg) (M"/>
   <result pre="mg/0.1 kg) (M +NP+CC (1)) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and curcumin solution (2 mg/0.1 kg) (M"/>
   <result pre="mg/0.1 kg) (M +NP+CC (2)) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and liposomal curcumin solution (1 mg/0.1 kg)"/>
   <result pre="(1 mg/0.1 kg) (M+NP+CCl (1)) (n=9) a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and liposomal curcumin solution (2 mg/0.1 kg)"/>
   <result pre="of migraine (M) (n=54), was induced by intraperitoneal injection of" exact="nitroglycerin" post="(1 mg/0.1 kg). The groups include the untreated control"/>
   <result pre="the untreated control group (M-C) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) (M+NP) (n=9), a group pretreated with naproxen"/>
   <result pre="with naproxen (2.8 mg/kg) (M+NP) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and curcumin solution (1 mg/0.1 kg) (M+NP+CC"/>
   <result pre="(1 mg/0.1 kg) (M+NP+CC (1)) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and curcumin solution (2 mg/0.1 kg) (M"/>
   <result pre="mg/0.1 kg) (M +NP+CC (2)) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and liposomal curcumin solution (1 mg/0.1 kg)"/>
   <result pre="(1 mg/0.1 kg) (M+NP+CCl (1)) (n=9) a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and liposomal curcumin solution (2 mg/0.1 kg)"/>
   <result pre="of migraine (M) (n=54), was induced by intraperitoneal injection of" exact="nitroglycerin" post="(1 mg/0.1 kg). The groups include the untreated control"/>
   <result pre="the untreated control group (M-C) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) (M+NP) (n=9), a group pretreated with naproxen"/>
   <result pre="with naproxen (2.8 mg/kg) (M+NP) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and curcumin solution (1 mg/0.1 kg) (M"/>
   <result pre="mg/0.1 kg) (M +NP+CC (1)) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and curcumin solution (2 mg/0.1 kg) (M"/>
   <result pre="mg/0.1 kg) (M +NP+CC (2)) (n=9), a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and liposomal curcumin solution (1 mg/0.1 kg)"/>
   <result pre="(1 mg/0.1 kg) (M+NP+CCl (1)) (n=9) a group pretreated with" exact="naproxen" post="(2.8 mg/kg) and liposomal curcumin solution (2 mg/0.1 kg)"/>
   <result pre="the M+NP group. Table 1 Design of the experimental migraine:" exact="naproxen" post="and curcumin pre-treatment. Group (abbreviation) Administration route | dose"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6646427/results/search/drugs/results.xml">
   <result pre="in this category of age. Given that the recently introduced" exact="calcitonin" post="gene-related peptide (CGRP) inhibitors (CGRP-r) are still limited to"/>
   <result pre="Study; RCT, Randomized Controlled Trial; TPM, topiramate; PZT, pizotifen; VPA," exact="valproic acid;" post="AMI, amitriptyline; PGB, pregabalin; PPL, propranolol; FNZ, flunarizine; CNZ,"/>
   <result pre="acid; AMI, amitriptyline; PGB, pregabalin; PPL, propranolol; FNZ, flunarizine; CNZ," exact="cinnarizine" post=". Pharmacological Treatment Calcium Channel Blockers Flunarizine is a"/>
   <result pre="calcium channel blocker with properties on the cerebrovascular circulation. How" exact="flunarizine" post="acts in preventing migraine is not yet established but"/>
   <result pre="In an RS (2012), Basheer Peer et al. demonstrated that" exact="flunarizine" post="(2.5–10 mg/day) shows good efficacy in children and adolescents"/>
   <result pre="patients with hemiplegic migraine (85%). The study also showed that" exact="flunarizine" post="was well-tolerated with a reasonable safety profile. Side effects"/>
   <result pre="al. ( 10) showed that the efficacy and tolerability of" exact="flunarizine" post="5 mg/day were comparable to those of topiramate. The"/>
   <result pre="(50% reduction in headache days/month) was 80% (89/111 patients) for" exact="flunarizine" post="(5 or 10 mg /day) and 81% (122/150 patients)"/>
   <result pre="(5 or 10 mg /day) and 81% (122/150 patients) for" exact="topiramate" post="(from 25 to 100 mg/day). The frequency of adverse"/>
   <result pre="100 mg/day). The frequency of adverse effects was higher in" exact="topiramate" post="(10%) than flunarizine (6%) ( 10). In 2014, Topcu"/>
   <result pre="frequency of adverse effects was higher in topiramate (10%) than" exact="flunarizine" post="(6%) ( 10). In 2014, Topcu et al. used"/>
   <result pre="age ranging from 6 to 17 years. They found that" exact="topiramate" post="(1–2 mg/Kg/day), propranolol (20–40 mg/day), and flunarizine (5–10 mg/day)"/>
   <result pre="6 to 17 years. They found that topiramate (1–2 mg/Kg/day)," exact="propranolol" post="(20–40 mg/day), and flunarizine (5–10 mg/day) significantly decreased PedMIDAS"/>
   <result pre="They found that topiramate (1–2 mg/Kg/day), propranolol (20–40 mg/day), and" exact="flunarizine" post="(5–10 mg/day) significantly decreased PedMIDAS score. The number of"/>
   <result pre="with analgesic treatment significantly decreased in the patients treated with" exact="topiramate" post="and propranolol ( p &amp;lt; 0.05), while it remained"/>
   <result pre="treatment significantly decreased in the patients treated with topiramate and" exact="propranolol" post="( p &amp;lt; 0.05), while it remained unchanged in"/>
   <result pre="( p &amp;lt; 0.05), while it remained unchanged in the" exact="flunarizine" post="( p &amp;gt; 0.05) ( 11). More recently, Toldo"/>
   <result pre="12). In patients with migraine, the most used drug was" exact="flunarizine" post="(18%), followed by antiepileptic drugs (7%) and pizotifen (6%)."/>
   <result pre="drug was flunarizine (18%), followed by antiepileptic drugs (7%) and" exact="pizotifen" post="(6%). Flunarizine and pizotifen were the most effective drugs"/>
   <result pre="followed by antiepileptic drugs (7%) and pizotifen (6%). Flunarizine and" exact="pizotifen" post="were the most effective drugs (72 and 82%, respectively)"/>
   <result pre="there are only a few studies supporting the efficacy of" exact="propranolol" post="in pediatric age ( 15– 17). In 2010, Bidabadi"/>
   <result pre="2010, Bidabadi et al. compared the efficacy and safety of" exact="propranolol" post="(started at a dosage of 3 mg/kg/day) and valproate"/>
   <result pre="of propranolol (started at a dosage of 3 mg/kg/day) and" exact="valproate" post="(30 mg/Kg/day) for migraine prophylaxis in childhood. In this"/>
   <result pre="patients were enrolled (30 in the group A that received" exact="propranolol" post="3 mg/kg/day and 30 in the group B treated"/>
   <result pre="mg/kg/day and 30 in the group B treated by sodium" exact="valproate" post="30 mg/kg/day). The mean age of the patients was"/>
   <result pre="by more than 50% in 83% of patients treated with" exact="propranolol" post="and in 63% of patients treated with sodium valproate"/>
   <result pre="with propranolol and in 63% of patients treated with sodium" exact="valproate" post="without significant differences between the drugs. Furthermore, no significant"/>
   <result pre="( 19) compared the efficacy of a low dose of" exact="propranolol" post="(the initial dose was 0.47 ± 0.17 mg/kg/day) with"/>
   <result pre="was 0.47 ± 0.17 mg/kg/day) with a low dose of" exact="amitriptyline" post="(mean initial dose, 0.26 ± 0.1 mg/kg/day) in children"/>
   <result pre="with a mean age of 12.54 ± 3.14 years). Both" exact="propranolol" post="and amitriptyline, when combined with non-pharmacologic treatments, showed efficacy"/>
   <result pre="In 2012, Fallah et al. compared efficacy and safety of" exact="propranolol" post="(1 mg/kg/day) and topiramate (3 mg/kg/day) in a parallel"/>
   <result pre="al. compared efficacy and safety of propranolol (1 mg/kg/day) and" exact="topiramate" post="(3 mg/kg/day) in a parallel single-blinded randomized clinical trial."/>
   <result pre="that were divided in two groups (50 patients treated with" exact="propranolol" post="and 50 patients treated with topiramate). After 3 months"/>
   <result pre="After 3 months of treatment, 62% of patients treated with" exact="propranolol" post="and 82% of patients treated with topiramate showed more"/>
   <result pre="patients treated with propranolol and 82% of patients treated with" exact="topiramate" post="showed more than a 50% reduction in monthly headache"/>
   <result pre="and, in particular, the main side effects after treatment with" exact="propranolol" post="were mild hypotension and drowsiness ( 20). In a"/>
   <result pre="Bakhshandeh Bali et al. compared effectiveness, safety and tolerability of" exact="propranolol" post="(10 to 20 mg/day divided in two doses; group"/>
   <result pre="to 20 mg/day divided in two doses; group b) and" exact="pregabalin" post="(50 to 75 mg/day; group a). After 4 and"/>
   <result pre="75 mg/day; group a). After 4 and 8 weeks of" exact="pregabalin" post="administration, headache frequency was reduced by 81.8 and 85.45%,"/>
   <result pre="by 81.8 and 85.45%, respectively. Using the same treatment intervals," exact="propranolol" post="reduced monthly headache frequency by 64.54 and 68.25%, respectively."/>
   <result pre="associated with anxiety, insomnia and depression ( 22). Efficacy of" exact="amitriptyline" post="prophylaxis is achieved with much lower doses than those"/>
   <result pre="( 22). As reported above, it was shown that low-dose" exact="propranolol" post="and low-dose amitriptyline, if combined with non-pharmacological measures, were"/>
   <result pre="In a period of 6 months, 52% of patients receiving" exact="amitriptyline" post="(dose 1 mg/kg per day), 55% of patients receiving"/>
   <result pre="amitriptyline (dose 1 mg/kg per day), 55% of patients receiving" exact="topiramate" post="(dose 2 mg/kg per day), and 61% of patients"/>
   <result pre="any significant difference between groups. Furthermore, the patients treated with" exact="amitriptyline" post="or topiramate presented higher rates of adverse events compared"/>
   <result pre="difference between groups. Furthermore, the patients treated with amitriptyline or" exact="topiramate" post="presented higher rates of adverse events compared to placebo"/>
   <result pre="of efficacy and the increased risk of undesirable effects from" exact="amitriptyline" post="or topiramate in this sensitive category of patients, the"/>
   <result pre="and the increased risk of undesirable effects from amitriptyline or" exact="topiramate" post="in this sensitive category of patients, the benefit /"/>
   <result pre="an Iranian parallel, single-blinded randomized clinical trial, the efficacy of" exact="amitriptyline" post="(1 mg/kg/day) was compared to melatonin (0.3 mg/kg/day) in"/>
   <result pre="trial, the efficacy of amitriptyline (1 mg/kg/day) was compared to" exact="melatonin" post="(0.3 mg/kg/day) in a population of migraineurs ranging from"/>
   <result pre="was seen in 82.5 and 62%.5 of patients treated with" exact="amitriptyline" post="and melatonin, respectively. Amitriptyline was significantly more effective ("/>
   <result pre="( 25– 28). Antiepileptic Drugs Sodium Valproate (500–1,500 mg/day) and" exact="topiramate" post="(50–100 mg/day) were evaluated for prophylactic therapy of pediatric"/>
   <result pre="the last 8 years, one RCT compared the efficacy of" exact="valproate" post="and propranolol for the preventive treatment of migraine in"/>
   <result pre="8 years, one RCT compared the efficacy of valproate and" exact="propranolol" post="for the preventive treatment of migraine in the pediatric"/>
   <result pre="5–15 years) with migraine without aura were included. Patients received" exact="propranolol" post="(3 mg/kg/day) or sodium valproate (30 mg/kg/day) for at"/>
   <result pre="aura were included. Patients received propranolol (3 mg/kg/day) or sodium" exact="valproate" post="(30 mg/kg/day) for at least 6 months. The main"/>
   <result pre="in monthly headache frequency) was observed in 83% of the" exact="propranolol" post="group and in 63% of sodium valproate group without"/>
   <result pre="83% of the propranolol group and in 63% of sodium" exact="valproate" post="group without statistical significance. The global reduction of baseline"/>
   <result pre="of baseline headache frequency was better in the group of" exact="propranolol" post="( p &amp;lt; 0.05) ( 18). Topiramate is a"/>
   <result pre="In 2014, the U.S. Food and Drug Administration (FDA) approved" exact="topiramate" post="for migraine treatment in the pediatric patients aged 12"/>
   <result pre="patients aged 12 to 17 years ( 29). In adults," exact="topiramate" post="proved efficacious in the preventive treatment of migraine with"/>
   <result pre="single-blinded randomized clinical pediatric trial, the efficacy and safety of" exact="topiramate" post="(3 mg/Kg/day) and propranolol (1 mg/Kg/day) were compared, and"/>
   <result pre="trial, the efficacy and safety of topiramate (3 mg/Kg/day) and" exact="propranolol" post="(1 mg/Kg/day) were compared, and the results showed that"/>
   <result pre="propranolol (1 mg/Kg/day) were compared, and the results showed that" exact="topiramate" post="was more effective in reducing the monthly frequency, severity,"/>
   <result pre="duration and disability of the headache. Topiramate was superior to" exact="propranolol" post="in reducing the frequency of the attacks by at"/>
   <result pre="patients (mean age of 10.46 ± 2.11 years) treated with" exact="topiramate" post="(3 mg/kg/day), the frequency and duration of headache attacks"/>
   <result pre="and weight loss, and drowsiness ( 32). Authors concluded that" exact="topiramate" post="could be considered a safe and effective drug for"/>
   <result pre="the rate of side effects were not significantly different between" exact="flunarizine" post="and topiramate ( 10). In a randomized, double-blind clinical"/>
   <result pre="of side effects were not significantly different between flunarizine and" exact="topiramate" post="( 10). In a randomized, double-blind clinical study of"/>
   <result pre="years), Ashrafi et al. compared the efficacy and safety of" exact="cinnarizine" post="and topiramate in the prevention of pediatric migraine. The"/>
   <result pre="et al. compared the efficacy and safety of cinnarizine and" exact="topiramate" post="in the prevention of pediatric migraine. The primary endpoint"/>
   <result pre="phase of the study (week 8), both patients treated with" exact="cinnarizine" post="and topiramate showed a statistically significant 50% responder rate"/>
   <result pre="the study (week 8), both patients treated with cinnarizine and" exact="topiramate" post="showed a statistically significant 50% responder rate (cinnarizine: 55%,"/>
   <result pre="significant reduction of monthly migraine frequency was observed for both" exact="cinnarizine" post="and topiramate ( p &amp;lt; 0.05) with no significant"/>
   <result pre="of monthly migraine frequency was observed for both cinnarizine and" exact="topiramate" post="( p &amp;lt; 0.05) with no significant differences between"/>
   <result pre="CHAMP study failed in showing any superiority of treatment with" exact="amitriptyline" post="or topiramate, as compared to placebo ( 23). Verapamil,"/>
   <result pre="amitriptyline or topiramate, as compared to placebo ( 23). Verapamil," exact="levetiracetam" post="and zonisamide have also been studied for treatment of"/>
   <result pre="topiramate, as compared to placebo ( 23). Verapamil, levetiracetam and" exact="zonisamide" post="have also been studied for treatment of migraine, but"/>
   <result pre="In the last decade, no trials have been conducted on" exact="pizotifen" post="from which definitive efficacy data can be drawn. Cyproheptadine"/>
   <result pre="headaches, in 13 specialized juvenile Italian headache centers, reported that" exact="pizotifen" post="(1 mg/kg/day) was one of the most efficacious (82%"/>
   <result pre="the efficacy of a complex of ginkgolide B, coenzyme Q10," exact="riboflavin" post="and magnesium (doses not specified) in pediatric patients with"/>
   <result pre="combination of ginkgolide B (80 mg/day), coenzyme Q10 (20 mg/day)," exact="riboflavin" post="(1.6 mg/day), and magnesium (300 mg/day) with a complex"/>
   <result pre="when this therapy was combined with pharmacological therapy, in particular" exact="amitriptyline" post="( 25– 28). A randomized study conducted on 135"/>
   <result pre="at 20 weeks of the combined treatment with CBT plus" exact="amitriptyline" post="vs. headache education plus amitriptyline. The authors found that"/>
   <result pre="authors found that 47% of patients in the CBT plus" exact="amitriptyline" post="group had less than four headache days per month"/>
   <result pre="per month compared to 20% in the headache education plus" exact="amitriptyline" post="group ( p &amp;lt; 0.005). At 12 months post"/>
   <result pre="months post treatment, 72% of patients in the CBT plus" exact="amitriptyline" post="group had less than four headache days per month"/>
   <result pre="per month compared to 52% in the headache education plus" exact="amitriptyline" post="group ( p &amp;lt; 0.05) ( 27). In a"/>
   <result pre="CHAMP study. This study showed that pharmacological treatments, such as" exact="amitriptyline" post="and topiramate, do not differ from placebo. Three main"/>
   <result pre="of view, there is high expectation for the use of" exact="calcitonin" post="gene-related peptide (CGRP) inhibitors (CGRP-r). The large trials conducted"/>
   <result pre="B Goadsby PJ Prabhakar P . Safety and efficacy of" exact="flunarizine" post="in childhood migraine: 11 years' experience, with emphasis on"/>
   <result pre="BC Chae JH Choi J et al. . Comparison of" exact="flunarizine" post="and topiramate for the prophylaxis of pediatric migraines. Eur"/>
   <result pre="JH Choi J et al. . Comparison of flunarizine and" exact="topiramate" post="for the prophylaxis of pediatric migraines. Eur J Paediatr"/>
   <result pre="DP Levin NW Suzman MM . The prophylactic value of" exact="propranolol" post="in angina pectoris. Am J Cardiol. ( 1966) 18:"/>
   <result pre="K MacDonald JT Uden DL . Comparison of self-hypnosis and" exact="propranolol" post="in the treatment of juvenile classic migraine. Pediatrics. ("/>
   <result pre="E Mashouf M A randomized trial of propanolol versus sodium" exact="valproate" post="for the prophylaxis of migraine in pediatric patients ."/>
   <result pre="Goldberg-Stern H Zeharia A Nonpharmacologic treatment of migraine with low-dose" exact="propranolol" post="or amitriptyline. Pediatr Neurol. ( 2012) 46: 345– 9."/>
   <result pre="Shajari A Fromandi M . The efficacy and safety of" exact="topiramate" post="for prophylaxis of migraine in children. Iran J Child"/>
   <result pre="M Sedighi M Karimzadeh P Ghofrani M . Comparison of" exact="propranolol" post="and pregabalin for prophylaxis of childhood migraine: a randomised"/>
   <result pre="M Karimzadeh P Ghofrani M . Comparison of propranolol and" exact="pregabalin" post="for prophylaxis of childhood migraine: a randomised controlled trial"/>
   <result pre="AD Powers SW Bentti AL Degrauw TJ . Effectiveness of" exact="amitriptyline" post="in the prophylactic management of childhood headaches. Headache. ("/>
   <result pre="L . A randomized clinical trial comparing the efficacy of" exact="melatonin" post="and amitriptyline in migraine prophylaxis of children . Iran"/>
   <result pre="A randomized clinical trial comparing the efficacy of melatonin and" exact="amitriptyline" post="in migraine prophylaxis of children . Iran J Child"/>
   <result pre="SK Zafar M et al. . Cognitive behavioral therapy plus" exact="amitriptyline" post="for chronic migraine in children and adolescents: a randomized"/>
   <result pre="JR Slater SK et al. . Cognitive behavioral therapy plus" exact="amitriptyline" post="for children and adolescents with chronic migraine reduces headache"/>
   <result pre="adolescents with chronic migraine: results from the cognitive-behavioral therapy and" exact="amitriptyline" post="trial . J Pain. ( 2017) 18: 637– 44."/>
   <result pre="MS Karimi M Mirouliaei M Shamszadeh A . Topiramate and" exact="propranolol" post="for prophylaxis of migraine. Indian J Pediatr. ( 2013)"/>
   <result pre="Shajari A Fromandi M . The efficacy and safety of" exact="topiramate" post="for prophylaxis of migraine in children. Iran J Child"/>
   <result pre="Z Shafiei M Heidari K Togha M . Cinnarizine versus" exact="topiramate" post="in prophylaxis of migraines among children and adolescents: a"/>
   <result pre="Passchier J Locher H Dijkstra N Arts WF . Medium-dose" exact="riboflavin" post="as a prophylactic agent in children with migraine: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6657237/results/search/drugs/results.xml">
   <result pre="dysfunction, cranial vasodilation and release of some neuromodulators, such as" exact="dopamine" post="[ 2]. Current migraine therapies are effective only in"/>
   <result pre="is provided by the observation of the protective action of" exact="riboflavin" post="and the Q10 coenzyme, both enhancing the function of"/>
   <result pre="23– 29]. As brain metabolism is disturbed in migraine and" exact="riboflavin" post="ameliorates the functioning of ETS, its evaluation in clinical"/>
   <result pre="migraine patients with non-H mtDNA haplogroup responded more frequently to" exact="riboflavin" post="than patients with the H group [ 34]. On"/>
   <result pre="group [ 34]. On the other hand, the frequency of" exact="riboflavin" post="non-responders was higher in the H group. There were"/>
   <result pre="There were no differences between MA and MO patients in" exact="riboflavin" post="responsiveness. These studies suggest that the efficacy of riboflavin"/>
   <result pre="in riboflavin responsiveness. These studies suggest that the efficacy of" exact="riboflavin" post="therapy can depend on the patient genotype. Riboflavin decreased"/>
   <result pre="of headache attacks [ 36]. Several other clinical trials with" exact="riboflavin" post="singly or in combination with other agents both in"/>
   <result pre="diabetic mice [ 37]. As we mentioned, the action of" exact="riboflavin" post="may depend on the genotype of the recipient. Therefore,"/>
   <result pre="action cannot be unequivocally associated with an epigenetic mechanism as" exact="valproate" post="is an anticonvulsive drug with several modes of action"/>
   <result pre="action [ 86– 88]. Moreover, it is not known how" exact="valproate" post="acts on mitochondria. Passaro et al. found a direct"/>
   <result pre="methodology of these trials as well as basic questions on" exact="riboflavin" post="pharmacokinetics and pharmacogenomics should be addressed. These concern first"/>
   <result pre="with n placebo groups and determination of optimal doses of" exact="riboflavin" post="as the mechanism of its absorption is not completely"/>
   <result pre="Ruitenbeek W Hamburger HL Treatment of complex I deficiency with" exact="riboflavin" post="J Neurol Sci 1993 118 181 7 8229067 25"/>
   <result pre="26 Henriques BJ Lucas TG Gomes CM Therapeutic approaches using" exact="riboflavin" post="in mitochondrial energy metabolism disorders Curr Drug Targets 2016"/>
   <result pre="A historical cohort study on the efficacy of glucocorticoids and" exact="riboflavin" post="among patients with late-onset multiple acyl-CoA dehydrogenase deficiency Chin"/>
   <result pre="28775706 33 Namazi N Heshmati J Tarighat-Esfanjani A Supplementation with" exact="riboflavin" post="(Vitamin B2) for migraine prophylaxis in adults and children:"/>
   <result pre="et al. Mitochondrial DNA haplogroups influence the therapeutic response to" exact="riboflavin" post="in migraineurs Neurology 2009 72 1588 94 19414726 35"/>
   <result pre="35 Schoenen J Jacquy J Lenaerts M Effectiveness of high-dose" exact="riboflavin" post="in migraine prophylaxis A randomized controlled trial. Neurology 1998"/>
   <result pre="Hajizadeh R Arefnia E Effectiveness of vitamin B2 versus sodium" exact="valproate" post="in migraine prophylaxis: a randomized clinical trial Electron Physician"/>
   <result pre="37 Alam MM Iqbal S Naseem I Ameliorative effect of" exact="riboflavin" post="on hyperglycemia, oxidative stress and DNA damage in type-2"/>
   <result pre="N Tavakoli M Charati JY Shamsizade M Single-dose intravenous sodium" exact="valproate" post="(Depakine) versus dexamethasone for the treatment of acute migraine"/>
   <result pre="Charati JY Shamsizade M Single-dose intravenous sodium valproate (Depakine) versus" exact="dexamethasone" post="for the treatment of acute migraine headache: a double-blind"/>
   <result pre="Wang Q Yu S The efficacy of venlafaxine, flunarizine, and" exact="valproic acid" post="in the prophylaxis of vestibular migraine Front Neurol 2017"/>
   <result pre="84 Kunder SK Bairy LK Arivazhahan A Effect of sodium" exact="valproate" post="and docosahexaenoic acid on pain in rats J Clin"/>
   <result pre="LH Chen XP Luo J Zhang ZL The pharmacogenomics of" exact="valproic acid" post="J Hum Genet 2017 62 1009 14 28878340 86"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6664028/results/search/drugs/results.xml">
   <result pre="In addition, glutamate metabolism ( 76), serotonin metabolism ( 77)," exact="dopamine" post="metabolism ( 78), and ion channel (sodium, potassium, and"/>
   <result pre="as substance P (SP) and the peptide related to the" exact="calcitonin" post="gene (CGRP). They, originating from the trigeminal ganglion, reach"/>
   <result pre="an ictal migraine manifestation with a good response to intravenous" exact="diazepam" post=". Epilepsia. ( 2007) 48: 2181– 6. 10.1111/j.1528-1167.2007.01265.x 17711460"/>
   <result pre="10.1007/s10038-005-0301-5 16200390 78. Chen SC . Epilepsy and migraine: the" exact="dopamine" post="hypotheses. Med Hypotheses. ( 2006) 66: 466– 72. 10.1016/j.mehy.2005.09.045"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6679182/results/search/drugs/results.xml">
   <result pre="aliquots, where the total RNA binds to the membrane and" exact="phenol" post="and other contaminants were efficiently washed away using specific"/>
   <result pre="chronically treated with magnesium (400 mg/day for 3 months) +" exact="acetaminophen" post="(15 mg/kg) or ibuprofen (10 mg/kg) during the acute"/>
   <result pre="(400 mg/day for 3 months) + acetaminophen (15 mg/kg) or" exact="ibuprofen" post="(10 mg/kg) during the acute attack ( Table 1)."/>
   <result pre="M. De Sarro G. Carotenuto M. Guidetti V. Effects of" exact="acetaminophen" post="and ibuprofen in children with migraine receiving preventive treatment"/>
   <result pre="Sarro G. Carotenuto M. Guidetti V. Effects of acetaminophen and" exact="ibuprofen" post="in children with migraine receiving preventive treatment with magnesium"/>
   <result pre="P.K. Ghatei M.A. Bloom S.R. Infusion of a novel peptide," exact="calcitonin" post="gene-related peptide (CGRP) in man. Pharmacokinetics and effects on"/>
   <result pre="channel protein in trigeminal ganglion neurons and the effect of" exact="buprenorphine" post="Neuroscience 2009 162 453 461 10.1016/j.neuroscience.2009.04.063 19409968 42. Walker"/>
   <result pre="study. Patients enrolled in treated group (acetaminophen (15 mg/kg) or" exact="ibuprofen" post="(10 mg/kg) during the acute attack) underwent also to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6680509/results/search/drugs/results.xml">
   <result pre="release of vasoactive neuropeptides from nociceptive sensory nerve terminals, including" exact="calcitonin" post="gene-related peptide (CGRP), substance P (SP), and neurokinin A."/>
   <result pre="new therapeutic strategies for the treatment of migraine, such as" exact="anakinra" post="[ 82]. Anakinra is a recombinant nonglycosylated analogue of"/>
   <result pre="all subtypes of cryopyrin-associated periodic syndrome (CAPS). In nonhuman primates," exact="anakinra" post="has been shown to be able to cross the"/>
   <result pre="43 patients with severe cryopyrin-associated periodic syndromes (CAPS) demonstrated that" exact="anakinra" post="treatment significantly decreased central nervous system inflammation and headaches"/>
   <result pre="S. Walker A. Wiens S. Randomized controlled trial of intravenous" exact="dexamethasone" post="to prevent relapse in acute migraine headache Headache 2008"/>
   <result pre="predicting the response of patients with relapsing-remitting multiple sclerosis to" exact="natalizumab" post="treatment Mol. Med. Rep. 2019 20 678 684 10.3892/mmr.2019.10283"/>
   <result pre="M. et al. Long-term efficacy of the interleukin-1 receptor antagonist" exact="anakinra" post="in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6681503/results/search/drugs/results.xml">
   <result pre="a negative role in the proliferation of mast cells, regulates" exact="nitric oxide" post="production, and inhibits inducible nitric oxide synthase (iNOS) expression"/>
   <result pre="of mast cells, regulates nitric oxide production, and inhibits inducible" exact="nitric oxide" post="synthase (iNOS) expression (Nitric oxide is a vasoactive substance"/>
   <result pre="Vitamin D deficiency causes inflammation because of the dysregulation of" exact="nitric oxide" post="production, which adversely affects immune responses, cell migration, and"/>
   <result pre="pain and migraine attacks, the levels of substance P, the" exact="calcitonin" post="gene-related peptide (GCRP), and neuroexcitator mediator increase [ 34,"/>
   <result pre="[ 36]. Also, PTH upregulates the activity of the endothelial" exact="nitric oxide" post="synthase system via protein kinase pathways [ 37]. Vitamin"/>
   <result pre="aged 8–16 years and reported that vitamin D therapy with" exact="amitriptyline" post="reduces the recurrence of migraine attacks in pediatric patients"/>
   <result pre="Tan H. Effect of vitamin D therapy in addition to" exact="amitriptyline" post="on migraine attacks in pediatric patients Braz. J. Med."/>
   <result pre="G. Di Bella P. Buscone S. Nappi G. Role of" exact="calcitonin" post="gene-related peptide and substance P in different models of"/>
   <result pre="J. Green J. Benchetrit S. Parathyroid hormone stimulates the endothelial" exact="nitric oxide" post="synthase through protein kinase A and C pathways Nephrol."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6682174/results/search/drugs/results.xml">
   <result pre="hormone and follicle stimulating hormone, together with low levels of" exact="testosterone" post="in boys and estradiol in girls. Due to a"/>
   <result pre="hormone, together with low levels of testosterone in boys and" exact="estradiol" post="in girls. Due to a strong correlation between olfactory"/>
   <result pre="HH can be treated by hormone replacement therapy, either with" exact="testosterone" post="or human chorionic gonadotropin (which stimulates the production of"/>
   <result pre="treated by hormone replacement therapy, either with testosterone or human" exact="chorionic gonadotropin" post="(which stimulates the production of testosterone in the testis)"/>
   <result pre="testosterone or human chorionic gonadotropin (which stimulates the production of" exact="testosterone" post="in the testis) in boys and estrogens in girls."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6709659/results/search/drugs/results.xml">
   <result pre="and lower lid ptosis. Instillation of one drop of 1%" exact="apraclonidine" post="resulted in reversal of anisocoria and subtle retraction of"/>
   <result pre="2B). The palpebral fissures were symmetric. Instillation of topical 1%" exact="apraclonidine" post="resulted in reversal of the anisocoria. A diagnosis of"/>
   <result pre="hypersensitivity of the left but not right pupil. Topical 1%" exact="apraclonidine" post="had no effect on either pupil. A diagnosis of"/>
   <result pre="could not be confirmed from old photographs. Testing with topical" exact="apraclonidine" post="did not show any dilation of the smaller left"/>
   <result pre="muscular contraction. Also in these patients, one might expect topical" exact="apraclonidine" post="to reproduce the tadpole shape as evidence of a"/>
   <result pre="may respond directly to hormonal stimuli. For example, estrogen and" exact="progesterone" post="receptors located on smooth muscles surfaces can influence muscle"/>
   <result pre="trials, we have found that treating a patient with topical" exact="brimonidine" post="did abort further episodes of tadpole pupil, as well"/>
   <result pre="(RK, personal experience and communication). It is not clear if" exact="brimonidine" post="will have a similarly favorable effect on tadpole pupil"/>
   <result pre="Waite L Abboud FM Conklin JL . Nongenomic effects of" exact="progesterone" post="on human intestinal smooth muscle cells. Am J Physiol."/>
   <result pre="GA Bast A van Kerrebroeck PEV . Relaxant effects of" exact="estradiol" post="through non-genomic pathways in male and female pig bladder"/>
   <result pre="Ono M Sullivan DA . Identification of androgen, estrogen and" exact="progesterone" post="receptor mRNAs in the eye. Acta Ophthalmol Scand. ("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6709817/results/search/drugs/results.xml">
   <result pre="new option for migraine preventive treatment. Keywords fremanezumab migraine headache" exact="calcitonin" post="gene-related peptide, CGRP treatment monoclonal antibody table-count: ref-count: page-count:"/>
   <result pre="data also showed benefit in CM in patients with concurrent" exact="topiramate" post="or onabotulinumtoxinA. 16 The first 6 months of data"/>
   <result pre=", Eyde NM , et al. Prevention of stress- or" exact="nitric oxide" post="donor-induced medication overuse headache by a calcitonin gene-related peptide"/>
   <result pre="stress- or nitric oxide donor-induced medication overuse headache by a" exact="calcitonin" post="gene-related peptide antibody in rodents . Cephalalgia . 2017;"/>
   <result pre="in patients with chronic migraine who had prior use of" exact="topiramate" post="or onabotulinumtoxinA (P4.104) . Neurology . 2018; 90( 15"/>
   <result pre="Booker MW , Whitehead MI . Increased concentration of circulating" exact="calcitonin" post="gene related peptide during normal human pregnancy . BMJ"/>
   <result pre="U . Evaluation of a peptide family encoded by the" exact="calcitonin" post="gene in selected healthy pregnant women. A longitudinal study"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6716213/results/search/drugs/results.xml">
   <result pre="on pharmacological treatment of headache in the pediatric population. Only" exact="ibuprofen" post="and sumatriptan are significantly more effective than placebo in"/>
   <result pre="treatment of headache in the pediatric population. Only ibuprofen and" exact="sumatriptan" post="are significantly more effective than placebo in determining headache"/>
   <result pre="mg sumatriptan/60 mg naproxen, max dose 85 mg sumatriptan/500 mg" exact="naproxen" post="IN, Intranasal; Max, Maximum; ODT, Orally disintegrating tablet; PO,"/>
   <result pre="kg: 4–8 mg Sedation Dystonic reaction Oral analgesics such as" exact="paracetamol" post="(10–15 mg per kg) and ibuprofen (10 mg per"/>
   <result pre="Oral analgesics such as paracetamol (10–15 mg per kg) and" exact="ibuprofen" post="(10 mg per kg) are the mainstay of acute"/>
   <result pre="Administration for acute migraine in adolescents 12–17 years of age:" exact="almotriptan" post="(oral), zolmitriptan (nasal spray), rizatriptan (oral), and sumatriptan/naproxen (oral);"/>
   <result pre="acute migraine in adolescents 12–17 years of age: almotriptan (oral)," exact="zolmitriptan" post="(nasal spray), rizatriptan (oral), and sumatriptan/naproxen (oral); and one"/>
   <result pre="adolescents 12–17 years of age: almotriptan (oral), zolmitriptan (nasal spray)," exact="rizatriptan" post="(oral), and sumatriptan/naproxen (oral); and one medication, rizatriptan (melt),"/>
   <result pre="(nasal spray), rizatriptan (oral), and sumatriptan/naproxen (oral); and one medication," exact="rizatriptan" post="(melt), is labeled for use in children 6 years"/>
   <result pre="h after acute headache treatment. Based on a systematic review," exact="ibuprofen" post="seems more effective, making it an excellent choice for"/>
   <result pre="it an excellent choice for the treatment of head pain;" exact="paracetamol" post="has not been shown to be effective in providing"/>
   <result pre="relief. In a small cross-over study, predominantly in children, oral" exact="paracetamol" post="was not superior to placebo or ibuprofen ( 88)."/>
   <result pre="in children, oral paracetamol was not superior to placebo or" exact="ibuprofen" post="( 88). Triptans were more effective than placebo in"/>
   <result pre="nasal symptoms, and nausea with intranasal preparations. The combination of" exact="sumatriptan" post="with naproxen sodium was also more effective than placebo"/>
   <result pre="and nausea with intranasal preparations. The combination of sumatriptan with" exact="naproxen" post="sodium was also more effective than placebo in producing"/>
   <result pre="Acute treatment of head pain via saline infusion, with intravenous" exact="ketorolac" post="(0.5 mg/kg with a maximum dose of 30 mg)"/>
   <result pre="(0.5 mg/kg with a maximum dose of 30 mg) and" exact="prochlorperazine" post="(0.15 mg/kg with a maximum dose of 10 mg),"/>
   <result pre="recent study comparing the effectiveness of three commonly used parenteral" exact="dopamine" post="antagonists (prochlorperazine, metoclopramide, and promethazine) to abort pediatric migraine,"/>
   <result pre="(prochlorperazine, metoclopramide, and promethazine) to abort pediatric migraine, found that" exact="promethazine" post="was significantly associated with higher odds of treatment failure"/>
   <result pre="opioid administration and poor pain control. The authors recommend using" exact="prochlorperazine" post="or metoclopramide instead of promethazine for pediatric ED migraine"/>
   <result pre="and poor pain control. The authors recommend using prochlorperazine or" exact="metoclopramide" post="instead of promethazine for pediatric ED migraine treatment ("/>
   <result pre="control. The authors recommend using prochlorperazine or metoclopramide instead of" exact="promethazine" post="for pediatric ED migraine treatment ( 91). Dihydroergotamine (DHE)"/>
   <result pre="studies were weakened by prior treatment of the subjects with" exact="dopamine" post="agonists. A recent study on treatment of 145 patients"/>
   <result pre="while recurrence of headache after ED discharge was 33%. Sodium" exact="valproate" post="IV could represent a treatment option for acute migraine,"/>
   <result pre="ML Hoppu K Valkeila E Santavuori P . Ibuprofen or" exact="acetaminophen" post="for the acute treatment of migraine in children: a"/>
   <result pre="Treatment of pediatric migraine headaches: a randomized, double-blind trial of" exact="prochlorperazine" post="versus ketorolac . Ann Emerg Med. ( 2004) 43:"/>
   <result pre="pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus" exact="ketorolac" post=". Ann Emerg Med. ( 2004) 43: 256– 62."/>
   <result pre="Hansen ML Ma OJ et al. . Relative effectiveness of" exact="dopamine" post="antagonists for pediatric migraine in the emergency department ."/>
   <result pre="30234648 93. Linder SL . Treatment of childhood headache with" exact="dihydroergotamine" post="mesylate. Headache. ( 1994) 34: 578– 80. 7843951 94."/>
   <result pre="S et al. . Inpatient treatment of status migraine with" exact="dihydroergotamine" post="in children and adolescents. Headache. ( 2009) 49: 106–"/>
   <result pre="19125879 95. Hämäläinen ML Hoppu K Santavuori PR . Oral" exact="dihydroergotamine" post="for therapy-resistant migraine attacks in children. Pediatr Neurol. ("/>
   <result pre="LM . Outcome and cost of inpatient hospitalization for intravenous" exact="dihydroergotamine" post="treatment of refractory pediatric headache . Pediatr eurol. ("/>
   <result pre="Nickisch J Merritt G . Efficacy and tolerability of intravenous" exact="valproic acid" post="in acute adolescent migraine. Headache. ( 2005) 45: 899–"/>
   <result pre="D Sun B O'Brien P Hansen M . Intravenous sodium" exact="valproate" post="for acute pediatric headache. J Emerg Med. ( 2015)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6732618/results/search/drugs/results.xml">
   <result pre="intervention. For example, a pulsatile press coated drug delivery of" exact="sumatriptan" post="succinate for bedtime administration was created to ensure early"/>
   <result pre="hormones secreted in hypothalamus during the night: a phase-delay in" exact="melatonin" post="peak and lower melatonin levels among CM patients with"/>
   <result pre="during the night: a phase-delay in melatonin peak and lower" exact="melatonin" post="levels among CM patients with insomnia, suggesting a possible"/>
   <result pre="of migraine attack onset. The related studies mostly show lower" exact="melatonin" post="levels among migraineurs versus controls [ 22], but future"/>
   <result pre="future studies are needed to understand the exact role of" exact="melatonin" post="in migraine pathophysiology and its potential effect on attack"/>
   <result pre="is responsible for sleep disturbances possibly caused by reduced nocturnal" exact="melatonin" post="release [ 36]. Concerning sleep medication, short-acting benzodiazepines may"/>
   <result pre="of attacks in a dose-dependent way [ 37]; meanwhile Z-drug" exact="eszopiclone" post="has no influence on migraine [ 38]. Contraceptives can"/>
   <result pre="clock itself [ 40]. Nonsteroidal anti-inflammatory drugs ( NSAIDs) like" exact="naproxen" post="show no significant changes in circadian patterns of ACTH"/>
   <result pre="levels depends on treatment duration. After a singular intake of" exact="indomethacin" post="or acetylsalicylic acid (ASA), no changes were detected, while"/>
   <result pre="on treatment duration. After a singular intake of indomethacin or" exact="acetylsalicylic acid" post="(ASA), no changes were detected, while after a 4-day"/>
   <result pre="in stress hormone level. In insulin induced hypoglycemia stress test," exact="indomethacin" post="intake resulted in increased ACTH and decreased cortisol levels,"/>
   <result pre="for polyox and xanthan gum coated floating pulsatile delivery of" exact="sumatriptan" post="succinate in migraine treatment BioMed Research International 2014 2014"/>
   <result pre="Tepper S. J. Sheftell F. Bigal M. E. Role of" exact="melatonin" post="in the pathophysiology of migraine CNS Drugs 2006 20"/>
   <result pre="A. et al. NO-induced migraine attack: strong increase in plasma" exact="calcitonin" post="gene-related peptide (CGRP) concentration and negative correlation with platelet"/>
   <result pre="Sakotnik A. Lercher P. et al. Influence of beta-blockers on" exact="melatonin" post="release European Journal of Clinical Pharmacology 1999 55 2"/>
   <result pre="T. R. Efficacy of treatment of insomnia in migraineurs with" exact="eszopiclone" post="(LunestaR) and its effect on total sleep time, headache"/>
   <result pre="J. Smith M. Menstrual migraine: a double-blind trial of percutaneous" exact="estradiol" post="Gynecological Endocrinology 1988 2 2 113 120 10.3109/09513598809023619 3055819"/>
   <result pre="Kempers M. J. Kramer R. S. et al. Effect of" exact="naproxen" post="on the hypothalamic-pituitary- adrenal axis in healthy volunteers British"/>
   <result pre="C. Pinto M. L. Effect of two prostaglandin synthesis inhibitors," exact="indomethacin" post="and acetylsalicylic acid, on plasma acth and cortisol levels"/>
   <result pre="M. L. Effect of two prostaglandin synthesis inhibitors, indomethacin and" exact="acetylsalicylic acid," post="on plasma acth and cortisol levels in man Acta"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734209/results/search/drugs/results.xml">
   <result pre="been statistically verified as a stroke risk factor but high" exact="ergotamine" post="consumption is possibly associated with an increased risk of"/>
   <result pre="regimen after PFO closure, and found that the combination of" exact="clopidogrel" post="and aspirin resulted in fewer patients (12.2%) reported aura"/>
   <result pre="state-of the-art RCT of transcatheter ASD closure, the use of" exact="clopidogrel" post="and aspirin, compared with aspirin alone, resulted in a"/>
   <result pre="double-blinded, randomized parallel-group controlled study, the effect of 25 mg intranasal" exact="ketamine" post="was compared to 2 mg intranasal midazolam as an active"/>
   <result pre="effect of 25 mg intranasal ketamine was compared to 2 mg intranasal" exact="midazolam" post="as an active control. In the 18 subjects with"/>
   <result pre="18 subjects with migraine with prolonged aura completing the study," exact="ketamine" post="reduced the severity but not duration of aura, while"/>
   <result pre="ketamine reduced the severity but not duration of aura, while" exact="midazolam" post="was ineffective [ 59]. The usefulness of ketamine for"/>
   <result pre="aura, while midazolam was ineffective [ 59]. The usefulness of" exact="ketamine" post="for aura-treatment in classical migraine aura remains to be"/>
   <result pre="with migraine with aura, out of whom 95 (46.8%) used" exact="acetylsalicylic acid" post="and reported a &quot;positive effect&quot; and a significant reduction"/>
   <result pre="a larger double-blind, placebo-controlled study. A small open-label trial of" exact="levetiracetam" post="included 16 patients with migraine with aura, and led"/>
   <result pre="[ 63]. Another potential way of targeting CSD is using" exact="amiloride" post="a blocker of epithelial sodium channels based upon the"/>
   <result pre="CSD in animal studies. In a small open-labelled pilot study," exact="amiloride" post="reduced aura and headache symptoms in 4 of 7"/>
   <result pre="Triptans Previous studies indicated that triptans, specifically sumatriptan, eletriptan, and" exact="zolmitriptan" post="[ 67– 69], were not effective in relieving migraine"/>
   <result pre="the placebo, neither statistically not clinically significant [ 67]. The" exact="eletriptan" post="study found no significant difference in the proportion of"/>
   <result pre="of patients not developing moderate-to-severe headache within 6 h post-dose of" exact="eletriptan" post="(61%, 22/36 patients) versus placebo (46%, 19/41); P = 0.25)."/>
   <result pre="therapeutic gain of 15% and a NNT of 6.7 for" exact="eletriptan" post="taken during aura. In a small, four-way crossover open-label"/>
   <result pre="aura. In a small, four-way crossover open-label study, treatment with" exact="sumatriptan" post="100 mg during aura prevented the development of the headache"/>
   <result pre="phase [ 70– 72]. In the seminal RCT of subcutaneous" exact="sumatriptan" post="[ 73] the primary endpoint was pain relief at"/>
   <result pre="with their migraine and those without aura responded similarly to" exact="sumatriptan" post="with a therapeutic gain of 43% for attacks with"/>
   <result pre="consistent with our report of numerically better treatment effect of" exact="sumatriptan" post="in attacks without aura (see below). In another of"/>
   <result pre="aura (see below). In another of the first RCTs of" exact="sumatriptan" post="(200 mg vs placebo), patients were asked to treat three"/>
   <result pre="to a higher placebo respons [ 74]. Systematic reviews of" exact="sumatriptan" post="trials found insufficient data to carry out any sensitivity"/>
   <result pre="individual migraine attacks with aura vs. without aura, and for" exact="sumatriptan" post="we also compared patients with a diagnosis of MA"/>
   <result pre="[ 79]. The pooled pain free rates 2 h post-dose for" exact="sumatriptan" post="100 mg were significantly higher in patients treating attacks without"/>
   <result pre="analysis of pooled data from multiple randomized trials indicates that" exact="sumatriptan" post="is less effective as acute therapy for migraine attacks"/>
   <result pre="a translational model for migraine prophylaxis [ 90]. In rats" exact="lamotrigine" post="and valproate also suppressed CSD [ 91]. If CSD"/>
   <result pre="model for migraine prophylaxis [ 90]. In rats lamotrigine and" exact="valproate" post="also suppressed CSD [ 91]. If CSD plays a"/>
   <result pre="randomized, double-blind, placebo-controlled trial in patients with migraine without aura," exact="memantine" post="led to an significant reduction in headache [ 94]."/>
   <result pre="headache [ 94]. Based on the proposed mode of action," exact="memantine" post="should also work in migraine with aura. In a"/>
   <result pre="with the release of glutamate into the extracellular space and" exact="lamotrigine" post="has been shown to suppress CSD in the rat"/>
   <result pre="a positive pilot-study [ 97], a larger open-label study of" exact="lamotrigine" post="examined the prevention of migraine aura and reported that"/>
   <result pre="of migraine headaches [ 98]. Another open-label study examined whether" exact="lamotrigine" post="could cause a &amp;gt; 50% reduction in the mean frequency of"/>
   <result pre="responders). Auras reappeared in 9 out of 13 patients when" exact="lamotrigine" post="was stopped, but could be controlled as soon as"/>
   <result pre="The authors also state that the reduction in auras during" exact="topiramate" post="treatment tended to be somewhat more pronounced than the"/>
   <result pre="103]. Another study randomized 213 subjects from 27 centers to" exact="topiramate" post="or placebo [ 104]. Seventy-five (35.5%) subjects in the"/>
   <result pre="change in mean monthly migraine frequency was not different between" exact="topiramate" post="and placebo. In a subgroup analysis, a significant difference"/>
   <result pre="analysis, a significant difference was found in MA patients between" exact="topiramate" post="( n = 46) and placebo ( n = 29). In"/>
   <result pre="&quot;visual symptoms&quot; was not a predictor for treatment response to" exact="topiramate" post="[ 105]. Transcranial magnetic simulation Transcranial magnetic simulation (TMS)"/>
   <result pre="of ischemic complications related to the intensity of triptan and" exact="ergotamine" post="use Neurology 2006 67 7 1128 1134 10.1212/01.wnl.0000240128.76399.fa 17030745"/>
   <result pre="patients with familial hemiplegic migraine can be stopped by intranasal" exact="ketamine" post="Neurology 2000 55 1 139 141 10.1212/WNL.55.1.139 10891926 59."/>
   <result pre="Afridi SK et al. A randomized controlled trial of intranasal" exact="ketamine" post="in migraine with prolonged aura Neurology 2013 80 7"/>
   <result pre="1 S161 S163 10.1007/s10072-013-1413-x 67. Bates, D., et al., Subcutaneous" exact="sumatriptan" post="during the migraine aura . Sumatriptan Aura Study Group"/>
   <result pre="10.1159/000119101 8791030 69. Olesen J et al. No effect of" exact="eletriptan" post="administration during the aura phase of migraine European journal"/>
   <result pre="10.1111/j.1468-1331.2004.00914.x 70. Aurora SK et al. Revisiting the efficacy of" exact="sumatriptan" post="therapy during the aura phase of migraine Headache 2009"/>
   <result pre="79. Hansen JM Goadsby PJ Charles A Reduced efficacy of" exact="sumatriptan" post="in migraine with aura vs without aura Neurology 2015"/>
   <result pre="al. Cessation versus continuation of 6-month migraine preventive therapy with" exact="topiramate" post="(PROMPT): a randomised, double-blind, placebo-controlled trial Lancet Neurol 2007"/>
   <result pre="and without aura and their response to preventive therapy with" exact="topiramate" post="Cephalalgia 2009 30 5 543 551 10.1111/j.1468-2982.2009.01999.x 104. Silberstein"/>
   <result pre="10.1111/j.1468-2982.2009.01999.x 104. Silberstein SD et al. Efficacy and tolerability of" exact="topiramate" post="200 mg/d in the prevention of migraine with/without aura"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734211/results/search/drugs/results.xml">
   <result pre="currently available evidence-based prophylactic treatment options for chronic migraine are" exact="topiramate" post="and onabotulinumtoxinA. Improved prophylactic therapy is needed to reduce"/>
   <result pre="of chronic migraine in Italy. Monoclonal antibodies that target the" exact="calcitonin" post="gene-related peptide (CGRP) pathway of migraine pathogenesis have been"/>
   <result pre="system structures and increased release of nociceptive neuropeptides, such as" exact="calcitonin" post="gene-related peptide (CGRP), which is highly expressed in trigeminal"/>
   <result pre="used in chronic migraine and emerging treatments in relation to" exact="calcitonin" post="gene-related peptide (CGRP). Modified with permission from Benemei, et"/>
   <result pre="physical therapies (e.g. acupuncture) and nutraceutical therapies (e.g. supplementary magnesium," exact="riboflavin" post="and Coenzyme Q10) can all be used to complement"/>
   <result pre="methysergide), antihypertensives (lisinopril, candesartan), and antidepressants that act as serotonin" exact="norepinephrine" post="reuptake inhibitors (venlafaxine), selective serotonin reuptake inhibitors (paroxetine, fluvoxamine)"/>
   <result pre="formulation of botulinum toxin A administered by intramuscular injection, and" exact="topiramate" post="are the only currently available therapies with high-quality evidence"/>
   <result pre="to be better tolerated than various oral prophylactic treatments, including" exact="topiramate" post="[ 50– 53]. Based on the PREEMPT clinical trial"/>
   <result pre="sensitisation, a key pathophysiological mechanisms of CM. Topiramate Like OBT-A," exact="topiramate" post="has the highest level of recommendation for the prophylactic"/>
   <result pre="treatment of CM in Italian treatment guidelines [ 41]. Although" exact="topiramate" post="reduced headache days versus placebo and was relatively well"/>
   <result pre="controlled trials [ 54, 55], adverse events commonly associated with" exact="topiramate" post="include paresthesia, memory and concentration disturbances, fatigue and nausea"/>
   <result pre="disturbances, fatigue and nausea [ 41]. It is believed that" exact="topiramate" post="is able to prevent the development of cortical spreading"/>
   <result pre="analysis of clinical trial results suggests that prophylactic treatment with" exact="topiramate" post="in patients with EM may help to prevent migraine"/>
   <result pre="C Caproni S Pisani A et al. Critical role of" exact="calcitonin" post="gene-related peptide receptors in cortical spreading depression Proc Natl"/>
   <result pre="C Cardeal M Melo A Botulinum toxin type a versus" exact="amitriptyline" post="for the treatment of chronic daily migraine Clin Neurol"/>
   <result pre="NT Jaffri SF A double-blind comparison of onabotulinumtoxina (BOTOX) and" exact="topiramate" post="(TOPAMAX) for the prophylactic treatment of chronic migraine: a"/>
   <result pre="Ramadan N Mathew N et al. Efficacy and safety of" exact="topiramate" post="for the treatment of chronic migraine: a randomized, double-blind,"/>
   <result pre="DA Morris BA Frost M et al. Rimegepant, an oral" exact="calcitonin" post="gene–related peptide receptor antagonist, for migraine N Engl J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734284/results/search/drugs/results.xml">
   <result pre="For patients who do not respond to common prophylactic drugs," exact="ketamine" post="infusion, onabotulinum toxin type A, intravenous (IV) lidocaine, IV"/>
   <result pre="ketamine infusion, onabotulinum toxin type A, intravenous (IV) lidocaine, IV" exact="methylprednisolone" post="and nerve blockade are possible treatment options, but even"/>
   <result pre="observed treatment response to a course of 5-days high dose" exact="methylprednisolone" post="in 9 post-infectious NDPH patients. Six of them also"/>
   <result pre="with high TNF-α levels in the CSF were given 100 mg" exact="doxycycline" post="twice daily for 3 months. Three patients reported that their"/>
   <result pre="severity of daily headaches. Rozen, has described some effects for" exact="montelukast" post="(10 mg twice daily) when added to doxycycline or minocycline"/>
   <result pre="some effects for montelukast (10 mg twice daily) when added to" exact="doxycycline" post="or minocycline to treat NDPH. However, there is no"/>
   <result pre="for montelukast (10 mg twice daily) when added to doxycycline or" exact="minocycline" post="to treat NDPH. However, there is no evidence in"/>
   <result pre="there is no evidence in the literature to support using" exact="montelukast" post="in the treatment of NDPH [ 6]. Topiramate and"/>
   <result pre="montelukast in the treatment of NDPH [ 6]. Topiramate and" exact="gabapentine" post="Rozen presented 5 NDPH patients in an abstract with"/>
   <result pre="NDPH patients in an abstract with favorable response to either" exact="gabapentin" post="or topiramate but again no good scientific evidence supports"/>
   <result pre="in an abstract with favorable response to either gabapentin or" exact="topiramate" post="but again no good scientific evidence supports using these"/>
   <result pre="et al. performed nerve blocks in painful areas with 0.5%" exact="bupivacaine" post="in 23 NDPH patients. It provided 60% acute response,"/>
   <result pre="with NDPH who received greater occipital nerve block using 1%" exact="lidocaine" post="and methylprednisolone [ 29]. Onabotulinum toxin type a (BTX)"/>
   <result pre="who received greater occipital nerve block using 1% lidocaine and" exact="methylprednisolone" post="[ 29]. Onabotulinum toxin type a (BTX) In a"/>
   <result pre="were treated with BTX injection every 3 month [ 32]. Intravenous" exact="lidocaine" post="Marmura et al. in a retrospective study, studied 68"/>
   <result pre="They suggested that patients with NDPH may benefit from IV" exact="lidocaine" post="treatment [ 33]. Akbar reported a 16-year-old boy diagnosed"/>
   <result pre="to several aggressive inpatient therapies. He was treated with IV" exact="lidocaine" post="infusion and reported that the headache fully resolved for"/>
   <result pre="severity and frequency decreased for almost 3 months [ 34]. Intravenous" exact="dihydroergotamine" post="(IV DHE) Nagy et al. studied the effect of"/>
   <result pre="those with non-migranous characteristics is less encouraging [ 35]. Intravenous" exact="ketamine" post="In a retrospective study, Pomeroy et al. treated 14"/>
   <result pre="who had previously failed aggressive treatments with a sub-anesthetic dose" exact="ketamine" post="infusion. Acute response was seen in 8 (57.1%) NDPH"/>
   <result pre="of it. As it is well tolerated, a trial of" exact="ketamine" post="might be considered reasonable in refractory NDPH cases ["/>
   <result pre="IV methylprednisolone, IV sodium valproate, anti-depressant (amitriptyline or dothiepin) and" exact="naproxene" post="for at least 3–6 months. After a median follow-up of"/>
   <result pre="month) in 30% of NDPH patients [ 16]. In summary," exact="ketamine" post="infusion, onabotulinum toxin type A, intravenous (IV) lidocaine, IV"/>
   <result pre="ketamine infusion, onabotulinum toxin type A, intravenous (IV) lidocaine, IV" exact="methylprednisolone" post="and nerve blockade are possible treatment options for patients"/>
   <result pre="ND Post-infectious new daily persistent headache may respond to intravenous" exact="methylprednisolone" post="J Headache Pain 2010 11 1 59 66 10.1007/s10194-009-0171-x"/>
   <result pre="A Response of refractory new daily persistent headache to intravenous" exact="lidocaine" post="treatment in a pediatric patient J Pain Relief 2017"/>
   <result pre="35. Nagy AJ Gandhi S Bhola R Goadsby PJ Intravenous" exact="dihydroergotamine" post="for inpatient management of refractory primary headaches Neurology 2011"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734342/results/search/drugs/results.xml">
   <result pre="neurons is transmitted by endogenous mediators, including the vasoactive neuropeptides" exact="calcitonin" post="gene-related peptide (CGRP), substance P, neurokinin A, and pituitary"/>
   <result pre="as well as release of vasoactive inflammatory mediators such as" exact="nitric oxide," post="coincident with inflammation in the meninges [ 2, 5]."/>
   <result pre="Dale RC Gardiner A Branson JA Houlden H Benefit of" exact="carbamazepine" post="in a patient with hemiplegic migraine associated with PRRT2"/>
   <result pre="Chronicle EP, McCrory DC (2013) Valproate (valproic acid or sodium" exact="valproate" post="or a combination of the two) for the prophylaxis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734460/results/search/drugs/results.xml">
   <result pre="vessels, since the dilatation of the intracranial vessels due to" exact="acetazolamide" post="is less than that in younger patients [ 80]."/>
   <result pre="function lasting a relatively short time. The disorder responds to" exact="acetazolamide" post="which may be also beneficial in migraine with hemiparetic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734472/results/search/drugs/results.xml">
   <result pre="as an active mTrP [ 6, 21, 33, 34]. Two" exact="nitroglycerin" post="capsules were attached to the skin adjacent to an"/>
   <result pre="image In all subjects, the investigator first identified the attached" exact="nitroglycerin" post="capsules and re-angulated the images to be able to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6753025/results/search/drugs/results.xml">
   <result pre="fluoroscopic guidance in all cases. All patients were pre-medicated with" exact="acetylsalicylic acid" post="(100 mg). Cardiac catheterization was performed to evaluate the"/>
   <result pre="ICE or TTE, and by fluoroscopy. Post-interventional treatment consisted of" exact="acetylsalicylic acid" post="(100 mg) once daily for 6 months. For peri-interventional"/>
   <result pre="retrieval of the ASO via catheterization. He was treated with" exact="dexamethasone" post="for 7 days and recovered normal sinus rhythm. He"/>
   <result pre="migraine were occurred in group 1, and one case of" exact="lidocaine" post="toxicity complained of dizziness was occurred in group 2."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6755590/results/search/drugs/results.xml">
   <result pre="pmid: 30419806 940 doi: 10.1186/s10194-018-0940-5 : Research Article Perampanel inhibits" exact="calcitonin" post="gene-related peptide release from rat brainstem in vitro http://orcid.org/0000-0002-1030-9429"/>
   <result pre="in this study we investigated the putative anti-migraine activity of" exact="perampanel" post="in an in vitro animal model involving the static"/>
   <result pre="of rat brainstem explants and the subsequent measurement of immune-reactive" exact="calcitonin" post="gene-related peptide released into the incubation medium. Methods Acute"/>
   <result pre="in the range 0.01–100 μM, inhibited in a concentration-dependent manner" exact="calcitonin" post="gene-related peptide’s release compared to controls; the decrease was"/>
   <result pre="from 10 μM; 2) a significant and consistent increase in" exact="calcitonin" post="gene-related peptide’s secretion was induced by all depolarizing stimuli"/>
   <result pre="stimuli after 1 h of incubation; 3) under these conditions," exact="calcitonin" post="gene-related peptide’s release stimulated by 56 mM KCl was"/>
   <result pre="release stimulated by 56 mM KCl was significantly reduced by" exact="perampanel" post="from 0.1 μM onward, whereas secretion stimulated by veratridine"/>
   <result pre="significantly reduced as from 1 μM; 4) on the contrary," exact="perampanel" post="had no effect on capsaicin-induced calcitonin gene-related peptide’s release"/>
   <result pre="4) on the contrary, perampanel had no effect on capsaicin-induced" exact="calcitonin" post="gene-related peptide’s release up to 100 μM. Conclusions Here"/>
   <result pre="Conclusions Here we provided preliminary in vitro evidence suggesting that" exact="perampanel" post="might control pain transmission under conditions of activated trigeminal"/>
   <result pre="via non-competitive AMPA antagonism [ 1]. Pre-clinical studies showed that" exact="perampanel" post="inhibits AMPA-induced Ca ++ influx in isolated rat cortical"/>
   <result pre="of about 0.1 μM [ 2]. The binding of radiolabeled" exact="perampanel" post="to neuronal rat membranes was not displaced by glutamate,"/>
   <result pre="non-competitive AMPA antagonists such as CP465022 or GYK152466 effectively displaced" exact="perampanel" post="[ 2]; such drug-receptor interaction is fully consistent with"/>
   <result pre="interaction is fully consistent with the functional effects exerted by" exact="perampanel" post="on Ca ++ influx. Perampanel has been approved for"/>
   <result pre="pediatric patients from 12 years on. The clinical efficacy of" exact="perampanel" post="in partial-onset seizures was demonstrated in 3 double-blind, randomized"/>
   <result pre="randomized controlled trial, study 332 [ 7]. In all studies," exact="perampanel" post="or placebo were given on top of standard-of-care AEDs"/>
   <result pre="migraine, in the present study we tested the hypothesis that" exact="perampanel" post="can modulate the release of immune-reactive calcitonin gene-related peptide"/>
   <result pre="the hypothesis that perampanel can modulate the release of immune-reactive" exact="calcitonin" post="gene-related peptide (CGRP, a peptide neurotransmitter most important in"/>
   <result pre="with Earle’s salts (MEM), supplemented with bovine serum albumin, glutamine," exact="ascorbic acid" post="and aprotinin; pH 7,4] at 37 °C in a"/>
   <result pre="experiments shown in Fig. 1, media contained graded concentrations of" exact="perampanel" post="or medium alone in the control group; b) in"/>
   <result pre="until assay for CGRP immunoreactivity. Fig. 1 Inhibitory effect of" exact="perampanel" post="on basal CGRP release from rat brainstem explants. Data"/>
   <result pre="the secretagogue given alone, respectively Fig. 3 The effect of" exact="perampanel" post="on veratridine-stimulated CGRP release from rat brainstem explants. Data"/>
   <result pre="vs veratridine given alone, respectively Fig. 4 The effects of" exact="perampanel" post="on capsaicin-stimulated CGRP release from rat brainstem explants. Data"/>
   <result pre="i.e. -23%. The EC50 was achieved at a 0.1 μM" exact="perampanel" post="concentration. A significant and consistent increase in CGRP secretion"/>
   <result pre="of incubation (Figs. 2, 3 and 4). Under these conditions," exact="perampanel" post="was able to antagonize the increase in CGRP secretion"/>
   <result pre="secretion stimulated by 56 mM KCl was significantly reduced by" exact="perampanel" post="as from 0.1 μM (Fig. 2), whereas secretion stimulated"/>
   <result pre="and veratridine-stimulated CGRP release (− 39.5% and − 60%, respectively) was achieved by" exact="perampanel" post="at 100 μM. At variance, perampanel had no effect"/>
   <result pre="respectively) was achieved by perampanel at 100 μM. At variance," exact="perampanel" post="had no effect on capsaicin-induced CGRP release up to"/>
   <result pre="per experimental group. Discussion In this work, we found that" exact="perampanel" post="is able to inhibit in a concentration-dependent manner basal"/>
   <result pre="elsewhere [ 19]. Under these conditions, the size effect of" exact="perampanel" post="over peptide release is − 46% compared to baseline release,"/>
   <result pre="− 46% compared to baseline release, obtained at a 100 μM" exact="perampanel" post="concentration. Half of the size effect (i.e. -23%, representing"/>
   <result pre="a 0.1 μM concentration, which corresponds to the EC50 of" exact="perampanel" post="in reducing Ca ++ influx in rat cortical neurons"/>
   <result pre="Ca ++ influx in rat cortical neurons [ 2]. Likewise," exact="perampanel" post="was able to inhibit the release of CGRP stimulated"/>
   <result pre="the stimulatory effects of 10 μM capsaicin. The EC50 of" exact="perampanel" post="on KCl-stimulated release was in the same order of"/>
   <result pre="of that observed under baseline conditions, whereas 1–10 μM of" exact="perampanel" post="were needed to achieve the EC50 after veratridine stimulation."/>
   <result pre="Ca ++ influx within the neurons (and the effect of" exact="perampanel" post="is mostly based on Ca ++ influx modulation), whereas"/>
   <result pre="-notably including morphine and lacosamide- failed to counteract capsaicin, whereas" exact="tapentadol" post="and reboxetine had a weak inhibitory effect in the"/>
   <result pre="is too strong, and the same reasoning might apply to" exact="perampanel" post="as well. Here we report preclinical in vitro evidence"/>
   <result pre="as well. Here we report preclinical in vitro evidence that" exact="perampanel" post="might be useful in the treatment of disorders related"/>
   <result pre="presentation in humans is migraine. There is also evidence that" exact="perampanel" post="was found effective in a model of neuropathic pain"/>
   <result pre="findings represent an initial background suggesting the opportunity to test" exact="perampanel" post="in the clinical setting of migraine. At this stage,"/>
   <result pre="field toward clinical investigations. Indeed, other investigational agents related to" exact="perampanel" post="(including the AMPA antagonist BGG492, the kainate antagonist LY466195,"/>
   <result pre="(reviewed in [ 9]). Compared to the above-mentioned investigational tools," exact="perampanel" post="may present some advantage regarding clinical studies. First, perampanel"/>
   <result pre="tools, perampanel may present some advantage regarding clinical studies. First," exact="perampanel" post="is already approved in two different populations of epileptic"/>
   <result pre="making easier the design and conductance of dose-finding studies. Moreover," exact="perampanel" post="presents a favorable pharmacokinetic profile; after oral administration, the"/>
   <result pre="options. Conclusions Here we showed that the novel antiepileptic agent" exact="perampanel" post="is able to inhibit both basal and secretagogue-stimulated CGRP"/>
   <result pre="have also discussed the issue of testing the efficacy of" exact="perampanel" post="in the clinical setting of migraine, providing some argument"/>
   <result pre="institutional affiliations. References References 1. Löscher W Schmidt D Epilepsy:" exact="perampanel" post="- new promise for refractory epilepsy? Nat Rev Neurol"/>
   <result pre="D Yang H Laurenza A Kumar D Rogawski MA Adjunctive" exact="perampanel" post="for refractory partial-onset seizures: randomized phase III study 304"/>
   <result pre="D Yang H Kumar D Laurenza A Evaluation of adjunctive" exact="perampanel" post="in patients with refractory partial-onset seizures: results of randomized"/>
   <result pre="Zhu J Laurenza A Randomized phase III study 306: adjunctive" exact="perampanel" post="for refractory partial-onset seizures Neurology 2012 78 1408 1415"/>
   <result pre="M Gee M Zhu J Squillacote D Long-term safety of" exact="perampanel" post="and seizure outcomes in refractory partial-onset seizures and secondarily"/>
   <result pre="Lisi L Currò D Navarra P Tringali G Tapentadol inhibits" exact="calcitonin" post="gene-related peptide release from rat brainstem in vitro Peptides"/>
   <result pre="Greco MC Capuano A Navarra P Tringali G Lacosamide inhibits" exact="calcitonin" post="gene-related peptide production and release at trigeminal level in"/>
   <result pre="Capuano A Currò D Navarra P Tringali G Cortistatin modulates" exact="calcitonin" post="gene-related peptide release from neuronal tissues of rat. Comparison"/>
   <result pre="gene-related peptide release from neuronal tissues of rat. Comparison with" exact="somatostatin" post="Peptides 2011 32 138 143 10.1016/j.peptides.2010.09.018 20883741 21. Capuano"/>
   <result pre="22. Greco MC Navarra P Tringali G The analgesic agent" exact="tapentadol" post="inhibits calcitonin gene-related peptide release from isolated rat brainstem"/>
   <result pre="MC Navarra P Tringali G The analgesic agent tapentadol inhibits" exact="calcitonin" post="gene-related peptide release from isolated rat brainstem via a"/>
   <result pre="G Singh N Jaggi AS Neuropathic pain attenuating effects of" exact="perampanel" post="in an experimental model of chronic constriction injury in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6755612/results/search/drugs/results.xml">
   <result pre="The remaining 5 patients (3/5 females) used the following medications:" exact="acetaminophen" post="(15 mg/kg), ibuprofen (10 mg/kg) and ketoprofen (1.5 mg/kg)"/>
   <result pre="patients (3/5 females) used the following medications: acetaminophen (15 mg/kg)," exact="ibuprofen" post="(10 mg/kg) and ketoprofen (1.5 mg/kg) were taken within"/>
   <result pre="the following medications: acetaminophen (15 mg/kg), ibuprofen (10 mg/kg) and" exact="ketoprofen" post="(1.5 mg/kg) were taken within few minutes after the"/>
   <result pre="No 5 F 8.2 20 9 Pulsating Frontal, bilateral Yes," exact="acetaminophen" post="6 M 11 30 1 Pulsating Frontal, bilateral Yes,"/>
   <result pre="acetaminophen 6 M 11 30 1 Pulsating Frontal, bilateral Yes," exact="acetaminophen" post="7 F 15.5 20 8 Pressing Frontal, bilateral No"/>
   <result pre="No 11 F 12 20 9 Pulsating Diffuse, bilateral Yes," exact="ketoprofen" post="12 F 16 30 8 Pulsating Frontal, bilateral No"/>
   <result pre="No 14 M 9 30 7 Tightening Diffuse, unilateral Yes," exact="acetaminophen" post="15 F 12.5 30 8 Tightening Occipital, unilateral Yes,"/>
   <result pre="acetaminophen 15 F 12.5 30 8 Tightening Occipital, unilateral Yes," exact="ibuprofen" post="Discussion The present study was performed on a selected"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6755928/results/search/drugs/results.xml">
   <result pre="stages. Moreover, recent neurometabolic studies have reported altered levels of" exact="melatonin" post="both in migraine sufferers and enuretics. Children with NE"/>
   <result pre="often subjected to unnecessary therapies, for example, high doses of" exact="desmopressin" post="or adenotonsillectomy in the hope that the treatment of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6771736/results/search/drugs/results.xml">
   <result pre="authors’ expertise. Study Selection Articles were selected concentrating on the" exact="nitric oxide" post="(NO)‐soluble guanylate cyclase (sGC)‐cyclic guanosine monophosphate (cGMP) pathway in"/>
   <result pre="The methodology of an ongoing study evaluating the sGC stimulator" exact="riociguat" post="in children with PAH is also described. Results Despite"/>
   <result pre="for pediatric PAH are needed. The efficacy and tolerability of" exact="riociguat" post="in adults with PAH have been well trialed. Conclusion"/>
   <result pre="stimulators in the treatment strategy for pediatric PAH. PAH pediatrics" exact="riociguat" post="sGC stimulators Funding Bayer AG, Berlin, Germany fig-count: table-count:"/>
   <result pre="be viewed at wileyonlinelibrary.com] In AVT, a vasodilator (eg, inhaled" exact="nitric oxide;" post="NO) is administered. A decrease in mPAP by ≥10 mm"/>
   <result pre="smooth muscle cells and other tissues, increasing production of cyclic" exact="adenosine" post="monophosphate, which induces pulmonary vasodilation as well as antithrombotic,"/>
   <result pre="adults, and several newer prostanoids have since been developed, including" exact="treprostinil" post="and iloprost, as well as the nonprostanoid prostacyclin receptor"/>
   <result pre="with historical controls. 46 In children with severe PAH, subcutaneous" exact="treprostinil" post="has been shown to improve WHO FC, exercise tolerance,"/>
   <result pre="47 Numerous case studies and small trials suggest that inhaled" exact="iloprost" post="may have a role in neonates and children with"/>
   <result pre="in 22 children with iPAH or PAH‐CHD found that inhaled" exact="iloprost" post="reduced mPAP, but also reduced forced expiratory volume in"/>
   <result pre="with wholly or partly pediatric cohorts with PAH. These include" exact="treprostinil" post="(ClinicalTrials.gov: NCT01027949), iloprost (NCT02825160), and selexipag (NCT03492177), while ralinepag"/>
   <result pre="partly pediatric cohorts with PAH. These include treprostinil (ClinicalTrials.gov: NCT01027949)," exact="iloprost" post="(NCT02825160), and selexipag (NCT03492177), while ralinepag is being evaluated"/>
   <result pre="with PAH. These include treprostinil (ClinicalTrials.gov: NCT01027949), iloprost (NCT02825160), and" exact="selexipag" post="(NCT03492177), while ralinepag is being evaluated in adults with"/>
   <result pre="of ET‐1. Ambrisentan is a selective ET A receptor antagonist:" exact="macitentan" post="and bosentan are dual ET A and ET B"/>
   <result pre="Ambrisentan is a selective ET A receptor antagonist: macitentan and" exact="bosentan" post="are dual ET A and ET B receptor antagonists."/>
   <result pre="A and ET B receptor antagonists. In children with PAH," exact="bosentan" post="has been shown to improve exercise capacity and functional"/>
   <result pre="functional status. 51, 52, 53 The efficacy and tolerability of" exact="bosentan" post="are maintained during long‐term treatment. 54, 55 In practice,"/>
   <result pre="bosentan are maintained during long‐term treatment. 54, 55 In practice," exact="bosentan" post="is often combined with PDE5i, mainly sildenafil, although there"/>
   <result pre="support this combination. In the USA and several other countries," exact="bosentan" post="is licensed for use in children aged ≥3 years, while"/>
   <result pre="licensed for use in children aged ≥3 years, while in Europe," exact="bosentan" post="is approved for use in children aged ≥1 year. In"/>
   <result pre="approved for use in children aged ≥1 year. In many countries," exact="bosentan" post="is available as a dispersible pediatric formulation, with similar"/>
   <result pre="being treated with ambrisentan (NCT01342952 and NCT01406327) and another ERA," exact="macitentan" post="(NCT02932410 and NCT00667823) are ongoing. 2.4 Drugs acting on"/>
   <result pre="is deactivated by phosphodiesterases (PDEs), notably PDE5. PDE5i such as" exact="sildenafil" post="and tadalafil prevent the breakdown of cGMP. 58 The"/>
   <result pre="by phosphodiesterases (PDEs), notably PDE5. PDE5i such as sildenafil and" exact="tadalafil" post="prevent the breakdown of cGMP. 58 The consequent increase"/>
   <result pre="adolescents (age, 1–17 years) with PAH were randomized double‐blind to" exact="sildenafil" post="at low (10 mg three times daily [tid]), medium (10–40 mg"/>
   <result pre="the percentage change in peak oxygen consumption (PVO 2) for" exact="sildenafil" post="vs placebo. The difference in PVO 2 between sildenafil"/>
   <result pre="for sildenafil vs placebo. The difference in PVO 2 between" exact="sildenafil" post="and placebo was not significant, with a mean (±SE)"/>
   <result pre="open‐label extension (STARTS‐2), in which those who had previously received" exact="sildenafil" post="continued their previous dose, while those who had received"/>
   <result pre="61 The result showed an increase in mortality with high‐dose" exact="sildenafil" post="compared with low and medium doses. Analyses adjusted for"/>
   <result pre="Agency (EMA) subsequently added a warning to the labeling for" exact="sildenafil" post="(originally approved in 2011) to avoid use of the"/>
   <result pre="strong warning in August 2012 against the (chronic) use of" exact="sildenafil" post="for pediatric patients with PAH ( https://www.fda.gov/Drugs/DrugSafety/ucm317123.htm). In 2014,"/>
   <result pre="is still not recommended ( https://www.fda.gov/drugs/drugsafety/ucm390876.htm). Additional pediatric trials of" exact="sildenafil" post="in PAH have been performed but are not discussed"/>
   <result pre="73, 74, 75 Table 1 Summary of key studies evaluating" exact="sildenafil" post="for the treatment of children and adolescents with PAH"/>
   <result pre="or PAH associated with connective tissue disease or CHD Low‐dose" exact="sildenafil" post="(10 mg tid) • Estimated mean change in PVO 2"/>
   <result pre="• Estimated mean change in PVO 2 (primary endpoint) for" exact="sildenafil" post="(pooled) vs placebo was 7.7% (95% CI, −0.2‐15.6%; P = .056)"/>
   <result pre="(pooled) vs placebo was 7.7% (95% CI, −0.2‐15.6%; P = .056) Medium‐dose" exact="sildenafil" post="(10–40 mg tid) • PVO 2, FC, and hemodynamics improved"/>
   <result pre="hemodynamics improved with medium and high doses vs placebo; low‐dose" exact="sildenafil" post="was ineffective High‐dose sildenafil (20–80 mg tid) • Most adverse"/>
   <result pre="and high doses vs placebo; low‐dose sildenafil was ineffective High‐dose" exact="sildenafil" post="(20–80 mg tid) • Most adverse events were mild to"/>
   <result pre="children (age, 1‐17 y) with PAH and Down syndrome Low‐dose" exact="sildenafil" post="(10 mg tid) • Sildenafil had no effect on PVRI"/>
   <result pre="• Sildenafil had no effect on PVRI and mPAP Medium‐dose" exact="sildenafil" post="(10–40 mg tid) • Sildenafil was well tolerated in children"/>
   <result pre="Sildenafil was well tolerated in children with Down syndrome High‐dose" exact="sildenafil" post="(20–80 mg tid) Placebo STARTS‐2 61 Long‐term open‐label extension in"/>
   <result pre="Long‐term open‐label extension in 220 children who completed STARTS‐1 Low‐dose" exact="sildenafil" post="(10 mg tid) • Deaths reported in 37 patients, of"/>
   <result pre="37 patients, of whom 28 had idiopathic or hPAH Medium‐dose" exact="sildenafil" post="(10–40 mg tid) • Deaths more likely in patients in"/>
   <result pre="cohort (15%), and in patients with worse baseline hemodynamics High‐dose" exact="sildenafil" post="(20–80 mg tid) • 3‐y survival rates: 94%, 93%, and"/>
   <result pre="patients previously treated with sildenafil, 83, 84, 85 suggested that" exact="tadalafil" post="improves hemodynamics and exercise capacity, and is generally well"/>
   <result pre="exercise capacity, and is generally well tolerated (Table 2). While" exact="tadalafil" post="is licensed for use in adults with PAH in"/>
   <result pre="either region. Table 2 Summary of key published studies evaluating" exact="tadalafil" post="for the treatment of children and adolescents with PAH"/>
   <result pre="14 patients who underwent repeat catheterization, improvements after switching from" exact="sildenafil" post="were observed in mPAP (53.2 vs 47.4 mm Hg;"/>
   <result pre="similar in treatment‐naïve and switched patients • Two patients discontinued" exact="tadalafil" post="due to adverse events (migraine; allergic reaction) Sabri et"/>
   <result pre="and young adults (age, 4–24 y) with PAH previously receiving" exact="sildenafil" post="Tadalafil 1 mg/kg/day (maximum: 40 mg/day) • No change in FC"/>
   <result pre="6MWD improved ( P = .005) • No significant side effects of" exact="tadalafil" post="Shiva et al 83 Prospective open‐label study of 25"/>
   <result pre="( P &amp;lt; .01), including in six patients who had previously received" exact="sildenafil" post="for &amp;gt;6 mo • Tadalafil was generally safe and well"/>
   <result pre="sPAP, systolic pulmonary artery pressure. a 29 patients switched from" exact="sildenafil" post="(mean, 3.4 mg/kg/day) to tadalafil. (C) John Wiley &amp;amp; Sons,"/>
   <result pre="tadalafil. (C) John Wiley &amp;amp; Sons, Ltd., Ongoing trials of" exact="sildenafil" post="in children with PAH include trials in neonates (ClinicalTrials.gov:"/>
   <result pre="NCT01642407). Pharmacokinetic (NCT01484431) and safety and efficacy (NCT01824290) studies of" exact="tadalafil" post="are also under way. Combination therapy that targets multiple"/>
   <result pre="NO, increasing cGMP levels. 96, 97, 98 The ability of" exact="riociguat" post="to stimulate sGC independently of NO means that it"/>
   <result pre="be reduced. 99, 100, 101 The efficacy and tolerability of" exact="riociguat" post="in patients with PAH were demonstrated in the double‐blind,"/>
   <result pre="PATENT‐1 study. 102 Patients ( n = 443) were randomized to placebo;" exact="riociguat" post="individually dose‐adjusted up to 2.5 mg tid; or an exploratory"/>
   <result pre="up to 2.5 mg tid; or an exploratory arm in which" exact="riociguat" post="was capped at 1.5 mg tid. At week 12, significant"/>
   <result pre="[the primary endpoint]) and several secondary endpoints, were seen with" exact="riociguat" post="2.5 mg tid‐maximum compared with placebo, and riociguat was generally"/>
   <result pre="were seen with riociguat 2.5 mg tid‐maximum compared with placebo, and" exact="riociguat" post="was generally well tolerated. On the basis of PATENT‐1,"/>
   <result pre="riociguat was generally well tolerated. On the basis of PATENT‐1," exact="riociguat" post="is indicated for the treatment of adults with PAH."/>
   <result pre="open‐label extension (PATENT‐2) in which all patients ( n = 396) received" exact="riociguat" post="2.5 mg tid‐maximum. 103 The improvements in 6MWD and WHO"/>
   <result pre="FC observed in PATENT‐1 were maintained after 2 years of" exact="riociguat" post="treatment, with survival rates at 1 and 2 years"/>
   <result pre="and 83%, respectively. The RESPITE study reported that switching to" exact="riociguat" post="was effective and generally well tolerated in patients with"/>
   <result pre="treatment. 104 A second study of switching from PDE5i to" exact="riociguat" post="(REPLACE) is currently recruiting 105 (ClinicalTrials.gov: NCT02891850). Riociguat is"/>
   <result pre="placental transfer in animal studies. 106, 107 In the USA," exact="riociguat" post="is available to female patients only through a restricted"/>
   <result pre="evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of" exact="riociguat" post="in children and adolescents with PAH. At least 20"/>
   <result pre="before the baseline visit, will be enrolled. Concomitant use of" exact="riociguat" post="and PDE5i is contraindicated 106, 107 and is therefore"/>
   <result pre="contraindicated 106, 107 and is therefore not permitted. Pretreatment with" exact="sildenafil" post="or tadalafil is, however, allowed up to 1 day and"/>
   <result pre="107 and is therefore not permitted. Pretreatment with sildenafil or" exact="tadalafil" post="is, however, allowed up to 1 day and 3 days,"/>
   <result pre="to the 6–11 years of age group. Patients will receive" exact="riociguat" post="as film‐coated tablets, adjusted to doses of 1.0–2.5 mg tid,"/>
   <result pre="assessments throughout clinical trials in PAH. 1 In preclinical studies," exact="riociguat" post="induced alterations to bone morphology in juvenile and adolescent"/>
   <result pre="progress to assess the pharmacokinetics, safety, and exploratory efficacy of" exact="riociguat" post="in children and adolescents with PAH. Until results from"/>
   <result pre="Until results from PATENT‐CHILD are available, we strongly recommend that" exact="riociguat" post="should be given to children only when participating in"/>
   <result pre="in a clinical trial, and that clinicians should not use" exact="riociguat" post="empirically in pediatric patients. CONFLICTS OF INTEREST MB is"/>
   <result pre="on opportunities and challenges in pediatric drug development: Learning from" exact="sildenafil" post=". J Am Coll Cardiol. 2017; 70: 495‐ 503."/>
   <result pre="S , et al. Safety, efficacy and management of subcutaneous" exact="treprostinil" post="infusions in the treatment of severe pediatric pulmonary hypertension"/>
   <result pre="153‐ 157. 29650343 48 Mulligan C , Beghetti M. Inhaled" exact="iloprost" post="for the control of acute pulmonary hypertension in children:"/>
   <result pre="KJ , et al. Short‐ and long‐term effects of inhaled" exact="iloprost" post="therapy in children with pulmonary arterial hypertension . J"/>
   <result pre="Dingemanse J , et al. Pharmacokinetics, safety, and efficacy of" exact="bosentan" post="in pediatric patients with pulmonary arterial hypertension . Clin"/>
   <result pre="AA , Flynn Y , Haworth SG . Response to" exact="bosentan" post="in children with pulmonary hypertension. Heart. 2006; 92: 664‐"/>
   <result pre="al. Pharmacokinetic and clinical profile of a novel formulation of" exact="bosentan" post="in children with pulmonary arterial hypertension: the FUTURE‐1 study"/>
   <result pre=", Schulze‐Neick I , Haworth SG . Long‐term efficacy of" exact="bosentan" post="in treatment of pulmonary arterial hypertension in children ."/>
   <result pre="safety and tolerability extension study using the pediatric formulation of" exact="bosentan" post="in pulmonary arterial hypertension . Int J Cardiol. 2016;"/>
   <result pre="MM , Kiely DG , et al. Safety experience with" exact="bosentan" post="in 146 children 2‐11 years old with pulmonary arterial"/>
   <result pre="et al. A randomized, double‐blind, placebo‐controlled, dose‐ranging study of oral" exact="sildenafil" post="citrate in treatment‐naive children with pulmonary arterial hypertension ."/>
   <result pre="Pulido T , et al. STARTS‐2: long‐term survival with oral" exact="sildenafil" post="monotherapy in treatment‐naive pediatric pulmonary arterial hypertension . Circulation."/>
   <result pre=", Redington AN . Pharmacokinetic and hemodynamic responses to oral" exact="sildenafil" post="during invasive testing in children with pulmonary hypertension ."/>
   <result pre="63 Bigdelian H , Sedighi M. The role of preoperative" exact="sildenafil" post="therapy in controlling of postoperative pulmonary hypertension in children"/>
   <result pre="Harthan AA . Evaluation of the tolerability of intermittent intravenous" exact="sildenafil" post="in pediatric patients with pulmonary hypertension . J Pediatr"/>
   <result pre="D. Treatment of pulmonary arterial hypertension using extemporaneous formulation of" exact="sildenafil" post="in Mexican children . Pediatr Cardiol. 2015; 36: 1019‐"/>
   <result pre="Martinez HO , Perez CF , et al. Pharmacokinetics of" exact="sildenafil" post="in children with pulmonary arterial hypertension. World J Pediatr."/>
   <result pre="Xiong CM , et al. The efficacy and safety of" exact="sildenafil" post="in patients with pulmonary arterial hypertension associated with the"/>
   <result pre=", Jiang X , Zhang R , et al. Oral" exact="sildenafil" post="treatment for eisenmenger syndrome: a prospective, open‐label, multicentre study"/>
   <result pre="M. Comparison of the therapeutic effects and side effects of" exact="tadalafil" post="and sildenafil after surgery in young infants with pulmonary"/>
   <result pre="of the therapeutic effects and side effects of tadalafil and" exact="sildenafil" post="after surgery in young infants with pulmonary arterial hypertension"/>
   <result pre="Rudzinski A , Zhang M. Efficacy and safety of oral" exact="sildenafil" post="in children with Down syndrome and pulmonary hypertension ."/>
   <result pre=", Yan WX , Chen H. [Efficacy and safety of" exact="sildenafil" post="in the treatment of high altitude heart disease associated"/>
   <result pre=", Stephens D , Adatia I. Beneficial effect of oral" exact="sildenafil" post="therapy on childhood pulmonary arterial hypertension: twelve‐month clinical trial"/>
   <result pre="Bush A , Magee AG . Safety and efficacy of" exact="sildenafil" post="therapy in children with pulmonary hypertension. Int J Cardiol."/>
   <result pre=", Ivy DD , Abman SH . Effects of long‐term" exact="sildenafil" post="treatment for pulmonary hypertension in infants with chronic lung"/>
   <result pre="et al. First experience with an oral combination therapy using" exact="bosentan" post="and sildenafil for pulmonary arterial hypertension . Eur J"/>
   <result pre="First experience with an oral combination therapy using bosentan and" exact="sildenafil" post="for pulmonary arterial hypertension . Eur J Clin Invest."/>
   <result pre=", Shiran M , Rafati M , et al. Oral" exact="tadalafil" post="in children with pulmonary arterial hypertension. Drug Res (Stuttg)."/>
   <result pre=", Calderbank M , Ivy DD . Initial experience with" exact="tadalafil" post="in pediatric pulmonary arterial hypertension. Pediatr Cardiol. 2012; 33:"/>
   <result pre="Beheshtian E. Comparison of the therapeutic and side effects of" exact="tadalafil" post="and sildenafil in children and adolescents with pulmonary arterial"/>
   <result pre="Comparison of the therapeutic and side effects of tadalafil and" exact="sildenafil" post="in children and adolescents with pulmonary arterial hypertension ."/>
   <result pre="F , Hirono K , et al. Plasma concentrations of" exact="tadalafil" post="in children with pulmonary arterial hypertension. Ther Drug Monit."/>
   <result pre=", Suzuki N , Murakami M. Safety and effectiveness of" exact="tadalafil" post="in pediatric patients with pulmonary arterial hypertension: A sub‐group"/>
   <result pre="et al. Usefulness of first‐line combination therapy with epoprostenol and" exact="bosentan" post="in pulmonary arterial hypertension: an observational study . J"/>
   <result pre="JA , et al. Initial combination therapy with ambrisentan and" exact="tadalafil" post="and mortality in patients with pulmonary arterial hypertension: a"/>
   <result pre="Frost AE , et al. Initial use of ambrisentan plus" exact="tadalafil" post="in pulmonary arterial hypertension. N Engl J Med. 2015;"/>
   <result pre="al. First acute haemodynamic study of soluble guanylate cyclase stimulator" exact="riociguat" post="in pulmonary hypertension . Eur Respir J. 2009; 33:"/>
   <result pre="al. Chronically elevated endothelin levels reduce pulmonary vascular reactivity to" exact="nitric oxide" post=". Am J Respir Crit Care Med. 2005; 171:"/>
   <result pre="et al. Predictors of long‐term outcomes in patients treated with" exact="riociguat" post="for pulmonary arterial hypertension: data from the PATENT‐2 open‐label,"/>
   <result pre="PA , Ghofrani H‐A , et al. RESPITE: switching to" exact="riociguat" post="in pulmonary arterial hypertension patients with inadequate response to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6778936/results/search/drugs/results.xml">
   <result pre="corticosteroid therapy because of the partial and transient responsiveness with" exact="paracetamol" post="during acute episodes of right eye pain. He showed"/>
   <result pre="lasting more time and with partial responsiveness to administration of" exact="paracetamol" post="with association of right ocular pain, ipsilateral ptosis, and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6780403/results/search/drugs/results.xml">
   <result pre="release of vasoactive peptides and other biochemical mediators, such as" exact="nitric oxide," post="which ultimately lead to inflammation [ 16] and the"/>
   <result pre="American Gut Project identified significant differences in nitrate, nitrite, and" exact="nitric oxide" post="reductase genes (bacterial origin: genera Streptococcus and Pseudomonas) in"/>
   <result pre="they may cause migraines via release of substances such as" exact="calcitonin" post="gene-related peptide (CGRP) [ 30, 31]. Similarly, in the"/>
   <result pre="into context, in a recent Cochrane review and meta-analysis of" exact="topiramate" post="as a migraine prophylaxis for EM patients, Linde et"/>
   <result pre="al. [ 33] reported that the difference in effect between" exact="topiramate" post="and placebo in the combined analysis corresponded to a"/>
   <result pre="a low serotonin state and evidence suggests that depletion of" exact="tryptophan" post="(the precursor to serotonin) exacerbates migraine symptoms [ 40]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6790872/results/search/drugs/results.xml">
   <result pre="include an antihypertensive and a combination of amitriptyline, topiramate, and" exact="sumatriptan" post="for newly-diagnosed migraine headache. Discussion We report a challenging"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6791607/results/search/drugs/results.xml">
   <result pre="taken to a primary care provider who started her on" exact="ranitidine" post="with no improvement in symptoms. The patient was cruising"/>
   <result pre="on a gluten-free diet. 15 Deficiencies in nutrients such as" exact="pyridoxine" post="have been described as a causative factor in depression"/>
   <result pre="of psychopathology in adult coeliac disease with the aid of" exact="pyridoxine" post="(vitamin B6) . Scand J Gastroenterol. 1983; 18: 299–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6802300/results/search/drugs/results.xml">
   <result pre="IV therapies included one of the following four options: -" exact="ketorolac" post="only ( n = 55) - ketorolac and metoclopramide / prochlorperazine"/>
   <result pre="the following four options: - ketorolac only ( n = 55) -" exact="ketorolac" post="and metoclopramide / prochlorperazine ( n = 132) - metoclopramide or"/>
   <result pre="four options: - ketorolac only ( n = 55) - ketorolac and" exact="metoclopramide" post="/ prochlorperazine ( n = 132) - metoclopramide or prochlorperazine ("/>
   <result pre="- ketorolac only ( n = 55) - ketorolac and metoclopramide /" exact="prochlorperazine" post="( n = 132) - metoclopramide or prochlorperazine ( n = 30) -"/>
   <result pre="n = 55) - ketorolac and metoclopramide / prochlorperazine ( n = 132) -" exact="metoclopramide" post="or prochlorperazine ( n = 30) - ondansetron only ( n = 37)"/>
   <result pre="ketorolac and metoclopramide / prochlorperazine ( n = 132) - metoclopramide or" exact="prochlorperazine" post="( n = 30) - ondansetron only ( n = 37) The dosages"/>
   <result pre="prochlorperazine ( n = 132) - metoclopramide or prochlorperazine ( n = 30) -" exact="ondansetron" post="only ( n = 37) The dosages used were not reported."/>
   <result pre="reported. Thirty-seven percent of the subjects were pretreated with either" exact="acetaminophen" post="or ibuprofen. None Treatment success defined as ≥50% reduction"/>
   <result pre="10. Treatment success: - Ketorolac only: 80% - Ketorolac plus" exact="metoclopramide" post="or prochlorperazine: 89% - Metoclopramide or prochlorperazine only: 93%"/>
   <result pre="- Ketorolac plus metoclopramide or prochlorperazine: 89% - Metoclopramide or" exact="prochlorperazine" post="only: 93% - Ondansetron only: 78% Dubrovsky et al."/>
   <result pre="center, retrospective mTBI Acute Pharmacological Treatment. - GON block (2%" exact="lidocaine" post="with epinephrine) - Peripheral nerve blocks of the lesser"/>
   <result pre="decrease in headache frequency was significant for subjects treated with" exact="topiramate" post="(n = 29, P = 0.02), but not for any other of the"/>
   <result pre="45 years Single-center, ED, prospective NS Acute Pharmacological Treatment. IV" exact="metoclopramide" post="20 mg + dephenhydramine 25 mg. 48 h + 7 days, 2 patients lost to follow-up. &quot;Sustained"/>
   <result pre="Melatonin 3–10 mg/day ( n = 12) - Nortriptyline ( n = 9) a and" exact="flunarizine" post="( n = 8) a doses were not specified - 17"/>
   <result pre="Treatment. Administration of GON block was done with 2,5 mL 2%" exact="lidocaine" post="(50 mg) + 0.5 ml methylprednisolone acetate (20 mg) or 2.5 ml triamcinolone (25 mg). Follow-up"/>
   <result pre="of GON block was done with 2,5 mL 2% lidocaine (50 mg) + 0.5 ml" exact="methylprednisolone" post="acetate (20 mg) or 2.5 ml triamcinolone (25 mg). Follow-up assessment was"/>
   <result pre="with 2,5 mL 2% lidocaine (50 mg) + 0.5 ml methylprednisolone acetate (20 mg) or 2.5 ml" exact="triamcinolone" post="(25 mg). Follow-up assessment was conducted at a mean of"/>
   <result pre="The list of acute medications included common analgesics such as" exact="ketorolac" post="[ 12], unspecified non-steroidal anti-inflammatory drugs (NSAIDs) [ 15],"/>
   <result pre="ketorolac [ 12], unspecified non-steroidal anti-inflammatory drugs (NSAIDs) [ 15]," exact="acetaminophen" post="[ 15] and combination drugs (Excedrin, Cafergot and Midrin)"/>
   <result pre="(Excedrin, Cafergot and Midrin) [ 15]. Specific analgesics used were" exact="lidocaine" post="[ 9, 10], triptans [ 15] and opioids ["/>
   <result pre="triptans [ 15] and opioids [ 15]. Antiemetics used were" exact="ondansetron" post="[ 12], metoclopramide [ 11, 12] and prochlorperazine ["/>
   <result pre="and opioids [ 15]. Antiemetics used were ondansetron [ 12]," exact="metoclopramide" post="[ 11, 12] and prochlorperazine [ 12]. Other drugs"/>
   <result pre="used were ondansetron [ 12], metoclopramide [ 11, 12] and" exact="prochlorperazine" post="[ 12]. Other drugs used were diphenhydramine [ 11],"/>
   <result pre="11, 12] and prochlorperazine [ 12]. Other drugs used were" exact="diphenhydramine" post="[ 11], methylprednisolone acetate [ 9] and triamcinolone ["/>
   <result pre="prochlorperazine [ 12]. Other drugs used were diphenhydramine [ 11]," exact="methylprednisolone" post="acetate [ 9] and triamcinolone [ 9]. A retrospective"/>
   <result pre="used were diphenhydramine [ 11], methylprednisolone acetate [ 9] and" exact="triamcinolone" post="[ 9]. A retrospective cross-sectional emergency department (ED) based"/>
   <result pre="of the following four intravenous (IV) acute treatment options: 1)" exact="ketorolac" post="only ( n = 55), 2) ketorolac and metoclopramide/prochlorperazine ( n = 132),"/>
   <result pre="(IV) acute treatment options: 1) ketorolac only ( n = 55), 2)" exact="ketorolac" post="and metoclopramide/prochlorperazine ( n = 132), 3) metoclopramide or prochlorperazine ("/>
   <result pre="only ( n = 55), 2) ketorolac and metoclopramide/prochlorperazine ( n = 132), 3)" exact="metoclopramide" post="or prochlorperazine ( n = 30) and 4) ondansetron only ("/>
   <result pre="n = 55), 2) ketorolac and metoclopramide/prochlorperazine ( n = 132), 3) metoclopramide or" exact="prochlorperazine" post="( n = 30) and 4) ondansetron only ( n = 37). The"/>
   <result pre="( n = 132), 3) metoclopramide or prochlorperazine ( n = 30) and 4)" exact="ondansetron" post="only ( n = 37). The dosages used were not reported."/>
   <result pre="nerve blocks and supraorbital nerve blocks. The blocks contained 2%" exact="lidocaine" post="with epinephrine. The primary outcome was to examine the"/>
   <result pre="further specified. Moreover, the authors reported that 82% received intravenous" exact="metoclopramide" post="treatment prior to the first treatment with peripheral nerve"/>
   <result pre="prior to the first treatment with peripheral nerve blocks. Following" exact="metoclopramide" post="treatment, 32% of subjects reported complete immediate headache resolution"/>
   <result pre="44% achieved partial and 24% no headache relief, respectively. Intravenous" exact="metoclopramide" post="treatment was conducted at a mean of 39 days since"/>
   <result pre="The authors did not report the dosages used for intravenous" exact="metoclopramide" post="treatment. In another case series, Seeger et al. ["/>
   <result pre="study investigated headache relief in 21 patients treated with intravenous" exact="metoclopramide" post="20 mg and diphenhydramine 25 mg after acute PTH attributed to"/>
   <result pre="relief in 21 patients treated with intravenous metoclopramide 20 mg and" exact="diphenhydramine" post="25 mg after acute PTH attributed to TBI [ 11]."/>
   <result pre="population [ 13]. The list of preventive medications used included:" exact="amitriptyline" post="[ 13– 15], nortriptyline [ 14, 15], topiramate ["/>
   <result pre="list of preventive medications used included: amitriptyline [ 13– 15]," exact="nortriptyline" post="[ 14, 15], topiramate [ 14, 15], propranolol ["/>
   <result pre="used included: amitriptyline [ 13– 15], nortriptyline [ 14, 15]," exact="topiramate" post="[ 14, 15], propranolol [ 15], valproate [ 15],"/>
   <result pre="13– 15], nortriptyline [ 14, 15], topiramate [ 14, 15]," exact="propranolol" post="[ 15], valproate [ 15], melatonin [ 14], gabapentin"/>
   <result pre="[ 14, 15], topiramate [ 14, 15], propranolol [ 15]," exact="valproate" post="[ 15], melatonin [ 14], gabapentin [ 13] and"/>
   <result pre="topiramate [ 14, 15], propranolol [ 15], valproate [ 15]," exact="melatonin" post="[ 14], gabapentin [ 13] and flunarizine [ 14]."/>
   <result pre="15], propranolol [ 15], valproate [ 15], melatonin [ 14]," exact="gabapentin" post="[ 13] and flunarizine [ 14]. In the aforementioned"/>
   <result pre="valproate [ 15], melatonin [ 14], gabapentin [ 13] and" exact="flunarizine" post="[ 14]. In the aforementioned military study [ 15],"/>
   <result pre="following prophylactic medications: tricyclic antidepressants (amitriptyline or nortriptyline, n = 48) 25–50 mg/day," exact="topiramate" post="( n = 29) 100 mg/day, propranolol ( n = 18) 80 mg/day and valproate"/>
   <result pre="antidepressants (amitriptyline or nortriptyline, n = 48) 25–50 mg/day, topiramate ( n = 29) 100 mg/day," exact="propranolol" post="( n = 18) 80 mg/day and valproate ( n = 5) 500 mg/day). Some"/>
   <result pre="25–50 mg/day, topiramate ( n = 29) 100 mg/day, propranolol ( n = 18) 80 mg/day and" exact="valproate" post="( n = 5) 500 mg/day). Some patients also received non-pharmacological treatment"/>
   <result pre="decrease in headache frequency was significant for subjects treated with" exact="topiramate" post="( n = 29, P = 0.02), but not for any of the"/>
   <result pre="as measured by MIDAS. In conclusion, the authors stated that" exact="topiramate" post="could be an effective prophylactic drug for PTH, while"/>
   <result pre="The list of prophylactic treatments used in the study included:" exact="amitriptyline" post="(5 mg/day to 1 mg/kg/day), nortriptyline (dosage not specified), topiramate (12.5"/>
   <result pre="treatments used in the study included: amitriptyline (5 mg/day to 1 mg/kg/day)," exact="nortriptyline" post="(dosage not specified), topiramate (12.5 to 200 mg/day), melatonin (3–10 mg/day)"/>
   <result pre="study included: amitriptyline (5 mg/day to 1 mg/kg/day), nortriptyline (dosage not specified)," exact="topiramate" post="(12.5 to 200 mg/day), melatonin (3–10 mg/day) and flunarizine (dosage not"/>
   <result pre="to 1 mg/kg/day), nortriptyline (dosage not specified), topiramate (12.5 to 200 mg/day)," exact="melatonin" post="(3–10 mg/day) and flunarizine (dosage not specified). The primary outcome"/>
   <result pre="(dosage not specified), topiramate (12.5 to 200 mg/day), melatonin (3–10 mg/day) and" exact="flunarizine" post="(dosage not specified). The primary outcome was a ≥ 50% reduction"/>
   <result pre="reported that the overall treatment response was 64%. More specifically," exact="melatonin" post="and amitriptyline yielded a treatment success rate of 75%"/>
   <result pre="the overall treatment response was 64%. More specifically, melatonin and" exact="amitriptyline" post="yielded a treatment success rate of 75% (9 of"/>
   <result pre="an academic sports medicine practice classified patients into three groups:" exact="gabapentin" post="group (median dose: 900 mg, n = 60), amitriptyline group (median dose:"/>
   <result pre="patients into three groups: gabapentin group (median dose: 900 mg, n = 60)," exact="amitriptyline" post="group (median dose: 20 mg, n = 94) and no medication group"/>
   <result pre="treatment during the study period. No patient was prescribed both" exact="gabapentin" post="and amitriptyline. A 7-point numeric rating scale from 0"/>
   <result pre="severe headache) was used to record headache scores. In the" exact="gabapentin" post="and amitriptyline groups, most subjects (~ 80%) were prescribed pharmacological"/>
   <result pre="was used to record headache scores. In the gabapentin and" exact="amitriptyline" post="groups, most subjects (~ 80%) were prescribed pharmacological treatment at"/>
   <result pre="White Deborah John Gallagher E. An exploratory study of IV" exact="metoclopramide" post="+ diphenhydramine for acute post-traumatic headache The American Journal"/>
   <result pre="John Gallagher E. An exploratory study of IV metoclopramide +" exact="diphenhydramine" post="for acute post-traumatic headache The American Journal of Emergency"/>
   <result pre="al. Cessation versus continuation of 6-month migraine preventive therapy with" exact="topiramate" post="(PROMPT): a randomised, double-blind, placebo-controlled trial Lancet Neurol 2007"/>
   <result pre="Ramadan N Mathew N et al. Efficacy and safety of" exact="topiramate" post="for the treatment of chronic migraine: a randomized, double-blind,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6803542/results/search/drugs/results.xml">
   <result pre="(1/12), and low sustained attention (1/12). Preventive drugs (in particular" exact="flunarizine" post="and topiramate) were used overall by 9/46 (20%) patients"/>
   <result pre="Speckmann EJ Gorji A . The effect of estrogen and" exact="progesterone" post="on spreading depression in rat neocortical tissues . Neurobiol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6815497/results/search/drugs/results.xml">
   <result pre="Conventional treatments such as tricyclic antidepressants and low dose oestrogen" exact="progesterone" post="pills did not prevent the symptoms recurrence on the"/>
   <result pre="CP Hiller H Ovarian suppression with the gonadotrophin-releasing hormone agonist" exact="goserelin" post="(Zoladex) in the management of the premenstrual tension syndrome"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6817617/results/search/drugs/results.xml">
   <result pre="action of these drugs. In particular, the traditional mood stabilizer" exact="valproic acid," post="the widely used antidepressants fluoxetine and escitalopram oxalate, and"/>
   <result pre="the traditional mood stabilizer valproic acid, the widely used antidepressants" exact="fluoxetine" post="and escitalopram oxalate, and the atypical psychiatric drug aripiprazole"/>
   <result pre="mood stabilizer valproic acid, the widely used antidepressants fluoxetine and" exact="escitalopram" post="oxalate, and the atypical psychiatric drug aripiprazole have demonstrated"/>
   <result pre="antidepressants fluoxetine and escitalopram oxalate, and the atypical psychiatric drug" exact="aripiprazole" post="have demonstrated promise for application in brain tumor treatment"/>
   <result pre="range of malignant tumors, including those in the brain [e.g.," exact="valproic acid" post="(VPA), fluoxetine (FLX), escitalopram oxalate, and aripiprazole (ARP)]. These"/>
   <result pre="tumors, including those in the brain [e.g., valproic acid (VPA)," exact="fluoxetine" post="(FLX), escitalopram oxalate, and aripiprazole (ARP)]. These new findings"/>
   <result pre="those in the brain [e.g., valproic acid (VPA), fluoxetine (FLX)," exact="escitalopram" post="oxalate, and aripiprazole (ARP)]. These new findings regarding the"/>
   <result pre="brain [e.g., valproic acid (VPA), fluoxetine (FLX), escitalopram oxalate, and" exact="aripiprazole" post="(ARP)]. These new findings regarding the repurposing potential of"/>
   <result pre="Shin et al., 2006). Further studies showed that treatment with" exact="clozapine" post="led to cell cycle arrest at the G0/G1 phase"/>
   <result pre="and apoptosis; Inhibition of proliferation The Dopamine Receptor Pathway The" exact="dopamine" post="(DA) receptor pathway is a well-recognized neurotransmitter in the"/>
   <result pre="found integrated molecular signaling between epidermal growth factor receptor and" exact="dopamine" post="receptor D2 (DRD2) in GBM ( Li et al.,"/>
   <result pre="common mechanisms involving voltage-gated ion channels and transporters. For example," exact="valproate" post="is well documented to potentiate GABA-ergic effects; inhibit voltage-gated"/>
   <result pre="pathway has been identified as a molecular mechanism by which" exact="clozapine" post="stimulates CLC-4 ( Jeon et al., 2015). CLC-4 has"/>
   <result pre="modulation of apoptosis and proliferation of various cell types, and" exact="clozapine" post="may suppress tumor growth and promote apoptotic events in"/>
   <result pre="Chen et al., 2018). Chen and colleagues (2018) found that" exact="escitalopram" post="oxalate induced autophagy in GBM8401 cells, indicating that the"/>
   <result pre="and viability ( Chen et al., 2019). In addition to" exact="escitalopram" post="oxalate, other psychiatric medications, including clozapine and fluphenazine, have"/>
   <result pre="2019). In addition to escitalopram oxalate, other psychiatric medications, including" exact="clozapine" post="and fluphenazine, have been recently reported to induce autophagic"/>
   <result pre="progress toward GBM treatment via the induction of autophagy. Notably," exact="escitalopram" post="oxalate’s induction of autophagy in GBM8401 cells in culture"/>
   <result pre="M. A. et al. ( 2014). A randomized trial of" exact="bevacizumab" post="for newly diagnosed glioblastoma. N. Engl. J. Med. 370,"/>
   <result pre="Girault J. A. Greengard P. ( 2004). The neurobiology of" exact="dopamine" post="signaling. Arch. Neurol. 61, 641– 644. 10.1001/archneur.61.5.641 15148138 Gong"/>
   <result pre="Cloning of the cDNA and gene for a human D2" exact="dopamine" post="receptor. Proc. Natl. Acad. Sci. 86, 9762– 9766. 10.1073/pnas.86.24.9762"/>
   <result pre="D. L. et al. ( 2002). Efficacy and safety of" exact="aripiprazole" post="and haloperidol versus placebo in patients with schizophrenia and"/>
   <result pre="et al. ( 2002). Efficacy and safety of aripiprazole and" exact="haloperidol" post="versus placebo in patients with schizophrenia and schizoaffective disorder"/>
   <result pre="Park S. Yu H. S. ( 2018b). The antipsychotic agent" exact="clozapine" post="induces autophagy via the AMPK-ULK1-Beclin1 signaling pathway in the"/>
   <result pre="( 2014). Genome-wide shRNA screen revealed integrated mitogenic signaling between" exact="dopamine" post="receptor D2 (DRD2) and epidermal growth factor receptor (EGFR)"/>
   <result pre="10.3390/genes9110522 Ruda R. Pellerino A. Soffietti R. ( 2016). Does" exact="valproic acid" post="affect tumor growth and improve survival in glioblastomas? CNS"/>
   <result pre="Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of" exact="quetiapine" post="for the treatment of malignant glioma . Oncotarget 8,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6826633/results/search/drugs/results.xml">
   <result pre="to the raphe nuclei, and VNS increases the production of" exact="norepinephrine" post="(NE, aka noradrenaline (NA)) and serotonin, which have been"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6827519/results/search/drugs/results.xml">
   <result pre="limited to only two small studies exploring two pharmacological interventions:" exact="midodrine" post="and beta-blockers. 14, 15 Ross and colleagues (2014) 14"/>
   <result pre="and beta-blockers. 14, 15 Ross and colleagues (2014) 14 surmised" exact="midodrine" post="hydrochloride may be an effective treatment for POTS in"/>
   <result pre="improved heart rate control. For pediatric patients, propranolol, metoprolol, and" exact="labetalol" post="have been used. 8 Midodrine is an alpha-1 adrenergic"/>
   <result pre="hypertension. Midodrine can also be used as dual therapy with" exact="fludrocortisone" post="in patients with POTS to improve their symptoms, particularly"/>
   <result pre="more severe POTS symptoms, greater perceived symptom disability, lower supine" exact="norepinephrine" post="levels, and greater likelihood of blood pressure abnormality during"/>
   <result pre="A double-blind placebo-controlled cross-over study of the vascular effects of" exact="midodrine" post="in neuropathic compared with hyperadrenergic postural tachycardia syndrome ."/>
   <result pre="Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with" exact="midodrine" post="and β‐blockers . Pacing Clin Electrophysiol . 2009; 32("/>
   <result pre=", Williams GH , Levine BD . Exercise training versus" exact="propranolol" post="in the treatment of the postural orthostatic tachycardia syndrome"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6854770/results/search/drugs/results.xml">
   <result pre="improving mitochondrial function and energy metabolism, compensating serotoninergic dysfunction, decreasing" exact="calcitonin" post="gene-related peptide (CGRP) level and suppressing neuro-inflammation. It can"/>
   <result pre="with a role in migraine pathogenesis (such as Calctonin-Gene-Related-Peptide (CGRP)," exact="nitric oxide" post="(NO), adiponectin, and leptin), brain mitochondrial function, neuro-inflammation, hypothalamic"/>
   <result pre="factor might be mediated following prophylactic treatment of migraine with" exact="topiramate" post="[ 23]. Thus, it could be hypothesized that chronic"/>
   <result pre="plasma of migraine suffers may be elevated following treatment with" exact="flunarizine" post="or amitriptyline. It has been also proposed that the"/>
   <result pre="Bowen EJ Russo AF Durham PL Nitric oxide regulation of" exact="calcitonin" post="gene-related peptide gene expression in rat trigeminal ganglia neurons"/>
   <result pre="Irkec C Aksakal FN The importance of cytokines, chemokines and" exact="nitric oxide" post="in pathophysiology of migraine J Neuroimmunol 2006 171 1–2"/>
   <result pre="M Elm T Svendsen O Carr RD et al. Plasma" exact="calcitonin" post="gene-related peptide is increased prior to obesity, and sensory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6858833/results/search/drugs/results.xml">
   <result pre="trial evaluating the efficacy, safety, and tolerability of fingolimod. Currently," exact="fingolimod" post="is the only Food and Drug Administration and European"/>
   <result pre="POMS. This review will critically evaluate the available evidence of" exact="fingolimod" post="in the treatment of POMS in detail, as well"/>
   <result pre="delay disability progression. Injectable therapies, which comprise of interferons and" exact="glatiramer acetate," post="have been approved by the European Medicines Agency (EMA)"/>
   <result pre="focus on discussing the safety, efficacy, and tolerability profile of" exact="fingolimod" post="in the POMS population. Fingolimod Experience In POMS Observational"/>
   <result pre="Observational Studies Prior to the randomized controlled PARADIGMS trial, 18" exact="fingolimod" post="experience in POMS population has been limited to small"/>
   <result pre="Huppke et al, involving highly active POMS patients on either" exact="natalizumab" post="or fingolimod published in 2017, analyzed relapse rate and"/>
   <result pre="al, involving highly active POMS patients on either natalizumab or" exact="fingolimod" post="published in 2017, analyzed relapse rate and MRI data"/>
   <result pre="There were a total of 23 POMS patients in the" exact="fingolimod" post="group with available data. Compared to the general POMS"/>
   <result pre="more aggressive disease at onset and were only switched from" exact="natalizumab" post="to fingolimod due to prolonged treatment duration and John"/>
   <result pre="disease at onset and were only switched from natalizumab to" exact="fingolimod" post="due to prolonged treatment duration and John Cunningham Virus"/>
   <result pre="adverse cardiac events or any serious side effects while on" exact="fingolimod" post="reported in this cohort. Of the side effects that"/>
   <result pre="2005, the combined group comprised of POMS patients on either" exact="natalizumab" post="or fingolimod in this more contemporary cohort experienced lower"/>
   <result pre="combined group comprised of POMS patients on either natalizumab or" exact="fingolimod" post="in this more contemporary cohort experienced lower relapse rate"/>
   <result pre="lower scores confer less disability). The other observational study of" exact="fingolimod" post="in POMS was published by Fragoso et al in"/>
   <result pre="Descriptive data from 17 POMS patients who were treated with" exact="fingolimod" post="before the age of 18 were reported. The POMS"/>
   <result pre="of 18 were reported. The POMS patients were treated with" exact="fingolimod" post="for an average of 8.6 months (range 1–18 months)."/>
   <result pre="registry, there were a total of 8 patients treated with" exact="fingolimod" post="(3 treated within 1 year of symptom onset and"/>
   <result pre="2 patients had abnormal blood counts with 1 patient discontinuing" exact="fingolimod" post="as well. Case Report Rebound of disease activity following"/>
   <result pre="fingolimod as well. Case Report Rebound of disease activity following" exact="fingolimod" post="discontinuation has been reported in AOMS. 22– 24 To"/>
   <result pre="she continued to have clinical and radiographic relapses, resulting in" exact="fingolimod" post="discontinuation for lack of efficacy. Fifty days following fingolimod"/>
   <result pre="in fingolimod discontinuation for lack of efficacy. Fifty days following" exact="fingolimod" post="discontinuation, she experienced a more severe relapse with significantly"/>
   <result pre="is only 1 published pivotal trial which evaluated efficacy of" exact="fingolimod" post="in POMS. The PARADIGMS study is a randomized, multicenter,"/>
   <result pre="multicenter, double-blind, double-dummy, active-controlled, parallel-group trial that compared efficacy of" exact="fingolimod" post="against interferon beta-1a in POMS. 18 Patients enrolled in"/>
   <result pre="double-dummy, active-controlled, parallel-group trial that compared efficacy of fingolimod against" exact="interferon beta-1a" post="in POMS. 18 Patients enrolled in PARADIGMS had confirmed"/>
   <result pre="prior to randomization. Patients were randomly assigned to receive either" exact="fingolimod" post="(oral 0.25 mg – 0.5 mg capsule once daily"/>
   <result pre="0.5 mg capsule once daily depending on body weight), or" exact="interferon beta-1a" post="(intramuscular injection 30 µg once weekly) for up to"/>
   <result pre="profile of both drugs in this trial. The effect of" exact="fingolimod" post="on time to 3-month sustained and confirmed disability worsening"/>
   <result pre="patients were enrolled, and 107 patients were randomly assigned to" exact="fingolimod" post="and 108 to interferon beta-1a. Trial completion rates were"/>
   <result pre="107 patients were randomly assigned to fingolimod and 108 to" exact="interferon beta-1a." post="Trial completion rates were 93.5% in fingolimod group and"/>
   <result pre="108 to interferon beta-1a. Trial completion rates were 93.5% in" exact="fingolimod" post="group and 81.5% in interferon beta-1a group. The demographic"/>
   <result pre="completion rates were 93.5% in fingolimod group and 81.5% in" exact="interferon beta-1a" post="group. The demographic spread of recruited patients in the"/>
   <result pre="group had significantly lower annualized relapse rate (0.12) compared to" exact="interferon beta-1a" post="(0.67). Similar favorable trends for fingolimod were found in"/>
   <result pre="(0.12) compared to interferon beta-1a (0.67). Similar favorable trends for" exact="fingolimod" post="were found in secondary end-points as well, including time"/>
   <result pre="well, including time to first relapse (fingolimod 720 days vs." exact="interferon beta-1a" post="488 days), percentage of patient free of relapse at"/>
   <result pre="free of relapse at 24 months (fingolimod group 85.7% vs." exact="interferon beta-1a" post="38.8%), annualized rate of new or enlarging T2-weighted MRI"/>
   <result pre="of new or enlarging T2-weighted MRI lesions (fingolimod 4.39 vs." exact="interferon beta-1a" post="9.27), gadolinium-enhancing lesions (fingolimod 0.44 vs. interferon beta-1a 1.28)."/>
   <result pre="4.39 vs. interferon beta-1a 9.27), gadolinium-enhancing lesions (fingolimod 0.44 vs." exact="interferon beta-1a" post="1.28). Exploratory analysis involving brain volume change, T2-weighted MRI"/>
   <result pre="analysis of time to confirmed 3-month disability worsening showed that" exact="fingolimod" post="significantly delayed its onset compared to interferon beta-1a. Overall"/>
   <result pre="worsening showed that fingolimod significantly delayed its onset compared to" exact="interferon beta-1a." post="Overall adverse events incidence for fingolimod (88.8%) was comparable"/>
   <result pre="onset compared to interferon beta-1a. Overall adverse events incidence for" exact="fingolimod" post="(88.8%) was comparable to that of interferon beta-1a (95.3%)."/>
   <result pre="events incidence for fingolimod (88.8%) was comparable to that of" exact="interferon beta-1a" post="(95.3%). Fingolimod group experienced more adverse events that led"/>
   <result pre="experienced more adverse events that led to discontinuation (5.6% vs" exact="interferon beta-1a" post="0.9%). There were more serious adverse events in the"/>
   <result pre="beta-1a 0.9%). There were more serious adverse events in the" exact="fingolimod" post="group (16.8%) compared to interferon beta-1a (6.5%). In the"/>
   <result pre="serious adverse events in the fingolimod group (16.8%) compared to" exact="interferon beta-1a" post="(6.5%). In the fingolimod group, there were 6 patients"/>
   <result pre="fingolimod group (16.8%) compared to interferon beta-1a (6.5%). In the" exact="fingolimod" post="group, there were 6 patients who had convulsions compared"/>
   <result pre="had convulsions compared to 1 patient with convulsions in the" exact="interferon beta-1a" post="group. Out of the 6 patients with convulsions in"/>
   <result pre="beta-1a group. Out of the 6 patients with convulsions in" exact="fingolimod" post="group, 2 were categorized as having serious adverse events."/>
   <result pre="macular edema reported, among others. Serious infections occurred in 4" exact="fingolimod" post="patients (3.7%) compared to 2 patients in the interferon"/>
   <result pre="4 fingolimod patients (3.7%) compared to 2 patients in the" exact="interferon beta-1a" post="group (1.9%), the infections included appendicitis, cellulitis, gastrointestinal infection,"/>
   <result pre="the PARADIGMS trial, 18 both FDA and EMA have approved" exact="fingolimod" post="use in POMS population. Results from the PARADIGMS trial"/>
   <result pre="Results from the PARADIGMS trial demonstrated that fingolimod, compared to" exact="interferon beta-1a," post="significantly reduced annualized relapse rate (82% reduction), annualized rate"/>
   <result pre="and mean number of gadolinium enhancing lesions (63% reduction). Furthermore," exact="fingolimod" post="also significantly delayed time to first relapse and 3-month"/>
   <result pre="in the limited number of previously published observational studies involving" exact="fingolimod" post="in POMS. 19– 21 Based on safety and tolerability"/>
   <result pre="tolerability data from both observational studies and the PARADIGMS trial," exact="fingolimod" post="appeared to be well-tolerated in POMS. Adverse events from"/>
   <result pre="fingolimod’s mechanism of action, increase infection risks. Discontinuation rate of" exact="fingolimod" post="was less than 6% in PARADIGMS. Despite only 1"/>
   <result pre="bradyarrythmia and herpes virus infection should be applied when prescribing" exact="fingolimod" post="for POMS as per protocol in AOMS. There was"/>
   <result pre="report of rebound disease activity in a POMS patient following" exact="fingolimod" post="discontinuation. 25 Therefore, strict adherence should be emphasized to"/>
   <result pre="prescribing fingolimod. There is a theoretical risk of PML with" exact="fingolimod" post="in POMS, as there have been 19 AOMS patients"/>
   <result pre="developing neurological and immunological systems. The long-term neurodevelopmental effects of" exact="fingolimod" post="in POMS is unknown, due to lack of longitudinal"/>
   <result pre="delaying disability worsening. 18 The unique lymphocytic sequestration mechanism of" exact="fingolimod" post="should also be taken into consideration when prescribing fingolimod"/>
   <result pre="of fingolimod should also be taken into consideration when prescribing" exact="fingolimod" post="in POMS patients with maturing adaptive immune systems. The"/>
   <result pre="repeated immune challenges. 13 Therefore, the potential long-term effects of" exact="fingolimod" post="on the development of comprehensive adaptive immune defense system"/>
   <result pre="Arnold DL , Banwell B , et al. Trial of" exact="fingolimod" post="versus interferon beta-1a in pediatric multiple sclerosis. N Engl"/>
   <result pre=", Banwell B , et al. Trial of fingolimod versus" exact="interferon beta-1a" post="in pediatric multiple sclerosis. N Engl J Med ."/>
   <result pre="MA , Baroncini D , et al. Disease reactivation after" exact="fingolimod" post="discontinuation in two multiple sclerosis patients. J Neurol ."/>
   <result pre="L , Pasto L , Amato MP . Withdrawal of" exact="fingolimod" post="treatment for relapsing-remitting multiple sclerosis: report of six cases"/>
   <result pre="Kumpfel T . Rebound of disease activity after withdrawal of" exact="fingolimod" post="(FTY720) treatment. Arch Neurol . 2012; 69( 2): 262–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6868651/results/search/drugs/results.xml">
   <result pre="clinical improvement of their POTS symptoms with the addition of" exact="testosterone" post="therapy. Conclusion: We present our clinical experience of three"/>
   <result pre="the symptoms of POTS. Keywords dysautonomia LGBT health orthostatic intolerance" exact="testosterone" post="therapy ref-count: page-count: Introduction Postural orthostatic tachycardia syndrome (POTS),"/>
   <result pre="an otherwise normal examination and ECG. He was treated with" exact="cyproheptadine" post="for headache prophylaxis, fludrocortisone for dizziness, and pregabalin for"/>
   <result pre="and ECG. He was treated with cyproheptadine for headache prophylaxis," exact="fludrocortisone" post="for dizziness, and pregabalin for pain—his three worst symptoms."/>
   <result pre="treated with cyproheptadine for headache prophylaxis, fludrocortisone for dizziness, and" exact="pregabalin" post="for pain—his three worst symptoms. The headaches resolved, but"/>
   <result pre="fludrocortisone, midodrine, and desmopressin. His pain did not respond to" exact="pregabalin" post="or duloxetine. The pain was severe enough to prevent"/>
   <result pre="of POTS. He was diagnosed with gender dysphoria, and started" exact="testosterone" post="therapy for hormonal management of female to male gender-affirming"/>
   <result pre="for hormonal management of female to male gender-affirming therapy. Subsequent" exact="testosterone" post="levels have been in the low-normal physiological male range."/>
   <result pre="with no other significant clinical findings. He was treated with" exact="cyproheptadine" post="for headaches, fludrocortisone for dizziness, and pyridostigmine for early"/>
   <result pre="significant clinical findings. He was treated with cyproheptadine for headaches," exact="fludrocortisone" post="for dizziness, and pyridostigmine for early satiety—his three worst"/>
   <result pre="exercise. Attempts to control dizziness were unsuccessful, despite therapy with" exact="fludrocortisone" post="and desmopressin. Increased pyridostigmine dosing for persistent constipation led"/>
   <result pre="He was subsequently diagnosed with gender dysphoria and started on" exact="testosterone" post="therapy. In March 2019, resting blood pressure was 117/72"/>
   <result pre="Medications at diagnosis included albuterol, azelastine, diclofenac, fludrocortisone, fluoxetine, fluticasone/salmeterol," exact="folic acid," post="gabapentin, levothyroxine, melatonin, methotrexate, salt tablets, ranitidine, tramadol, and"/>
   <result pre="of the examination demonstrated no abnormalities. He was started on" exact="desmopressin" post="for dizziness, lansoprazole for symptoms of gastroesophageal reflux, and"/>
   <result pre="demonstrated no abnormalities. He was started on desmopressin for dizziness," exact="lansoprazole" post="for symptoms of gastroesophageal reflux, and methylphenidate for fatigue—his"/>
   <result pre="desmopressin for dizziness, lansoprazole for symptoms of gastroesophageal reflux, and" exact="methylphenidate" post="for fatigue—his three worst symptoms. He also started exercising"/>
   <result pre="exercise protocol for POTS. Dizziness was persistent, and required increased" exact="desmopressin" post="and subsequent addition of midodrine. With regular exercise, symptoms"/>
   <result pre="and Sexuality Clinic, was diagnosed with gender dysphoria, and started" exact="testosterone" post="therapy. Subsequently, his symptoms associated with POTS, including dizziness,"/>
   <result pre="report. Interestingly, he reported that when he had gaps in" exact="testosterone" post="therapy, his POTS symptoms would return. In March 2019,"/>
   <result pre="return. In March 2019, resting blood pressure was 122/68 on" exact="midodrine" post="and desmopressin as blood pressure supportive therapy. He was"/>
   <result pre="March 2019, resting blood pressure was 122/68 on midodrine and" exact="desmopressin" post="as blood pressure supportive therapy. He was exercising regularly"/>
   <result pre="POTS as natal females identifying as males who subsequently started" exact="testosterone" post="for gender-affirming therapy. All three patients demonstrated apparent clinical"/>
   <result pre="these patients also demonstrated that symptom control drastically improved after" exact="testosterone" post="was added. Notably, by patient report, when one of"/>
   <result pre="patient report, when one of our patients would miss supplemental" exact="testosterone" post="therapy, symptoms of POTS would subjectively worsen. Some caveats"/>
   <result pre="male for these transgender adolescents. Certainly, hormone therapies, such as" exact="fludrocortisone" post="18, 19 and desmopressin, 18, 20 are used in"/>
   <result pre="Clinical improvement in patients with orthostatic intolerance after treatment with" exact="bisoprolol" post="and fludrocortisone . Clin Auton Res. 2000; 10: 293–"/>
   <result pre="in patients with orthostatic intolerance after treatment with bisoprolol and" exact="fludrocortisone" post=". Clin Auton Res. 2000; 10: 293– 299 11198485"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6878943/results/search/drugs/results.xml">
   <result pre="was diagnosed as having paroxysmal kinesigenic dyskinesias (PKD). Treatment with" exact="carbamazepine" post="led to a complete remission of the movements. There"/>
   <result pre="Saddichha BA , Talukdar D Serpentine tongue syndrome associated with" exact="risperidone" post="long-acting injection treatment. J Clin Psychopharmacol 2014; 34: 657–"/>
   <result pre="Prashantha DK Serpentingue tongue: a rare manifestation following initiation of" exact="levodopa" post="therapy in a patient with Parkinson's disease . Parkinsonism"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6885267/results/search/drugs/results.xml">
   <result pre="circadian rhythm: they reach maximal severity at night, when the" exact="dopamine" post="levels are at their nadir, with consequent disruption of"/>
   <result pre="the therapeutic response to opioids and the physiologic link between" exact="dopamine" post="and pain control [ 5]. The exact role of"/>
   <result pre="associated with chronic musculoskeletal or neuropathic pain, (5) intake of" exact="dopamine" post="agonists, antidopaminergic, as well as other neurological active drugs"/>
   <result pre="Goedknegt H. Gosens T. Bongers C. M. H. Distribution of" exact="dopamine" post="immunoreactivity in the rat, cat, and monkey spinal cord"/>
   <result pre="J. Pan T. H. Le W. D. Projections of diencephalic" exact="dopamine" post="neurons into the spinal cord in mice Experimental Brain"/>
   <result pre="H. Ansah O. B. Pertovaara A. The role of the" exact="dopamine" post="D2 receptor in descending control of pain induced by"/>
   <result pre="S. Rye D. Hochman S. Restless legs syndrome: revisiting the" exact="dopamine" post="hypothesis from the spinal cord perspective Neurology 2006 67"/>
   <result pre="37 Leone M. Lucini V. D’Amico D. et al. Twenty-four-hour" exact="melatonin" post="and cortisol plasma levels in relation to timing of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6888880/results/search/drugs/results.xml">
   <result pre="available evidence including the conventional 21/7 combined hormonal contraception, the" exact="desogestrel" post="only oral pill, combined oral contraceptives with shortened pill-free"/>
   <result pre="oral contraceptives with shortened pill-free interval, combined oral contraceptives with" exact="estradiol" post="supplementation during the pill-free interval, extended regimen of combined"/>
   <result pre="with pill or patch, combined hormonal contraceptive vaginal ring, transdermal" exact="estradiol" post="supplementation with gel, transdermal estradiol supplementation with patch, subcutaneous"/>
   <result pre="hormonal contraceptive vaginal ring, transdermal estradiol supplementation with gel, transdermal" exact="estradiol" post="supplementation with patch, subcutaneous estrogen implant with cyclical oral"/>
   <result pre="of new treatments for migraine prevention which act on the" exact="calcitonin" post="gene-related peptide (CGRP) pathway. This offsets the lack of"/>
   <result pre="have success in its treatment, and inflammatory molecules such as" exact="nitric oxide," post="CGRP, and cytokines are able to recreate migraine pain."/>
   <result pre="University Hospital, Glostrup, Denmark. Correspondence: Lars Edvinsson (lars.edvinsson@med.lu.se) Background. The" exact="calcitonin" post="gene-related peptide (CGRP) family of neuropeptides consists besides CGRP"/>
   <result pre="family of neuropeptides consists besides CGRP of adrenomedullin, amylin and" exact="calcitonin" post="(CT). They share receptor components and structure, and have"/>
   <result pre="have several similar biological actions. The receptors consist of either" exact="calcitonin" post="receptor like-receptor (CLR) or calcitonin receptor (CTR) which for"/>
   <result pre="The receptors consist of either calcitonin receptor like-receptor (CLR) or" exact="calcitonin" post="receptor (CTR) which for function needs an accessory protein,"/>
   <result pre="progestogen-only methods (progestogen-only pill [POP], subdermal implant [SDI], intramuscular/subcutaneous depot" exact="medroxyprogesterone" post="acetate [DMPA], and levonorgestrel intrauterine system [LNG-IUS]), all of"/>
   <result pre="[POP], subdermal implant [SDI], intramuscular/subcutaneous depot medroxyprogesterone acetate [DMPA], and" exact="levonorgestrel" post="intrauterine system [LNG-IUS]), all of which, with the exception"/>
   <result pre="recruited follicles undergo atresia, resulting in a drop in endogenous" exact="estradiol" post="levels. Continuous or extended regimens with a shorted CFI"/>
   <result pre="to reduce the frequency and severity of estrogen-withdrawal symptoms. The" exact="desogestrel" post="POP and implant inhibit ovulation but do not predictably"/>
   <result pre="Guidelines. Previous (2014) European recommendations on limiting the use of" exact="valproate" post="in women of childbearing age did not achieve their"/>
   <result pre="achieve their objective in terms of limiting the use of" exact="valproate" post="in women of child bearing age and raising awareness"/>
   <result pre="bearing age and raising awareness regarding the hazardous effect of" exact="valproate" post="to children exposed in utero. The teratogenic and foetotoxic"/>
   <result pre="children exposed in utero. The teratogenic and foetotoxic effects of" exact="valproate" post="are well documented, and more recent studies show that"/>
   <result pre="is an even greater neurodevelopmental risk to children exposed to" exact="valproate" post="in the womb. The latest 2018 European review from"/>
   <result pre="the observations leading to the development of lisinioril and later" exact="candesartan" post="as migraine prophylactics. The large epidemiological survey in Nord-Trøndelag"/>
   <result pre="In susceptible individuals, the trigeminovascular neurons release neurotransmitters, such as" exact="calcitonin" post="gene-related peptide and substance P, when headache triggers are"/>
   <result pre="Savino A. Epidural blood patch in Trendelenburg position pre–medicated with" exact="acetazolamide" post="to treat spontaneous intracranial hypotension. Eur J Neurol 2010,"/>
   <result pre="to worsen the comorbid psychiatric disorder should be avoided (i.e." exact="topiramate" post="in migraine and depression). Drugs able to control both"/>
   <result pre="control both disorders, possibly in monotherapy, should be preferred (i.e." exact="propranolol" post="in migraine and mild anxiety). The migraine treatment plan"/>
   <result pre="is high interest in blocking the actions of the neuropeptide" exact="calcitonin" post="gene-related peptide (CGRP) for the treatment of migraine and"/>
   <result pre="efforts have focussed on the canonical CGRP receptor, comprising the" exact="calcitonin" post="receptor-like receptor (CLR) with receptor activity-modifying protein 1 (RAMP1)."/>
   <result pre="1 receptor, which is a complex of RAMP1 with the" exact="calcitonin" post="receptor (CTR). Very few studies have directly compared the"/>
   <result pre="activation of the trigemino-autonomic reflex of which the vasoactive peptides" exact="calcitonin" post="gene-related peptide (CGRP), vasoactive intestinal polypeptide (VIP) and pituitary"/>
   <result pre="Galcanezumab, a humanised monoclonal antibody that selectively binds to the" exact="calcitonin" post="gene-related peptide, was superior to placebo in the prevention"/>
   <result pre="of galcanezumab, a humanized monoclonal antibody that selectively binds to" exact="calcitonin" post="gene-related peptide (CGRP), in individuals with episodic cluster headache."/>
   <result pre="in the final analysis. Eleven patients treated their migraine with" exact="sumatriptan" post="while the remaining 15 patients did not treat their"/>
   <result pre="a meningeal site of migraine headache. O11 Migraine induction with" exact="calcitonin" post="gene-related peptide in patients from erenumab trials Casper Emil"/>
   <result pre="Food and Drug Administration as a monoclonal antibody against the" exact="calcitonin" post="gene-related peptide (CGRP) receptor for migraine-specific preventive treatment. Identifying"/>
   <result pre="methylation in migraine. Several studies have shown that the neuropeptide" exact="calcitonin" post="gene–related peptide (CGRP), encoded by CALCA gene, has a"/>
   <result pre="USA Background Galcanezumab (GMB) is a humanised monoclonal antibody against" exact="calcitonin" post="gene-related peptide under development for prevention of migraine. Objective"/>
   <result pre="Susan P. Mollan (susan.mollan@uhb.nhs.uk) Introduction: The efficacy and safety of" exact="tocilizumab" post="(TCZ), an IL-6 receptor-α inhibitor, was evaluated in patients"/>
   <result pre="reactant elevation attributable to GCA. Randomization was stratified by baseline" exact="prednisone" post="dose (≤30 or &amp;gt;30 mg/day) as selected by the"/>
   <result pre="(20-60 mg/day). Patients were randomized 1:1:2:1 to 4 groups: short-course" exact="prednisone" post="(SCP) or long-course prednisone (LCP) (26-week or 52-week prednisone"/>
   <result pre="randomized 1:1:2:1 to 4 groups: short-course prednisone (SCP) or long-course" exact="prednisone" post="(LCP) (26-week or 52-week prednisone taper + weekly subcutaneous"/>
   <result pre="short-course prednisone (SCP) or long-course prednisone (LCP) (26-week or 52-week" exact="prednisone" post="taper + weekly subcutaneous [SC] placebo, respectively); or weekly"/>
   <result pre="every other week (TCZ-Q2W) SC TCZ 162 mg + 26-week" exact="prednisone" post="taper. Prednisone doses &amp;lt;20 mg/day were blinded. Patients who"/>
   <result pre="could not adhere to the protocol-defined tapering schedule received open-label" exact="prednisone" post="escape therapy but continued on double-blind TCZ/placebo. Sustained remission"/>
   <result pre="C-reactive protein after week 12, and adherence to the protocol-defined" exact="prednisone" post="taper. The primary and key secondary endpoint was the"/>
   <result pre="deaths or new vision loss occurred. Conclusion: TCZ plus 26-week" exact="prednisone" post="taper was superior to SCP and LCP tapers for"/>
   <result pre="LCP tapers for sustained remission at 52 weeks. TCZ plus" exact="prednisone" post="also led to a substantial reduction in the cumulative"/>
   <result pre="prednisone also led to a substantial reduction in the cumulative" exact="prednisone" post="doses required to control GCA. Trial registration: NCT01791153 /"/>
   <result pre="medications available. Galcanezumab, a humanized monoclonal antibody that binds to" exact="calcitonin" post="gene-related peptide (CGRP), was developed for the prevention of"/>
   <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), is efficacious in preventing EM, but"/>
   <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), is efficacious in preventing chronic migraine"/>
   <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has been shown to be effective"/>
   <result pre=". In regards to preventive treatment choice; in chronic migraine" exact="topiramate" post="(57%) amytriptiline (17.9%) and beta-blockers (14.6%), whereas in episodic"/>
   <result pre="whereas in episodic migraine the preferred drugs were beta-blockers (47.7%)," exact="topiramate" post="(21.5%) and amytriptiline (13.4%). Regarding perceived efficacy, topiramate was"/>
   <result pre="beta-blockers (47.7%), topiramate (21.5%) and amytriptiline (13.4%). Regarding perceived efficacy," exact="topiramate" post="was considered the best option in chronic migraine (42.7%)"/>
   <result pre="onabotulinumtoxinA (25.5%) and amitryptiline (22.4%). In episodic migraine, neurologist preferred" exact="topiramate" post="(43.7%) and beta-blockers (30.3%). Regarding the duration of preventive"/>
   <result pre="the most effective therapy. O43 Effect of the H 1-antihistamine" exact="clemastine" post="on PACAP38 induced migraine Luise Haulund Vollesen 1, Song"/>
   <result pre="(ashina@dadlnet.dk) Objective To investigate the effect of the H 1-antihistamine" exact="clemastine" post="on the migraine inducing abilities of pituitary adenylate cyclase"/>
   <result pre="migraine without aura patients were randomly allocated to receive bolus" exact="clemastine" post="2 mg (1 mg/ml) or bolus saline 2 ml"/>
   <result pre="factor-alpha (TNF-alpha) before and after infusion of PACAP38. Results After" exact="clemastine" post="pretreatment 5/20 participants developed a migraine-like attack in response"/>
   <result pre="PACAP38 infusion compared to 9/20 after placebo pretreatment (P=0.288). Following" exact="clemastine" post="pretreatment 15/20 participants reported headache in response to a"/>
   <result pre="tryptase (P = 0.525) or TNF-alpha (P = 0.487) between" exact="clemastine" post="and placebo pretreatment days. Conclusion H1-antihistamine, clemastine, failed to"/>
   <result pre="Neurol 2017;264:1023-8. O47 Association of Tanacethum Parthenium, 5 - hydroxy" exact="tryptophan" post="and magnesium ( Aurastop) versus Mg tablet impact on"/>
   <result pre="phytotherapic combination of Tanacethum Parthenium (150 mg), 5 - hydroxy" exact="tryptophan" post="(20 mg) and magnesium (185 mg) (Aurastop ®) is"/>
   <result pre="disability of the combination of Tanacethum Parthenium, 5 - hydroxy" exact="tryptophan" post="and magnesium versus magnesium alone, when taken at the"/>
   <result pre="the next two days there was complete relief with oral" exact="indomethacin" post="200 mg per day and an improvement of the"/>
   <result pre="found in DWI sequences . The patient was started on" exact="acetylsalicylic acid" post="100 mg daily. An extended CT angiography showed extensive"/>
   <result pre="syndrome. The history of cluster headache, a specific response to" exact="indomethacin" post="and the absence of neurological focal signs does not"/>
   <result pre="treatments, they were effective in 69% of patients. Pregabalin and" exact="amitriptyline" post="were the most effective prophylaxis therapies (in 80% and"/>
   <result pre="quality and intensity of pain are highly heterogeneous, whereas NSAIDs," exact="pregabalin" post="and amitriptyline were the most prescribed and effective therapies."/>
   <result pre="intensity of pain are highly heterogeneous, whereas NSAIDs, pregabalin and" exact="amitriptyline" post="were the most prescribed and effective therapies. Ethics approval"/>
   <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), reduced the number of migraine days"/>
   <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), reduced the frequency and severity of"/>
   <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has demonstrated efficacy in preventing episodic"/>
   <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has been shown to be effective"/>
   <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has demonstrated efficacy in migraine prevention."/>
   <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has demonstrated efficacy in migraine prevention."/>
   <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has demonstrated efficacy in migraine prevention."/>
   <result pre="OBJECTIVES: The long-term efficacy of monoclonal antibodies that selectively target" exact="calcitonin" post="gene-related peptide (CGRP) in patients with early treatment failure"/>
   <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), reduced the frequency and severity of"/>
   <result pre="release a number of vasodilatory and cytoprotective mediators, including the" exact="calcitonin" post="gene-related peptide (CGRP). Erenumab, a fully human anti-CGRP receptor"/>
   <result pre="Stauffer (stauffer_virginia@lilly.com) Objective: Galcanezumab, a humanized monoclonal antibody that binds" exact="calcitonin" post="gene-related peptide, has a half-life of 27 days so"/>
   <result pre="profile of galcanezumab, a humanized monoclonal antibody that selectively binds" exact="calcitonin" post="gene-related peptide (CGRP) and inhibits its activity, in patients"/>
   <result pre="duration, Headache frequency, Migraine, Visual Analog Scale P29 Effect of" exact="propranolol" post="in a non-invasive human model of trigeminovascular activation Eloísa"/>
   <result pre="migraine since many years. However, the mechanism of action of" exact="propranolol" post="in preventing migraine attacks has not yet been elucidated."/>
   <result pre="suggested. In our study, we set out to assess whether" exact="propranolol" post="has an inhibitory effect on the trigeminovascular system in"/>
   <result pre="our human forehead perfusion model. We investigated the effect of" exact="propranolol" post="(80 mg, 90 min after oral administration, corresponding to"/>
   <result pre="electrical stimulation(0.2-1.0 mA) before and after placebo (grapefruit juice) and" exact="propranolol" post="(oral solution with tangerine taste, diluted in grapefruit juice)"/>
   <result pre="DBF responses to capsaicin (mean±SEM: 512.72±33.14 A.U.) were attenuated after" exact="propranolol" post="(mean±SEM: 465.67±35.12 A.U., p&amp;lt;0.05) but no after placebo (mean±SEM:"/>
   <result pre="by either placebo or propranolol. When sexes were analyzed separately," exact="propranolol" post="had no effect on the DBF responses to capsaicin"/>
   <result pre="males (mean±SEM: 472±54.57 A.U. vs. 394.7±51.09 A.U.; p&amp;lt;0.05). In conclusion," exact="propranolol" post="80 mg inhibits the capsaicin-induced increases in DBF, suggesting"/>
   <result pre="days was reported by two patients. In the second study," exact="sumatriptan" post="25 mg 4 doses/day resulted superior to placebo in"/>
   <result pre="40: 316-319. 6. Hodgson C, Roiberg-Henry A. The use of" exact="sumatriptan" post="in the treatment of postdural headache. Anaesthesia 1997; 52:"/>
   <result pre="Anaesthesia 1996; 51: 1078. 8. Sprigge JS. The use of" exact="sumatriptan" post="in the treatment of postdural puncture headache after accidental"/>
   <result pre="31-year-old woman presented with thunderclap headache after 1 week of" exact="paroxetine" post="and alprazolam treatment due to new onset psychiatric symptoms."/>
   <result pre="presented with thunderclap headache after 1 week of paroxetine and" exact="alprazolam" post="treatment due to new onset psychiatric symptoms. Brain MRI"/>
   <result pre="interleukin 6 (IL-6), interleukin 10 (IL-10), high-sensitivity C-reactive protein (hs-CRP)," exact="calcitonin" post="gene-related peptide (CGRP); endothelial dysfunction: pentraxin 3 (PTX3), soluble"/>
   <result pre="to episodic migraine with erenumab, a specific inhibitor of the" exact="calcitonin" post="gene-related peptide receptor Richard B. Lipton 1, Stewart J."/>
   <result pre="a fully human monoclonal antibody that specifically inhibits the canonical" exact="calcitonin" post="gene-related peptide receptor and was developed as a preventive"/>
   <result pre="analgesics or ≥10 days/month on triptans, combination of therapies, or" exact="ergotamine" post="derivatives). The objective of this study was to evaluate"/>
   <result pre="the rat evoked by recurrent administration of systemic administration of" exact="isosorbide dinitrate" post="(ISDN), a nitric oxide donor (NO). Recurrent ISDN injection"/>
   <result pre="recurrent administration of systemic administration of isosorbide dinitrate (ISDN), a" exact="nitric oxide" post="donor (NO). Recurrent ISDN injection (10 mg/kg, i.p., 5"/>
   <result pre="patients. Average of headache attack / day: 5.7, main sc" exact="sumatriptan" post="/ day consumption: 4.4. Efficacy of NOM-S: 50%. NOM-S"/>
   <result pre="then. Average of headache attack / day: 6.5, mean sc" exact="sumatriptan" post="/ day consumption: 5.7. Efficacy: 85.7%. DBS reduced NRS"/>
   <result pre="ADM_12 was able to abolish the increased levels of TRPA1," exact="calcitonin" post="gene-related peptide (CGRP) and substance P (SP) gene expression"/>
   <result pre="in the final analysis. Eleven patients treated their migraine with" exact="sumatriptan" post="while the remaining 15 patients did not treat their"/>
   <result pre="A multicenter, prospective, randomized, open-label study to compare onabotulinumtoxinA and" exact="topiramate" post="for headache prevention in adults with chronic migraine: patient"/>
   <result pre="world effectiveness. Safety, tolerability, and PROs of onabotulinumtoxinA (onabotA) vs" exact="topiramate" post="(TPM) for CM are presented. Methods: FORWARD, a multicenter,"/>
   <result pre="drug concentration (C max, ng/ml) were found only for frovatriptan," exact="zolmitriptan" post="and rizatriptan. Women appeared to have a higher AUC"/>
   <result pre="differences were revealed on plasma half-life Times (T 1/2) of" exact="frovatriptan" post="(2 studies, RoM 0.90, CI: 0.70-1.14) and zolmitriptan (8"/>
   <result pre="1/2) of frovatriptan (2 studies, RoM 0.90, CI: 0.70-1.14) and" exact="zolmitriptan" post="(8 studies, RoM 0.93, CI: 0.85-1.01). Conclusions Given the"/>
   <result pre="max are higher in women than in men for frovatriptan," exact="zolmitriptan" post="and rizatriptan, which may be an explanation for the"/>
   <result pre="plots of AUC0-∞ and Cmax after the intake of frovatriptan," exact="rizatriptan" post="or zolmitriptan in male and female migraine patients. P86"/>
   <result pre="AUC0-∞ and Cmax after the intake of frovatriptan, rizatriptan or" exact="zolmitriptan" post="in male and female migraine patients. P86 Migraine induction"/>
   <result pre="in male and female migraine patients. P86 Migraine induction with" exact="calcitonin" post="gene-related peptide in patients from erenumab trials Casper Emil"/>
   <result pre="Food and Drug Administration as a monoclonal antibody against the" exact="calcitonin" post="gene-related peptide (CGRP) receptor for migraine-specific preventive treatment. Identifying"/>
   <result pre="education. The most commonly overused medication was multi-therapy (acetylsalicylic acid," exact="acetaminophen" post="and caffeine) among the population. Conclusion. The prevalence of"/>
   <result pre="(31%). For the treatment of migraine the preferred option was" exact="paracetamol" post="(47,6%) followed by NSAID (9,5%). Conclusions: Despite headache is"/>
   <result pre="is a fully human monoclonal antibody (mAb) targeting the canonical" exact="calcitonin" post="gene-related peptide (CGRP) receptor [2]. The objective of this"/>
   <result pre="We administered an intravenous (IV) cocktail consisting of ketorolac, Compazine," exact="diphenhydramine" post="and 20mg/kg bolus of normal saline. The infusion was"/>
   <result pre="(8-14 HD), and 36% (15+HD) received preventive treatment. Sumatriptan and" exact="ibuprofen" post="were the most commonly prescribed acute treatments across all"/>
   <result pre="commonly prescribed acute treatments across all headache frequency categories, while" exact="metoprolol" post="and topiramate were the most frequently prescribed preventive treatments."/>
   <result pre="acute treatments across all headache frequency categories, while metoprolol and" exact="topiramate" post="were the most frequently prescribed preventive treatments. Over the"/>
   <result pre="patients based on duration of remissions. Increased blood levels of" exact="calcitonin" post="gene-related peptide (CGRP) have been associated with CH, making"/>
   <result pre="15.5 hours. The proportion of patients using oxygen and/or subcutaneous" exact="sumatriptan" post="during the prospective baseline period was 45.3% and 56.6%,"/>
   <result pre="and acute therapy to stop the attack. Although amitriptyline, topiramate," exact="flunarizine" post="and valproic acid have the most data on their"/>
   <result pre="therapy to stop the attack. Although amitriptyline, topiramate, flunarizine and" exact="valproic acid" post="have the most data on their use for prophylaxis"/>
   <result pre="D., Lavano, A., 2016. Administration of palmitoylethanolamide in combination with" exact="topiramate" post="in the preventive treatment of nummular headache. International medical"/>
   <result pre="applicable P130 Efficient therapy for treatment of migraine without aura:" exact="ergotamine" post="based drugs or sumatriptan Sinisa Miljkovic 1, Dz. Smajlovic"/>
   <result pre="for treatment of migraine without aura: ergotamine based drugs or" exact="sumatriptan" post="Sinisa Miljkovic 1, Dz. Smajlovic 2, S. Crncevic 1,"/>
   <result pre="Neurology, Bosnia and Herzegovina Correspondence: Sinisa Miljkovic (sinisa.miljkovic@kc-bl.com) Background: Triptans," exact="ergotamine" post="and dihydroergotamine are the most effective medications in the"/>
   <result pre="and Herzegovina Correspondence: Sinisa Miljkovic (sinisa.miljkovic@kc-bl.com) Background: Triptans, ergotamine and" exact="dihydroergotamine" post="are the most effective medications in the treatment of"/>
   <result pre="to one of the two study groups - Nomigren® or" exact="sumatriptan" post="group. Diagnosis was based on International Headache Society Criteria"/>
   <result pre="51.12% attacks in Nomigren® group, and in 33.70% attacks in" exact="sumatriptan" post="group (p=0.0015). Nomigren® has shown equally sustainable high efficiency"/>
   <result pre="in repeated attacks in Nomigren® group was 50.91%, and in" exact="sumatriptan" post="group it was 23.73% (p=0,005). Reversal of photophobia, phonophobia"/>
   <result pre="complete cessation of migraine pain and accompanying symptoms compared to" exact="sumatriptan" post="in the treatment of migraine without aura. P131 Analysis"/>
   <result pre="Objective: The humanized monoclonal antibody galcanezumab (LY2951742), which binds to" exact="calcitonin" post="gene-related peptide, has been evaluated for migraine prevention. The"/>
   <result pre="as unilateral pain, common pharmacological triggers such glyceryl trinitrate, histamine," exact="calcitonin" post="gene-related peptide (CGRP) and response to triptans and neuromodulation."/>
   <result pre="a significant increase in the number of patients treated with" exact="oxcarbazepine" post="but there was no significant dosage increment of any"/>
   <result pre="2 (abstract P155). Topography of headache P156 Ibuprofen and not" exact="paracetamol" post="as first line analgesic for acute migraine due to"/>
   <result pre="acute migraine headache, many patients rely on over-the-counter analgesics. Both" exact="ibuprofen" post="and paracetamol are cornerstone therapies, without consensus on which"/>
   <result pre="headache, many patients rely on over-the-counter analgesics. Both ibuprofen and" exact="paracetamol" post="are cornerstone therapies, without consensus on which one is"/>
   <result pre="A recent overview of systematic reviews and meta-analyses directly compared" exact="ibuprofen" post="and paracetamol at standard doses and concluded that ibuprofen"/>
   <result pre="overview of systematic reviews and meta-analyses directly compared ibuprofen and" exact="paracetamol" post="at standard doses and concluded that ibuprofen was superior"/>
   <result pre="compared ibuprofen and paracetamol at standard doses and concluded that" exact="ibuprofen" post="was superior in relieving headache pain at two hours"/>
   <result pre="remains elusive. This study aimed to assess the effect of" exact="ibuprofen" post="and paracetamol on TRPA1, an ion channel implicated in"/>
   <result pre="This study aimed to assess the effect of ibuprofen and" exact="paracetamol" post="on TRPA1, an ion channel implicated in the pathophysiology"/>
   <result pre="healthy male volunteers were included to evaluate the effect of" exact="ibuprofen" post="(600 mg) and paracetamol (1 g) on TRPA1 in"/>
   <result pre="included to evaluate the effect of ibuprofen (600 mg) and" exact="paracetamol" post="(1 g) on TRPA1 in a randomized, double blind,"/>
   <result pre="a 60 minutes period (AUC 0-60min) following administration of ibuprofen," exact="paracetamol" post="or no drug was analyzed using one-way ANOVA with"/>
   <result pre="with post-hoc Bonferroni correction. Results: As shown in figure 1," exact="paracetamol" post="had no significant effect on the CA-induced DBF response"/>
   <result pre="CA-induced DBF response compared to no drug treatment, while after" exact="ibuprofen" post="administration this DBF response was clearly reduced (p &amp;lt;"/>
   <result pre="target engagement biomarker model, we demonstrated that the non-selective COX-inhibitor" exact="ibuprofen" post="reduces the DBF increase induced by CA. This possibly"/>
   <result pre="the DBF increase induced by CA. This possibly elucidates why" exact="ibuprofen" post="was found superior in reducing headache pain compared to"/>
   <result pre="Moore RA et al. Overview review: Comparative efficacy of oral" exact="ibuprofen" post="and paracetamol (acetaminophen) across acute and chronic pain conditions."/>
   <result pre="et al. Overview review: Comparative efficacy of oral ibuprofen and" exact="paracetamol" post="(acetaminophen) across acute and chronic pain conditions. Eur. J."/>
   <result pre="Eur. J. Pain 2015;19:1213–1223. Fig. 1 (abstract P156). Influence of" exact="paracetamol" post="and ibuprofen on the CA-induced DBF response (n ="/>
   <result pre="Pain 2015;19:1213–1223. Fig. 1 (abstract P156). Influence of paracetamol and" exact="ibuprofen" post="on the CA-induced DBF response (n = 16). One-way"/>
   <result pre="morning stiffness or loss of strength. For the medical treatment" exact="duloxetine" post="30 mg was given to the patient and the"/>
   <result pre="and severity of the pain was detected. The dose of" exact="flunarizine" post="was increased to 10 mg and the patient was"/>
   <result pre="in serotonin metabolism. Tryptophan is a precursor of serotonin. Once" exact="tryptophan" post="concentrations diminished, it results in a short-term drop in"/>
   <result pre="level. However, much uncertainty still exists about the association between" exact="tryptophan" post="and migraine. Regarding the importance of adequate tryptophan intake"/>
   <result pre="association between tryptophan and migraine. Regarding the importance of adequate" exact="tryptophan" post="intake in regulating serotonin hemostasis and subsequent effects on"/>
   <result pre="designed the current study to assess the relationship between dietary" exact="tryptophan" post="intake and migraine headache risk. Methods The migraine group"/>
   <result pre="in order to explore the relationship between migraine and dietary" exact="tryptophan" post="intake. Results The mean(SD) of the age of participants"/>
   <result pre="fat(g/d), and cholesterol(mg/d). the models showed significant inverse association between" exact="tryptophan" post="intake and migraine risk [(OR in the 3 rd"/>
   <result pre="based investigation of the migraine headache risk according to dietary" exact="tryptophan" post="intake. Our results showed that subjects who had a"/>
   <result pre="subjects who had a median intake of 0.90-1.15 grams of" exact="tryptophan" post="per day had a reduced odds of developing migraine"/>
   <result pre="g/d. These findings therefore highlighted that considering enough intake of" exact="tryptophan" post="rich foods such as milk, poultry, egg, seafood, soybeans,"/>
   <result pre="prevention of a combination of Tanacethum Parthenium, 5 - hydroxy" exact="tryptophan" post="and magnesium (Aurastop ©) Giorgio Dalla Volta, Paola Zavarise,"/>
   <result pre="the novel phytotherapic combination of Tanacethum Parthenium (150 mg), 5-hydroxy" exact="tryptophan" post="(20 mg) and magnesium (185 mg) (Aurastop ©) acts"/>
   <result pre="is a fully human monoclonal antibody that selectively inhibits the" exact="calcitonin" post="gene-related peptide (CGRP) receptor and is under investigation for"/>
   <result pre="two years the headache frequency has been &amp;gt;20 days/month, with" exact="indomethacin" post="overuse. Along this period, the patient underwent prophylactic treatment"/>
   <result pre="overuse. Along this period, the patient underwent prophylactic treatment with" exact="propranolol" post="and flunarizine, both ineffective. Detoxification with dexamethasone was prescribed,"/>
   <result pre="prophylactic treatment with propranolol and flunarizine, both ineffective. Detoxification with" exact="dexamethasone" post="was prescribed, along with prophylactic treatment with amitriptyline up"/>
   <result pre="Detoxification with dexamethasone was prescribed, along with prophylactic treatment with" exact="amitriptyline" post="up to 30 mg/days. This therapy, although well tolerated,"/>
   <result pre="coeruleus in a well-known animal model of migraine based on" exact="nitroglycerin" post="(NTG) administration. Methods - Here, we tested the potential"/>
   <result pre="neurogenic pain [1]. Migraine sufferers refractory to conventional therapies as" exact="topiramate" post="and amitriptyline, volunteered a treatment with selective cannabinoids. Method:"/>
   <result pre="males, 58 females, mean age 42,7±14,1SD) who choose to re-test" exact="amitriptyline" post="50 mg/day/orally. Drugs were increased starting from 20 and"/>
   <result pre="1. Menon S et al The effect of 1 mg" exact="folic acid" post="supplementation on clinical outcomes in female migraine with aura"/>
   <result pre="paracetamol) and showed only a partial and unsatisfactory improvement from" exact="pregabalin" post="and amitriptyline, which are effective in treatment of neuropathic"/>
   <result pre="to have had a satisfactory response to topical corticosteroid (intranasal" exact="fluticasone" post="spray): at 6 months follow-up the patient referred symptom"/>
   <result pre="and acute therapy to stop the attack. Although amitriptyline, topiramate," exact="flunarizine" post="and valproic acid have the most data on their"/>
   <result pre="therapy to stop the attack. Although amitriptyline, topiramate, flunarizine and" exact="valproic acid" post="have the most data on their use for prophylaxis"/>
   <result pre="D., Lavano, A., 2016. Administration of palmitoylethanolamide in combination with" exact="topiramate" post="in the preventive treatment of nummular headache. International medical"/>
   <result pre="exogenous, at the time of menstruation estrogen and / or" exact="progesterone" post="levels are not low, The &quot;uterine wound&quot;, with large"/>
   <result pre="to conventional therapies in other centres. Controls choose to re-test" exact="amitriptyline" post="50 mg/day/orally in a 15 days treatment. No patient"/>
   <result pre="6%THC-7.5%CBD fixed combination induceed 20 fold higher anti-allodynic effect versus" exact="amitriptyline" post="short treatment: THC-CBD run-in value 16.5±4.6 SD versus post-treatment"/>
   <result pre="treatment: THC-CBD run-in value 16.5±4.6 SD versus post-treatment 8.1±4.9SD p&amp;gt;0.00001," exact="amitriptyline" post="run–in value versus post-treatment values: 16.1±4.6 SD versus 12.07±4.02SD,"/>
   <result pre="(0-10) temples/forehead 8.4±1.2SD after run–in, 2.2±1.6SD after THC-CBD, 6.8±3.4SD after" exact="amitriptyline" post="p&amp;gt;0.00001. Side Effects of 6%THC-7.5%CBD: Somnolence: n=1, amitriptyline group"/>
   <result pre="6.8±3.4SD after amitriptyline p&amp;gt;0.00001. Side Effects of 6%THC-7.5%CBD: Somnolence: n=1," exact="amitriptyline" post="group n=2, withdrawal at discontinuation n=0. Conclusion Bediol-induced anti-allodynic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6899706/results/search/drugs/results.xml">
   <result pre="only one recent RCT was published reporting comparable effectiveness of" exact="amitriptyline" post="and cyproheptadine. 8 2 PATHOPHYSIOLOGY AND COMORBID CONDITIONS To"/>
   <result pre="Why do some patients respond to certain medications such as" exact="amitriptyline" post="while others do not? These are a few examples"/>
   <result pre="Antidepressant/atypical neuroleptic Amitriptyline Tricyclic antidepressant inhibits reuptake of serotonin and" exact="norepinephrine" post="Mirtazapine CNS 5‐HT 1A agonism, 5‐HT 2 antagonism, 5‐HT"/>
   <result pre="1 antagonists NK 1 receptor antagonists Abortive antimigraine agents Nasal/injectable" exact="sumatriptan" post="5‐HT 1B/1D receptor agonist Other triptans 5‐HT 1B/1D receptor"/>
   <result pre="6 years in a trial to compare the effects of" exact="amitriptyline" post="to escitalopram or placebo in 292 patients with functional"/>
   <result pre="in a trial to compare the effects of amitriptyline to" exact="escitalopram" post="or placebo in 292 patients with functional dyspepsia. 48"/>
   <result pre="to enroll 130 patients into a negative placebo‐controlled trial of" exact="nortriptyline" post="in idiopathic gastroparesis. 49 The only published RCT of"/>
   <result pre="nortriptyline in idiopathic gastroparesis. 49 The only published RCT of" exact="amitriptyline" post="in CVS employed cyproheptadine as the comparator in a"/>
   <result pre="49 The only published RCT of amitriptyline in CVS employed" exact="cyproheptadine" post="as the comparator in a total of 64 children."/>
   <result pre="in CVS episode severity and frequency with the antiepileptic drugs" exact="zonisamide" post="and levetiracetam in patients failing tricyclic medications. 51 Others"/>
   <result pre="episode severity and frequency with the antiepileptic drugs zonisamide and" exact="levetiracetam" post="in patients failing tricyclic medications. 51 Others have reported"/>
   <result pre="Others have reported a beneficial impact of the antiepileptic medication" exact="topiramate" post="when used as CVS prophylaxis. 52 Data supporting these"/>
   <result pre="aborting CVS attacks once started. The NK 1 receptor antagonist" exact="aprepitant" post="appears to have beneficial effects in pediatric CVS patients,"/>
   <result pre="major benefit in adult CVS patients as well; 50 also," exact="aprepitant" post="was found to improve several outcome end points relating"/>
   <result pre="particular, controlled trials of 5‐HT 1B,1D receptor agonists including intranasal" exact="sumatriptan" post="should be considered for controlling acute emetic episodes in"/>
   <result pre="Prophylactic therapy of cyclic vomiting syndrome in children: comparison of" exact="amitriptyline" post="and cyproheptadine: a randomized clinical trial . Am J"/>
   <result pre="Whitehead WE , et al. Cognitive‐behavioral therapy versus education and" exact="desipramine" post="versus placebo for moderate to severe functional bowel disorders"/>
   <result pre="Locke GR , Saito YA , et al. Effect of" exact="amitriptyline" post="and escitalopram on functional dyspepsia: a multicenter, randomized controlled"/>
   <result pre=", Saito YA , et al. Effect of amitriptyline and" exact="escitalopram" post="on functional dyspepsia: a multicenter, randomized controlled study ."/>
   <result pre="Natta ML , Abell TL , et al. Effect of" exact="nortriptyline" post="on symptoms of idiopathic gastroparesis: the NORIG randomized clinical"/>
   <result pre="E , et al. Efficacy of the neurokinin‐1 receptor antagonist" exact="aprepitant" post="in children with cyclical vomiting syndrome . Aliment Pharmacol"/>
   <result pre="GS , Lustman PJ , Prakash C . Zonisamide or" exact="levetiracetam" post="for adults with cyclic vomiting syndrome: a case series."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6899751/results/search/drugs/results.xml">
   <result pre="such as amitriptyline, as a first‐line prophylactic medication and receive" exact="topiramate" post="or aprepitant as alternate prophylactic medications. Zonisamide or levetiracetam"/>
   <result pre="amitriptyline, as a first‐line prophylactic medication and receive topiramate or" exact="aprepitant" post="as alternate prophylactic medications. Zonisamide or levetiracetam and mitochondrial"/>
   <result pre="receive topiramate or aprepitant as alternate prophylactic medications. Zonisamide or" exact="levetiracetam" post="and mitochondrial supplements (Coenzyme Q10, L‐carnitine, and riboflavin) are"/>
   <result pre="using serotonin antagonists, such as ondansetron, and/or triptans, such as" exact="sumatriptan" post="or aprepitant to abort symptoms . Emergency department treatment"/>
   <result pre="antagonists, such as ondansetron, and/or triptans, such as sumatriptan or" exact="aprepitant" post="to abort symptoms . Emergency department treatment is best"/>
   <result pre="using serotonin antagonists such as ondansetron, and/or triptans such as" exact="sumatriptan" post="or newer agents such as aprepitant (NK1 receptor antagonist)"/>
   <result pre="and/or triptans such as sumatriptan or newer agents such as" exact="aprepitant" post="(NK1 receptor antagonist) to abort symptoms. An individualized treatment"/>
   <result pre="Amitriptyline (AT) is a tricyclic antidepressant, a mixed serotonin and" exact="norepinephrine" post="reuptake inhibitor that also interacts with cholinergic, and multiple"/>
   <result pre="channels. 11 Amitriptyline is converted by cytochrome P4502C19 (CYP2C19) to" exact="nortriptyline" post="(NT). 12 Both AT and NT are converted by"/>
   <result pre="these patients were also treated with other agents such as" exact="topiramate" post="and mitochondrial supplements such as Co‐Q10 and L‐carnitine. An"/>
   <result pre="and delirium may occur with the treatment of depression with" exact="amitriptyline" post="but are not reported in CVS, perhaps due to"/>
   <result pre="2. We conditionally recommend that adults with moderate‐to‐severe CVS receive" exact="topiramate" post="as an alternate prophylactic medication Grade: Conditional recommendation, very"/>
   <result pre="alternative prophylactic medication in moderate‐to‐severe CVS. Several studies show that" exact="topiramate" post="is effective in preventing migraine headaches, but there is"/>
   <result pre="in CVS. One retrospective study of 16 children treated with" exact="topiramate" post="found that 81% became episode free, 13% showed at"/>
   <result pre="≥50% reduction in frequency/severity of CVS episodes. Some patients on" exact="topiramate" post="were also receiving AT and mitochondrial supplements in this"/>
   <result pre="and mitochondrial supplements in this study. 3 We recommend starting" exact="topiramate" post="at 25 mg daily and titrating by 25 mg"/>
   <result pre="developing renal stones. 39 Female patients should be informed that" exact="topiramate" post="can interfere with the efficacy of oral contraceptives. 3.3"/>
   <result pre="3. We conditionally recommend that adults with moderate‐to‐severe CVS receive" exact="aprepitant" post="as an alternate prophylactic medication Grade: Conditional recommendation, very"/>
   <result pre="severe liver disease. There is a single open‐label trial of" exact="aprepitant" post="used prophylactically to treat CVS in children and adolescents"/>
   <result pre="of 126 adults with gastroparesis (and related syndromes), although oral" exact="aprepitant" post="(125 mg) failed to significantly reduce nausea when measured"/>
   <result pre="Gastroparesis Clinical Symptom Index. 44 Most trials in CINV used" exact="aprepitant" post="in combination with 5HT 3 antagonists and corticosteroids. 45,"/>
   <result pre="and corticosteroids. 45, 46 Nine task force members have used" exact="aprepitant" post="prophylactically in adolescents or adults with some success in"/>
   <result pre="and the clinical experince of committee members, we recommend initiating" exact="aprepitant" post="as an alternate/second‐line prophylactic treatment in patients who are"/>
   <result pre="kg. Costs per capsule of Emend ® ($120‐230) or generic" exact="aprepitant" post="($47‐90) are high and must be considered when prescribing"/>
   <result pre="4. We conditionally recommend that adults with moderate‐to‐severe CVS receive" exact="zonisamide" post="or levetiracetam as an alternate prophylactic medication Grade: Conditional"/>
   <result pre="conditionally recommend that adults with moderate‐to‐severe CVS receive zonisamide or" exact="levetiracetam" post="as an alternate prophylactic medication Grade: Conditional recommendation, very"/>
   <result pre="metabolized before renal excretion. The evidence supporting the use of" exact="zonisamide" post="or levetiracetam as prophylactic therapy in CVS is based"/>
   <result pre="renal excretion. The evidence supporting the use of zonisamide or" exact="levetiracetam" post="as prophylactic therapy in CVS is based on one"/>
   <result pre="± 0.3 to 0.5 ± 0.2 episodes/year in response to" exact="zonisamide" post="or levetiracetam was quite notable. Ultimately, the majority (75%)"/>
   <result pre="to 0.5 ± 0.2 episodes/year in response to zonisamide or" exact="levetiracetam" post="was quite notable. Ultimately, the majority (75%) of patients"/>
   <result pre="was quite notable. Ultimately, the majority (75%) of patients on" exact="zonisamide" post="or levetiracetam reported a moderate clinical response, and 20%"/>
   <result pre="notable. Ultimately, the majority (75%) of patients on zonisamide or" exact="levetiracetam" post="reported a moderate clinical response, and 20% experienced a"/>
   <result pre="switch to the alternative AED very well. The doses of" exact="zonisamide" post="and levetiracetam used for CVS prophylaxis mirror those used"/>
   <result pre="the alternative AED very well. The doses of zonisamide and" exact="levetiracetam" post="used for CVS prophylaxis mirror those used to prevent"/>
   <result pre="established liver or renal disease. Finally, newer AEDs related to" exact="zonisamide" post="and levetiracetam, such as lacosamide or brivaracetam, are now"/>
   <result pre="Finally, newer AEDs related to zonisamide and levetiracetam, such as" exact="lacosamide" post="or brivaracetam, are now available, but it remains to"/>
   <result pre="We conditionally recommend using mitochondrial supplements such as Co‐Q10, and" exact="riboflavin" post="as prophylactic therapy in the treatment of CVS. Mitochondrial"/>
   <result pre="tolerability, and patient satisfaction of Co‐Q10 (n = 32) with" exact="amitriptyline" post="(n = 249) in children with CVS. 19 The"/>
   <result pre="tolerability. 58 In a systematic review of the efficacy of" exact="riboflavin" post="as prophylactic therapy, riboflavin was associated with a positive"/>
   <result pre="systematic review of the efficacy of riboflavin as prophylactic therapy," exact="riboflavin" post="was associated with a positive therapeutic effect in five"/>
   <result pre="adults with migraine. 59 Most migraine studies report doses of" exact="riboflavin" post="of 200 mg twice daily. Based upon this indirect"/>
   <result pre="daily. Based upon this indirect evidence, one may also consider" exact="riboflavin" post="as an additional prophylactic supplement in adult CVS patients."/>
   <result pre="CVS 4.1 Recommendation 6. We conditionally recommend using triptans like" exact="sumatriptan" post="to abort symptoms of a CVS episode Grade: Conditional"/>
   <result pre="producing constriction of distended dural blood vessels. The efficacy of" exact="sumatriptan" post="in migraine is due to multiple sites of action"/>
   <result pre="(vascular, neural, and central). There are reports of efficacy of" exact="sumatriptan" post="in abdominal migraine, a condition classified in the subgroup"/>
   <result pre="non–placebo‐controlled study of 11 children with CVS, the efficacy of" exact="sumatriptan" post="treatment was high in those with a family history"/>
   <result pre="those without a family history of migraine still responded to" exact="sumatriptan" post="in 50% of their attacks. In this study, sumatriptan"/>
   <result pre="to sumatriptan in 50% of their attacks. In this study," exact="sumatriptan" post="was administered by SC injection in nine and via"/>
   <result pre="Although the number of patients was small, the administration of" exact="sumatriptan" post="reduced vomiting in nine patients (82%) and the nasal"/>
   <result pre="effective. Three other case reports describe the efficacy of injectable" exact="sumatriptan" post="in aborting episodes of CVS. 65 The committee believes"/>
   <result pre="in aborting episodes of CVS. 65 The committee believes that" exact="sumatriptan" post="is effective in the acute treatment of CVS although"/>
   <result pre="of CVS although randomized placebo‐controlled studies investigating the efficacy of" exact="sumatriptan" post="in CVS attacks are lacking. We recommend administration of"/>
   <result pre="which can have a bitter taste. 66 We recommend using" exact="sumatriptan" post="as a nasal spray at 20 mg initially, while"/>
   <result pre="nasal spray at 20 mg initially, while a comparable subcutaneous" exact="sumatriptan" post="dose in adults is 6 mg. The dose may"/>
   <result pre="Recommendation 7. We conditionally recommend using serotonin antagonists such as" exact="ondansetron" post="to abort symptoms of a CVS episode Vote: 100%"/>
   <result pre="and anticipatory nausea and vomiting. 70, 71 Studies indicate that" exact="ondansetron" post="is as effective as other 5‐HT 3 receptor antagonists"/>
   <result pre="antagonists in the treatment of CINV. 72 The committee recommends" exact="ondansetron" post="as a first‐line agent in aborting an episode of"/>
   <result pre="to initiating this medication. We recommend using 8 mg of" exact="ondansetron" post="as a sublingual preparation or rectally (reformulated) at the"/>
   <result pre="an episode of vomiting. 4.3 Recommendation 8. We conditionally recommend" exact="aprepitant" post="to abort symptoms of a CVS episode Grade: Conditional"/>
   <result pre="&amp;gt;80% agreement There is a single open‐label trial of oral" exact="aprepitant" post="used as abortive treatment of CVS in children and"/>
   <result pre="mg daily for the following 2 days as needed. Oral" exact="aprepitant" post="could be retained if administered during a prodrome at"/>
   <result pre="tolerated. There are no data on the use of intravenous" exact="fosaprepitant" post="(phosphorylated prodrug of aprepitant) in CVS, although it has"/>
   <result pre="children and adolescents and positive clinical experience, the committee recommends" exact="aprepitant" post="as a potentially effective second‐line abortive agent. We recommend"/>
   <result pre="the onset of vomiting. The target individuals in whom abortive" exact="aprepitant" post="is recommended include those who are refractory to standard"/>
   <result pre="include those who are refractory to standard abortive therapy (eg," exact="sumatriptan" post="and ondansetron) and those who have a defined prodrome"/>
   <result pre="which occurs in relation to the menstrual cycle) in which" exact="aprepitant" post="can be initiated a day or two before the"/>
   <result pre="anticipated onset of vomiting. Difficulties with obtaining insurance approval for" exact="aprepitant" post="and IV fosaprepitant have been a barrier to its"/>
   <result pre="vomiting. Difficulties with obtaining insurance approval for aprepitant and IV" exact="fosaprepitant" post="have been a barrier to its use despite demonstrated"/>
   <result pre="2. We conditionally recommend that adults with moderate‐to‐severe CVS receive" exact="topiramate" post="as an alternate prophylactic medication (very low‐quality evidence) 3."/>
   <result pre="3. We conditionally recommend that adults with moderate‐to‐severe CVS receive" exact="aprepitant" post="as an alternate prophylactic medication (very low‐quality evidence) 4."/>
   <result pre="4. We conditionally recommend that adults with moderate‐to‐severe CVS receive" exact="zonisamide" post="or levetiracetam as an alternate prophylactic medication (very low‐quality"/>
   <result pre="conditionally recommend that adults with moderate‐to‐severe CVS receive zonisamide or" exact="levetiracetam" post="as an alternate prophylactic medication (very low‐quality evidence) 5."/>
   <result pre="(very low‐quality evidence) 5. We conditionally recommend using Co‐Q10, and" exact="riboflavin" post="as prophylactic therapy in the treatment of CVS. Mitochondrial"/>
   <result pre="(very low‐quality evidence) 6. We conditionally recommend using triptans like" exact="sumatriptan" post="to abort symptoms of a CVS episode. (moderate‐quality evidence)"/>
   <result pre="evidence) 7. We conditionally recommend using serotonin antagonists such as" exact="ondansetron" post="to abort symptoms of a CVS episode (consensus statement)"/>
   <result pre="of a CVS episode (consensus statement) 8. We conditionally recommend" exact="aprepitant" post="to abort symptoms of a CVS episode (very low‐quality"/>
   <result pre="(dose and duration) and response to medications TCAs such as" exact="amitriptyline" post="Anti‐epileptic drugs (topiramate, zonisamide, and levetiracetam) NK1 receptor antagonists"/>
   <result pre="studies of the abdomen Abortive medications such as triptans and" exact="ondansetron" post="and anxiolytics are most effective when used early in"/>
   <result pre="it is preferable to opt for the use of intravenous" exact="ketorolac" post="and non‐opiate sedation to avoid development of dependence or"/>
   <result pre="for a 70 kg adult.) For vomiting and nausea IV" exact="ondansetron" post="8 mg IV × 1—may repeat q 4‐6 h"/>
   <result pre="8 mg IV × 1—may repeat q 4‐6 h if" exact="ondansetron" post="is ineffective Consider diphenhydramine 50 mg IV and metoclopramide"/>
   <result pre="1—may repeat q 4‐6 h if ondansetron is ineffective Consider" exact="diphenhydramine" post="50 mg IV and metoclopramide 10 mg IV Consider"/>
   <result pre="if ondansetron is ineffective Consider diphenhydramine 50 mg IV and" exact="metoclopramide" post="10 mg IV Consider IV fosaprepitant 150 mg if"/>
   <result pre="50 mg IV and metoclopramide 10 mg IV Consider IV" exact="fosaprepitant" post="150 mg if available For sedation IV lorazepam 1‐2"/>
   <result pre="Consider IV fosaprepitant 150 mg if available For sedation IV" exact="lorazepam" post="1‐2 mg and b. IV diphenhydramine 50 mg for"/>
   <result pre="available For sedation IV lorazepam 1‐2 mg and b. IV" exact="diphenhydramine" post="50 mg for additional sedation For migraine‐like presentation Sumatriptan"/>
   <result pre="or Sumatriptan subcutaneous injection 6 mg/0.5 mL For pain IV" exact="ketorolac" post="30 mg if &amp;gt; 60 minutes from onset; may"/>
   <result pre="as indicated above or admit patient Positive treatment response—discharge Continue" exact="ondansetron" post="(soluble tablets) q 6‐8 h × 24‐48 h if"/>
   <result pre="q 6‐8 h × 24‐48 h if initially effective Continue" exact="lorazepam" post="× 24‐48 h if initially effective Continue NSAIDs for"/>
   <result pre="Czorlich P , Nagaraj C , et al. Amitriptyline and" exact="carbamazepine" post="utilize voltage‐gated ion channel suppression to impair excitability of"/>
   <result pre="Prophylactic therapy of cyclic vomiting syndrome in children: comparison of" exact="amitriptyline" post="and cyproheptadine: a randomized clinical trial . Am J"/>
   <result pre="Effective prophylactic therapy for cyclic vomiting syndrome in children using" exact="amitriptyline" post="or cyproheptadine . Pediatrics. 1997; 100: 977‐ 981. 9374568"/>
   <result pre="therapy for cyclic vomiting syndrome in children using amitriptyline or" exact="cyproheptadine" post=". Pediatrics. 1997; 100: 977‐ 981. 9374568 23 Boles"/>
   <result pre="29 Baldessarini RJ , Willmuth RL . Psychotic reactions during" exact="amitriptyline" post="therapy. Can Psychiatr Assoc J. 1968; 13: 571‐ 573."/>
   <result pre="open‐label study to evaluate the dosing, effectiveness, and safety of" exact="topiramate" post="as monotherapy in the treatment of epilepsy in clinical"/>
   <result pre="Kim WJ , et al. Long‐term efficacy and tolerability of" exact="topiramate" post="as add‐on therapy in refractory partial epilepsy: an observational"/>
   <result pre="course of adverse events in patients with localization‐related epilepsy receiving" exact="topiramate" post="added to carbamazepine . Epilepsia. 2005; 46: 648‐ 653."/>
   <result pre="events in patients with localization‐related epilepsy receiving topiramate added to" exact="carbamazepine" post=". Epilepsia. 2005; 46: 648‐ 653. 15857429 36 El"/>
   <result pre=", Mikati MA . Long‐term patterns of weight changes during" exact="topiramate" post="therapy: an observational study. Neurology. 2007; 69: 310‐ 311."/>
   <result pre="D , Grabnar I , et al. Effect of long‐term" exact="topiramate" post="therapy on serum bicarbonate and potassium levels in adult"/>
   <result pre="al. Equivalent dynamic human brain NK1‐receptor occupancy following single‐dose i.v." exact="fosaprepitant" post="vs. oral aprepitant as assessed by PET imaging ."/>
   <result pre="human brain NK1‐receptor occupancy following single‐dose i.v. fosaprepitant vs. oral" exact="aprepitant" post="as assessed by PET imaging . Clin Pharmacol Ther"/>
   <result pre="E , et al. Efficacy of the neurokinin‐1 receptor antagonist" exact="aprepitant" post="in children with cyclical vomiting syndrome . Aliment Pharmacol"/>
   <result pre="28. 49 Deshpande LS , Delorenzo RJ . Mechanisms of" exact="levetiracetam" post="in the control of status epilepticus and epilepsy. Front"/>
   <result pre="GS , Lustman PJ , Prakash C . Zonisamide or" exact="levetiracetam" post="for adults with cyclic vomiting syndrome: a case series."/>
   <result pre="Schuh‐Hofer S , Einhaupl KM , Arnold G . High‐dose" exact="riboflavin" post="treatment is efficacious in migraine prophylaxis: an open study"/>
   <result pre=", LeCates S , Bentti AL . Effectiveness of nasal" exact="sumatriptan" post="in 5‐ to 12‐year‐old children. Headache. 2001; 41: 693‐"/>
   <result pre="Wakusawa K , Haginoya K , et al. Efficacy of" exact="sumatriptan" post="in two pediatric cases with abdominal pain‐related functional gastrointestinal"/>
   <result pre="507. 21147834 65 Calhoun AH , Pruitt AP . Injectable" exact="sumatriptan" post="for cyclic vomiting syndrome in adults: a case series."/>
   <result pre="Caparroz C , Castro PC . Granisetron is equivalent to" exact="ondansetron" post="for prophylaxis of chemotherapy‐induced nausea and vomiting: results of"/>
   <result pre="KL . Comparative efficacy and safety of ondansetron, droperidol, and" exact="metoclopramide" post="for preventing postoperative nausea and vomiting: a meta‐analysis ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6899798/results/search/drugs/results.xml">
   <result pre="therapy. We found limited evidence to support the use of" exact="ondansetron" post="and the treatment of co‐morbid conditions and complementary therapies."/>
   <result pre="to patient at 2‐week intervals. Prophylactic Pediatric Randomized trial of" exact="amitriptyline" post="vs cyproheptadine. MD visits every 2 weeks over 6"/>
   <result pre="3 Hikita et al. (2016) Valproic acid Valproic acid with" exact="phenobarbital" post="Phenobarbital Amitriptyline Phenytoin Carbamazepine Cyproheptadine Primidone Propranolol Clonidine hydrochloride"/>
   <result pre="chart review and patient questionnaire. Turkey 38 (16 patients on" exact="topiramate" post="and 22 patients on propranolol) CVS diagnosed by Rome"/>
   <result pre="specified 7 Treepongkaruna et al. (2014) Amitriptyline Propranolol Cyproheptadine Sodium" exact="valproate" post="(Medication dosages not explicitly stated but prior clinical practice"/>
   <result pre="dosages) Prophylactic Pediatric Retrospective cohort Thailand 29 patients received either" exact="propranolol" post="(n = 11), cyproheptadine (n = 4), and amitriptyline"/>
   <result pre="cohort Thailand 29 patients received either propranolol (n = 11)," exact="cyproheptadine" post="(n = 4), and amitriptyline (n = 14). Long‐term"/>
   <result pre="either propranolol (n = 11), cyproheptadine (n = 4), and" exact="amitriptyline" post="(n = 14). Long‐term outcomes were available in 19"/>
   <result pre="kg, 125 mg if &amp;gt; 60 kg Abortive regimen of" exact="aprepitant" post="given if prodromal phase* suggested imminent CVS attack. Otherwise,"/>
   <result pre="given if prodromal phase* suggested imminent CVS attack. Otherwise, prophylactic" exact="aprepitant" post="dose given. All oral administration. *Prodromal phase= symptoms such"/>
   <result pre="1 gram twice daily, Co‐enzyme Q‐10 200 mg twice daily," exact="riboflavin" post="100 mg once daily) Abortive and prophylactic Adult Retrospective"/>
   <result pre="months. 10 Lee et al. (2012) TCA Propranolol L‐carnitine and" exact="amitriptyline" post="Erythromycin Coenzyme Q Phenobarbital Valproate Pizotifen Cyproheptadine L‐Carnitine Sumatriptan"/>
   <result pre="Propranolol (1 mg/kg per day) Prophylactic Pediatric Randomized trial of" exact="amitriptyline" post="vs propranolol Iran 164 patients (81 on propranolol and"/>
   <result pre="mg/kg per day) Prophylactic Pediatric Randomized trial of amitriptyline vs" exact="propranolol" post="Iran 164 patients (81 on propranolol and 83 on"/>
   <result pre="trial of amitriptyline vs propranolol Iran 164 patients (81 on" exact="propranolol" post="and 83 on amitriptyline) CVS diagnosis: &amp;gt;/= 3 episodes"/>
   <result pre="patients on listed medication Valproic acid (9/4/15) Valproic acid with" exact="phenobarbital" post="(4/0/4) Phenobarbital (3/6/9) Amitriptyline (1/4/5) Phenytoin (0/4/4) Carbamazepine (0/2/2)"/>
   <result pre="success with my treatments.&quot; b) Abortive treatment ‐10/16 (63%) said" exact="ondansetron" post="was most effective abortive medication ‐7/16 (44%) said benzodiazepines"/>
   <result pre="Short‐term outcomes Good response: Amitriptyline 11/15 (73%) (significantly better than" exact="propranolol" post="P = 0.04) Propranolol 5/14 (36%) Cyproheptadine 0/4 (0%)"/>
   <result pre="P = 0.04) Propranolol 5/14 (36%) Cyproheptadine 0/4 (0%) Sodium" exact="valproate" post="1/3 (33%) Long‐term outcomes (diagnosis ≥ 2 years) Data"/>
   <result pre="interval length (days) School attendance percentage Prophylactic group had higher" exact="aprepitant" post="doses than the abortive group. All outcomes below measured"/>
   <result pre="to medication TCA 168/244 (68%) Propranolol 79/91 (87%) L‐carnitine and" exact="amitriptyline" post="23/30 (77%) Erythromycin 13/20 (65%) Coenzyme Q 12/18 (67%)"/>
   <result pre="+ Co‐Q10: Resolution: 3 patients (in one of these cases," exact="amitriptyline" post="was not tolerated, yet episodes resolved on topiramate +"/>
   <result pre="these cases, amitriptyline was not tolerated, yet episodes resolved on" exact="topiramate" post="+ co‐enzyme Q10) Amitriptyline + L‐carnitine: Resolution: 2 patients"/>
   <result pre="treatment was not effective in preventing vomiting) 11 patients received" exact="sumatriptan" post="subcutaneous injection: Complete resolution: 4/11(36%) Effective response: 5/11 (46%)"/>
   <result pre="improvement in VAS at 3 months: 22/27(81%) 24 patients on" exact="amitriptyline" post="for at least 3 months: 93% had a &quot;favorable"/>
   <result pre="good/fair response. Medication &quot;non‐effective&quot; if poor response. Pizotifen: 8/25 received" exact="pizotifen" post="Good response: 3 (2 with mild disease, 1 with"/>
   <result pre="Poor response: 4 (3 had severe disease) In 3 patients," exact="pizotifen" post="changed to amitriptyline Amitriptyline (18/25 patents received) Good response:"/>
   <result pre="(3 had severe disease) In 3 patients, pizotifen changed to" exact="amitriptyline" post="Amitriptyline (18/25 patents received) Good response: 11 (4 with"/>
   <result pre="(1 with severe disease) No statistical difference in response between" exact="pizotifen" post="and amitriptyline No adverse events observed 20 Prakash et"/>
   <result pre="severe disease) No statistical difference in response between pizotifen and" exact="amitriptyline" post="No adverse events observed 20 Prakash et al. (1999)"/>
   <result pre="vs non‐migraine CVS (1/3 (33%). No statistically significant difference in" exact="sumatriptan" post="usage between groups None reported 22 Andersen et al."/>
   <result pre="the randomized trials were converted to a single‐arm cohort of" exact="amitriptyline" post="for inclusion into a summary estimate for amitriptyline's symptomatic"/>
   <result pre="and 29/137 pediatric patients and 13/61 (21%) adult patients discontinued" exact="amitriptyline" post="because of side effects. 7 However, adverse events leading"/>
   <result pre="and imprecision (for a few of the outcomes). 3.2.2 Should" exact="topiramate" post="be used as prophylactic therapy in adults with CVS?"/>
   <result pre="message There is very low certainty in the evidence that" exact="topiramate" post="should be used as prophylactic therapy in CVS. See"/>
   <result pre="See Table 4 for full evidence profile Table 4 Should" exact="topiramate" post="be used as prophylactic therapy in adults with CVS?"/>
   <result pre="In one additional study (Kumar 2012), 17/76 adult patients received" exact="topiramate" post="but there was not enough detail provided for the"/>
   <result pre="the analysis (as patients may also have been treated with" exact="amitriptyline" post="and mitochondrial supplements. In this study, overall response was"/>
   <result pre="One study met inclusion criteria that investigated the role of" exact="topiramate" post="in CVS. 15 Sezer et al. investigated the use"/>
   <result pre="in CVS. 15 Sezer et al. investigated the use of" exact="topiramate" post="(n = 16) and propranolol (n = 22) in"/>
   <result pre="al. investigated the use of topiramate (n = 16) and" exact="propranolol" post="(n = 22) in 38 pediatric patients with CVS"/>
   <result pre="in a retrospective cohort study in Turkey. At baseline, the" exact="topiramate" post="group (compared to the propranolol group) had significantly fewer"/>
   <result pre="in Turkey. At baseline, the topiramate group (compared to the" exact="propranolol" post="group) had significantly fewer episodes of vomiting/cycle before treatment,"/>
   <result pre="of emeses/hour during an attack. As such, patients in the" exact="topiramate" post="group might have been less severe prior to treatment"/>
   <result pre="might have been less severe prior to treatment than the" exact="propranolol" post="group. Patients were followed for 1 year. At follow‐up,"/>
   <result pre="≥ 50% reduction in attacks) were significantly higher in the" exact="topiramate" post="group 15/16 (94%) compared to the propranolol group 18/22"/>
   <result pre="higher in the topiramate group 15/16 (94%) compared to the" exact="propranolol" post="group 18/22 (81%). In the topiramate arm, 81% became"/>
   <result pre="(94%) compared to the propranolol group 18/22 (81%). In the" exact="topiramate" post="arm, 81% became episode free and 13% showed at"/>
   <result pre="Per the study, the four patients who were non‐responsive to" exact="propranolol" post="were treated with topiramate, and all of them had"/>
   <result pre="by the authors. The one patient who was non‐responsive to" exact="topiramate" post="was also non‐responsive to other medications, including propranolol, amitriptyline,"/>
   <result pre="including propranolol, amitriptyline, and cyproheptadine. One additional study reported on" exact="topiramate" post="use in adults (Kumar et al.); in this study,"/>
   <result pre="not enough detail was provided to discern the efficacy of" exact="topiramate" post="alone, as patients in this cohort also received treatment"/>
   <result pre="alone, as patients in this cohort also received treatment with" exact="amitriptyline" post="and mitochondrial supplements. 12 In the study by Sezer"/>
   <result pre="and no statistically significant difference in adverse events between the" exact="propranolol" post="and topiramate groups. 15 Two patients experienced drowsiness and"/>
   <result pre="statistically significant difference in adverse events between the propranolol and" exact="topiramate" post="groups. 15 Two patients experienced drowsiness and dizziness with"/>
   <result pre="and indirectness (the study population was pediatric patients) 3.2.3 Should" exact="aprepitant" post="be used as prophylactic therapy in adults with CVS?"/>
   <result pre="very low certainty in the evidence for the use of" exact="aprepitant" post="as prophylactic therapy in CVS. See Table 5 for"/>
   <result pre="See Table 5 for full evidence profile Table 5 Should" exact="aprepitant" post="be used as prophylactic therapy in adults with CVS?"/>
   <result pre="Ltd, Potential benefits/harms One observational study investigated the use of" exact="aprepitant" post="both as abortive therapy and as prophylactic therapy in"/>
   <result pre="Forty‐one children and adolescents were included with 25 being administered" exact="aprepitant" post="as an abortive medication and 16 as prophylaxis. Some"/>
   <result pre="no control group. Patients were given an &quot;abortive&quot; regimen of" exact="aprepitant" post="if they had a prodromal phase that suggested an"/>
   <result pre="With respect to co‐interventions, individuals were also being treated with" exact="propranolol" post="9/15 (60%), amitriptyline 7/15 (46%), coenzyme Q10 5/15 (33%),"/>
   <result pre="co‐interventions, individuals were also being treated with propranolol 9/15 (60%)," exact="amitriptyline" post="7/15 (46%), coenzyme Q10 5/15 (33%), and L‐carnitine 3/15"/>
   <result pre="dosed accordingly, making this less of a concern. 3.2.4 Should" exact="zonisamide" post="or levetiracetam be used as prophylactic therapy in adults"/>
   <result pre="making this less of a concern. 3.2.4 Should zonisamide or" exact="levetiracetam" post="be used as prophylactic therapy in adults with CVS?"/>
   <result pre="very low certainty in the evidence for the use of" exact="zonisamide" post="or levetiracetam as prophylactic therapy. See Table 6 for"/>
   <result pre="certainty in the evidence for the use of zonisamide or" exact="levetiracetam" post="as prophylactic therapy. See Table 6 for full evidence"/>
   <result pre="Table 6 for full evidence profile Table 6 Should (antiepileptics)" exact="zonisamide" post="or levetiracetam be used as prophylactic therapy in adults"/>
   <result pre="for full evidence profile Table 6 Should (antiepileptics) zonisamide or" exact="levetiracetam" post="be used as prophylactic therapy in adults with CVS?"/>
   <result pre="Serious [Link] None Severe AEs: 4/20 (20%). One subject on" exact="levetiracetam" post="developed angioedema, which resolved when switched to zonisamide. One"/>
   <result pre="the 20 patients with a &quot;favorable&quot; clinical response, 12/16 received" exact="zonisamide" post="and 3/4 received levetiracetam. This retrospective study was based"/>
   <result pre="of 20 adult patients with CVS who had received prophylactic" exact="zonisamide" post="(median dose, 400 mg/day) or levetiracetam (median dose, 1000"/>
   <result pre="who had received prophylactic zonisamide (median dose, 400 mg/day) or" exact="levetiracetam" post="(median dose, 1000 mg/day) when tricyclic antidepressants (TCAs) alone"/>
   <result pre="failed, were intolerable, or unsuitable. Sixteen patients were treated with" exact="zonisamide" post="and four with levetiracetam for CVS prophylactic therapy. Median"/>
   <result pre="unsuitable. Sixteen patients were treated with zonisamide and four with" exact="levetiracetam" post="for CVS prophylactic therapy. Median follow‐up after initiation of"/>
   <result pre="satisfaction with therapy. Twelve out of 16 patients in the" exact="zonisamide" post="group and 3 out of 4 in the levetiracetam"/>
   <result pre="the zonisamide group and 3 out of 4 in the" exact="levetiracetam" post="group reported a favorable clinical response. Frequency of vomiting"/>
   <result pre="Frequency of vomiting episodes decreased significantly after initiation of either" exact="zonisamide" post="or levetiracetam from 1.3 to 0.5 episodes/month. In total,"/>
   <result pre="vomiting episodes decreased significantly after initiation of either zonisamide or" exact="levetiracetam" post="from 1.3 to 0.5 episodes/month. In total, 18/20 (90%)"/>
   <result pre="of the 4 patients was on a high dose of" exact="levetiracetam" post="(3000 mg/day). Five subjects out of 20 reported depression,"/>
   <result pre="sleeping, dizziness, poor concentration/memory, confusion, or tiredness/fatigue. One subject on" exact="levetiracetam" post="developed angioedema, which resolved when switched to zonisamide. Only"/>
   <result pre="the use of mitochondrial supplements, such as Co‐enzyme Q10, and" exact="riboflavin" post="as prophylactic therapy. See Table 7 for full evidence"/>
   <result pre="study, the authors compared the efficacy of Coenzyme Q10 to" exact="amitriptyline" post="in patients with CVS via an Internet‐based survey that"/>
   <result pre="self‐selection bias. No published studies reported on the efficacy of" exact="riboflavin" post="in CVS patients. The Boles 2011 study included riboflavin"/>
   <result pre="of riboflavin in CVS patients. The Boles 2011 study included" exact="riboflavin" post="but did not report on response for these patients."/>
   <result pre="54% of attacks in 11 kids/1 adult were responsive to" exact="sumatriptan" post="therapy (defined as complete improvement or at least a"/>
   <result pre="effective in preventing vomiting). For the 11 patients receiving subcutaneous" exact="sumatriptan" post="injection, 4/11 had complete resolution, 5/11 had effective response,"/>
   <result pre="episodes) with subcutaneous sumatriptan. Indirect estimates for the effect of" exact="sumatriptan" post="on symptom reduction (nausea and vomiting) were derived from"/>
   <result pre="higher rates of symptom improvement were seen in individuals receiving" exact="sumatriptan" post="by either intranasal (50%‐60% range) and subcutaneous routes (76%)."/>
   <result pre="adults with CVS? No published studies examining the use of" exact="ondansetron" post="as abortive therapy for CVS were identified despite its"/>
   <result pre="in CVS. No GRADE evidence profile was created. 3.3.3 Should" exact="aprepitant" post="be used as abortive therapy in adults with CVS?"/>
   <result pre="very low certainty in the evidence for the use of" exact="aprepitant" post="as abortive therapy. See Table 9 for full evidence"/>
   <result pre="See Table 9 for full evidence profile Table 9 Should" exact="aprepitant" post="be used as abortive therapy in adults with CVS?"/>
   <result pre="Ltd, Potential benefits/harms One observational study investigated the use of" exact="aprepitant" post="as abortive therapy and as prophylactic therapy in CVS."/>
   <result pre="well as telephone interviews with patients’ parents (see section on" exact="aprepitant" post="as prophylactic therapy in CVS for more details). In"/>
   <result pre="the abortive group. There were no noted adverse events from" exact="aprepitant" post="administration in the abortive group. Certainty in the evidence"/>
   <result pre="the committee relied on indirect evidence on the efficacy of" exact="ondansetron" post="in patients with chemotherapy‐induced nausea and vomiting (CINV) and"/>
   <result pre="Effective prophylactic therapy for cyclic vomiting syndrome in children using" exact="amitriptyline" post="or cyproheptadine . Pediatrics. 1997; 100: 977‐ 981. 9374568"/>
   <result pre="therapy for cyclic vomiting syndrome in children using amitriptyline or" exact="cyproheptadine" post=". Pediatrics. 1997; 100: 977‐ 981. 9374568 6 Badihian"/>
   <result pre="E , et al. Efficacy of the neurokinin‐1 receptor antagonist" exact="aprepitant" post="in children with cyclical vomiting syndrome . Aliment Pharmacol"/>
   <result pre="GS , Lustman PJ , Prakash C . Zonisamide or" exact="levetiracetam" post="for adults with cyclic vomiting syndrome: a case series."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6904992/results/search/drugs/results.xml">
   <result pre="nocebo responses in clinical trials of monoclonal antibodies against the" exact="calcitonin" post="gene-related peptide (CGRP) pathway for episodic (EM) and chronic"/>
   <result pre="and chronic migraine (CM) and compare them to those of" exact="topiramate" post="and onabotulinum toxin A as standard treatments for EM"/>
   <result pre="all randomised, placebo controlled, phase 3 trials of anti-CGRP monoclonals," exact="topiramate" post="and onabotulinum toxin A. A meta analysis of the"/>
   <result pre="trials of anti-CGRP monoclonal, whereas the pooled placebo frequency in" exact="topiramate" post="trials in EM was estimated to be 24.2% (95%"/>
   <result pre="hand, the pooled incidence of dropouts due to nocebo in" exact="topiramate" post="trials in EM was 9.2% (95% CI: 7 –"/>
   <result pre="monoclonal trials are average and comparable to those seen in" exact="topiramate" post="trials. Nocebo responses in trials of anti-CGRP monoclonals for"/>
   <result pre="other neurological disorders and were lower than those seen in" exact="topiramate" post="trials for EM. Nocebo responses in trials of anti-CGRP"/>
   <result pre="L( lmunozdelgado12@gmail.com) Background:Chronic cluster headache(CCH) pathophysiology involves an increase of" exact="calcitonin" post="gene-related peptide(CGRP) plasma levels during attacks,on analogy to what"/>
   <result pre="sample. A37 A case of supraorbital neuralgia successfully treated with" exact="pregabalin" post="Koutsokera, Pasqua Acquaviva Department, &quot;Thriassio&quot; General Hospital, Elefsis, Greece"/>
   <result pre="patient was advised to change his helmet and to receive" exact="pregabalin" post="to a total dose of 150mg. The patient improved"/>
   <result pre="with a long-standing diagnosis of sporadic HM treated successfully with" exact="valproic acid" post="who reports a mild difficulty in walking and a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6908502/results/search/drugs/results.xml">
   <result pre="DJ Klingner EA Yankey JW et al. . Trial of" exact="amitriptyline" post="topiramate and placebo for pediatric migraine. N Engl J"/>
   <result pre="Klingner EA Yankey JW et al. . Trial of amitriptyline" exact="topiramate" post="and placebo for pediatric migraine. N Engl J Med."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6916280/results/search/drugs/results.xml">
   <result pre="demeclocycline‐HCl) 20 and 8 days before each biopsy. The use of" exact="tetracycline" post="allowed for dynamic histomorphometric analysis, in which unstained sections"/>
   <result pre="the mineralization defect was profound and therefore the uptake of" exact="tetracycline" post="label very low, mineralization lag time was calculated using"/>
   <result pre="56 instead of week 48. Another subject was treated with" exact="tetracycline" post="for sinusitis/bronchitis during the tetracycline labeling period before the"/>
   <result pre="Another subject was treated with tetracycline for sinusitis/bronchitis during the" exact="tetracycline" post="labeling period before the week 48 biopsy, requiring the"/>
   <result pre="tetracycline labeling period before the week 48 biopsy, requiring the" exact="tetracycline" post="label to be repeated and the biopsy to be"/>
   <result pre="mineralization defect was so profound at baseline and uptake of" exact="tetracycline" post="so low that imputation was needed to calculate mineralization"/>
   <result pre="amelioration in dental disease with long‐term administration of phosphorus and" exact="calcitriol" post="to adults. 25 Unlike the pivotal, double‐blind, randomized clinical"/>
   <result pre="Delvin EE . Bone response to phosphate salts, ergocalciferol, and" exact="calcitriol" post="in hypophosphatemic vitamin D‐resistant rickets . N Engl J"/>
   <result pre="in X‐linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and" exact="calcitriol" post=". J Clin Invest. 1985; 75( 6): 1858– 68."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6918555/results/search/drugs/results.xml">
   <result pre="current body of evidence, including safety issues. In this perspective," exact="omalizumab" post="-an anti-IgE monoclonal antibody-, alone or combined with oral"/>
   <result pre="Dawson P, et al. A randomized, double-blind, placebo-controlled study of" exact="omalizumab" post="combined with oral immunotherapy for the treatment of cow's"/>
   <result pre="Mennini M, Pecora V, Fierro V, et al. Impact of" exact="omalizumab" post="on food allergy in patients treated for asthma: a"/>
   <result pre="trial in sJIA, MAS was observed in some patients receiving" exact="tocilizumab" post="[2-3]. High serum levels of IL-18 have been observed"/>
   <result pre="aggregation test showed severe defect in response to ADP, collagen," exact="epinephrine" post="and reduced to ristocetin. Further evaluation showed total GpIIb"/>
   <result pre="syndrome and pulmonary disorders, spleen sequestration and splenectomy, transfusion and" exact="hydroxyurea" post="therapy were some of the most relevant issues addressed"/>
   <result pre="at high risk of this life-threatening complication [5] and on" exact="hydroxyurea" post="therapy in SCD children [6]. Acknowledgements We thank SITE"/>
   <result pre="indicators: the total antibiotic prescription rate and the ratio of" exact="amoxicillin" post="versus amoxicillin-clavulanic acid. Throughout the project, papers both in"/>
   <result pre="children), along with a relative growth of the use of" exact="amoxicillin" post="(the ratio of amoxicillin to amoxicillin-clavulanic acid increased from"/>
   <result pre="relative growth of the use of amoxicillin (the ratio of" exact="amoxicillin" post="to amoxicillin-clavulanic acid increased from 0.6 to 1.3 in"/>
   <result pre="(quite higher than the one in Emilia-Romagna), and ratio of" exact="amoxicillin" post="to amoxicillin-clavulanic acid 0.3 (much lower than the one"/>
   <result pre="antibiotic prophylaxis; the promising results reported with the CXCR4 antagonist" exact="plerixafor" post="[8] paved the way to the future treatment of"/>
   <result pre="(43%) no germ was isolated. The most used antibiotics were" exact="ceftriaxone" post="(36 %), rifampicin (36 %), meropenem (29 %), linezolid"/>
   <result pre="was isolated. The most used antibiotics were ceftriaxone (36 %)," exact="rifampicin" post="(36 %), meropenem (29 %), linezolid (21%), amoxicillin (14%)"/>
   <result pre="most used antibiotics were ceftriaxone (36 %), rifampicin (36 %)," exact="meropenem" post="(29 %), linezolid (21%), amoxicillin (14%) and vancomycin (14"/>
   <result pre="were ceftriaxone (36 %), rifampicin (36 %), meropenem (29 %)," exact="linezolid" post="(21%), amoxicillin (14%) and vancomycin (14 %). Ciprofloxacin was"/>
   <result pre="(36 %), rifampicin (36 %), meropenem (29 %), linezolid (21%)," exact="amoxicillin" post="(14%) and vancomycin (14 %). Ciprofloxacin was largely used"/>
   <result pre="(36 %), meropenem (29 %), linezolid (21%), amoxicillin (14%) and" exact="vancomycin" post="(14 %). Ciprofloxacin was largely used (57 %), mainly"/>
   <result pre="for children with severe allergic asthma. Binding to free IgE," exact="omalizumab" post="reduces cell-bound IgE, down-regulates IgE receptors and prevents the"/>
   <result pre="release of pro-inflammatory mediators [2]. The efficacy and safety of" exact="omalizumab" post="have been established by several randomized controlled trials specifically"/>
   <result pre="randomized controlled trials specifically conducted in pediatric patients [3]. Overall," exact="omalizumab" post="was effective in reducing the rate of asthma exacerbations,"/>
   <result pre="subjects [3]. A large amount of safety data showed that" exact="omalizumab" post="is generally well-tolerated. The main side effects reported were"/>
   <result pre="support an increased risk of malignancy in patients treated with" exact="omalizumab" post="[3]. Other biologic therapies have provided new evidence of"/>
   <result pre="R, Marseglia A, Ciprandi G. The discovery and development of" exact="omalizumab" post="for the treatment of asthma. Expert Opin Drug Discov."/>
   <result pre="first line-steroid-sparing agent, whilst anti-tumor necrosis factor-α (anti-TNFα) agents, as" exact="adalimumab" post="and infliximab are currently used as second line agents,"/>
   <result pre="agent, whilst anti-tumor necrosis factor-α (anti-TNFα) agents, as adalimumab and" exact="infliximab" post="are currently used as second line agents, in case"/>
   <result pre="has been shown a higher probability of maintaining remission on" exact="adalimumab" post="than infliximab during the time of treatment, and a"/>
   <result pre="shown a higher probability of maintaining remission on adalimumab than" exact="infliximab" post="during the time of treatment, and a better efficacy"/>
   <result pre="the first anti-TNFα agent failed, there is evidence that increasing" exact="adalimumab" post="dose and/or administration or switching to a second anti-TNFα"/>
   <result pre="emerging treatment for uveitis and cystoid macular oedema. Rituximab and" exact="canakinumab" post="are progressively showing an emerging role in chronic resistant"/>
   <result pre="Emmi G, et al. Safety profile of the interleukin-1 inhibitors" exact="anakinra" post="and canakinumab in real-life clinical practice: a nationwide multicenter"/>
   <result pre="et al. Safety profile of the interleukin-1 inhibitors anakinra and" exact="canakinumab" post="in real-life clinical practice: a nationwide multicenter retrospective observational"/>
   <result pre="Corsello G. Early treatment of systemic juvenile idiopathic arthritis with" exact="canakinumab" post="and complete remission after 2 years of treatment suspension:"/>
   <result pre="In the last years increasing evidence supports the use of" exact="anakinra" post="in the treatment of MAS associated with sJIA. Recently,"/>
   <result pre="in the management of rheumatic diseases. Since the introduction of" exact="methotrexate" post="in the early ‘90s, the treatment of JIA was"/>
   <result pre="assessed at the arrival, at 1 and 2 hours after" exact="paracetamol" post="(20 mg/kg orally or 15 mg/kg IV) or ibuprofen"/>
   <result pre="after paracetamol (20 mg/kg orally or 15 mg/kg IV) or" exact="ibuprofen" post="(10mg/kg orally) administration according to OMS guidelines and pain"/>
   <result pre="effective in TTH at 2 hours after administration compared to" exact="paracetamol" post="(OR 6.00). Paracetamol administered both orally (OR 2.00) and"/>
   <result pre="IV (OR 2.50) is more effective in mixed headaches than" exact="ibuprofen" post="(OR 1.75). Ibuprofen (OR 5.50) and paracetamol administered IV"/>
   <result pre="mixed headaches than ibuprofen (OR 1.75). Ibuprofen (OR 5.50) and" exact="paracetamol" post="administered IV (OR 5.50) are more effective than paracetamol"/>
   <result pre="and paracetamol administered IV (OR 5.50) are more effective than" exact="paracetamol" post="administered orally (OR 1.50). Conclusion It may need easier"/>
   <result pre="Ibuprofen maybe more effective in the migraine and TTH than" exact="paracetamol" post="administered orally, but it needs more studies to confirm"/>
   <result pre="in 6 out of 56 emergency departments in Lombardy region" exact="amoxicillin" post="was prescribed to more than 50% of children treated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6921558/results/search/drugs/results.xml">
   <result pre="failure rate and poor predictability (chloral hydrate [ 6– 9]," exact="dexmedetomidine" post="[ 10, 11], thiopental [ 9], midazolam [ 7]),"/>
   <result pre="[ 6– 9], dexmedetomidine [ 10, 11], thiopental [ 9]," exact="midazolam" post="[ 7]), hemodynamic side effects (dexmedetomidine [ 10, 11]),"/>
   <result pre="practice consists in sevoflurane-based anesthesia induction and maintenance, obtained with" exact="sevoflurane" post="inhaled by a reservoir bag mask at 8.0 and"/>
   <result pre="a canopy and aspiration system. If a premedication is indicated," exact="midazolam" post="(0.1 mg/kg administered intramuscularly (IM) 30 min before anesthesia) is administered."/>
   <result pre="breathing, either spontaneously or with an oral cannula, with inhaled" exact="sevoflurane" post="by bag mask. Otherwise a laryngeal mask airway (LMA)"/>
   <result pre="dose of 8.0% (IQR 2.5 to 8.0). Much less frequently," exact="propofol" post="(4.7%), midazolam (1.3%), ketamine (0.6%) or thiopental (0.1%) were"/>
   <result pre="8.0% (IQR 2.5 to 8.0). Much less frequently, propofol (4.7%)," exact="midazolam" post="(1.3%), ketamine (0.6%) or thiopental (0.1%) were used. A"/>
   <result pre="2.5 to 8.0). Much less frequently, propofol (4.7%), midazolam (1.3%)," exact="ketamine" post="(0.6%) or thiopental (0.1%) were used. A standard premedication"/>
   <result pre="(0.6%) or thiopental (0.1%) were used. A standard premedication with" exact="midazolam" post="IM with a median dose of 0.10 [0.09 to"/>
   <result pre="1126 (99.3)  Atropine 4 (0.3)  Ketamine 2 (0.2)  Midazolam +" exact="atropine" post="1 (0.1)  Midazolam + atropine + ketamine 1 (0.1)"/>
   <result pre=" Ketamine 2 (0.2)  Midazolam + atropine 1 (0.1)  Midazolam +" exact="atropine" post="+ ketamine 1 (0.1) Induction, No. (%):  Sevoflurane 1296"/>
   <result pre="(0.2)  Midazolam + atropine 1 (0.1)  Midazolam + atropine +" exact="ketamine" post="1 (0.1) Induction, No. (%):  Sevoflurane 1296 (93.3)  Propofol"/>
   <result pre="drug for both induction and maintenance) was preferred (sevoflurane 96.0%," exact="propofol" post="3.0%, ketamine 0.4%, midazolam 0.5%, thiopental 0.1%). Among the"/>
   <result pre="both induction and maintenance) was preferred (sevoflurane 96.0%, propofol 3.0%," exact="ketamine" post="0.4%, midazolam 0.5%, thiopental 0.1%). Among the 9.1% of"/>
   <result pre="and maintenance) was preferred (sevoflurane 96.0%, propofol 3.0%, ketamine 0.4%," exact="midazolam" post="0.5%, thiopental 0.1%). Among the 9.1% of ventilated patients,"/>
   <result pre="of around 30 min is reported [ 8]. The association of" exact="pentobarbital" post="and chloral hydrate has also been proposed but is"/>
   <result pre="of respiratory complications (10.6–31.9%) [ 13, 14]. A low dose" exact="propofol" post="anesthesia combined with nalbuphine has been proposed in a"/>
   <result pre="[ 13, 14]. A low dose propofol anesthesia combined with" exact="nalbuphine" post="has been proposed in a mixed pediatric population with"/>
   <result pre="Sanctis et al. [ 17] safely used a mix of" exact="sevoflurane" post="1.5–2%, oxygen and nitrous oxide in newborns and infants"/>
   <result pre="17] safely used a mix of sevoflurane 1.5–2%, oxygen and" exact="nitrous oxide" post="in newborns and infants younger than 1-year-old with a"/>
   <result pre="to literature, possibly thanks to the speedy awakening provided by" exact="sevoflurane" post="and the possibility to avoid mechanical ventilation in more"/>
   <result pre="of different pharmacological approaches in specific neuropsychiatric classes. Finally, IM" exact="midazolam" post="administration could be easily replaced by less invasive approaches"/>
   <result pre="nature of adverse events during paediatric sedation / anaesthesia with" exact="propofol" post="for procedures outside the operating room: a report from"/>
   <result pre="Kamat PP McCracken CE Simon HK Is procedural sedation with" exact="propofol" post="acceptable for complex imaging? A comparison of short vs."/>
   <result pre="in newborns and infants: a study of 640 cases using" exact="sevoflurane" post="Paediatr Anaesth 2005 15 9 15 10.1111/j.1460-9592.2005.01360.x 15649157 18."/>
   <result pre="Haemmerle MH Brunner R Kern C Minimum alveolar concentration for" exact="halothane" post="in children with cerebral palsy and severe mental retardation"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6926624/results/search/drugs/results.xml">
   <result pre="with previous guidelines for the definition of vitamin D status," exact="calcifediol" post="concentrations &amp;lt;50 nmol/L were defined as VDD [ 32]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6928139/results/search/drugs/results.xml">
   <result pre="medicines ( 11). The conventional medicines increase the activity of" exact="dopamine" post="and norepinephrine and those stimulants have a high effectiveness"/>
   <result pre="11). The conventional medicines increase the activity of dopamine and" exact="norepinephrine" post="and those stimulants have a high effectiveness in TD"/>
   <result pre="12), concentrations in the basal ganglia ( 13), neurotransmitters and" exact="dopamine" post="metabolism ( 14, 15). They are proposed to be"/>
   <result pre="neuroimaging diagnosis with brain structural abnormalities; (2) history of taking" exact="dopamine" post="receptor blockers, cocaine and other drugs for controlling TD;"/>
   <result pre="essential for the production and regulation of the pineal hormone" exact="melatonin" post="which helps to regulate dopamine function and is widely"/>
   <result pre="regulation of the pineal hormone melatonin which helps to regulate" exact="dopamine" post="function and is widely recognized as a key factor"/>
   <result pre="38, 39); (3) zinc can also bind to and regulate" exact="dopamine" post="transporters, which are targets of psychostimulants for the treatment"/>
   <result pre="the tyrosine hydroxylase enzyme which is a rate-limiting step in" exact="dopamine" post="synthesis ( 43). Second, iron deficiency is associated with"/>
   <result pre="iron deficiency is associated with decreased density and activity of" exact="dopamine" post="transporters, which in turn leads to an increase in"/>
   <result pre="transporters, which in turn leads to an increase in extracellular" exact="dopamine" post="and a decrease in dopamine receptors in the striatum"/>
   <result pre="to an increase in extracellular dopamine and a decrease in" exact="dopamine" post="receptors in the striatum ( 44, 45). Third, iron"/>
   <result pre="enzymes, which play important roles in neurophysiology, including cellular antioxidants," exact="dopamine" post="metabolism, norepinephrine, catecholamine degradation ( 50). Excess copper levels"/>
   <result pre="associated with the formation of a copper-dopamine complex which oxidizes" exact="dopamine" post="and might be related to depression and other mental"/>
   <result pre="Dual action of Zn2+ on the transport cycle of the" exact="dopamine" post="transporter. J Biol Chem. ( 2015) 290: 31069– 76."/>
   <result pre="PY Sheu WH . Zinc coadministration attenuates melatonin's effect on" exact="nitric oxide" post="production in mice . Biol Trace Elem Res. ("/>
   <result pre="Erikson KM Jones BC Beard JL . Iron deficiency alters" exact="dopamine" post="transporter functioning in rat striatum. J Nutr. ( 2000)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6929435/results/search/drugs/results.xml">
   <result pre="carrying the CACNA1A mutation exhibit blunted trigeminovascular nociceptive responses and" exact="calcitonin" post="gene-related peptide (CGRP) expression [ 30, 31] . Although"/>
   <result pre="use of the newly designed migraine treatments designed against the" exact="calcitonin" post="gene-related peptide (CGRP) and its receptors [ 72], further"/>
   <result pre="attacks [ 77, 78] and during the premonitory phase of" exact="nitroglycerin" post="(nitric oxide-NO donor)-induced migraine attacks [ 79]. A disturbance"/>
   <result pre="the A11 nucleus has been shown to be susceptible to" exact="nitric oxide" post="donors in animal models of migraine [ 90, 91]."/>
   <result pre="on the painful side, which was normalised after treatment with" exact="sumatriptan" post="[ 160], as well as, with dilatation of the"/>
   <result pre="release and respond to numerous mediators including growth factors, cytokines," exact="adenosine" post="triphosphate (ATP), and nitric oxide (NO), many of which"/>
   <result pre="numerous mediators including growth factors, cytokines, adenosine triphosphate (ATP), and" exact="nitric oxide" post="(NO), many of which can sensitize trigeminal neurons. In"/>
   <result pre="den Maagdenberg A Ferrari MD et al. Immunohistochemical characterization of" exact="calcitonin" post="gene-related peptide in the trigeminal system of the familial"/>
   <result pre="for a major spinal cord projection from the diencephalic A11" exact="dopamine" post="cell group in the rat using transmitter-specific fluorescent retrograde"/>
   <result pre="complex responses after lesioning dopaminergic A11 nucleus are modified by" exact="dopamine" post="and serotonin mechanisms Pain. 2011 152 10 2365 2376"/>
   <result pre="C et al. The A11 hypothalamic nucleus is susceptible to" exact="nitric oxide" post="signalling J Headache Pain 2014 15 F2 10.1186/1129-2377-15-S1-F2 4182264"/>
   <result pre="21893557 119. Andreou AP Shields KG Goadsby PJ GABA and" exact="valproate" post="modulate trigeminovascular nociceptive transmission in the thalamus Neurobiol Dis"/>
   <result pre="Suzuki N Shimizu T Lee TJ Origin and co-localization of" exact="nitric oxide" post="synthase, CGRP, PACAP, and VIP in the cerebral circulation"/>
   <result pre="G Panara C Pecile A Sotgiu ML Facilitatory role of" exact="calcitonin" post="gene-related peptide (CGRP) on excitation induced by substance P"/>
   <result pre="Kim YS Nam TS Effects of iontophoretically applied substance P," exact="calcitonin" post="gene-related peptide on excitability of dorsal horn neurones in"/>
   <result pre="Migraine pain associated with middle cerebral artery dilatation: reversal by" exact="sumatriptan" post="Lancet. 1991 338 8758 13 17 10.1016/0140-6736(91)90005-A 1676084 161."/>
   <result pre="LL Birk S Olesen J Migraine can be induced by" exact="sildenafil" post="without changes in middle cerebral artery diameter Brain. 2003"/>
   <result pre="M Gill BK Effect of neurokinin a, substance P and" exact="calcitonin" post="gene related peptide in peripheral hyperalgesia in the rat"/>
   <result pre="A Kane SA Tajti J Edvinsson L Differential distribution of" exact="calcitonin" post="gene-related peptide and its receptor components in the human"/>
   <result pre="Organ culture of the trigeminal ganglion induces enhanced expression of" exact="calcitonin" post="gene-related peptide via activation of extracellular signal-regulated protein kinase"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6935960/results/search/drugs/results.xml">
   <result pre="diagnosis of SM was established, and he was treated with" exact="prochlorperazine" post="0.15 mg/kg intravenous after preloading with normal saline; the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6935986/results/search/drugs/results.xml">
   <result pre="out to investigate the effect of treatment of constipation with" exact="lactulose" post="on the improvement of migraine headache in patients who"/>
   <result pre="group and a control group. A 15 cc daily of" exact="lactulose" post="syrup was prescribed to the experimental group with the"/>
   <result pre="prescribed to the experimental group with the antimigraine drugs (10-mg" exact="nortriptyline" post="and 10-mg propranonol daily). In contrast, only the standard"/>
   <result pre="a way that after one and/or two months of using" exact="lactulose" post="syrup, the severity of disability and pain in the"/>
   <result pre="&amp;lt; 0.001). Conclusion: Short-term follow-up of this study showed that" exact="lactulose" post="syrup could remove the constipation with no significant side"/>
   <result pre="treat constipation. These are prescribed as the first-line drugs. However," exact="bisacodyl" post="and the senna compounds, are prescribed as the next-step"/>
   <result pre="prescribed as the next-step drugs.[ 9] Among the available drugs," exact="lactulose" post="is a low-dose drug that is more commonly used"/>
   <result pre="out to investigate the effect of treatment of constipation with" exact="lactulose" post="on improving the symptoms of patients with migraine. M"/>
   <result pre="experimental group and a control group. In the experimental group," exact="lactulose" post="syrup (15 cc daily) and antimigraine drugs (10–25mg nortriptyline"/>
   <result pre="group, lactulose syrup (15 cc daily) and antimigraine drugs (10–25mg" exact="nortriptyline" post="and 20–40mg propranonol daily) were prescribed.[ 1] In the"/>
   <result pre="the control group, only the standard treatment for migraine (10–25mg" exact="nortriptyline" post="and 20–40mg propranonol daily) was prescribed. When the constipation"/>
   <result pre="the ethics, only those patients who tended to use the" exact="lactulose" post="syrup were included in the intervention group, and other"/>
   <result pre="a result, the short-term follow-up of this study showed that" exact="lactulose" post="syrup––being able to remove the constipation with no significant"/>
   <result pre="Sharafkhah M Abdolrazaghnejad A Mohammadbeigi A Faraji F Use of" exact="melatonin" post="versus valproic acid in prophylaxis of migraine patients: a"/>
   <result pre="Abdolrazaghnejad A Mohammadbeigi A Faraji F Use of melatonin versus" exact="valproic acid" post="in prophylaxis of migraine patients: a double-blind randomized clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6936047/results/search/drugs/results.xml">
   <result pre="Bakkali H Belyamani L Thrombolysis for acute ischemic stroke by" exact="tenecteplase" post="in the emergency department of a Moroccan hospital Pan"/>
   <result pre="Yahyaoui ME Alaoui MME Habbal R Sellama N G894T endothelial" exact="nitric oxide" post="synthase polymorphism and ischemic stroke in Morocco Meta Gene"/>
   <result pre="BK Guo ZN Jin H Yang Y Relationship between endothelial" exact="nitric oxide" post="synthase gene polymorphisms and ischemic stroke: a meta-analysis Acta"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6939407/results/search/drugs/results.xml">
   <result pre="disorder, attention deficit hyperactivity disorder and other psychiatric diagnoses, pharmacology," exact="melatonin" post="and solely or primarily biofeedback were excluded, as were"/>
   <result pre="arms To determine the benefits of CBT when combined with" exact="amitriptyline" post="vs headache education plus amitriptyline on pain, disability and"/>
   <result pre="of CBT when combined with amitriptyline vs headache education plus" exact="amitriptyline" post="on pain, disability and credibility Chronic migraine by ICHD-II"/>
   <result pre="sessions over 8 weeks and 2 booster sessions; 1mg/kg/day of" exact="amitriptyline" post="T2: Headache Education (HE) 10 sessions; 1mg/kg/day of amitriptyline"/>
   <result pre="of amitriptyline T2: Headache Education (HE) 10 sessions; 1mg/kg/day of" exact="amitriptyline" post="66% in the CBT group had a headache reduction"/>
   <result pre="d Palermo 2016 47 x c/x d Notes: * aPlus" exact="amitriptyline" post="in both groups. bSpecialised headache treatment in both groups."/>
   <result pre="al 51 and Kroner et al 45 used CBT plus" exact="amitriptyline" post="as the primary intervention. Kroner et al 45 collected"/>
   <result pre=", Kashikar-Zuck SM , et al. Cognitive behavioral therapy plus" exact="amitriptyline" post="for children and adolescents with chronic migraine reduces headache"/>
   <result pre=", Allen JR , et al. Cognitive behavioral therapy plus" exact="amitriptyline" post="for chronic migraine in children and adolescents: a randomized"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6949664/results/search/drugs/results.xml">
   <result pre="At age 3.5 years, she was started on topical 0.5%" exact="timolol" post="and then referred to the Vanderbilt University Medical Center"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6957294/results/search/drugs/results.xml">
   <result pre="infection, no laboratory examination 14 days before commencement of IVIG," exact="prednisolone" post="treatment, and history of methylprednisolone pulse or adrenocorticotropic hormone"/>
   <result pre="days before commencement of IVIG, prednisolone treatment, and history of" exact="methylprednisolone" post="pulse or adrenocorticotropic hormone treatment before IVIG. As previous"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
